<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN">
<HTML>
<HEAD>
<!-- Created by: EDGAR Online, Inc. EDGAR Filing HTML Converter, Version: 4.66, http://www.edgar-online.com -->
<TITLE> Vanda Pharmaceuticals Inc. (Form: 10-K, Received: 02/17/2017 07:04:59) </TITLE>
<META NAME="TABLES" CONTENT="FIS_FORM **FIS_PART_I **FIS_BUSINESS **FIS_RISK_FACTORS **FIS_UNRESOLVED_STAFF_COMMENTS **FIS_PROPERTIES **FIS_LEGAL_PROCEEDINGS **FIS_MINE_SAFETY_DISCLOSURE **FIS_PART_II **FIS_MARKET **FIS_FINANCIAL_DATA **FIS_MANAGEMENTS_DISCUSSION **FIS_RESULTS_OF_OPERATIONS **FIS_LIQUIDITY_CAPITAL **FIS_MARKET_RISK **FIS_FINANCIAL_STATEMENTS **FIS_ACCOUNTING_CHANGES **FIS_CONTROL_AND_PROCEDURES **FIS_OTHER_INFORMATION **FIS_PART_III **FIS_DIRECTORS_AND_OFFICERS **FIS_COMPENSATION **FIS_SECURITY_OWNERS **FIS_OFFICER_TRANSACTIONS **FIS_ACCOUNTANT_FEES **FIS_PART_IV **FIS_EXHIBITS **FIS_SIGNATURES **FIS_AUDITORS_OPINION **FIS_BALANCE_SHEET **FIS_INCOME_STATEMENT **FIS_STOCKHOLDERS_EQUITY **FIS_CASH_FLOW **FIS_NOTES_TO_FINANCIAL_STATEMENT **FIS_EXHIBIT_INDEX FIS_EXHIBIT_10 FIS_EXHIBIT_10_2 FIS_EXHIBIT_21 **FIS_SUBSIDIARIES FIS_EXHIBIT_23 **FIS_EXPERTS_CONSENT FIS_EXHIBIT_31 **FIS_CERTIFICATION FIS_EXHIBIT_31_2 **FIS_CERTIFICATION_2 FIS_EXHIBIT_32 **FIS_CERTIFICATION_3 ">
<META NAME="DETECTED PAGES" CONTENT="141">
<STYLE TYPE="text/css">
<!--
	body          { background-color: white; color: black }
	.eolNewPage   { page-break-after: always; line-height: 0; height: 0; margin: 0; padding: 0 }
	.eolLeftAlign { text-align: left; margin-left: auto; margin-right: auto }
	.eolCenter    { text-align: center }
	a:link        { color: blue }
	a:active      { color: red }
	a:visited     { color: purple }
	
	@media print
	{
		@page           { margin: 0.25in }
		body            { font-size: 10pt }
		a               { text-decoration: none }
		thead           { display: table-header-group }
		tfoot           { display: table-footer-group }
		hr.eolPageBreak { display: none }
		.eolPrint50pt   { font-size: 5pt }
		.eolPrint55pt   { font-size: 5.5pt }
		.eolPrint60pt   { font-size: 6pt }
		.eolPrint65pt   { font-size: 6.5pt }
		.eolPrint70pt   { font-size: 7pt }
		.eolPrint75pt   { font-size: 7.5pt }
		.eolPrint80pt   { font-size: 8pt }
		.eolPrint85pt   { font-size: 8.5pt }
		.eolPrint90pt   { font-size: 9pt }
		.eolPrint95pt   { font-size: 9.5pt }
	}
-->
</STYLE>
</HEAD>
<BODY>
<A NAME="eolPage1"></A>
<A NAME="FIS_TOP_OF_DOCUMENT"></A>

<A NAME="D474152D10K_HTM"></A>
<EFX_FORM>
<A NAME="FIS_FORM"></A>
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="LINE-HEIGHT:1.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
<P STYLE="LINE-HEIGHT:3.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:4PT; MARGIN-BOTTOM:0PT; FONT-SIZE:18PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	UNITED STATES
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:18PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	SECURITIES AND EXCHANGE COMMISSION
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:12PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Washington, D.C. 20549
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1.00PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:18PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Form 10-K
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1.00PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:12PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<B>
</B>
	&#9746;
<B>
</B>
<B>
</B>
<B>
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
</B>
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:12PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	SECURITIES EXCHANGE ACT OF 1934
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	For the fiscal year ended December&nbsp;31, 2016
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:12PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
<B>
</B>
	&#9744;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
</B>
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:12PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	SECURITIES EXCHANGE ACT OF 1934
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Commission File No.&nbsp;001-34186
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1.00PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:24PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	VANDA PHARMACEUTICALS INC.
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(Exact name of registrant as specified in its charter)
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1.00PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="48%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" ALIGN="CENTER">
<B>
	Delaware
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<B>
	03-0491827
</B>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(State or other jurisdiction of
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	incorporation or organization)
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(I.R.S. Employer
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Identification No.)
</B>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	2200 Pennsylvania Avenue NW, Suite 300 E
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Washington D.C. 20037
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(202) 734-3400
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(Address
	and telephone number, including area code, of registrant&#146;s principal executive offices)
</B>
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_2"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Securities registered pursuant to
	Section&nbsp;12(b) of the Exchange Act:
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="48%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:64.15PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Title of Each Class
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:156.85PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Name of Each Exchange on Which
	Registered
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" ALIGN="CENTER">
<B>
	Common Stock, par value $0.001
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<B>
	The Nasdaq Stock Market LLC
</B>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<B>
	(NASDAQ Global Market)
</B>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
<B>
	Rights to Purchase Series A Junior Participating Preferred Stock
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	The Nasdaq Stock Market LLC
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(NASDAQ Global Market)
</B>
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Securities registered pursuant to Section&nbsp;12(g) of the Exchange Act: None
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<CENTER>
<P STYLE="LINE-HEIGHT:6.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1.00PT SOLID #000000;WIDTH:21%">
	&nbsp;
</P>
</CENTER>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities
	Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indicate by check mark if the registrant
	is not required to file reports pursuant to Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indicate by check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the
	Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90
	days.&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indicate by check mark whether the
	registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12
	months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9744;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indicate by check mark if disclosure of delinquent filers pursuant to Item&nbsp;405 of Regulation S-K is not contained herein, and will not be
	contained, to the best of registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.&nbsp;&nbsp;&nbsp;&nbsp;&#9746;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
	reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. (Check one):
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="16%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="60%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="20%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="1%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
	Large&nbsp;accelerated&nbsp;filer
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&#9744;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Accelerated&nbsp;filer
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&#9746;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
	Non-accelerated filer
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&#9744;&nbsp;&nbsp;(Do not check if a smaller reporting company)
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Smaller&nbsp;reporting&nbsp;company
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&#9744;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Securities
	Exchange Act of 1934).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp;&#9746;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of June&nbsp;30,
	2016, the last business day of the registrant&#146;s last completed second quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was approximately $473.6 million based on the closing price of the
	registrant&#146;s Common Stock, as reported by the NASDAQ Global Market, on such date. Shares of Common Stock held by each executive officer and director and stockholders known by the registrant to own 10% or more of the outstanding stock based on
	public filings and other information known to the registrant have been excluded since such persons may be deemed affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The number of shares of the registrant&#146;s Common Stock, par value $0.001 per share, outstanding as of February&nbsp;6, 2017 was
	44,346,431.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The exhibit index as required by Item&nbsp;601(a) of Regulation S-K is included in Item&nbsp;15 of Part IV of this report.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	DOCUMENTS INCORPORATED BY REFERENCE
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Specified portions of the registrant&#146;s proxy statement with respect to the registrant&#146;s 2017 Annual Meeting of Stockholders, which
	is to be filed pursuant to Regulation 14A within 120 days after the end of the registrant&#146;s fiscal year ended December&nbsp;31, 2016, are incorporated by reference into Part III of this Form 10-K.
</P>
<P STYLE="FONT-SIZE:10PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="LINE-HEIGHT:1.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
<P STYLE="LINE-HEIGHT:3.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
<A NAME="eolPage2"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Vanda Pharmaceuticals Inc.
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Form 10-K
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D474152D10K_HTM_TOC">
</A>
	Table of Contents
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="6%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="89%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Page
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<B>
	Part I
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_1">
	Cautionary Note Regarding Forward-Looking Statements
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_2">
	Item&nbsp;1
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_2">
	Business
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_3">
	Item&nbsp;1A
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_3">
	Risk Factors
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_4">
	Item&nbsp;1B
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_4">
	Unresolved Staff Comments
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	36
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_5">
	Item&nbsp;2
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_5">
	Properties
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	36
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_6">
	Item&nbsp;3
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_6">
	Legal Proceedings
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	36
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_7">
	Item&nbsp;4
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_7">
	Mine Safety Disclosures
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	38
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<B>
	Part II
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_8">
	Item&nbsp;5
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_8">
	Market for Registrant&#146;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	38
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_9">
	Item&nbsp;6
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_9">
	Selected Consolidated Financial Data
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	39
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_10">
	Item&nbsp;7
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_10">
	Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	41
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_11">
	Item&nbsp;7A
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_11">
	Qualitative and Quantitative Disclosures about Market Risk
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	52
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_12">
	Item&nbsp;8
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_12">
	Financial Statements and Supplementary Data
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	53
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_13">
	Item&nbsp;9
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_13">
	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	53
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_14">
	Item&nbsp;9A
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_14">
	Controls and Procedures
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	53
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_15">
	Item&nbsp;9B
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_15">
	Other Information
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	53
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<B>
	Part III
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_16">
	Item&nbsp;10
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_16">
	Directors, Executive Officers and Corporate Governance
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	53
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_17">
	Item&nbsp;11
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_17">
	Executive Compensation
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	53
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_18">
	Item&nbsp;12
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_18">
	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	54
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_19">
	Item&nbsp;13
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_19">
	Certain Relationships and Related Transactions, and Director Independence
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	54
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_20">
	Item&nbsp;14
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_20">
	Principal Accountant Fees and Services
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	54
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<B>
	Part IV
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_21">
	Item&nbsp;15
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<A HREF="#D474152D10K_HTM_TOC474152_21">
	Exhibits and Financial Statement Schedules
</A>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	54
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_22">
	Signatures
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	55
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TOC474152_23">
	Exhibits
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	84
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<A NAME="eolPage3"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_PART_I>
<A NAME="FIS_PART_I"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	PART I
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<U>
<A NAME="D474152D10K_HTM_TOC474152_1">
</A>
	CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
</U>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Various statements throughout this report are &#147;forward-looking statements&#148; within the meaning of the Private Securities Litigation
	Reform Act of 1995. Forward-looking statements may appear throughout this report. Words such as, but not limited to, &#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;estimate,&#148; &#147;intend,&#148; &#147;plan,&#148;
	&#147;project,&#148; &#147;target,&#148; &#147;goal,&#148; &#147;likely,&#148; &#147;will,&#148; &#147;would,&#148; and &#147;could,&#148; or the negative of these terms and similar expressions or words, identify forward-looking statements.
	Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in our
	forward-looking statements include, among others:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the ability of Vanda Pharmaceuticals Inc. (we, our or Vanda) to continue to commercialize HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(tasimelteon) for the treatment of Non-24-Hour Sleep-Wake
	Disorder (Non-24) in the U.S. and Europe;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	uncertainty as to the market awareness of Non-24 and the market acceptance of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to generate U.S. sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(iloperidone) for the treatment of schizophrenia;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the timing and costs of continuing to build a sales and marketing, supply chain, distribution, pharmacovigilance, compliance and safety infrastructure to promote
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S.;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our dependence on third-party manufacturers to manufacture HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in sufficient quantities
	and quality;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the regulatory status of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Europe;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to successfully commercialize HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	outside of the U.S.;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to prepare, file, prosecute, defend and enforce any patent claims and other intellectual property rights;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	a loss of rights to develop and commercialize our products under our license agreements;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the ability to obtain and maintain regulatory approval of our products, and the labeling for any approved products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the timing and success of preclinical studies and clinical trials conducted by us and our development partners;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	a failure of our products to be demonstrably safe and effective;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the size and growth of the potential markets for our products and the ability to serve those markets;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our expectations regarding trends with respect to our revenues, costs, expenses and liabilities;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the scope, progress, expansion, and costs of developing and commercializing our products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our failure to identify or obtain rights to new products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	a loss of any of our key scientists or management personnel;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	limitations on our ability to utilize some of all of our prior net operating losses and orphan drug and research and development credits;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the cost and effects of litigation;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to obtain the capital necessary to fund our research and development or commercial activities;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	losses incurred from product liability claims made against us; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	use of our existing cash, cash equivalents and marketable securities.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	All written and verbal
	forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section. We caution investors not to rely too heavily on the
	forward-looking statements we make or that are made on our behalf. We undertake no obligation, and specifically decline any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future
	events or otherwise.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We encourage you to read
<I>
	Management&#146;s Discussion and Analysis of our Financial Condition and Results of
	Operations
</I>
	and our consolidated financial statements contained in this annual report on Form 10-K. We also encourage you to read Item&nbsp;1A of Part&nbsp;I of this annual report on Form 10-K, entitled
<I>
	Risk Factors
</I>
	, which contains a more
	complete discussion of the risks and uncertainties associated with our business. In addition to the risks described above and in Item&nbsp;1A of this report, other unknown or unpredictable factors also could affect our results. Therefore, the
	information in this report should be read together with other reports and documents that we file with the Securities and Exchange Commission from time to time, including on Form 10-Q and Form 8-K, which may supplement, modify, supersede or update
	those risk factors. As a result of these factors, we cannot assure you that the forward-looking statements in this report will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be
	material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified
	time frame, or at all.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	1
</P>
<A NAME="eolPage4"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_BUSINESS>
<A NAME="FIS_BUSINESS"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<A NAME="D474152D10K_HTM_TOC474152_2">
</A>
	ITEM 1. BUSINESS
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Overview
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vanda Pharmaceuticals Inc. (we
	or Vanda ) is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. Vanda commenced its operations in 2003 and our product
	portfolio includes:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	&nbsp;(tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24), was approved by the U.S. Food and Drug Administration (FDA)
	in January 2014 and launched commercially in the U.S. in April 2014. In July 2015, the European Commission (EC) granted centralized marketing authorization with unified labeling for
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	&nbsp;for the treatment of Non-24 in totally blind adults. HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	&nbsp;was commercially launched in Germany in August 2016.
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	&nbsp;has potential utility in a number of other circadian rhythm disorders and is presently in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and
	Smith-Magenis Syndrome (SMS).
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	&nbsp;(iloperidone), a product for the treatment of schizophrenia, the oral formulation of which was approved by the FDA in May 2009 and launched
	commercially in the U.S. by Novartis Pharma AG (Novartis) in January of 2010. Novartis transferred all the U.S. and Canadian commercial rights to the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	&nbsp;franchise to us on
	December&nbsp;31, 2014. Additionally, our distribution partners launched Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	&nbsp;in Israel and Mexico in 2014. Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	&nbsp;has
	potential utility in a number of other disorders. An assessment of new Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	&nbsp;clinical opportunities is ongoing.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is presently in clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Trichostatin A, a small molecule histone deacetylase (HDAC) inhibitor which is in development for the treatment of hematologic malignancies.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Since we began
	operations in March 2003, we have devoted substantially all of our resources to the in-licensing, clinical development and commercialization of our products. Our ability to generate meaningful product sales and achieve profitability largely depends
	on our ability to successfully commercialize HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	&nbsp;and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	&nbsp;in the U.S. and Europe alone or with others, to complete
	the development of our products, and to obtain the regulatory approvals for and to manufacture, market and sell our products.&nbsp;The results of our operations will vary significantly from year-to-year and quarter-to-quarter and depend on a number
	of factors, including risks related to our business, risks related to our industry, and other risks which are detailed in Item&nbsp;1A of Part I entitled
<I>
	Risk Factors
</I>
	and Item&nbsp;7 of Part II entitled
<I>
	Management&#146;s Discussion and
	Analysis of Financial Condition and Results of Operations
</I>
	of this annual report on Form 10-K.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our activities will necessitate
	significant uses of working capital in 2017 and beyond. We are currently concentrating our efforts on selling HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in
	the U.S. and our continued commercialization of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Europe. Additionally, we continue to pursue market approval of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in
	other regions and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Europe and other regions. We will continue to work with our distribution partners who launched Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in
	Mexico and Israel. We see opportunities to grow our commercial products through life cycle management strategies that include the addition of new indications and formulations. We have built a research and development organization that includes
	extensive expertise in the scientific disciplines of pharmacogenetics and pharmacogenomics. We operate cross-functionally and are led by an experienced research and development management team. Our pipeline includes novel programs that could address
	largely unmet medical needs.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our founder and Chief Executive Officer, Mihael H. Polymeropoulos, M.D., started Vanda&#146;s operations in
	early 2003 after establishing and leading the Pharmacogenetics Department at Novartis. In acquiring and developing our products, we have relied upon our deep expertise in the scientific disciplines of pharmacogenetics and pharmacogenomics. These
	scientific disciplines examine both genetic variations among people that influence response to a particular drug, and the multiple pathways through which drugs affect people.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Our Strategy
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our goal is to create a
	leading global biopharmaceutical company focused on developing and commercializing innovative therapies addressing high unmet medical needs through the application of our drug development expertise and our pharmacogenetics and pharmacogenomics
	expertise. The key elements of our strategy to accomplish this goal are to:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<I>
	&#149;
</I>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<I>
	Maximize the commercial success of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	;
</I>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<I>
	&#149;
</I>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<I>
</I>
<I>
	Enter into strategic partnerships to supplement our capabilities and to extend our commercial reach;
</I>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<I>
	&#149;
</I>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<I>
	Pursue the clinical development and regulatory approval of our products;
</I>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<I>
	&#149;
</I>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<I>
</I>
<I>
	Apply our pharmacogenetics and pharmacogenomics expertise to differentiate our products; and
</I>
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
<I>
	&#149;
</I>
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<I>
</I>
<I>
	Expand our product portfolio through the identification and acquisition of additional products.
</I>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	2
</P>
<A NAME="eolPage5"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_3"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Products
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have the following products on the market or under regulatory review:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="13%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD WIDTH="10%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="9%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="58%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:27.55PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Product
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Indication
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Geography
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Select&nbsp;Historical Milestones
</B>
</P>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(tasimelteon)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Non-24
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	United&nbsp;States
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	FDA&nbsp;approval&nbsp;in&nbsp;January&nbsp;2014;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Commercial&nbsp;launch&nbsp;in&nbsp;April&nbsp;2014
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	Europe
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	EC approval in July 2015;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Commercial launch in Germany in August 2016
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(Oral)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(iloperidone)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Schizophrenia
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	United States
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	FDA approval in May 2009;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Commercial&nbsp;launch&nbsp;in&nbsp;January&nbsp;2010;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	U.S. and
	Canada rights sublicensed to Novartis in October 2009 and reacquired by Vanda in December 2014;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Long term maintenance sNDA approval in May
	2016
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Fanaptum
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	&nbsp;(Oral)
</I>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	(iloperidone)
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Europe
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	EMA accepted for evaluation our MAA in December 2015
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Mexico
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Market approval in October 2013;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Commercial
	launch in the fourth quarter of 2014 by our local distribution partner, Probiomed S.A. de C.V.
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Israel
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Market approval August 2012;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Commercial launch
	in the fourth quarter of 2014 by our local distribution partner, Megapharm Ltd.
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have the following products in clinical development:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_4"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="17%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="17%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="62%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:27.55PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Product
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Target Indication
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Select Historical Milestones
</B>
</P>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(tasimelteon)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Pediatric Non-24
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Initiated a liquid formulation pharmacokinetic study in the fourth quarter of 2016
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	SMS
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Initiated a placebo controlled study in the fourth quarter of 2016
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	Jet Lag Disorder
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	Initiated a placebo controlled study in the fourth quarter of 2016
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(Oral)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(iloperidone)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Schizophrenia
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Long-acting injectable under evaluation;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	Other Disorders
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	Potential indications are under evaluation including bipolar depression, major depressive disorder and post-traumatic stress disorder &#150; nightmares
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Tradipitant&nbsp;(VLY-686)
</FONT>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Pruritus&nbsp;in&nbsp;patients&nbsp;with Atopic Dermatitis
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Initiated a placebo controlled pruritus clinical study in the second quarter of 2016
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	Gastroparesis
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	Initiated a placebo controlled study in fourth quarter of 2016
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	Trichostatin A
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	Oncology
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In development for hematologic malignancies
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	AQW051
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	CNS Disorders
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	Potential indications are under strategic evaluation including cognitive impairment
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	3
</P>
<A NAME="eolPage6"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Commercial opportunity: Non-24
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In January 2014, HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was approved in the U.S. for the treatment of Non-24. Non-24
	is a serious, rare and chronic circadian rhythm disorder characterized by the inability to entrain (synchronize) the master body clock with the 24-hour day-night cycle. HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is the first
	FDA approved treatment for Non-24. HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is a melatonin agonist of the human MT1 and MT2 receptors, with greater specificity for MT2. These receptors are thought to be involved in the
	control of circadian rhythms. HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is believed to reset the master body clock in the suprachiasmatic nucleus (SCN), located in the hypothalamus, resulting in the entrainment and alignment
	of the body&#146;s melatonin and cortisol rhythms to the 24-hour day-night cycle. HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was launched commercially in the U.S. in April 2014. In addition, in July 2015, the EC granted
	centralized marketing authorization with unified labeling for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for the treatment of Non-24 in totally blind adults and included post-marketing commitments related to a pediatric
	investigation plan. This authorization is valid in the 28 countries that are members of the European Union, as well as European Economic Area members Iceland, Liechtenstein and Norway.
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was launched commercially in Germany in August 2016.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In January 2010,
	the FDA granted orphan drug designation status for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Non-24 in blind individuals. The FDA grants orphan drug designation to drugs that may provide significant therapeutic advantage
	over existing treatments and target conditions affecting 200,000 or fewer U.S. patients per year. Orphan drug designation provides potential financial and regulatory incentives, including study design assistance, tax credits, waiver of FDA user
	fees, and up to seven years of market exclusivity upon marketing approval. In February 2011, the European Medicines Agency (EMA) designated HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	as an orphan medicinal product for the same
	indication.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Non-24 is a serious, rare and chronic circadian rhythm disorder characterized by the inability to synchronize the master body
	clock with the 24-hour day-night cycle. Non-24 affects a majority of totally blind individuals, or approximately 80,000 people in the U.S. Non-24 occurs almost entirely in individuals who lack the light sensitivity necessary to synchronize the
	master body clock in the brain with the 24-hour day-night cycle. Most people have a master body clock that naturally runs longer than 24-hours and light is the primary environmental cue that resets it to 24 hours each day. Individuals with Non-24
	have a master body clock that is not reset, and continually delays, resulting in prolonged periods of misalignment between their circadian rhythms and the 24-hour day-night cycle, including the timing of melatonin and cortisol secretion. As a result
	of this misalignment, Non-24 is associated with significant disruption of the sleep-wake cycle and impairments in social and occupational functioning, and marked subjective distress. Individuals with Non-24 cycle in-and out-of phase and suffer from
	disrupted nighttime sleep patterns and/or excessive daytime sleepiness.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	While there are no FDA or EC approved treatments for Non-24 other
	than HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, there are a number of drugs approved and prescribed for patients with sleep disorders. The most commonly prescribed drugs are hypnotics. See
<I>
	Competition
</I>
	below for a
	discussion of commonly prescribed drugs for patients with sleep disorders.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Therapeutic opportunity: Circadian Rhythm Sleep
	Disorders
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Sleep disorders are segmented into three major categories: primary insomnia, secondary insomnia and circadian rhythm
	sleep disorders (CRSDs). Insomnia is a symptom complex that comprises difficulty falling asleep or staying asleep, or non-refreshing sleep, in combination with daytime dysfunction or distress. The symptom complex can be an independent disorder
	(primary insomnia) or be a result of another condition such as depression or anxiety (secondary insomnia). CRSDs result from a misalignment of the sleep/wake cycle and an individual&#146;s daily activities or lifestyle. The circadian rhythm is the
	rhythmic output of the human biological clock and is governed by the hormones melatonin and cortisol. Both the timing of behavioral events (activity, sleep, and social interactions) and the environmental light/dark cycle result in a sleep/wake cycle
	that follows the circadian rhythm. Examples of CRSDs include transient disorders such as jet lag and chronic disorders such as delayed sleep phase disorder, shift work sleep disorder and Non-24. We are planning to develop HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for the treatment of pediatric Non-24. We initiated a pediatric liquid formulation pharmacokinetic study in the fourth quarter of 2016.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We initiated an open label interventional study in patients with SMS in the fourth quarter of 2015 and a SMS placebo controlled study in the
	fourth quarter of 2016. Enrollment in these studies is ongoing. SMS is a rare genetic disorder caused by a deletion on chromosome 17. The U.S. National Institute of Health estimates that SMS affects approximately one in 20,000 births in the U.S.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We initiated an observational study in Jet Lag Disorder in the fourth quarter of 2015, which has been extended. We initiated a placebo
	controlled study in the fourth quarter of 2016.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Commercial Opportunity: Schizophrenia
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is a product for the treatment of schizophrenia. In May 2009, the FDA granted
	U.S. marketing approval of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for the acute treatment of schizophrenia in adults. In October 2009, we entered into an amended and restated sublicense agreement with Novartis. We had
	originally entered into a sublicense agreement with Novartis in June 2004 pursuant to which we obtained certain worldwide exclusive licenses from Novartis relating to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. Pursuant to the
	amended and restated sublicense agreement, Novartis
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	4
</P>
<A NAME="eolPage7"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	had exclusive commercialization rights to all formulations of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and Canada. In January 2010, Novartis launched Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. On December&nbsp;31, 2014, Novartis transferred all the U.S. and Canadian commercial rights to the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	franchise to Vanda
	as part of the Settlement Agreement. See Note 3,
<I>
	Settlement Agreement with Novartis
</I>
	, to the consolidated financial statements included in Part II of this annual report on Form 10-K for additional information. In June 2015, we announced
	positive results from REPRIEVE, a Phase III long-term maintenance study that was conducted by Novartis. In May 2016, the FDA approved a supplemental New Drug Application (sNDA) for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for
	the maintenance treatment of schizophrenia in adults.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We continue to explore the regulatory path and commercial opportunity for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	oral formulation outside of the U.S. In December 2012, the EMA&#146;s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion recommending against approval of Fanaptum
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(oral iloperidone tablets) for the treatment of schizophrenia in adult patients in the European Union. The CHMP was of the opinion that the benefits of Fanaptum
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	did not outweigh its risks and recommended against marketing authorization. We initiated an appeal of this opinion and requested a re-examination of the decision by the CHMP, but withdrew our
	Marketing Authorization Application (MAA) in the first quarter of 2013 because the additional clinical data requested by the CHMP would not have been available in the timeframe allowed by the EMA&#146;s Centralized Procedure. In December 2015, we
	refiled a MAA with the EMA for Fanaptum
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	which included the results from the REPRIEVE study.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have entered into agreements with the following partners for the commercialization of
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the countries set forth below:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_5"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="54%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:28.90PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Country
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Partner
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Market&nbsp;Approval&nbsp;Date
</B>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Mexico
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Probiomed&nbsp;S.A.&nbsp;de&nbsp;C.V.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	October&nbsp;2013
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Israel
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Megapharm Ltd.
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	August 2012
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Schizophrenia is a chronic, debilitating mental disorder characterized by hallucinations, delusions, racing
	thoughts and other psychotic symptoms (collectively referred to as &#147;positive symptoms&#148;), as well as moodiness, anhedonia (inability to feel pleasure), loss of interest, eating disturbances and withdrawal (collectively referred to as
	&#147;negative symptoms&#148;), and attention and memory deficits (collectively referred to as &#147;cognitive symptoms&#148;). Schizophrenia develops in late adolescence or early adulthood in approximately 1% of the world&#146;s population. Most
	schizophrenia patients today are treated with drugs known as &#147;atypical&#148; antipsychotics, which were first approved in the U.S. in the late 1980s. These antipsychotics have been named &#147;atypical&#148; for their ability to treat a broader
	range of negative symptoms than the first-generation &#147;typical&#148; antipsychotics, which were introduced in the 1950s and are now generic. Atypical antipsychotics are generally regarded as having improved side effect profiles and efficacy
	relative to typical antipsychotics. See
<I>
	Competition
</I>
	below for a discussion of commonly prescribed atypical antipsychotics in addition to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to the Settlement Agreement with Novartis, we reacquired the U.S. and Canadian rights to the long-acting injectable (depot)
	formulation of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	.&nbsp;We are evaluating the commercial opportunity around the depot formulation.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Therapeutic opportunity: Other
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are currently in the process of evaluating potential indications, including bipolar depression, major depressive disorder and post-traumatic
	stress disorder &#150; nightmares.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Tradipitant (VLY-686)
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Tradipitant is a small molecule NK-1R antagonist that we licensed from Eli Lilly and Company (Lilly) in April 2012. NK-1R antagonists have been
	evaluated in a number of indications including chemotherapy-induced nausea and vomiting (CINV), post-operative nausea and vomiting (PONV), gastroparesis, alcohol dependence, anxiety, depression and chronic pruritus associated with atopic dermatitis.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We commenced a Phase II clinical study of tradipitant in the treatment of chronic pruritus in patients with atopic dermatitis in 2014.
	Results from this study, which were announced in March 2015, showed no significant difference from placebo on the pre-specified primary endpoint. Vanda believes this proof of concept study was informative, in that through subsequent analyses, it
	revealed statistically significant and clinically meaningful responses across multiple outcomes evaluated in individuals with higher blood plasma levels of tradipitant at the time of their pruritus assessments. We initiated a placebo controlled
	pruritus proof of concept study in the second quarter of 2016.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We initiated a placebo controlled Phase II clinical study of tradipitant
	in the treatment of gastroparesis in the fourth quarter of 2016.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Trichostatin A
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Trichostatin A is a small molecule HDAC inhibitor with potential use as a treatment for several oncology indications. We plan to file an IND
	application in 2017.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	5
</P>
<A NAME="eolPage8"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	AQW051
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	AQW051 is a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist that we licensed from Novartis on December&nbsp;31, 2014 pursuant
	to the Settlement Agreement. We are evaluating potential indications, including cognitive impairment.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	License Agreements
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our rights to develop and commercialize our products are subject to the terms and conditions of licenses granted to us by other pharmaceutical
	companies.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In February 2004, we entered into a license agreement with Bristol-Myers Squibb Company (BMS) under which we received an exclusive worldwide
	license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. In partial consideration for the license, we paid BMS
	an initial license fee of $0.5 million. We made developmental milestone payments to BMS totaling $12.0 million under the license agreement, including an $8.0 million milestone payment in the first quarter of 2014 as a result of the FDA&#146;s
	approval of our HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	NDA. The $8.0 million milestone payment was capitalized as an intangible asset and is being amortized over the expected HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	patent life in the U.S. We are obligated to make a future milestone payment to BMS of $25.0 million in the event that cumulative worldwide sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	reach $250.0&nbsp;million, which we expect to reach by the end of 2018. Additionally, we are obligated to make royalty payments on
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	net sales to BMS in any territory where we commercialize HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for a period equal to the greater of 10 years post the first
	commercial sale in the territory or the expiry of the new chemical entity patent in that territory.&nbsp;During the period prior to the expiry of the new chemical entity patent in a territory, we are obligated to pay a 10% royalty on net sales in
	that territory.&nbsp;The royalty rate is decreased by half for countries in which no new chemical entity patent existed or for the remainder of the 10 years after the expiry of the new chemical entity patent. We are also obligated under the license
	agreement to pay BMS a percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that we receive from a third party in connection with any sublicensing arrangement, at a rate which is in the
	mid-twenties. We have agreed with BMS in our license agreement for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	to use our commercially reasonable efforts to develop and commercialize HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Either party may terminate the
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	license agreement under certain circumstances, including a material breach of the agreement by the other. In the event we terminate our license, or if BMS terminates our license due
	to our breach, all rights licensed and developed by us under this agreement will revert or otherwise be licensed back to BMS on an exclusive basis.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Fanapt
</I>
</B>
<B>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</B>
<B>
<I>
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to the terms of the Settlement Agreement with Novartis, Novartis transferred all U.S. and Canadian rights in the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	franchise to Vanda on December&nbsp;31, 2014.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A predecessor company of Sanofi,
	Hoechst Marion Roussel, Inc. (HMRI), discovered Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and completed early clinical work on the compound. In 1996, HMRI licensed its rights to the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	patents and patent applications to Titan Pharmaceuticals, Inc. (Titan) on an exclusive basis. In 1997, soon after it had acquired its rights, Titan sublicensed its rights to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	on an exclusive basis to Novartis. In June 2004, we acquired exclusive worldwide rights to these patents and patent applications as well as certain Novartis patents and patent applications to
	develop and commercialize Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	through a sublicense agreement with Novartis. In partial consideration for this sublicense, we paid Novartis an initial license fee of $0.5 million and were
	obligated to make future milestone payments to Novartis of less than $100.0 million in the aggregate (the majority of which were tied to sales milestones), as well as royalty payments to Novartis at a rate which, as a percentage of net sales, was in
	the mid-twenties. As a result of the FDA&#146;s approval of the NDA for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in May 2009, we met a milestone under the sublicense agreement, which required us to make a payment of $12.0
	million to Novartis.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In October 2009, we entered into an amended and restated sublicense agreement with Novartis, which amended and
	restated the June 2004 sublicense agreement. Pursuant to the amended and restated sublicense agreement, Novartis had exclusive commercialization rights to all formulations of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the
	U.S. and Canada. Novartis began selling Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. during the first quarter of 2010. Novartis was responsible for the further clinical development activities in the U.S. and Canada.
	Pursuant to the amended and restated sublicense agreement, we received an upfront payment of $200.0 million and were eligible for additional payments totaling up to $265.0 million upon Novartis&#146; achievement of certain commercial and development
	milestones for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and Canada. We also received royalties, which, as a percentage of net sales, were in the low double-digits, on net sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and Canada. We retained exclusive rights to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	outside the U.S. and Canada and are obligated to make royalty payments to
	Sanofi S.A. on Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	sales outside the U.S. and Canada.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to the terms
	of the Settlement Agreement, Novartis transferred all U.S. and Canadian rights in the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	franchise to us on December&nbsp;31, 2014. We are obligated to make royalty payments to Sanofi,
	S.A. (Sanofi) and Titan, at a percentage rate equal to 23% on annual U.S. net sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	up to $200.0 million, and at a percentage rate in the mid-twenties on sales over
	$200.0&nbsp;million through November 2016. See Note 3,
<I>
	Settlement Agreement with Novartis
</I>
	, to the consolidated financial statements included in Part II of this annual report on Form 10-K for additional information. In February 2016, we
	amended the agreement with Sanofi and Titan to remove Titan as the entity through which royalty payments from us are directed to Sanofi following the expiration of the new
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	6
</P>
<A NAME="eolPage9"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	chemical entity (NCE) patent for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. on November&nbsp;15, 2016. Under the amended agreement, we will pay directly to
	Sanofi a fixed royalty of 3% of net sales from November&nbsp;16, 2016 through December&nbsp;31, 2019 related to manufacturing know-how. We made a $2.0 million payment during the year ended December&nbsp;31, 2016 that applied to this 3% manufacturing
	know-how royalty and will make additional royalty payments only to the extent that our cumulative royalty obligations during this period exceed the amount of the pre-payment. No further royalties on manufacturing know-how are payable by us after
	December&nbsp;31, 2019. This amended agreement does not alter Titan&#146;s obligation under the License Agreement to make royalty payments to Sanofi prior to November&nbsp;16, 2016 or our obligations under the Sublicense Agreement to pay Sanofi a
	fixed royalty on Fanapt net sales equal up to 6% on Sanofi know-how not related to manufacturing under certain conditions for a period of up to 10 years in markets where the NCE patent has expired or was not issued.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Tradipitant (VLY-686)
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In April 2012, we entered into a license agreement with Lilly pursuant to which we acquired an exclusive worldwide license under certain
	patents and patent applications, and other licenses to intellectual property, to develop and commercialize an NK-1R antagonist, tradipitant, for all human indications.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to the agreement, we paid Lilly an initial license fee of $1.0 million and we will be responsible for all development costs for
	tradipitant. Lilly is also eligible to receive additional payments based upon achievement of specified development and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the low double digits. These
	milestones include $4.0 million for pre-NDA approval milestones and up to $95.0 million for future regulatory approval and sales milestones. We have agreed to use commercially reasonable efforts to develop and commercialize tradipitant.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Either party may terminate the agreement under certain circumstances, including a material breach of the agreement by the other. In the event
	that we terminate the agreement, or if Lilly terminates the agreement due to our breach or for certain other reasons set forth in the agreement, all rights licensed and developed by us under the agreement will revert or otherwise be licensed back to
	Lilly on an exclusive basis, subject to payment by Lilly to us of a royalty on net sales of products that contain tradipitant.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	AQW051
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In
	December 2014, we entered into a license agreement with Novartis pursuant to which we acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize an
	alpha-7 nicotinic acetylcholine receptor partial agonist, AQW051, for all human indications.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to the agreement, we will be
	responsible for all development costs for AQW051. Novartis is eligible to receive tiered royalties on net sales at percentage rates up to the low double digits. We have agreed to use commercially reasonable efforts to develop and commercialize
	AQW051.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Either party may terminate the agreement under certain circumstances, including a material breach of the agreement by the other.
	In the event that we terminate the agreement, or if Novartis terminates the agreement due to our breach or for certain other reasons set forth in the agreement, all rights licensed and developed by us under the agreement will revert or otherwise be
	licensed back to Novartis on an exclusive basis, subject to payment by Novartis to us of a royalty on net sales of products that contain AQW051.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Government Regulation
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Government
	authorities in the U.S., at the federal, state and local level, as well as foreign countries and local foreign governments, regulate the research, development, testing, manufacture, labeling, promotion, advertising, distribution, sampling,
	marketing, import and export of our products. Other than HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and the European Union and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S., Israel
	and Mexico, all of our products will require regulatory approval by government agencies prior to commercialization. In particular, human pharmaceutical products are subject to rigorous pre-clinical and clinical trials and other approval procedures
	of the FDA and similar regulatory authorities in foreign countries. The process of obtaining these approvals and the subsequent compliance with appropriate domestic and foreign laws, rules and regulations require the expenditure of significant time
	and human and financial resources.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	United States government regulation
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	FDA approval process
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In
	the U.S., the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act, as amended, and implements regulations. If we fail to comply with the applicable requirements at any time during the product development process, approval process, or
	after approval, we may become subject to administrative or judicial sanctions. These sanctions could include the FDA&#146;s refusal to approve pending applications, withdrawals of approvals, clinical holds, warning letters, product recalls, product
	seizures, total or partial suspension of our operations, injunctions, fines, civil penalties or criminal prosecution. Any such sanction could have a material adverse effect on our business.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	7
</P>
<A NAME="eolPage10"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The steps required before a drug may be marketed in the U.S. include:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	pre-clinical laboratory tests, animal studies and formulation studies under Current Good Laboratory Practices (cGLP);
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	submission to the FDA of an investigational new drug application (IND), which must become effective before human clinical trials may begin;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	execution of adequate and well-controlled clinical trials to establish the safety and efficacy of the drug for each indication for which approval is sought;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	submission to the FDA of an NDA;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with Current Good Manufacturing Practices (cGMP); and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	FDA review and approval of the NDA.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pre-clinical studies generally are conducted in
	laboratory animals to evaluate the potential safety and activity of a drug. Violation of the FDA&#146;s cGLP regulations can, in some cases, lead to invalidation of the studies, requiring these studies to be replicated. In the U.S., drug developers
	submit the results of pre-clinical trials, together with manufacturing information and analytical and stability data, to the FDA as part of the IND, which must become effective before clinical trials can begin in the U.S. An IND becomes effective 30
	days after receipt by the FDA unless before that time the FDA raises concerns or questions about issues such as the proposed clinical trials outlined in the IND. In that case, the IND sponsor and the FDA must resolve any outstanding FDA concerns or
	questions before clinical trials can proceed. If these concerns or questions are unresolved, the FDA may not allow the clinical trials to commence.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pilot studies generally are conducted in a limited patient population, approximately three to 25 subjects, to determine whether the drug
	warrants further clinical trials based on preliminary indications of efficacy. These pilot studies may be performed in the U.S. after an IND has become effective or outside of the U.S. prior to the filing of an IND in the U.S. in accordance with
	applicable government regulations and institutional procedures.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Clinical trials involve the administration of the investigational new
	drug to human subjects under the supervision of qualified investigators. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in assessing the safety and the
	effectiveness of the drug. Each protocol must be submitted to the FDA as part of the IND prior to beginning the trial.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Typically,
	clinical evaluation involves a time-consuming and costly three-Phase sequential process, but the phases may overlap. Each trial must be reviewed, approved and conducted under the auspices of an independent Institutional Review Board, and each trial
	must include the patient&#146;s informed consent.
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Phase I: refers typically to closely-monitored clinical trials and includes the initial introduction of an investigational new drug into human patients or healthy volunteer subjects. Phase I trials are designed to
	determine the safety, metabolism and pharmacologic actions of a drug in humans, the potential side effects associated with increasing drug doses and, if possible, to gain early evidence of the drug&#146;s effectiveness. Phase I trials also include
	the study of structure-activity relationships and mechanism of action in humans, as well as studies in which investigational new drugs are used as research tools to explore biological phenomena or disease processes. During Phase I trials, sufficient
	information about a drug&#146;s pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid Phase II studies. The total number of subjects and patients included in Phase I trials
	varies, but is generally in the range of 20 to 80 people.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Phase II: refers to controlled clinical trials conducted to evaluate appropriate dosage and the effectiveness of a drug for a particular indication or indications in patients with a disease or condition under study and
	to determine the common short-term side effects and risks associated with the drug. These trials are typically well-controlled, closely monitored and conducted in a relatively small number of patients, usually involving no more than several hundred
	subjects.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Phase III: refers to expanded controlled and uncontrolled clinical trials. These trials are performed after preliminary evidence suggesting effectiveness of a drug has been obtained. Phase III trials are intended to
	gather additional information about the effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. Phase III trials usually include several hundred
	to several thousand subjects.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Phase I, II and III testing may not be completed successfully within any specified time
	period, if at all. The FDA closely monitors the progress of each of the three phases of clinical trials that are conducted in the U.S. and may, at its discretion, reevaluate, alter, suspend or terminate the testing based upon the data accumulated to
	that point and the FDA&#146;s assessment of the risk/benefit ratio to the patient. A clinical program is designed after assessing the causes of the disease, the mechanism of action of the active pharmaceutical ingredient of the drug and all clinical
	and pre-clinical data of previous trials performed. Typically, the trial design protocols and efficacy endpoints are established in consultation with the FDA. Upon request through a special protocol assessment, the FDA can also provide specific
	guidance on the acceptability of protocol design for clinical trials. The FDA, we or our partners may suspend or terminate clinical trials at any time for various reasons, including a finding that the subjects or patients are being exposed to an
	unacceptable health risk. The FDA can also request additional clinical trials be conducted as a condition to drug approval. During all clinical trials, physicians monitor the patients to determine effectiveness and to observe and report any
	reactions or other safety risks that may result from use of the drug.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	8
</P>
<A NAME="eolPage11"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Assuming successful completion of the required clinical trials, drug developers submit the
	results of pre-clinical studies and clinical trials, together with other detailed information including information on the manufacture and composition of the drug, to the FDA, in the form of an NDA, requesting approval to market the drug for one or
	more indications. In most cases, the NDA must be accompanied by a substantial user fee. The FDA reviews an NDA to determine, among other things, whether a drug is safe and effective for its intended use.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Before approving an NDA, the FDA will inspect the facility or facilities where the drug is manufactured. The FDA will not approve the
	application unless cGMP compliance is satisfactory. The FDA will issue an approval letter if it determines that the application, manufacturing process and manufacturing facilities are acceptable. If the FDA determines that the NDA, manufacturing
	process or manufacturing facilities are not acceptable, it will issue a complete response letter (CRL), in which it will outline the deficiencies in the submission and will often request additional testing or information. Notwithstanding the
	submission of any requested additional information, the FDA may ultimately decide that the NDA does not satisfy the regulatory criteria for approval and refuse to approve the NDA.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The testing and approval process requires substantial time, effort and financial resources, and each may take several years to complete. The
	FDA may not grant approval on a timely basis, or at all. We or our partners may encounter difficulties or unanticipated costs in our efforts to secure necessary governmental approvals, which could delay or preclude us or our partners from marketing
	our products. Furthermore, the FDA may prevent a drug developer from marketing a drug under a label for its desired indications or place other conditions on distribution as a condition of any approvals, which may impair commercialization of the
	drug. After approval, some types of changes to the approved drug, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further FDA review and approval. Similar regulatory procedures must also be
	complied within countries outside the U.S.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If the FDA approves the NDA, the drug becomes available for physicians to prescribe in the
	U.S. After approval of our products, we have to comply with a number of post-approval requirements, including delivering periodic reports to the FDA, submitting descriptions of any adverse reactions reported, and complying with drug sampling and
	distribution requirements. We and our partners also are required to provide updated safety and efficacy information and to comply with requirements concerning advertising and promotional labeling. Also, our quality control and manufacturing
	procedures must continue to conform to cGMP after approval. Drug manufacturers and their subcontractors are required to register their facilities and are subject to periodic unannounced inspections by the FDA to assess compliance with cGMP which
	imposes certain procedural and documentation requirements relating to quality assurance and quality control. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain
	compliance with cGMP and other aspects of regulatory compliance. The FDA may require post market testing and surveillance to monitor the drug&#146;s safety or efficacy, including additional studies, known as Phase IV trials, to evaluate long-term
	effects.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition to studies requested by the FDA after approval, we or our partners may have to conduct other trials and studies to
	explore use of the approved product for treatment of new indications, which require FDA approval. The purpose of these trials and studies is to broaden the application and use of the product and its acceptance in the medical community.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We use, and will continue to use, third-party manufacturers to produce our products in clinical and commercial quantities. Future FDA
	inspections may identify compliance issues at our facilities or at the facilities of our contract manufacturers that may disrupt production or distribution, or require substantial resources to correct. In addition, discovery of problems with a
	product or the failure to comply with requirements may result in restrictions on a product, manufacturer or holder of an approved NDA, including withdrawal or recall of the product from the market or other voluntary or FDA-initiated action that
	could delay further marketing. Newly discovered or developed safety or effectiveness data may require changes to a product&#146;s approved labeling, including the addition of new warnings and contraindications.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In September 2007, the Food and Drug Administration Amendments Act (FDAAA), was enacted into law, amending the U.S. Federal Food, Drug, and
	Cosmetic Act and the Public Health Service Act. The FDAAA made a number of substantive and incremental changes to the review and approval processes in ways that could make it more difficult or costly to obtain approval for new pharmaceutical
	products, or to produce, market and distribute existing pharmaceutical products. Most significantly, the law changed the FDA&#146;s handling of postmarked drug product safety issues by giving the FDA authority to require post approval studies or
	clinical trials, to request that safety information be provided in labeling, or to require an NDA applicant to submit and execute a Risk Evaluation and Mitigation Strategy (REMS).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The FDAAA made certain changes to the user fee provisions to permit the use of user fee revenue to fund the FDA&#146;s drug product safety
	activities and the review of Direct-to-Consumer advertisements. The Food and Drug Administration Safety and Innovation Act of 2012, which became effective in October 2012, reauthorized the authority of the FDA to collect user fees to fund the
	FDA&#146;s review activities.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, new government requirements may be established that could delay or prevent regulatory approval
	of our products under development.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	9
</P>
<A NAME="eolPage12"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	The Hatch-Waxman Act
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent with claims that cover the
	applicant&#146;s drug. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#146;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs
	listed in the Orange Book can, in turn be cited by potential competitors in support of approval of an abbreviated new drug application (ANDA). An ANDA provides for marketing of a drug that has the same active ingredients in the same strengths and
	dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. ANDA applicants are not required to conduct or submit results of pre-clinical or clinical tests to prove the safety
	or effectiveness of their drug, other than the requirement for bioequivalence testing. Drugs approved in this way are commonly referred to as &#147;generic equivalents&#148; to the listed drug, and can often be substituted by pharmacists under
	prescriptions written for the original listed drug.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The ANDA applicant is required to certify to the FDA concerning any patents listed
	for the approved drug in the FDA&#146;s Orange Book. Specifically, the applicant must certify that: (i)&nbsp;the required patent information has not been filed; (ii)&nbsp;the listed patent has expired; (iii)&nbsp;the listed patent has not expired,
	but will expire on a particular date and approval is sought after patent expiration; or (iv)&nbsp;the listed patent is invalid or will not be infringed by the new drug. A certification that the new drug will not infringe the already approved
	drug&#146;s listed patents or that such patents are invalid is called a Paragraph IV certification. If the applicant does not challenge the listed patents, the ANDA application will not be approved until all the listed patents claiming the
	referenced drug have expired.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If the ANDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send
	notice of the Paragraph&nbsp;IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph
	IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement
	of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The ANDA application also will not be
	approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced drug has expired. The U.S. Drug Price Competition and Patent Term Restoration Act of 1984,
	more commonly known as the &#147;Hatch-Waxman Act,&#148; provides a period of five years following approval of a drug containing no previously approved active ingredients, during which ANDAs for generic versions of those drugs cannot be submitted
	unless the submission contains a Paragraph IV challenge to a listed patent, in which case the submission may be made four years following the original drug approval. Federal law provides for a period of three years of exclusivity following approval
	of a listed drug that contains previously approved active ingredients but is approved in a new dosage form, route of administration or combination, or for a new use, the approval of which was required to be supported by new clinical trials conducted
	by or for the sponsor, during which FDA cannot grant effective approval of an ANDA based on that listed drug.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Foreign regulation
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Whether or not we or our partners obtain FDA approval for a product, we must obtain approval by the comparable regulatory
	authorities of foreign countries before we can commence clinical trials or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval.
	The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement also vary greatly from country to country. Although governed by the applicable country, clinical trials conducted outside of the U.S. typically
	are administered with the three-Phase sequential process that is discussed above under &#147;United States government regulation.&#148; However, the foreign equivalent of an IND is not a prerequisite to performing pilot studies or Phase I clinical
	trials.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Under European Union regulatory systems, we may submit MAAs either under a centralized or decentralized procedure. The
	centralized procedure, which is available for drugs produced by biotechnology or which are highly innovative, provides for the grant of a single marketing authorization that is valid for all European Union member states. This authorization is a
	marketing authorization approval. The decentralized procedure provides for mutual recognition of national approval decisions. Under this procedure, the holder of a national marketing authorization may submit an application to the remaining member
	states. Within 90 days of receiving the applications and assessment report, each member state must decide whether to recognize approval. This procedure is referred to as the mutual recognition procedure.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, regulatory approval of prices is required in most countries other than the U.S. We face the risk that the resulting prices would
	be insufficient to generate an acceptable return to us or our partners.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Patents and proprietary rights; Hatch-Waxman protection
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We and our partners will be able to protect our products from unauthorized use by third parties only to the extent that our products are
	covered by valid and enforceable patents, either licensed in from third parties or generated internally, that give us or our partners sufficient proprietary rights. Accordingly, patents and other proprietary rights are essential elements of our
	business.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	,
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, tradipitant and AQW051 are covered by new chemical entity and other patents and patent applications. The patents cover the active pharmaceutical ingredient and provide patent
	protection for all formulations containing these active
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	10
</P>
<A NAME="eolPage13"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	pharmaceutical ingredients. For more on these license and sublicense arrangements, see
<I>
	License Agreements
</I>
	above. In addition, we have generated our own intellectual property, and filed
	patent applications covering this intellectual property, for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The table below is a summary of FDA&#146;s Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) listed patents for
	our commercial products. Members of these patent families are also issued or pending in a number of major market territories, such as Europe and Japan.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_6"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="57%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Number
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Type
</B>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	US&nbsp;5,856,529
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	NCE
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	US 8,785,492
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Method&nbsp;of&nbsp;treatment
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	US 9,060,995
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Method&nbsp;of&nbsp;treatment
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	US 9,539,234
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Method&nbsp;of&nbsp;treatment
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT SIZE="1">
	&nbsp;
</FONT>
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000" ALIGN="RIGHT">
	US 9,549,913
</TD>
<TD NOWRAP VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	Method&nbsp;of&nbsp;treatment
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="4">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	US 8,586,610
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Method&nbsp;of&nbsp;treatment
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	US 8,652,776
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Method&nbsp;of&nbsp;treatment
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	US 8,999,638
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Method&nbsp;of&nbsp;treatment
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	US 9,072,742
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Method&nbsp;of&nbsp;treatment
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	US 9,074,254
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Method&nbsp;of&nbsp;treatment
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	US 9,074,255
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Method&nbsp;of&nbsp;treatment
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	US 9,074,256
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Method&nbsp;of&nbsp;treatment
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	US 9,138,432
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Method&nbsp;of&nbsp;treatment
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	US 9,157,121
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	Method&nbsp;of&nbsp;treatment
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	HETLIOZ
</I>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<I>
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our rights to the new chemical entity patent covering HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and related
	intellectual property have been acquired through a license with BMS. HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and its formulations, genetic markers and uses are covered by a total of 14 patent and patent application families
	worldwide. The primary new chemical entity patent covering HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	expires normally in 2017 in the U.S. and in most European markets. The &#147;Hatch-Waxman Act&#148; provides for an
	extension of new chemical entity patents for a period of up to five years following the expiration of the patent covering that compound to compensate for time spent in development. We believe that
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	will meet the various criteria of the Hatch-Waxman Act and will receive five additional years of patent protection in the U.S., which would extend its new chemical entity patent
	protection in the U.S. until 2022. An application for the five year patent term extension has been filed and is being processed by the U.S. Patent and Trademark Office. In July 2014, a new method of use patent was issued to us by the U.S. Patent and
	Trademark Office for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the treatment of Non-24. This method of use patent is expected to expire in 2033, potentially further extending the exclusivity protection of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. In June 2015, an additional method of use patent was issued to us by the U.S. Patent and Trademark Office for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. This method of
	use patent is also expected to expire in 2033. Both the new chemical entity patent and the method of use patents are listed in the FDA&#146;s Orange Book.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In Europe, the law provides for ten years of data exclusivity (with the potential for an additional year if the drug is developed for a
	significant new indication). As such, in Europe, data exclusivity will protect HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for at least ten years from approval. A&nbsp;completed Pediatric Investigation Plan could further extend
	this exclusivity for two years in an orphan indication, for a total of 12&nbsp;years of exclusivity. It is also possible that the term of the new chemical entity patent in Europe could be extended by issuance of a&nbsp;supplementary protection
	certificate (SPC). The European Patent Office has granted our patent application directed to the 20&nbsp;mg/day dose. This patent will expire normally in 2027. Patent applications directed to the treatment of Non-24, if granted, would provide
	exclusivity in Europe for this indication until at least 2033.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Outside the U.S. and Europe, data exclusivity will protect HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	from generic competition for varying numbers of years depending on the country.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Additional patent applications directed to specific sleep disorders and to methods of treating patients with HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, if issued, would provide exclusivity for such indications and methods of treatment, potentially extending the effective patent protection period in the U.S., Europe, and other major markets.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The new chemical entity patent for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, which expired in 2016, is owned by Sanofi,
	and other patents and patent applications relating to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	previously owned by Novartis are now owned by Vanda. We originally obtained exclusive worldwide rights to develop and
	commercialize the products covered by these patents through license and sublicense arrangements. Then, pursuant to an amended sublicense agreement with Novartis, Novartis retained exclusive commercialization rights to all formulations of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and Canada. However, as of December 2014, pursuant to an asset transfer agreement, we acquired all rights in Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	,
	including in the U.S. and Canada.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and its metabolites, formulations,
	genetic markers and uses are covered by a total of 17 patent and patent application families in the U.S., Europe, and other markets. The primary new chemical entity patent covering Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	expired in November 2016
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	11
</P>
<A NAME="eolPage14"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	in the U.S. and expired in 2010 in major markets outside the U.S. In November 2013, a patent directed to a method of treating patients with
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	based on genotype was issued to us by the U.S. Patent and Trademark Office. This patent, which was listed in the FDA&#146;s Orange Book in January 2015, is set to expire in 2027,
	potentially further extending the exclusivity protection of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. Additional method of treatment patents were issued and listed in the Orange Book with the latest expected expiry in
	December 2031. See Note 18,
<I>
	Legal Matters
</I>
	, to the consolidated financial statements included in Part II of this annual report on Form 10-K for additional information.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In Europe, the law provides for ten years of data exclusivity (with the potential for an additional year if the drug is developed for a
	significant new indication). No generic versions of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	would be permitted to be marketed or sold during this 10-year (or
<FONT STYLE="WHITE-SPACE:NOWRAP">
	11-year)
</FONT>
	period in most
	European countries. Consequently, we expect our rights to commercialize Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	will be exclusive for at least 10 years from approval in Europe. Outside the U.S. and Europe, data exclusivity
	will protect Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	from generic competition for varying numbers of years depending upon the country. Several other patent applications covering metabolites, uses, formulations and genetic
	markers relating to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	extend beyond 2020. The patent family for the microsphere depot formulation of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	&nbsp;expires in 2024
	in the U.S. and 2022 in most of the major markets in Europe. The patent family for the aqueous microcrystals depot formulation of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	&nbsp;expires in 2023 in the U.S. and in most of the
	major markets in Europe.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Tradipitant
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Lilly owns a new chemical entity patent as well as patent applications directed to polymorphic forms of, and methods of making tradipitant.
	Thus, tradipitant is covered by a total of three patent and patent application families worldwide, which have been licensed to us. The new chemical entity patent covering tradipitant expires in 2023, except in the U.S., where it expires normally in
	2024 subject to any extension that may be received under Hatch-Waxman. We have filed additional patent applications based on discoveries made during recent studies with tradipitant.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	AQW051
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Novartis owns a
	new chemical entity patent as well as patent applications directed to methods of using AQW051, AQW051 formulations, and combinations of AQW051 with other active pharmaceutical ingredients. The new chemical entity patent expires normally in 2023 in
	the U.S., Europe, and other markets.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Trichostatin A
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Trichostatin A is a small molecule HDAC inhibitor with potential use as a treatment for several oncology indications. We have pending patent
	applications covering the use of Trichostatin A and plan on filing additional applications based on discoveries made throughout the development plan of this molecule.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Other Patents
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Aside from
	the new chemical entity patents and other in-licensed patents relating to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, tradipitant, and AQW051, we have numerous
	patent and patent application families, most of which have been filed in key markets including the U.S., relating to our products and development compounds. In addition, we have several other patent application families relating to drugs not
	presently in clinical studies. The claims in these various patents and patent applications are directed to compositions of matter, including claims covering other products, pharmaceutical compositions and methods of use.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Proprietary Know-how
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	For
	proprietary know-how that is not appropriate for patent protection, processes for which patents are difficult to enforce and any other elements of our discovery process that involve proprietary know-how and technology that are not covered by patent
	applications, we generally rely on trade secret protection and confidentiality agreements to protect our interests. We require all of our employees, consultants and advisors to enter into confidentiality agreements. Where it is necessary to share
	our proprietary information or data with outside parties, our policy is to make available only that information and data required to accomplish the desired purpose and only pursuant to a duty of confidentiality on the part of those parties.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Third-Party Reimbursement and Pricing Controls
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act of 2010 (together,
	PPACA), has changed and is expected to further significantly change the way healthcare is financed by both governmental and private insurers. The provisions of PPACA became effective over various periods from 2010 through 2014.&nbsp;We cannot
	predict the complete impact of PPACA on pharmaceutical companies because many of PPACA&#146;s reforms require the promulgation of detailed regulations to implement the statutory provisions, which has not yet occurred. While we cannot predict the
	complete impact on federal reimbursement policies this law will have in general or specifically on any product we commercialize, PPACA may result in downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance
	of new products.&nbsp;The rebates, discounts, taxes and other costs resulting from PPACA may have a significant effect on our profitability in the future. In addition, potential reductions of the per capita rate of growth in Medicare spending under
	PPACA, could potentially limit access to certain treatments or mandate price controls for our products. Moreover, although the United States Supreme Court has upheld the constitutionality of most of PPACA, some states have indicated that they intend
	not to implement certain sections of PPACA, and some members of the U.S. Congress are still working to repeal PPACA. We cannot predict whether these challenges will continue or other proposals will be made or adopted, or what impact these efforts
	may have on us or our partners.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	12
</P>
<A NAME="eolPage15"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In the U.S. and elsewhere, sales of pharmaceutical products depend in significant part on the
	availability of reimbursement to the consumer from third-party payors, such as government and private insurance plans. Third-party payors are increasingly challenging the prices charged for medical products and services. It will be time consuming
	and expensive for us or our partners to go through the process of seeking reimbursement from Medicare and private payors. Our products may not be considered cost-effective, and coverage and reimbursement may not be available or sufficient to allow
	us or our partners to sell our compounds on a competitive and profitable basis. The passage of the Medicare Prescription Drug and Modernization Act of 2003 imposes additional requirements for the distribution and pricing of prescription drugs which
	may affect the marketing of our products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In many foreign markets, including the countries in the European Union and Japan, pricing of
	pharmaceutical products is subject to governmental control. In the U.S., there have been, and we expect that there will continue to be, a number of federal and state proposals to implement similar governmental pricing control. While we cannot
	predict whether such legislative or regulatory proposals will be adopted, the adoption of such proposals could have a material adverse effect on our business, financial condition and profitability.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Marketing and Sales
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was approved in the U.S. for the treatment of Non-24 in January 2014 and commercially launched in the U.S. in April 2014. Additionally,
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was approved in the Europe Union for the treatment of Non-24 in July 2015. We commercially launched HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Germany in the
	third quarter of 2016.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Given the range of potential indications for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, we
	may pursue one or more partnerships for the development and commercialization of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	worldwide.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was approved in the U.S. for the treatment of schizophrenia in May 2009 and
	commercially launched in the U.S. in January 2010. In October 2009, we entered into an amended and restated sublicense agreement with Novartis pursuant to which Novartis has exclusive commercialization rights to all formulations of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and Canada. Novartis began selling Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. during the first quarter of 2010. Pursuant to the terms of the
	Settlement Agreement with Novartis, Novartis transferred all U.S. and Canadian rights in the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	franchise to Vanda on December&nbsp;31, 2014.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was launched in Israel and Mexico by our distribution partners in 2014. We
	continue to explore the regulatory path and commercial opportunity for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	oral formulation in other regions.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Manufacturing
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We currently utilize a
	virtual supply manufacturing and distribution chain in which we do not have our own facilities to manufacture commercial or clinical trial supplies of drugs and we do not have our own distribution facilities. Additionally, we do not intend to
	develop such facilities for any product in the near future. Instead, we contract with third parties for the manufacture, warehousing, order management, billing and collection and distribution of our products and product candidates.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We expect to continue to rely solely on third-party manufacturers to manufacture drug substance and final drug products for both clinical
	development and commercial sale. However, there are numerous factors that could cause interruptions in the supply of our products, including regulatory reviews, changes in our sources for manufacturing, disputes with a manufacturer, or financial
	instability of manufacturers, all of which could negatively impact our operation and our financial results.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In January 2014, we entered
	into a manufacturing agreement with Patheon Pharmaceuticals Inc. (Patheon) for the manufacture of commercial supplies of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	20 mg capsules at Patheon&#146;s Cincinnati, Ohio
	manufacturing site. Under the HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	manufacturing agreement, we are responsible for supplying the active pharmaceutical ingredient for
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	to Patheon and have agreed to certain minimum yearly order requirements. Patheon is responsible for manufacturing the HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	20 mg capsules, conducting quality control and stability testing, and packaging the HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	capsules. The HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	manufacturing
	agreement has an initial term of five years and will automatically renew after the initial term for successive terms of one year each, unless either party gives notice of its intention to terminate the agreement at least twelve months prior to the
	end of the then current term. Either party may terminate the HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	manufacturing agreement under certain circumstances upon specified written notice to the other party.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As part of the Settlement Agreement, we assumed Novartis&#146; manufacturing agreement with Patheon for the manufacture of commercial supplies
	of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	In May 2016, we entered into a new manufacturing agreement with Patheon for the manufacture of commercial supplies of
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	1, 2, 4, 6, 8, 10 and 12 mg tablets at Patheon&#146;s Mississauga, Ontario, Canada manufacturing site. Under the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	manufacturing agreement, we are responsible for sourcing the supply of the active pharmaceutical ingredient (iloperidone), and have agreed to order from Patheon at least 70% of the total yearly requirement of new units of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	tables for the U.S. and other specified countries each year for the term of the agreement. The Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	manufacturing agreement has an
	initial term of five years and will automatically renew after the initial term for successive terms of one year each, unless either party gives notice of its intention to terminate the agreement at least twelve months prior to the end of the then
	current term. Either party may terminate the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	manufacturing agreement under certain circumstances upon specified written notice to the other party.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	13
</P>
<A NAME="eolPage16"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Research and Development
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have built a research and development organization that includes extensive expertise in the scientific disciplines of pharmacogenetics and
	pharmacogenomics. We operate cross-functionally and are led by an experienced research and development management team. We use rigorous project management techniques to assist us in making disciplined strategic research and development program
	decisions and to help limit the risk profile of our product pipeline. We also access relevant market information and key opinion leaders in creating target product profiles and, when appropriate, as we advance our programs towards commercialization.
	We engage third parties to conduct portions of our preclinical research. In addition, we utilize multiple clinical sites to conduct our clinical trials; however, we are not substantially dependent upon any one of these sites for our clinical trials
	nor do any of them conduct a major portion of our clinical trials.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development expenses amounted to $29.2 million, $29.1
	million and $19.2 million for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Major Customers
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our revenues are generated from product sales and are concentrated with specialty pharmacies and wholesalers. There were five major customers
	that each accounted for more than 10% of total revenues and, as a group, represented 86% of total revenues for the year ended December&nbsp;31, 2016.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Competition
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The pharmaceutical industry
	and the central nervous system segment of that industry, in particular, is highly competitive and includes a number of established large and mid-sized companies with greater financial, technical and personnel resources than we have and significantly
	greater commercial infrastructures than we have. Our market segment also includes several smaller emerging companies whose activities are directly focused on our target markets and areas of expertise. Our products, once approved for commercial use,
	will compete with numerous therapeutic treatments offered by these competitors. While we believe that our products will have certain favorable features, existing and new treatments may also possess advantages. Additionally, the development of other
	drug technologies and methods of disease prevention are occurring at a rapid pace. These developments may render our products or technologies obsolete or noncompetitive.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We believe the primary competitors for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	are as follows:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	For HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the treatment of Non-24, there are no FDA approved direct competitors. Sedative-Hypnotic treatments for certain sleep related disorders include,
	Ambien
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(zolpidem) by Sanofi (including Ambien CR
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	), Lunesta
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(eszopiclone) by
	Sunovion Pharmaceuticals Inc., Sonata
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(zaleplon) by Pfizer Inc., Rozerem
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(ramelteon) by Takeda Pharmaceuticals Company Limited,
	Silenor
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(doxepin) by Pernix Therapeutics, Belsomra
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(suvorexant) by Merck&nbsp;&amp; Co., Inc., generic products such as zolpidem,
	trazodone and doxepin, and over-the-counter remedies such as Benadryl
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Tylenol PM
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. The class of melatonin agonists includes
	Rozerem
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(ramelteon) by Takeda Pharmaceuticals Company Limited, Valdoxan
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(agemelatine) by Servier, Circadin
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(long-acting melatonin) by Neurim Pharmaceuticals and the food supplement melatonin. Shift work and excessive sleepiness disorder treatments include Nuvigil
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(armodafinil) and Provigil
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(modafinil) both by Teva Pharmaceutical Industries Ltd.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	For Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the treatment of schizophrenia, the atypical antipsychotics competitors are Risperdal
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(risperidone), including the depot formulation Risperdal
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	Consta
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Invega
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(paliperidone), including the depot formulation Invega
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	Sustenna
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, each by Ortho-McNeil-Janssen Pharmaceuticals, Inc., Zyprexa
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(olanzapine), including the depot formulation Zyprexa
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	Relprevv&#153;, each by Eli Lilly and Company, Seroquel
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Seroquel XR (quetiapine) by AstraZeneca PLC, Abilify
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(aripiprazole) by BMS/Otsuka America Pharmaceutical Inc., Abilify
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	Maintena
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(the depot formulation of Abilify
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	) by Lundbeck/Otsuka America
	Pharmaceutical Inc., Geodon
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(ziprasidone) by Pfizer Inc., Saphris
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(asenapine) by Actavis plc, Latuda
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(lurasidone) by Sunovion Pharmaceuticals Inc., Rexulti
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(brexpiprazole) by Lundbeck/Otsuka America Pharmaceutical, Inc., Aristada&#153;
	(aripiprazole lauroxil) extended-release injectible suspension by Alkermes, Inc., Vraylar&#153; (cariprazine) by Teva Pharmaceutical Industries Ltd., and generic clozapine, as well as the typical antipsychotics haloperidol, chlorpromazine,
	thioridazine, and sulpiride (all of which are generic).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our ability to compete successfully will depend in part on our
	ability to utilize our pharmacogenetics and pharmacogenomics and drug development expertise to identify, develop, secure rights to and obtain regulatory approvals for promising pharmaceutical products before others are able to develop competitive
	products. Our ability to compete successfully will also depend on our ability to attract and retain skilled and experienced personnel. Additionally, our ability to compete may be affected because insurers and other third-party payors in some cases
	seek to encourage the use of cheaper, generic products, which could make our products less attractive.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	14
</P>
<A NAME="eolPage17"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Employees
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We had 142 full-time employees as of December&nbsp;31, 2016, compared with 118 employees as of December&nbsp;31, 2015. None of our employees
	are represented by a labor union. We have not experienced any work stoppages and consider our employee relations to be good.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Corporate Information
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We were incorporated in Delaware in 2002. Our principal executive offices are located at 2200 Pennsylvania Avenue NW, Suite 300E,
	Washington D.C. 20037, and our telephone number is (202)&nbsp;734-3400. Our website address is www.vandapharma.com and the information contained in, or that can be accessed through, our website is not part of this annual report and should not be
	considered part of this annual report.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Available Information
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We file annual, quarterly, and current reports, proxy statements, and other documents with the Securities and Exchange Commission (SEC) under
	the Securities Exchange Act of 1934 (the Exchange Act). The public may read and copy any materials that we file with the SEC at the SEC&#146;s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. The public may obtain information on
	the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. Also, the SEC maintains an internet website at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers, including
	us, that file electronically with the SEC.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We also make available free of charge on our Internet website at www.vandapharma.com our
	annual reports on
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Form&nbsp;10-K,
</FONT>
	quarterly reports on Form 10-Q, current reports on Form 8-K, and, if applicable, amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the
	Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our code of
	ethics, other corporate policies and procedures, and the charters of our Audit Committee, Compensation Committee and Nominating/Corporate Governance Committee are available through our Internet website at www.vandapharma.com.
</P>
</EFX_BUSINESS>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_RISK_FACTORS>
<A NAME="FIS_RISK_FACTORS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_3">
</A>
	ITEM&nbsp;1A.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	RISK FACTORS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Our business, financial condition and operating results can be affected
	by a number of factors, whether current known or unknown, including but not limited to those described below, any one or more of which could, directly or indirectly, cause our actual operating results and financial condition to vary materially from
	past, or anticipated future, operating results and financial condition. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, operating results and the price of our common stock.
</I>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	The following discussion of risk factors contains forward-looking statements. These risk factors may be important to understanding any
	statement in this annual report on Form 10-K or elsewhere. The following information should be read in conjunction with the consolidated financial statements and related notes in Part I, Item&nbsp;1, Financial Statements and Part I, Item&nbsp;2,
	Management&#146;s, Discussion and Analysis of Financial Condition and Results of Operations.
</I>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Because of the following factors, as
	well as other factors affecting our financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results
	or trends in future periods.
</I>
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Risks related to our business and industry
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We are dependent on the commercial success of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our future success is currently substantially dependent upon the commercial
	success of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for the treatment of
<FONT STYLE="WHITE-SPACE:NOWRAP">
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Non-24-Hour
</FONT>
</FONT>
	Sleep-Wake Disorder (Non-24) and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for the treatment of schizophrenia.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In January 2014, the FDA approved our New Drug
	Application (NDA) for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for the treatment of Non-24 and in April 2014, we commenced the U.S. commercial launch of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. In
	July 2015, the European Commission (EC) granted centralized marketing authorization with unified labeling for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for the treatment of Non-24 in blind adults, and in August 2016 we
	commenced the commercial launch of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Germany. This authorization is valid in the 28 countries that are members of the European Union, as well as European Economic Area members
	Iceland, Liechtenstein and Norway.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In the first quarter of 2015, we acquired the U.S. commercial rights to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, and began selling, marketing and distributing Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our ability to generate significant product revenue from sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, both in the U.S. and abroad, in the near term will depend on, among other things, our ability to:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	defend our patents and intellectual property from generic competition;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	maintain commercial manufacturing arrangements with third-party manufacturers;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	15
</P>
<A NAME="eolPage18"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	produce, through a validated process, sufficiently large quantities of inventory of our products to meet demand;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	continue to maintain and grow a wide variety of internal sales, distribution and marketing capabilities sufficient to sustain growth in sales of our products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	gain broad acceptance of our products from physicians, health care payors, patients, pharmacists and the medical community;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	properly price and obtain adequate coverage and reimbursement of these products by governmental authorities, private health insurers, managed care organizations and other third-party payors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	maintain compliance with ongoing FDA labeling, packaging, storage, advertising, promotion, recordkeeping, safety and other post-market requirements;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	obtain approval from the FDA to expand the labeling of our approved products for additional indications;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	obtain regulatory approval for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	or Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in additional countries;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	adequately protect against and effectively respond to any claims by holders of patents and other intellectual property rights that our products infringe their rights; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	adequately protect against and effectively respond to any unanticipated adverse effects or unfavorable publicity that develops in respect to our products, as well as the emergence of new or existing competitive
	products, which may be proven to be more clinically effective and cost-effective.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We expect to continue to incur
	significant expenses and to utilize a substantial portion of our cash resources as we continue the commercialization of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, evaluate foreign market opportunities for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and
	continue to grow our operational capabilities, both domestically and abroad. This activity represents a significant investment in the commercial success of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, which is uncertain.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If our continued commercial efforts are not successful with
	respect to HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S., Europe or other jurisdictions in which these products may be approved for sale, our
	ability to generate increased product sales revenue may be jeopardized and, consequently, our business may be seriously harmed.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The cost
	of growing and maintaining a sales, marketing and distribution organization may exceed its cost effectiveness. If we fail to continue to develop sales, marketing and distribution capabilities, if sales efforts are not effective or if costs of
	developing sales, marketing and distribution capabilities exceed their cost effectiveness, our business, results of operations and financial condition could be materially adversely affected.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Continued growth of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	may be slow or limited for a variety of reasons including competing products or unanticipated safety issues. If either HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	or Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is not successful in gaining broad commercial acceptance, our business would be harmed.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Any increase in sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	will be dependent on several factors, including our ability to educate physicians and to increase physician awareness of the benefits and cost-effectiveness of our products relative to competing
	products. The degree of further market acceptance of any of our products or market acceptance of approved product candidates among physicians, patients, health care payors and the medical community will depend on a number of factors, including:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	acceptable evidence of safety and efficacy;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	relative convenience and ease of administration;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the prevalence and severity of any adverse side effects;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	availability of alternative treatments; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	pricing and cost effectiveness.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	are subject to continual review by the FDA, and we cannot assure that newly discovered or reported safety issues will not
	arise. With the use of any newly marketed drug by a wider patient population, serious adverse events may occur from time to time that initially do not appear to relate to the drug itself. Any safety issues could cause us to suspend or cease
	marketing of our approved products, cause us to modify how we market our approved products, subject us to substantial liabilities and adversely affect our revenues and financial condition. In the event of a withdrawal of either HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	or Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	from the market, our revenues would decline significantly and our business would be seriously harmed.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We may enter into third party collaborations from time to time in order to commercialize our products. If we are unable to identify or
	enter into an agreement with any material third-party collaborator, if our collaborations with any such third-party are not commercially successful or if our agreement with any such third-party is terminated or allowed to expire, we could be
	adversely affected financially or our business reputation could be harmed.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	16
</P>
<A NAME="eolPage19"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our business strategy includes entering into collaborations with corporate collaborators for the
	commercialization of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and our other products. Areas in which we may potentially enter into third-party collaboration
	arrangements include joint sales and marketing arrangements for sales and marketing in certain European Union countries and elsewhere outside of the U.S., and future product development arrangements. If we are unable to identify or enter into an
	agreement with any material third-party collaborator, this could result in an adverse effect on our business, results of operations or financial condition. Any arrangements we do enter into may not be scientifically or commercially successful. The
	termination of any of these arrangements might adversely affect our ability to develop, commercialize and market our products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The
	success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Our collaborators will have significant discretion in determining the efforts and resources that they will apply to these
	collaborations. We expect that the risks which we face in connection with these future collaborations will include the following:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our collaboration agreements are expected to be for fixed terms and subject to termination under various circumstances, including, in many cases, on short notice without cause;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our collaborators may develop and commercialize, either alone or with others, products and services that are similar to or competitive with our products which are the subject of their collaboration with us; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our collaborators may change the focus of their commercialization efforts.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In recent years
	there have been a significant number of mergers and consolidations in the pharmaceutical and biotechnology industries, some of which have resulted in the participant companies reevaluating and shifting the focus of their business following the
	completion of these transactions. The ability of our products to reach their potential could be limited if any of our future collaborators decreases or fails to increase spending relating to such products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Collaborations with pharmaceutical companies and other third-parties often are terminated or allowed to expire by the other party. With
	respect to our future collaborations, any such termination or expiration could adversely affect us financially as well as harm our business reputation.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Even after we or our partners obtain regulatory approvals of a product, acceptance of the product in the marketplace is uncertain and
	failure to achieve commercial acceptance will prevent or delay our ability to generate significant revenue from such product.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Even
	after obtaining regulatory approvals for the sale of our products, the commercial success of these products will depend, among other things, on their acceptance by physicians, patients, third-party payors and other members of the medical community
	as therapeutic and cost-effective alternatives to competing products and treatments. The degree of market acceptance of any product will depend on a number of factors, including the demonstration of its safety and efficacy, its cost-effectiveness,
	its potential advantages over other therapies, the reimbursement policies of government and third-party payors with respect to such product, our ability to attract and maintain corporate partners, including pharmaceutical companies, to assist in
	commercializing our products, receipt of regulatory clearance of marketing claims for the uses that we or our partners are developing and the effectiveness of our and our partners&#146; marketing and distribution capabilities. If our approved
	products fail to gain market acceptance or do not become widely accepted by physicians, patients, third-party payors and other members of the medical community, it is unlikely that we will ever become profitable on a sustained basis or achieve
	significant revenues.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We rely and will continue to rely on outsourcing arrangements for many of our activities, including clinical
	development and supply of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and our other products.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of December&nbsp;31, 2016, we had 142 full-time employees. We rely on outsourcing arrangements for a significant portion of our activities,
	including distribution, clinical research and development, data collection and analysis and manufacturing, as well as for certain functions as a public company. We may have limited control over these third parties and we cannot guarantee that they
	will perform their obligations in an effective and timely manner.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Disruptions to our HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	or Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	supply chains could materially affect our ability to successfully commercialize HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	or Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, thereby reducing our future earnings and prospects.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A loss or disruption with any one of our manufacturers or suppliers could disrupt the supply of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	or Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, possibly for a significant time period, and we may not have sufficient inventories to maintain supply before the manufacturer
	or supplier could be replaced or the disruption is resolved. In addition, marketed drugs and their contract manufacturing organizations are subject to continual review, including review and approval of their manufacturing facilities and the
	manufacturing processes, which can result in delays in the regulatory approval process and/or commercialization. Introducing a replacement or backup manufacturer or supplier for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	or
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	requires a lengthy regulatory and commercial process and there can be no guarantee that we could obtain necessary regulatory approvals in a timely fashion or at all. In addition, it is
	difficult to identify and select qualified suppliers and manufacturers with the necessary technical capabilities, and establishing new supply and manufacturing sources involves a lengthy and technical engineering process.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Failure to comply with government regulations regarding the sale and marketing of our products could harm our business.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	17
</P>
<A NAME="eolPage20"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our business is subject to extensive government regulation and oversight. As a result, we may
	become subject to governmental actions which could materially and adversely affect our business, results of operations and financial condition, certain of which are described below.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Pharmaceutical Pricing and Reimbursement
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In U.S. markets, our ability and that of our partners to commercialize our products successfully, and to attract commercialization partners for
	our products, depends in significant part on the availability of adequate financial coverage and reimbursement from third-party payors, including, in the U.S., governmental payors such as the Medicare and Medicaid programs, managed care
	organizations, and private health insurers.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We participate in the Medicaid Drug Rebate Program for both HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. Under the Medicaid Drug Rebate Program, we are required to pay a rebate to each state Medicaid program for our covered
	outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having federal funds being made available to the states for our drugs under Medicaid and Medicare Part B. Those rebates are
	based on pricing data that are reported by us on a monthly and quarterly basis to the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS). Federal law requires that any company that participates in the Medicaid Drug Rebate Program also
	participate in the Public Health Service&#146;s 340B drug pricing discount program (the 340B program), in order for federal funds to be available for the manufacturer&#146;s drugs under Medicaid and Medicare Part B. The 340B program requires
	participating manufacturers to agree to charge statutorily-defined covered entities no more than the 340B &#147;ceiling price&#148; for the manufacturer&#146;s covered outpatient drugs. The ceiling price can represent a significant discount and is
	based on the pricing data reporting to the Medicaid Drug Rebate Program.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	PPACA expanded the 340B program to include additional entity
	types: certain free-standing cancer hospitals, critical access hospitals, rural referral centers and sole community hospitals, each as defined by PPACA. PPACA exempts drugs designated under section 526 of the FDC Act as &#147;orphan drugs&#148; from
	the ceiling price requirements for these newly-eligible entities.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	PPACA also obligates HRSA to create regulations and processes to
	improve the integrity of the 340B program and to update the agreement that manufacturers must sign to participate in the 340B program. HRSA issued a final regulation in January of 2017 regarding the calculation of the 340B ceiling price and the
	imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered entities. The final regulation regarding the 340B program include the requirement that a manufacturer calculate the 340B ceiling price on a
	quarterly basis, the requirement that a manufacturer charge $0.01 per unit of measure if the 340B ceiling price calculation results in a ceiling price that equals zero (penny pricing), the methodology manufacturers must use when estimating the
	ceiling price for a new covered outpatient drug, an explanation of how a civil monetary penalty (CMP) would be imposed on a manufacturer that knowingly and intentionally overcharges a covered entity; and an explanation of what would constitute an
	instance of overcharging to trigger a CMP. This final regulation becomes effective March 6, 2017, but recognizing such date is in the middle of a quarter, HRSA plans to begin enforcing the requirements of this final rule at the start of the next
	quarter, which begins April 1, 2017. HRSA recently issued a proposed regulation regarding an administrative dispute resolution process for the 340B program. Any final regulations and guidance could affect our obligations under the 340B program in
	ways we cannot anticipate. In addition, legislation may be introduced that, if passed, would further expand the 340B program to additional covered entities or otherwise expand the 340B program.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Federal law also requires that for a drug manufacturer&#146;s products to be eligible for payment with federal funds under the Medicaid and
	Medicare Part B programs and to be purchased by certain federal agencies and grantees, the manufacturer must participate in the Department of Veterans Affairs Federal Supply Schedule (FSS), pricing program, established by Section&nbsp;603 of the
	Veterans Health Care Act of 1992. Manufacturers that participate in the FSS pricing program must list their covered (innovator) drugs on an FSS contract and charge no more than Federal Ceiling Price (FCP), to the Department of Veterans Affairs,
	Department of Defense, Public Health Service, and Coast Guard when those agencies purchase from the FSS contract or a depot contract. FCP is calculated based on non-federal average manufacturer price data, which manufacturers must submit quarterly
	and annually. In addition, because our products are available in the retail and specialty pharmacy setting, we are required to provide rebates to the Department of Defense for prescriptions dispensed to Tricare beneficiaries from Tricare retail
	network pharmacies under the Tricare Retail Refund Program. These programs obligate the manufacturer to pay rebates and offer its drugs at certain prices to certain federal purchasers. To the extent we choose to participate in these government
	healthcare programs for our current and future products, these and other requirements may affect our ability to profitably sell any product for which we obtain marketing approval.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pricing and rebate calculations vary among products and programs. The calculations are complex and will often be subject to interpretation by
	us, governmental or regulatory agencies and the courts. If we become aware that our reporting of pricing data for a prior quarter was incorrect, we will be obligated to resubmit the corrected data. For the Medicaid Drug Rebate Program, corrected
	data must be submitted for a period not to exceed 12 quarters from the quarter in which the data originally were due. Such restatements and recalculations increase our costs for complying with the laws and regulations governing the Medicaid Drug
	Rebate Program and other governmental pricing programs.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We may be liable for errors associated with our submission of pricing data. If we
	are found to have knowingly submitted false pricing data to the Medicaid program or the FSS pricing program, we may be liable for civil monetary penalties in the amount of up to $100,000 per item of false information. Our failure to submit pricing
	data to the Medicaid program or the FSS pricing program on a timely basis could result in a civil monetary penalty of $10,000 per day for each day the information is late. Such failure also could be grounds for CMS to terminate our Medicaid drug
	rebate agreement, which is the agreement under which we would participate in the Medicaid Drug Rebate Program. In the event that CMS terminates our rebate agreement, federal payments may not be available under Medicaid or Medicare Part B for our
	covered outpatient drugs. We cannot assure you that our submissions will not be found to be incomplete or incorrect.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	18
</P>
<A NAME="eolPage21"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Third-party payors decide which drugs they will pay for and establish reimbursement and co-pay
	levels. Third-party payors are increasingly challenging the prices charged for medical products and services and examining their cost effectiveness, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies
	in order to demonstrate the cost effectiveness of our products. Even with such studies, any of our products that are commercialized may be considered less safe, less effective or less cost-effective than other products, and third-party payors may
	not provide coverage and reimbursement, in whole or in part, for our products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Political, economic and regulatory influences are
	subjecting the healthcare industry in the U.S. to fundamental changes. There have been, and we expect there will continue to be, legislative and regulatory proposals to change the healthcare system and reimbursement systems in ways that could impact
	our ability and that of our partners to profitably sell commercialized products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Payors also are increasingly considering new metrics as
	the basis for reimbursement rates, such as average sales price, average manufacturer price and actual acquisition cost. It is difficult to project the impact of these evolving reimbursement mechanics on the willingness of payors to cover any of our
	products that are commercialized.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, we anticipate that a significant portion of our or our partners&#146; revenue from sales
	of commercialized products will be obtained through government payors, including Medicaid, and any failure to qualify for reimbursement for products we are able to commercialize under those programs would have a material adverse effect on revenues
	and royalties from sales of such products.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Interactions with Healthcare Providers
</I>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Healthcare providers, physicians and others often play a primary role in the recommendation and prescription of pharmaceutical products.
	Manufacturers of branded prescription drugs are subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which manufacturers market,
	sell and distribute the products for which they obtain marketing approval. Some of the laws and regulations that may affect our ability to operate are described below.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Anti-Kickback Laws
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The federal
	Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully offering, paying, soliciting, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward the purchasing, leasing, ordering or
	arranging for the purchase, lease, or order of any health care item or service reimbursable under federal healthcare programs such as Medicare and Medicaid. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value,
	and the government can establish a violation of the Anti-Kickback Statute without proving that a person or entity had actual knowledge of the law or specific intent to violate it. This statute has been interpreted to apply to arrangements between
	pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution or other
	regulatory sanctions, however, the exceptions and safe harbors are drawn narrowly. Failure to meet all of the requirements of a particular statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback
	Statute, but the legality of the arrangement will be evaluated on a case-by-case basis based on the totality of the facts and circumstances. A number of states also have anti-kickback laws that establish similar prohibitions that may apply to items
	or services reimbursed by government programs, as well as any third-party payors, including commercial payors.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	False Claims Act
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The federal civil False Claims Act prohibits, among other things, individuals or entities from knowingly presenting, or causing to be presented
	false or fraudulent claims for payment of government funds and knowingly making, or causing to be made or used, a false record or statement to get a false claim paid. Certain marketing practices may implicate the federal civil False Claims Act,
	including promotion of pharmaceutical products for unapproved uses, providing free product to customers with the expectation that the customer would bill federal programs for the product, or inflating prices report to private price publication
	services used to set drug reimbursement rates under federal healthcare programs. In addition, PPACA amended the Social Security Act to provide that a claim including items or services resulting from a violation of the Anti-Kickback Statute
	constitutes a false or fraudulent claim for purposes of the False Claims Act. Actions under the False Claims Act may be brought by the government or as a qui tam action by a private individual in the name of the government. False Claims Act
	liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties of $5,500 to $11,000 per false claim or statement, which will increase to a range of $10,781 to $21,563 for
	violations after November&nbsp;2, 2015, and assessed after August&nbsp;1, 2016. Because of the potential for large monetary exposure, healthcare companies often resolve allegations without admissions of liability for significant and sometimes
	material amounts to avoid the uncertainty of treble damages and per claim penalties that may awarded in litigation proceedings. They may be required, however, to enter into corporate integrity agreements with the government, which may impose
	substantial costs on companies to ensure compliance. Pharmaceutical companies also are subject to other federal false claim laws, including laws that impose criminal penalties, including imprisonment and criminal fines, for making or presenting a
	false or fictitious or fraudulent claim to the federal government.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	19
</P>
<A NAME="eolPage22"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Health Insurance Portability and Accountability Act
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), created federal criminal statutes that prohibit among other
	actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program,
	willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the
	delivery of or payment for healthcare benefits, items or services.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Physician Payment Sunshine Act
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The federal Physician Payment Sunshine Act requires manufacturers of drugs, devices, biologics and medical supplies for which payment is
	available under Medicare, Medicaid or the Children&#146;s Health Insurance Program to report annually (with certain exceptions) to CMS, information related to payments or other &#147;transfers of value&#148; made to physicians and teaching
	hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to CMS ownership and investment interests held by physicians and their immediate family members and payments or other &#145;&#145;transfers of
	value&#146;&#146; to such physician owners.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Analogous State and Foreign Laws
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The majority of states also have statutes or regulations similar to the federal laws described above, including state anti-kickback and false
	claims laws. These state laws apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payor. In addition, a number of states require pharmaceutical companies to report expenses
	relating to the marketing and promotion of pharmaceutical products and to report gifts and payments to individual physicians in the states. Other states restrict when pharmaceutical companies may provide meals to prescribers or engage in other
	marketing related activities, or require pharmaceutical companies to implement compliance programs or marketing codes of conduct.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Outside
	the U.S., we are subject to similar regulations in those countries where we market and sell products. In some foreign countries, including major markets in the European Union and Japan, the pricing of prescription pharmaceuticals is subject to
	governmental control. In these countries, pricing negotiations with governmental authorities can take nine to twelve months or longer after the receipt of regulatory marketing approval for a product. To obtain reimbursement or pricing approval in
	some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies. Our business could be materially harmed if reimbursement of our products is unavailable or limited in
	scope or amount or if pricing is set at unsatisfactory levels.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Additionally, drug prices are under significant scrutiny, and along with
	other health care costs, continue to be subject to intense political and societal pressures, which we anticipate will continue and escalate, including on a global basis. As a result, our business and reputation may be harmed, our stock price may be
	adversely impacted and experience periods of volatility, and our results of operations may be adversely impacted.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Foreign Corrupt
	Practices Act
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The U.S. Foreign Corrupt Practices Act (FCPA), prohibits U.S. corporations and their representatives and intermediaries from
	offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA includes interactions
	with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Efforts to ensure that business activities and business arrangements comply with applicable healthcare laws and regulations can be costly for
	manufacturers of branded prescription products. If a manufacturer&#146;s operations, including activities conducted by its sales team, are found to be in violation of any of these laws or any other governmental regulations that apply to the company,
	the company may be subject to significant civil, criminal and administrative sanctions, including imprisonment, monetary penalties, damages, fines, exclusion from participation in federal healthcare programs, such as Medicare and Medicaid, and the
	curtailment or restructuring of operations.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We intend to seek regulatory approvals for our products in additional foreign
	jurisdictions, but we may not obtain any such approvals.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We intend to market our products, alone or with others, in foreign
	jurisdictions. In order to market our products in foreign jurisdictions, we or our partners may be required to obtain separate regulatory approvals and to comply with numerous and varying regulatory requirements. The approval procedure varies among
	countries and jurisdictions and can involve additional trials, and the time required to obtain approval may differ from that required to obtain FDA approval. Additionally, the foreign regulatory approval process may include all of the risks
	associated with obtaining FDA approval. For all of these reasons, we or our partners may not obtain foreign regulatory approvals on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	20
</P>
<A NAME="eolPage23"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or jurisdictions or
	by the FDA. We or our partners may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. The failure to obtain these approvals could harm our business materially.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We rely on a limited number of specialty pharmacies for distribution of
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S., and the loss of one or more of these specialty pharmacies or their failure to distribute HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	effectively
	would materially harm our business.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is only available for
	distribution through a limited number of specialty pharmacies in the U.S. A specialty pharmacy is a pharmacy that specializes in the dispensing of medications for complex or chronic conditions, which often require a high level of patient education
	and ongoing management. The use of specialty pharmacies involves certain risks, including, but not limited to, risks that these specialty pharmacies will:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	not provide us accurate or timely information regarding their inventories, the number of patients who are using HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	or complaints about HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	reduce their efforts or discontinue to sell or support or otherwise not effectively sell or support HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	not devote the resources necessary to sell HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the volumes and within the time frames that we expect;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	be unable to satisfy financial obligations to us or others; or
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	cease operations.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, if one or more of our specialty pharmacies do not fulfill
	their contractual obligations to us, or refuse or fail to adequately serve patients, or their agreements are terminated without adequate notice, shipments of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, and associated revenues,
	would be adversely affected. We expect that it would take a significant amount of time if we were required to replace one or more of our specialty pharmacies.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our revenues from Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	are substantially dependent on sales through a
	limited number of wholesalers, and such revenues may fluctuate from quarter to quarter.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We sell Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	primarily through a limited number of pharmaceutical wholesalers in the U.S. The use of pharmaceutical wholesalers involves certain risks, including, but not limited to, risks that these
	pharmaceutical wholesalers will:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	not provide us accurate or timely information regarding their inventories, demand from wholesaler customers buying Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	or complaints about Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	reduce their efforts or discontinue to sell or support or otherwise not effectively sell or support Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	not devote the resources necessary to sell Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the volumes and within the time frames that we expect;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	be unable to satisfy financial obligations to us or others; or
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	cease operations.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Additionally, our reliance on a small number of wholesalers could cause
	revenues to fluctuate from quarter to quarter based on the buying patterns of these wholesalers. In addition, if any of these wholesalers fails to pay on a timely basis or at all, our business, financial condition and results of operations could be
	materially adversely affected.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We face substantial competition, which may result in others developing or commercializing products
	before or more successfully than we do.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our future success will depend on our or our partners&#146; ability to demonstrate and
	maintain a competitive advantage with respect to our products and our ability to identify and develop additional products. Large, fully integrated pharmaceutical companies, either alone or together with collaborative partners, have substantially
	greater financial resources and have significantly greater experience than we do in:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	developing products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	undertaking pre-clinical testing and clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	obtaining FDA and other regulatory approvals of products; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	manufacturing, marketing and selling products.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	These companies may invest heavily and quickly
	to discover and develop novel products that could make our products obsolete. Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA or foreign regulatory approval or commercializing superior products or other
	competing products before we do. Technological developments or the FDA or foreign regulatory approval of new therapeutic indications for existing products may make our products obsolete or may make them more difficult to market successfully, any of
	which could have a material adverse effect on our business, results of operations and financial condition.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	21
</P>
<A NAME="eolPage24"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our products, if successfully developed and approved for commercial sale, will compete with a
	number of drugs and therapies currently manufactured and marketed by major pharmaceutical and other biotechnology companies. Our products may also compete with new products currently under development by others or with products which may cost less
	than our products. Physicians, patients, third party payors and the medical community may not accept or utilize any of our products that may be approved. If HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and our other products, if and when approved, do not achieve significant market acceptance, our business, results of operations and financial condition would be materially adversely affected. We
	believe the primary competitors for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	are as follows:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	For HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the treatment of Non-24, there are no FDA approved direct competitors. Sedative-Hypnotic treatments for certain sleep related disorders include,
	Ambien
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(zolpidem) by Sanofi (including Ambien CR
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	), Lunesta
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(eszopiclone) by
	Sunovion Pharmaceuticals Inc., Sonata
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(zaleplon) by Pfizer Inc., Rozerem
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(ramelteon) by Takeda Pharmaceuticals Company Limited,
	Silenor
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(doxepin) by Pernix Therapeutics, Belsomra
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(suvorexant) by Merck&nbsp;&amp; Co., Inc., generic products such as zolpidem,
	trazodone and doxepin, and over-the-counter remedies such as Benadryl
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Tylenol PM
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. The class of melatonin agonists includes
	Rozerem
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(ramelteon) by Takeda Pharmaceuticals Company Limited, Valdoxan
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(agemelatine) by Servier, Circadin
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(long-acting melatonin) by Neurim Pharmaceuticals and the food supplement melatonin. Shift work and excessive sleepiness disorder treatments include Nuvigil
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(armodafinil) and Provigil
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(modafinil) both by Teva Pharmaceutical Industries Ltd.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	For Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the treatment of schizophrenia, the atypical antipsychotics competitors are Risperdal
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(risperidone), including the depot formulation Risperdal
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	Consta
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Invega
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(paliperidone), including the depot formulation Invega
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	Sustenna
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, each by Ortho-McNeil-Janssen Pharmaceuticals, Inc., Zyprexa
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(olanzapine), including the depot formulation Zyprexa
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	Relprevv&#153;, each by Eli Lilly and Company, Seroquel
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Seroquel XR (quetiapine) by AstraZeneca PLC, Abilify
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(aripiprazole) by BMS/Otsuka America Pharmaceutical Inc., Abilify
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	Maintena
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(the depot formulation of Abilify
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	) by Lundbeck/Otsuka America
	Pharmaceutical Inc., Geodon
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(ziprasidone) by Pfizer Inc., Saphris
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(asenapine) by Actavis plc, Latuda
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(lurasidone) by Sunovion Pharmaceuticals Inc., Rexulti
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(brexpiprazole) by Lundbeck/Otsuka America Pharmaceutical, Inc., Aristada&#153;
	(aripiprazole lauroxil) extended-release injectible suspension by Alkermes, Inc., Vraylar&#153; (cariprazine) by Teva Pharmaceutical Industries Ltd., and generic clozapine, as well as the typical antipsychotics haloperidol, chlorpromazine,
	thioridazine, and sulpiride (all of which are generic).
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Additionally, we may face competition from newly developed generic
	products. Under the Hatch-Waxman Act newly approved drugs and indications may benefit from a statutory period of non-patent marketing exclusivity. The Hatch-Waxman Act seeks to stimulate competition by providing incentives to generic pharmaceutical
	manufacturers to introduce non-infringing forms of patented pharmaceutical products and to challenge patents on branded pharmaceutical products. If we are unsuccessful at challenging an Abbreviated New Drug Application (ANDA), filed pursuant to the
	Hatch-Waxman Act, cheaper generic versions of our products, which may be favored by insurers and third-party payors, may be launched commercially, which would significantly harm our business.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In June 2014, we filed suit against Roxane Laboratories, Inc. (Roxane) in the U.S. District Court for the District of Delaware (the Delaware
	District Court). The suit seeks an adjudication that Roxane has infringed one or more claims of our U.S. Patent No.&nbsp;8,586,610 (the &#145;610 Patent) by submitting to the U.S. Food and Drug Administration (the FDA) an ANDA for a generic version
	of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	prior to the expiration of the &#145;610 Patent in November 2027. In addition, pursuant to the Settlement Agreement with Novartis, we assumed Novartis&#146; patent infringement
	action against Roxane in the Delaware District Court. That suit alleges that Roxane has infringed one or more claims of U.S Patent RE39198 (the &#145;198 Patent), which is licensed exclusively to us, by filing an ANDA for a generic version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	prior to the expiration of the &#145;198 Patent in November 2016. These two cases against Roxane were consolidated by agreement of the parties and were tried together in a five-day bench trial
	that concluded on March&nbsp;4, 2016. On August&nbsp;25, 2016, the Delaware District Court ruled in our favor, finding that Roxane&#146;s ANDA product infringed the asserted claims of the &#145;610 Patent and the &#145;198 Patent. The Delaware
	District Court ruled that we are entitled to a permanent injunction against Roxane enjoining Roxane from infringing the &#145;610 Patent, including the manufacture, use, sale, offer to sell, sale, distribution or importation of any generic
	iloperidone product described in the &#145;610 Patent ANDA until the expiration of the &#145;610 Patent in November 2027. If we obtain pediatric exclusivity, the injunction against Roxane would be extended until May 2028 under the Delaware District
	Court&#146;s order. On September&nbsp;23, 2016, Roxane filed a notice of appeal with the Federal Circuit Court of Appeals. Roxane filed its opening appellate brief on February&nbsp;7, 2017.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In 2015, we filed six separate patent infringement lawsuits in the Delaware District Court against Roxane, Inventia Healthcare Pvt. Ltd.
	(Inventia), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (Taro), and Apotex Inc. and Apotex Corp., (collectively, the Defendants). The lawsuits each seek an adjudication
	that the respective Defendants infringed one or more claims of the &#145;610 Patent and/or our U.S. Patent No.&nbsp;9,138,432 (the &#145;432 Patent) by submitting to the FDA an ANDA for a generic version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	prior to the expiration of the &#145;610 Patent in November 2027 or the &#145;432 Patent in September 2025. The Defendants have denied infringement and counterclaimed for declaratory judgment of
	invalidity
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	22
</P>
<A NAME="eolPage25"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	and noninfringement of the &#145;610 Patent and the &#145;432 Patent. A trial on these matters was scheduled to begin on May&nbsp;15, 2017. On December&nbsp;15, 2016, following a submission by
	the parties that it may be appropriate to remove the May&nbsp;15, 2017 trial from the Delaware District Court&#146;s calendar pending the Federal Circuit&#146;s decision in Roxane&#146;s appeal of the Delaware District Court&#146;s August&nbsp;25,
	2016 ruling finding that Roxane&#146;s proposed products infringed the asserted claims of the &#145;610 Patent, the Delaware District Court removed the May&nbsp;15, 2017 trial from the calendar and adopted a new schedule for discovery. The parties
	agreed that within 14 days after any decision on the merits in the Roxane appeal, the parties will submit to the Delaware District Court a status report and request a schedule for trial. We entered into a confidential stipulation with Inventia
	regarding any potential launch of Inventia&#146;s generic ANDA product. We also entered into a confidential stipulation with Lupin regarding any potential launch of Lupin&#146;s generic ANDA product.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Lupin filed counter claims for declaratory judgment of invalidity and noninfringement of seven of our method of treatment patents that are
	listed in the
<I>
	Approved Drug Products with Therapeutic Equivalence Evaluations
</I>
	(the Orange Book) related to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(such seven patents, the Method of Treatment Patents). We have not
	sued Lupin for infringing the Method of Treatment Patents. On October&nbsp;13, 2016, we, along with Lupin, filed a Stipulation of Dismissal in the Delaware District Court pursuant to which Lupin&#146;s counterclaims relating to the Method of
	Treatment Patents were dismissed without prejudice in recognition of an agreement reached between Lupin and us by which we would not assert those patents against Lupin absent certain changes in Lupin&#146;s proposed prescribing information for its
	iloperidone tablets.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On October&nbsp;24, 2016, we entered into a License Agreement with Taro to resolve our patent litigation against
	Taro regarding Taro&#146;s ANDA seeking approval of its generic version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(the Taro License Agreement). Under the Taro License Agreement, we granted Taro a non-exclusive license to
	manufacture and commercialize Taro&#146;s version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. effective November&nbsp;2, 2027, unless prior to that date we obtain pediatric exclusivity for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, in which case, the license will be effective May&nbsp;2, 2028. Taro may enter the market earlier under certain limited circumstances. The Taro License Agreement, which is subject to review by
	the U.S. Federal Trade Commission (FTC) and the U.S. Department of Justice (DOJ), provides for a full settlement and release by us and Taro of all claims that are the subject of the litigation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On December&nbsp;7, 2016, we entered into a License Agreement with Apotex to resolve our patent litigation against Apotex regarding
	Apotex&#146;s ANDA seeking approval of its generic version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(the Apotex License Agreement). Under the Apotex License Agreement, we granted Apotex a non-exclusive license to
	manufacture and commercialize Apotex&#146;s version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. effective November&nbsp;2, 2027, unless prior to that date we obtain pediatric exclusivity for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, in which case, the license will be effective May&nbsp;2, 2028. Apotex may enter the market earlier under certain limited circumstances. The Apotex License Agreement, which is subject to review
	by the FTC and the DOJ, provides for a full settlement and release by us and Apotex of all claims that are the subject of the litigation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On February&nbsp;26, 2016, Roxane filed suit against us in the U.S. District Court for the Southern District of Ohio (Ohio District Court).
	The suit seeks a declaratory judgment of invalidity and noninfringement of the Method of Treatment Patents. We have not sued Roxane for infringing the Method of Treatment Patents. We filed a motion to dismiss this lawsuit for lack of personal
	jurisdiction or to transfer the lawsuit to the Delaware District Court. On December&nbsp;20, 2016, the Ohio District Court ruled in our favor, dismissing Roxane&#146;s suit without prejudice for lack of personal jurisdiction.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On February&nbsp;26, 2016, Roxane filed a Petition for
<I>
	Inter Partes
</I>
	Review (IPR) of the &#145;432 Patent with the Patent Trials and
	Appeals Board (PTAB) of the U.S. Patent and Trademark Office. We filed a Preliminary Response on June&nbsp;7, 2016, and on August&nbsp;30, 2016, the PTAB denied the request by Roxane to institute an IPR of the &#145;432 Patent. On September&nbsp;29,
	2016, Roxane filed a Petition for Rehearing with the PTAB, and on October&nbsp;13, 2016, we filed a Response to Roxane&#146;s Petition. On November&nbsp;4, 2016, the PTAB denied Roxane&#146;s Petition for Rehearing.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	FDA and foreign regulatory approval of our products is uncertain.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The research, testing, manufacturing and marketing of products such as those that we have developed or that we or our partners are developing
	are subject to extensive regulation by federal, state and local government authorities, including the FDA, as well as foreign regulatory authorities in jurisdictions in which we seek approval. To obtain regulatory approval of such products, we or
	our partners must demonstrate to the satisfaction of the applicable regulatory agency that, among other things, the product is safe and effective for its intended use. In addition, we or our partners must show that the manufacturing facilities used
	to produce such products are in compliance with current Good Manufacturing Practices regulations (cGMP).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The process of obtaining FDA and
	other required regulatory approvals and clearances can take many years and will require us and our partners, as applicable, to expend substantial time and capital. Despite the time and expense expended, regulatory approval is never guaranteed. The
	number of pre-clinical and clinical trials that will be required for FDA or foreign regulatory approval varies depending on the product, the disease or condition that the product is in development for, and the requirements applicable to that
	particular product. The FDA or applicable foreign regulatory agency can delay, limit or deny approval of a product for many reasons, including that:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	a product may not be shown to be safe or effective;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	23
</P>
<A NAME="eolPage26"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the FDA or foreign agency may interpret data from pre-clinical and clinical trials in different ways than we or our partners do;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the FDA or foreign agency may not approve our or our partners&#146; manufacturing processes or facilities;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	a product may not be approved for all the indications we or our partners request;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the FDA or foreign agency may change its approval policies or adopt new regulations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the FDA or foreign agency may not meet, or may extend, the Prescription Drug User Fee Act (PDUFA-V) date or its foreign equivalent with respect to a particular NDA or foreign application; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the FDA or foreign agency may not agree with our or our partners&#146; regulatory approval strategies or components of the regulatory filings, such as clinical trial designs.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	For example, if certain of our or our partners&#146; methods for analyzing trial data are not accepted by the FDA or the applicable foreign
	agency, we or our partners may fail to obtain regulatory approval for our products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Any delay or failure to obtain regulatory approvals
	for our products will result in increased costs, could diminish competitive advantages that we may attain and would adversely affect the marketing and sale of our products. Other than HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and the 31 countries in Europe covered by the centralized marketing authorization by the EC, and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S., Mexico and Israel, we have not received regulatory approval to
	market any of our products in any jurisdiction.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Even following regulatory approval of our products, the FDA or the applicable foreign
	agency may impose limitations on the indicated uses for which such products may be marketed, subsequently withdraw approval or take other actions against us, our partners or such products that are adverse to our business. The FDA and foreign
	agencies generally approve drugs for particular indications. An approval for a more limited indication reduces the size of the potential market for the product. Product approvals, once granted, may be withdrawn or modified if problems occur after
	initial marketing.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We and our partners also are subject to numerous federal, state, local and foreign laws, regulations and
	recommendations relating to safe working conditions, laboratory and manufacturing practices, the environment and the use and disposal of hazardous substances used in connection with discovery, research and development work. In addition, we cannot
	predict the extent to which new governmental regulations might significantly impede the discovery, development, production and marketing of our products. We or our partners may be required to incur significant costs to comply with current or future
	laws or regulations, and we may be adversely affected by the cost of such compliance or the inability to comply with such laws or regulations.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If our products are determined to be unsafe or ineffective in humans, whether commercially or in clinical trials, our business will be
	materially harmed.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Despite the FDA&#146;s approval of the NDA for
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in January 2014 and the NDA for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in May 2009, the EC&#146;s grant of the centralized marketing authorization for
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in July 2015, and the positive results of our completed trials for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, we are uncertain whether either of these products will ultimately prove to be effective and safe in humans long term and in all uses. Frequently, products that have shown promising results in
	clinical trials have suffered significant setbacks in later clinical trials or even after they are approved for commercial sale. Future uses of our products, whether in clinical trials or commercially, may reveal that the product is ineffective,
	unacceptably toxic, has other undesirable side effects, is difficult to manufacture on a large scale, is uneconomical, infringes on proprietary rights of another party or is otherwise not fit for further use. If our products are determined to be
	unsafe or ineffective in humans, our business will be materially harmed.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Clinical trials for our products are expensive and their
	outcomes are uncertain. Any failure or delay in completing clinical trials for our products could severely harm our business.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pre-clinical studies and clinical trials required to demonstrate the safety and efficacy of our products are time-consuming and expensive and
	together take several years to complete. Before obtaining regulatory approvals for the commercial sale of any of our products, we or our partners must demonstrate through preclinical testing and clinical trials that such product is safe and
	effective for use in humans. We have incurred, and we will continue to incur, substantial expense for, and devote a significant amount of time to, preclinical testing and clinical trials.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Historically, the results from preclinical testing and early clinical trials often have not predicted results of later clinical trials. A
	number of new drugs have shown promising results in clinical trials, but subsequently failed to establish sufficient safety and efficacy data to obtain necessary regulatory approvals. Clinical trials conducted by us, by our partners or by third
	parties on our or our partners&#146; behalf may not demonstrate sufficient safety and efficacy to obtain the requisite regulatory approvals for our products. Regulatory authorities may not permit us or our partners to undertake any additional
	clinical trials for our products, may force us to stop any ongoing clinical trials and it may be difficult to design efficacy studies for our products in new indications.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Clinical development efforts performed by us or our partners may not be successfully completed. Completion of clinical trials may take several
	years or more. The length of time can vary substantially with the type, complexity, novelty and intended use of the products and the size of the prospective patient population. The commencement and rate of completion of clinical trials for our
	products may be delayed by many factors, including:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the inability to manufacture or obtain from third parties materials sufficient for use in pre-clinical studies and clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	delays in beginning a clinical trial;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	24
</P>
<A NAME="eolPage27"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	delays in patient enrollment and variability in the number and types of patients available for clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	difficulty in maintaining contact with patients after treatment, resulting in incomplete data;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	poor effectiveness of our products during clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	unforeseen safety issues or side effects; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	governmental or regulatory delays and changes in regulatory requirements and guidelines.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If
	we or our partners fail to complete successfully one or more clinical trials for our products, we or they may not receive the regulatory approvals needed to market that product. Therefore, any failure or delay in commencing or completing these
	clinical trials would harm our business materially.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our products may cause undesirable side effects or have other properties that
	could delay, prevent or result in the revocation of their regulatory approval or limit their marketability.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Undesirable side
	effects caused by our products could interrupt, delay or halt clinical trials and could result in the denial of regulatory approval by the FDA or other regulatory authorities for any or all targeted indications, and in turn prevent us or our
	partners from commercializing or continuing the commercialization of such products and generating revenues from their sale. We will continue to assess the side effect profile of our products in ongoing clinical development programs. However, we
	cannot predict whether the commercial use of our approved products (or our products in development, if and when they are approved for commercial use) will produce undesirable or unintended side effects that have not been evident in the use of, or in
	clinical trials conducted for, such products to date. Additionally, incidents of product misuse may occur. These events, among others, could result in product recalls, product liability actions or withdrawals or additional regulatory controls, all
	of which could have a material adverse effect on our business, results of operations and financial condition.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, if after
	receiving marketing approval of a product, we, our partners or others identify undesirable side effects caused by such product, we or our partners could face one or more of the following:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	regulatory authorities may require the addition of labeling statements, such as a &#147;black box&#148; warning or a contraindication;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	regulatory authorities may withdraw their approval of the product;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	we or our partners may be required to change the way the product is administered, conduct additional clinical trials or change the labeling of the product; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our, our partner&#146;s or the product&#146;s reputation may suffer.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Any of these events
	could prevent us or our partners from achieving or maintaining market acceptance of the affected product or could substantially increase the costs and expenses of commercializing the product, which in turn could delay or prevent us from generating
	significant revenues from its sale.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We have a history of operating losses, anticipate future losses and may never become profitable
	on a sustained basis.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have been engaged in identifying and developing products since March 2003, which has required, and will
	continue to require, significant research and development expenditures. The continued commercialization of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	will
	require substantial additional expenditures.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of December&nbsp;31, 2016, we had an accumulated deficit of $345.9 million and we cannot
	estimate with precision the extent of our future losses. In April 2014, we commercially launched HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. for the treatment of Non-24 and in August 2016 we commercially launched
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Germany for the treatment of Non-24. We are currently evaluating the commercial opportunity for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the rest of
	Europe. In the fourth quarter of 2014, we acquired all further rights to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	from Novartis. The continued commercialization of
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	will require substantial additional expenditures. In addition, we may not succeed in commercializing HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	or any other products. Novartis launched Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. in the
	first quarter of 2010 and we began selling Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	on our own in the first quarter of 2015. We may not succeed in gaining additional market acceptance of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and we may not succeed in commercializing HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	or Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	outside
	of the U.S. We may not be profitable even if our products are successfully commercialized. We may be unable to fully develop, obtain regulatory approval for, commercialize, manufacture, market, sell and derive revenue from our products in the
	timeframes we project, if at all, and our inability to do so would materially and adversely impact the market price of our common stock and our ability to raise capital and continue operations.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	25
</P>
<A NAME="eolPage28"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	There can be no assurance that we will achieve sustained profitability. Our ability to achieve
	sustained profitability in the future depends, in part, upon:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to obtain and maintain regulatory approval for our products, particularly HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for the treatment of Non-24, both in the U.S. and in foreign
	countries;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to successfully commercialize HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S., Europe and other jurisdictions in which
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	may receive regulatory approval, if any;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to successfully raise awareness regarding Non-24 in the medical and patient communities;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to successfully market and sell Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and our or our partners&#146; ability to successfully market and sell Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Israel, Mexico and other jurisdictions in which we may receive regulatory approval, if any;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to enter into and maintain agreements to develop and commercialize our products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our and our partners&#146; ability to develop, have manufactured and market our products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our and our partners&#146; ability to obtain adequate reimbursement coverage for our products from insurance companies, government programs and other third party payors; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to obtain additional research and development funding from collaborative partners or funding for our products.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, the amount we spend will impact our profitability. Our spending will depend, in part, upon:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the costs of our marketing or awareness campaigns;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the progress of our research and development programs for our products, including clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the time and expense that will be required to pursue FDA and/or foreign regulatory approvals for our products and whether such approvals are obtained on a timely basis, if at all;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the time and expense required to prosecute, enforce and/or challenge patent and other intellectual property rights;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the cost of operating and maintaining development and research facilities;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the cost of third party manufacturers;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the number of additional products we pursue;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	how competing technological and market developments affect our products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the cost of possible acquisitions of technologies, products, product rights or companies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the cost of obtaining licenses to use technology owned by others for proprietary products and otherwise;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the costs and effects of potential litigation; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the costs associated with recruiting and compensating a highly skilled workforce in an environment where competition for such employees may be intense.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We may not achieve all or any of these goals and, thus, we cannot provide assurances that we will ever be profitable on a sustained basis or
	achieve significant revenues. Even if we do achieve some or all of these goals, we may not achieve significant or sustained commercial success.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our ability to use net operating loss carryforwards and tax credit carryforwards to offset future taxable income may be limited as a
	result of transactions involving our common stock.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In general, under Section&nbsp;382 of the Internal Revenue Code of 1986, as
	amended (IRC), a corporation that undergoes an &#147;ownership change&#148; is subject to limitations on its ability to utilize its pre-change net operating losses (NOLs) and certain other tax assets (tax attributes) to offset future taxable income.
	In general, an ownership change occurs if the aggregate stock ownership of certain stockholders increases by more than 50&nbsp;percentage points over such stockholders&#146; lowest percentage ownership during the testing period (generally
	three&nbsp;years). Transactions involving our common stock, even those outside our control, such as purchases or sales by investors, within the testing period could result in an ownership change. A limitation on our ability to utilize some or all of
	our NOLs or credits could have a material adverse effect on our results of operations and cash flows. Ownership changes did occur as of December&nbsp;31, 2008 and December&nbsp;31, 2014. Our management determined that there was sufficient
	Built-In-Gain as of December&nbsp;31, 2008 to offset the IRC Section&nbsp;382 limitation generated by the ownership change. Our management believes that there was sufficient Built-In-Gain as of December&nbsp;31, 2014 to offset the IRC
	Section&nbsp;382 limitation generated by the ownership change. Any future ownership changes may cause our existing tax attributes to have additional limitations.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	26
</P>
<A NAME="eolPage29"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If we fail to obtain the capital necessary to fund our research and development activities
	and commercialization efforts, we may be unable to continue operations or we may be forced to share our rights to commercialize our products with third parties on terms that may not be attractive to us.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our activities will necessitate significant uses of working capital throughout 2017 and beyond. It is uncertain whether our existing funds will
	be sufficient to meet our operating needs. As of December&nbsp;31, 2016, our total cash and cash equivalents and marketable securities were $141.3 million. Our long term capital requirements are expected to depend on many factors, including, among
	others:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to successfully commercialize HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	globally;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	outcomes of ongoing and potential patent litigation;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	costs of developing and maintaining sales, marketing and distribution channels and our ability to sell our products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	market acceptance of our products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	costs involved in establishing manufacturing capabilities for commercial quantities of our products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the number of potential formulations and products in development;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	progress with pre-clinical studies and clinical trials;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	time and costs involved in obtaining regulatory (including FDA) approval;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	costs involved in preparing, filing, prosecuting, maintaining and enforcing patent, trademark and other intellectual property claims;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	competing technological and market developments;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	costs for recruiting and retaining employees and consultants;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	costs for training physicians; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	legal, accounting, insurance and other professional and business related costs.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As a result,
	we may need to raise additional capital to fund our anticipated operating expenses and execute on our business plans. In our capital-raising efforts, we may seek to sell debt securities or additional equity securities, obtain a bank credit facility,
	or enter into partnerships or other collaboration agreements. The sale of additional equity or debt securities, if convertible, could result in dilution to our stockholders and may also result in a lower price for our common stock. The incurrence of
	indebtedness would result in increased fixed obligations and could also result in covenants that could restrict our operations. However, we may not be able to raise additional funds on acceptable terms, or at all. If we are unable to secure
	sufficient capital to fund our planned activities, we may not be able to continue operations, or we may have to enter into partnerships or other collaboration agreements that could require us to share commercial rights to our products to a greater
	extent or at earlier stages in the drug development process than is currently intended. These partnerships or collaborations, if consummated prior to proof-of-efficacy or safety of a given product, could impair our ability to realize value from that
	product. If additional financing is not available when required or is not available on acceptable terms, we may be unable to fund our operations and planned growth, develop or enhance our technologies or products, take advantage of business
	opportunities or respond to competitive market pressures, any of which would materially harm our business, financial condition and results of operations.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If our contract research organizations do not successfully carry out their duties or if we lose our relationships with contract research
	organizations, our drug development efforts could be delayed.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our arrangements with contract research organizations are critical
	to our success in bringing our products to the market and promoting such marketed products profitably. We are dependent on contract research organizations, third-party vendors and investigators for pre-clinical testing and clinical trials related to
	our drug discovery and development efforts and we will likely continue to depend on them to assist in our future discovery and development efforts. These parties are not our employees and we cannot control the amount or timing of resources that they
	devote to our programs. As such, they may not complete activities on schedule or may not conduct our clinical trials in accordance with regulatory requirements or our stated protocols. The parties with which we contract for execution of our clinical
	trials play a significant role in the conduct of the trials and the subsequent collection and analysis of data. If they fail to devote sufficient time and resources to our drug development programs or if their performance is substandard, it will
	delay the development, approval and commercialization of our products. Moreover, these parties may also have relationships with other commercial entities, some of which may compete with us. If they assist our competitors, it could harm our
	competitive position.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT;PAGE-BREAK-BEFORE:ALWAYS">
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our contract research organizations could
	merge with or be acquired by other companies or experience financial or other setbacks unrelated to our collaboration that could, nevertheless, materially adversely affect our business, results of operations and financial condition.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If we lose our relationship with any one or more of these parties, we could experience a significant delay in both identifying another
	comparable provider and then contracting for its services. We may be unable to retain an alternative provider on reasonable terms, if at all. Even if we locate an alternative provider, it is likely that this provider may need additional time to
	respond to our needs and may not provide the same type or level of service as the original provider. In addition, any provider that we retain will be subject to current Good Laboratory Practices, and similar foreign standards and we do not have
	control over compliance with these regulations by these providers. Consequently, if these practices and standards are not adhered to by these providers, the development and commercialization of our products could be delayed.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	27
</P>
<A NAME="eolPage30"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We rely on a limited number of third party manufacturers to formulate and manufacture our
	products and our business will be seriously harmed if these manufacturers are not able to satisfy our demand and alternative sources are not available.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our expertise is primarily in the research and development and pre-clinical and clinical trial phases of product development. We do not have an
	in-house manufacturing capability and depend completely on a small number of third-party manufacturers and active pharmaceutical ingredient formulators for the manufacture of our products. Therefore, we are dependent on third parties for our
	formulation development and manufacturing of our products. This may expose us to the risk of not being able to directly oversee the production and quality of the manufacturing process and provide ample commercial supplies to successfully launch and
	maintain the marketing of our products. Furthermore, these third party contractors, whether foreign or domestic, may experience regulatory compliance difficulty, mechanical shut downs, employee strikes, or other unforeseeable events that may delay
	or limit production. Our inability to adequately establish, supervise and conduct (either ourselves or through third parties) all aspects of the formulation and manufacturing processes would have a material adverse effect on our ability to develop
	and commercialize our products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In January 2014, we entered into a manufacturing agreement with Patheon Pharmaceuticals Inc. (Patheon)
	for the manufacture of commercial supplies of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	20 mg capsules. In May 2016, we entered into a manufacturing agreement with Patheon for the manufacture of commercial supplies of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	capsules. We do not have exclusive long-term agreements with any other third party manufacturers of our products. If Patheon, or any other third party manufacturer, is unable or unwilling to
	perform its obligations under our manufacturing agreements for any reason, we may not be able to locate alternative acceptable manufacturers or formulators or enter into favorable agreements with them. Any inability to acquire sufficient quantities
	of our products in a timely manner from these third parties could adversely affect sales of our products, delay clinical trials and prevent us from developing our products in a cost-effective manner or on a timely basis. In addition, manufacturers
	of our products are subject to cGMP and similar foreign standards and we do not have control over compliance with these regulations by our manufacturers. If one of our contract manufacturers fails to maintain compliance, the production of our
	products could be interrupted, resulting in delays and additional costs. In addition, if the facilities of such manufacturers do not pass a pre-approval or post-approval plant inspection, the FDA will not grant approval and may institute
	restrictions on the marketing or sale of our products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our manufacturing strategy presents the following additional risks:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	because most of our third-party manufacturers and formulators are located outside of the U.S., there may be difficulties in importing our products or their components into the U.S. as a result of, among other things,
	FDA import inspections, incomplete or inaccurate import documentation or defective packaging; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	because of the complex nature of our products, our manufacturers may not be able to successfully manufacture our products in a cost-effective and/or timely manner.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Materials necessary to manufacture our products may not be available on commercially reasonable terms, or at all, which may delay the
	development, regulatory approval and commercialization of our products.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We and our partners rely on manufacturers to purchase from
	third-party suppliers the materials necessary to produce our products for clinical trials and commercialization. Suppliers may not sell these materials to such manufacturers at the times we or our partners need them or on commercially reasonable
	terms. We do not have any control over the process or timing of the acquisition of these materials by these manufacturers. Moreover, we currently do not have any agreements for the commercial production of these materials. If the manufacturers are
	unable to obtain these materials for our or our partners&#146; clinical trials, product testing, potential regulatory approval of our products and commercial scale manufacturing could be delayed, significantly affecting our and our partners&#146;
	ability to further develop and commercialize our products. If we, our manufacturers or our partners, as applicable, are unable to purchase these materials for our products, there would be a shortage in supply or the commercial launch of such
	products would be delayed, which would materially and adversely affect our or our partners&#146; ability to generate revenues from the sale of such products.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If we cannot identify, or enter into licensing arrangements for, new products, our ability to develop a diverse product portfolio will
	be limited.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A component of our business strategy is acquiring rights to develop and commercialize products discovered or developed
	by other pharmaceutical and biotechnology companies for which we may find effective uses and markets through our unique pharmacogenetics and pharmacogenomics expertise for the treatment of central nervous system disorders. Competition for the
	acquisition of these products is intense. If we are not able to identify opportunities to acquire rights to commercialize additional products, we may not be able to develop a diverse portfolio of products and our business may be harmed.
	Additionally, it may take substantial human and financial resources to secure commercial rights to promising products. Moreover, if other firms develop pharmacogenetics and pharmacogenomics capabilities, we may face increased competition in
	identifying and acquiring additional products.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We may not be successful in the development of products for our own account.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition to our business strategy of acquiring rights to develop and commercialize products, we may develop products for our
	own account by applying our technologies to off-patent drugs as well as developing our own proprietary molecules. Because we will be funding the development of such programs, there is a risk that we may not be able to continue to fund all such
	programs to
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	28
</P>
<A NAME="eolPage31"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	completion or to provide the support necessary to perform the clinical trials, obtain regulatory approvals or market any approved products. We expect the development of products for our own
	account to consume substantial resources. If we are able to develop commercial products on our own, the risks associated with these programs may be greater than those associated with our programs with collaborative partners.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If we lose key scientists or management personnel, or if we fail to recruit additional highly skilled personnel, it will impair our
	ability to identify, develop and commercialize products.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are highly dependent on principal members of our management team and
	scientific staff, including our Chief Executive Officer, Mihael H. Polymeropoulos, M.D. These executives each have significant pharmaceutical industry experience. The loss of any such executives, including Dr.&nbsp;Polymeropoulos, or any other
	principal member of our management team or scientific staff, would impair our ability to identify, develop and market new products. Our management and other employees may voluntarily terminate their employment with us at any time. The loss of the
	services of these or other key personnel, or the inability to attract and retain additional qualified personnel, could result in delays to development or approval, loss of sales and diversion of management resources. In addition, we depend on our
	ability to attract and retain other highly skilled personnel, including research scientists. Competition for qualified personnel is intense, and the process of hiring and integrating such qualified personnel is often lengthy. We may be unable to
	recruit such personnel on a timely basis, if at all, which would negatively impact our development and commercialization programs.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Additionally, we do not currently maintain &#147;key person&#148; life insurance on the lives of our executives or any of our employees. This
	lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Product
	liability lawsuits could divert our resources, result in substantial liabilities and reduce the commercial potential of our products.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The risk that we may be sued on product liability claims is inherent in the development and sale of pharmaceutical products. For example, we
	face a risk of product liability exposure related to the testing of our products in clinical trials and will face even greater risks upon commercialization by us or our partners of our products. We believe that we may be at a greater risk of product
	liability claims relative to other pharmaceutical companies because our products are intended to treat central nervous system disorders, and it is possible that we may be held liable for the behavior and actions of patients who use our products.
	These lawsuits may divert our management from pursuing our business strategy and may be costly to defend. In addition, if we are held liable in any of these lawsuits, we may incur substantial liabilities and we or our partners may be forced to limit
	or forego further commercialization of one or more of our products. Although we maintain product liability insurance, our aggregate coverage limit under this insurance is $25.0 million, and while we believe this amount of insurance is sufficient to
	cover our product liability exposure, these limits may not be high enough to fully cover potential liabilities. As our development activities and commercialization efforts progress and we and our partners sell our products, this coverage may be
	inadequate, we may be unable to obtain adequate coverage at an acceptable cost or we may be unable to get adequate coverage at all or our insurer may disclaim coverage as to a future claim. This could prevent the commercialization or limit the
	commercial potential of our products. Even if we are able to maintain insurance that we believe is adequate, our results of operations and financial condition may be materially adversely affected by a product liability claim. Uncertainties resulting
	from the initiation and continuation of products liability litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Product liability litigation and other related proceedings may also require
	significant management time.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	European Union Member States tend to impose strict price controls, which may delay or prevent the
	further commercial launch or impede the commercial success of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Europe and adversely affect our future results of operations.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In the European Union, prescription drug pricing and reimbursement are subject to governmental control and reimbursement mechanisms used by
	private and public health insurers in the European Union vary by Member State. For the public systems, reimbursement is determined by guidelines established by the legislature or responsible national authority. As elsewhere, inclusion in
	reimbursement catalogues focuses on the medical usefulness, need, quality and economic benefits to patients and the health care system. Acceptance for reimbursement comes with cost, use and often volume restrictions, which can vary by Member State.
	Although we have received marketing authorization for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	from the EC, pricing negotiations with governmental authorities may take a considerable amount of time in those Member States
	that impose price controls. For example, we launched HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	commercially in Germany in August 2016, but we have not yet concluded our pricing negotiations with German authorities. In
	addition, to obtain reimbursement or pricing approval for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in some Member States, we may be required to conduct a clinical trial that compares the cost-effectiveness of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, to other available therapies.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Some Member States require approval of the sale
	price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some Member States, prescription pharmaceutical pricing remains subject to continuing
	governmental control even after initial approval is granted. As a result, we may be subject to lengthy price regulations that delay or prevent the commercial launch of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in a particular
	Member State and negatively impact the revenues that are generated from the sale of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in that country. If reimbursement of
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is unavailable or limited in scope or amount, or if pricing for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is set at unsatisfactory levels or takes too long to
	establish, or if there is competition from lower priced cross-border sales, our results of operations will be negatively affected.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	29
</P>
<A NAME="eolPage32"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We may not be able to effectively market and sell our future products, if approved, in the
	U.S.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We plan on building our sales and marketing capabilities in the U.S. to commercialize future products, if approved. We expect
	to build such capabilities by investing significant amounts of financial and management resources. Furthermore, the cost of establishing and maintaining marketing and sales capabilities may not be justifiable in light of the revenues generated by
	any future products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If we are unable to establish and maintain adequate sales and marketing capabilities for future products or are
	unable to do so in a timely manner, we may not be able to generate product revenues from these products which may prevent us from reaching or maintaining profitability.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Legislative or regulatory reform of the healthcare system in the U.S. may affect our ability to sell our products profitably.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	PPACA substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts
	the pharmaceutical industry. PPACA contains a number of provisions that are expected to impact our business and operations, in some cases in ways we cannot currently predict. Changes that may affect our business if we or our partners commercialize
	our products in the future include those governing enrollment in federal healthcare programs, reimbursement changes, rules regarding prescription drug benefits under the health insurance exchanges, and fraud and abuse and enforcement. In addition,
	continued implementation of PPACA may result in the expansion of new programs such as Medicare payment for performance initiatives, and may impact existing government healthcare programs, such as by improving the physician quality reporting system
	and feedback program.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Additional provisions of PPACA may negatively affect our revenues from products that we or our partners
	commercialize in the future. For example, as part of PPACA&#146;s provisions closing a coverage gap that currently exists in the Medicare Part D prescription drug program, manufacturers of branded prescription drugs are required to provide a 50%
	discount on branded prescription drugs dispensed to beneficiaries within this coverage gap. Medicare Part D is a prescription drug benefit available to all Medicare beneficiaries. It is a voluntary benefit that is implemented through private plans
	under contractual arrangements with the federal government. Similar to pharmaceutical coverage through private health insurance, Part D plans negotiate discounts from drug manufacturers and pass on some of those savings to Medicare beneficiaries.
	PPACA also makes changes to the Medicaid Drug Rebate Program, discussed in more detail below, including increasing the minimum rebate from 15.1% to 23.1% of the average manufacturer price for most innovator products. On February&nbsp;1, 2016, CMS,
	the federal agency that administers the Medicare and Medicaid programs, issued final regulations to implement the changes to the Medicaid Drug Rebate Program under PPACA. These regulations became effective on April&nbsp;1, 2016.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Many of PPACA&#146;s most significant reforms did not take effect until 2014 or thereafter, and the resulting new programs and requirements
	will continue to evolve in the next few years. Some states have chosen not to expand their Medicaid programs by raising the income limit to 133% of the federal poverty level. In part because not all states have expanded their Medicaid programs, it
	is unclear whether there will be more uninsured patients than anticipated when Congress passed PPACA. For each state that has opted not to expand its Medicaid program, there will be fewer insured patients overall. An increase in the proportion of
	uninsured patients who are prescribed products resulting from our proprietary or partnered programs could impact the future sales of any products that are commercialized in the future and our business and results of operations.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Further, in September 2007, the Food and Drug Administration Amendments Act of 2007 was enacted giving the FDA enhanced post-marketing
	authority including the authority to require post-marketing studies and clinical trials, labeling changes based on new safety information and compliance with REMS approved by the FDA. The FDA&#146;s exercise of this authority could result in delays
	or increased costs during product development, clinical trials and regulatory review, increased costs to ensure compliance with post-approval regulatory requirements and potential restrictions on the sale and/or distribution of approved products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, other legislative changes have been proposed and adopted in the U.S. since PPACA was enacted. On August&nbsp;2, 2011, the
	Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013
	through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2%&nbsp;per fiscal year,
	starting in 2013, which will remain in effect until 2024 unless additional congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, increased the statute of
	limitations period for the government to recover overpayments to providers from three to five years. We expect that additional federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and
	state governments will pay for healthcare products and services, and in turn could significantly reduce the projected value of certain development projects and reduce our profitability.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	More recently, the new presidential administration and the U.S. Congress have indicated that they may seek to replace PPACA and related
	legislation with new healthcare legislation. There is uncertainty with respect to the impact these potential changes may have, if any, and any changes will likely take time to unfold, and could have an impact on coverage and reimbursement for
	healthcare items and services covered by plans that were authorized by PPACA. However, we cannot predict the ultimate content, timing or effect of any healthcare reform legislation or the impact of potential legislation on us.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	30
</P>
<A NAME="eolPage33"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We expect that additional state and federal healthcare reform measures will be adopted in the
	future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures, and may adversely
	affect our operating results.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Future transactions may harm our business or the market price of our stock.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We regularly review potential transactions related to technologies, products or product rights and businesses complementary to our business.
	These transactions could include:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	mergers;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	acquisitions;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	strategic alliances;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	licensing agreements; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	co-promotion and similar agreements.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We may choose to enter into one or more of these
	transactions at any time, which may cause substantial fluctuations in the market price of our stock. Moreover, depending upon the nature of any transaction, we may experience a charge to earnings, which could also materially adversely affect our
	results of operations and could harm the market price of our stock.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We may undertake strategic acquisitions in the future, and
	difficulties integrating such acquisitions could damage our ability to achieve or sustain profitability.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Although we have no
	experience in acquiring businesses, we may acquire businesses or assets that complement or augment our existing business. If we acquire businesses with promising products or technologies, we may not be able to realize the benefit of acquiring such
	businesses if we are unable to move one or more products through preclinical and/or clinical development to regulatory approval and commercialization. Integrating any newly acquired businesses or technologies could be expensive and time-consuming,
	resulting in the diversion of resources from our current business. We may not be able to integrate any acquired business successfully. We cannot assure you that, following an acquisition, we will achieve revenues, specific net income or loss levels
	that justify the acquisition or that the acquisition will result in increased earnings, or reduced losses, for the combined company in any future period. Moreover, we may need to raise additional funds through public or private debt or equity
	financing to acquire any businesses, which would result in dilution for stockholders or the incurrence of indebtedness and may not be available on terms which would otherwise be acceptable to us. We may not be able to operate acquired businesses
	profitably or otherwise implement our growth strategy successfully.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our operating results may fluctuate significantly due to a
	number of factors which make our future results difficult to predict and could cause our operating results to fall below expectations or our guidance.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our operating results will continue to be subject to fluctuations. The revenues we generate and our operating results will be affected by
	numerous factors, including:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	product sales;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	cost of product sales;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	marketing and other expenses;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	manufacturing or supply issues;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the timing and amount of royalties or milestone payments;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our addition or termination of development programs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	variations in the level of expenses related to our products or future development programs;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	regulatory developments affecting our products or those of our competitors; our execution of collaborative, licensing or other arrangements, and the timing of payments we may make or receive under these arrangements;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	any intellectual property infringement or other lawsuit in which we may become involved; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the timing and recognition of stock-based compensation expense.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	If our operating results fall
	below the expectations of investors or securities analysts or below any guidance we may provide, the price of our common stock could decline substantially. Furthermore, any fluctuations in our operating results may, in turn, cause the price of our
	stock to fluctuate substantially. We believe that comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	31
</P>
<A NAME="eolPage34"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We are increasingly dependent on information technology systems, infrastructure and data.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are increasingly dependent upon information technology systems, infrastructure and data. Our computer systems may be vulnerable
	to service interruption or destruction, malicious intrusion and random attack. Security breaches pose a risk that sensitive data, including intellectual property, trade secrets or personal information may be exposed to unauthorized persons or to the
	public. Cyber-attacks are increasing in their frequency, sophistication and intensity, and have become increasingly difficult to detect. Cyber-attacks could include the deployment of harmful malware, denial-of service, social engineering and other
	means to affect service reliability and threaten data confidentiality, integrity and availability. Our key business partners face similar risks, and a security breach of their systems could adversely affect our security posture. While we continue to
	invest data protection and information technology, there can be no assurance that our efforts will prevent service interruptions, or identify breaches in our systems, that could adversely affect our business and operations and/or result in the loss
	of critical or sensitive information, which could result in financial, legal, business or reputational harm.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Risks related to intellectual property
	and other legal matters
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our rights to develop and commercialize our products are subject in part to the terms and conditions of
	licenses or sublicenses granted to us by other pharmaceutical companies.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is based in part on patents that we have licensed on an exclusive basis and
	other intellectual property licensed from Bristol-Myers Squibb Company (BMS). BMS holds certain rights with respect to HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the license agreement. Either party may terminate the license
	agreement under certain circumstances, including a material breach of the agreement by the other. In the event we terminate our license, or if BMS terminates our license due to our breach, all rights to HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(including any intellectual property we develop with respect to HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	) will revert or otherwise be licensed back to BMS on an exclusive
	basis. Any termination or reversion of our rights to develop or commercialize HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, including any reacquisition by BMS of our rights, would have a material adverse effect on our business.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is based in part on patents and other intellectual property owned by
	Sanofi. Titan Pharmaceuticals, Inc. (Titan) holds an exclusive license from Sanofi to the intellectual property owned by Sanofi, and Titan has sublicensed its rights under such license on an exclusive basis to Novartis. We acquired exclusive rights
	to this and other intellectual property through a further sublicense from Novartis. The sublicense with Novartis was amended and restated in October of 2009 to provide Novartis with exclusive rights to commercialize Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and Canada. We retained exclusive rights to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	outside the U.S. and Canada. We acquired all of Novartis&#146; rights to
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the fourth quarter of 2014 pursuant to an asset transfer agreement and related agreements with Novartis. We may lose our rights to develop and commercialize Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	if we fail to comply with certain requirements in the Titan license agreement regarding our financial condition, or if we fail to comply with certain diligence obligations regarding our
	development or commercialization activities. Our loss of rights in Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	would have a material adverse effect on our business, financial condition and results of operations.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Tradipitant is based in part on patents that we have licensed on an exclusive basis and other intellectual property licensed from Eli Lilly
	and Company (Lilly). Lilly may terminate our license if we fail to use our commercially reasonable efforts to develop and commercialize tradipitant or if we materially breach the agreement and fail to cure that breach. In the event that we terminate
	our license, or if Lilly terminates our license for the reasons stated above, all of our rights to tradipitant (including any intellectual property we develop with respect to tradipitant) will revert back to Lilly, subject to payment by Lilly to us
	of a royalty on net sales of products that contain tradipitant.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	AQW051, to which we acquired rights from Novartis in the fourth quarter
	of 2014, is based on patents and other intellectual property that we have licensed on an exclusive basis from Novartis. Novartis may terminate our license if we materially breach the agreement, which includes an obligation to use commercially
	reasonable efforts to develop and commercialize AQW051, and fail to cure that breach. In the event that Novartis terminates our license for the reasons stated above, all of our rights to AQW051 (including any intellectual property we develop with
	respect to AQW051) will revert back to Novartis without compensation.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If our efforts to protect the proprietary nature of the
	intellectual property related to our products are not adequate, we may not be able to compete effectively in our markets.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Method
	of treatment patents protect the use of a product for the method specified in the patent claims. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for a use that is outside the
	scope of the patented method. Moreover, even if competitors do not actively promote their product for our patented methods, physicians may prescribe these products &#147;off-label.&#148; Although off-label prescriptions may infringe or contribute to
	the infringement of method of treatment patents, such infringement may be difficult to prevent.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our patents and patent applications may
	be challenged or fail to result in issued patents and our existing or future patents may be too narrow to prevent third parties from developing or designing around these patents. In addition, we generally rely on trade secret protection and
	confidentiality agreements to protect certain proprietary know-how that is not patentable, for processes for which patents are difficult to enforce and for any other elements of our drug development processes that involve proprietary know-how,
	information and technology that is not covered by patent applications. While we require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information and technology to enter into
	confidentiality
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	32
</P>
<A NAME="eolPage35"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	agreements, we cannot be certain that this know-how, information and technology will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently
	develop substantially equivalent information and techniques. Further, the laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the U.S. As a result, we may encounter significant problems in protecting
	and defending our intellectual property both in the U.S. and abroad. If we are unable to protect or defend the intellectual property related to our technologies, we will not be able to establish or maintain a competitive advantage in our market.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If we do not obtain protection under the Hatch-Waxman Act and similar foreign legislation to extend our patents and to obtain
	market exclusivity for our products, our business will be harmed.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Hatch-Waxman Act provides for an extension of patent term
	for drugs for a period of up to five years to compensate for time spent in development. Assuming we gain a five-year patent term extension for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, and that we continue to have rights
	under our license agreement with respect to this product, we would have exclusive rights to the HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	U.S. new chemical entity patent (the primary patent covering the product as a new
	composition of matter) until 2022. We also own HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	U.S. method of treatment patents (directed to the approved method of treatment as described in the HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	label approved by the FDA). These patents expire normally in 2033. The Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	U.S. new chemical entity patent received the full five-year
	patent term extension under the Hatch-Waxman Act and so this patent in the U.S. expired in November 2016. In November 2013, a patent directed to a method of treating patients with Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	based on genotype was issued to us by the U.S.&nbsp;Patent and Trademark Office. This patent, which was listed in the FDA&#146;s Orange Book in January 2015, is set to expire in 2027. Please see the risk factor entitled &#147;We face substantial
	competition, which may result in others developing or commercializing products before or more successfully than we do,&#148; and Part I, Item&nbsp;3,
<I>
	Legal Proceedings,
</I>
	of this annual report on Form 10-K for additional information. See also
	Note 18,
<I>
	Legal Matters
</I>
	, to the consolidated financial statements included in Part II of this annual report on Form 10-K for additional information. Eight additional U.S. patents directed to methods of treating patients with Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, which are set to expire between 2025 and 2031, were issued to us in 2014 and 2015.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A directive in the European Union provides that companies that receive regulatory approval for a new medicinal product will have a 10-year
	period of market exclusivity for that product (with the possibility of a further one-year extension), beginning on the date of such European regulatory approval, regardless of when the European new chemical entity patent covering such product
	expires. A generic version of the approved drug may not be marketed or sold in Europe during such market exclusivity period. This directive is of material importance with respect to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	,
	since the European new chemical entity patent for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	has expired.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Assuming
	we gain a five-year patent term restoration for tradipitant, and that we continue to have rights under our license agreement with respect to this product, we would have exclusive rights to tradipitant&#146; s U.S. new chemical entity patent until
	2029. Assuming we gain a five-year patent term restoration for AQW051, and that we continue to have rights under our license agreement with respect to this product, we would have exclusive rights to AQW051&#146;s U.S. new chemical entity patent
	until 2028.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	However, there is no assurance that we will receive the extensions of our patents or other exclusive rights available under
	the Hatch-Waxman Act or similar foreign legislation. If we fail to receive such extensions or exclusive rights, our or our partners&#146; ability to prevent competitors from manufacturing, marketing and selling generic versions of our products will
	be materially impaired.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Litigation or third-party claims of intellectual property infringement could require us to divert resources
	and may prevent or delay our drug discovery and development efforts.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our commercial success depends in part on our not infringing
	the patents and proprietary rights of third parties. Third parties may assert that we are employing their proprietary technology without authorization. In addition, third parties may obtain patents in the future and claim that use of our
	technologies infringes upon these patents.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Furthermore, parties making claims against us may obtain injunctive or other equitable relief,
	which could effectively block our ability to develop and commercialize one or more of our products. Defense of these claims, regardless of their merit, would divert substantial financial and employee resources from our business. In the event of a
	successful claim of infringement against us, we may have to pay substantial damages, obtain one or more licenses from third parties or pay royalties. In addition, even in the absence of litigation, we may need to obtain additional licenses from
	third parties to advance our research or allow commercialization of our products. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to develop and commercialize
	further one or more of our products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, in the future we could be required to initiate litigation to enforce our proprietary
	rights against infringement by third parties. Prosecution of these claims to enforce our rights against others could divert substantial financial and employee resources from our business. If we fail to enforce our proprietary rights against others,
	our business will be harmed.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As described elsewhere in these risk factors and in Part I, Item&nbsp;3,
<I>
	Legal Proceedings
</I>
	, of this
	annual report on Form 10-K, we have initiated lawsuits to enforce our patent rights against certain generic pharmaceutical companies.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	33
</P>
<A NAME="eolPage36"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Risks related to our common stock
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our stock price has been highly volatile and may be volatile in the future, and purchasers of our common stock could incur substantial
	losses.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The realization of any of the risks described in these risk factors or other unforeseen risks could have a dramatic and
	adverse effect on the market price of our common stock. Between January&nbsp;1, 2016 and December&nbsp;31, 2016, the high and low sale prices of our common stock as reported on The NASDAQ Global Market varied between $6.91 and $18.00. Additionally,
	market prices for securities of biotechnology and pharmaceutical companies, including ours, have historically been very volatile. The market for these securities has from time to time experienced significant price and volume fluctuations for reasons
	that were unrelated to the operating performance of any one company.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following factors, in addition to the other risk factors
	described in this section, may also have a significant impact on the market price of our common stock:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our or our partners&#146; ability to successfully commercialize our products;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	our ability to successfully execute our commercialization strategies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	publicity regarding actual or potential testing or trial results relating to products under development by us or our competitors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the outcome of regulatory review relating to products under development by us or our competitors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	regulatory developments in the U.S. and foreign countries;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	developments concerning any collaboration or other strategic transaction we may undertake;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	publicity regarding actual or potential litigation involving us;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	announcements of patent issuances or denials, technological innovations or new commercial products by us or our competitors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	termination or delay of development or commercialization program(s) by our partners;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	safety issues with our products or those of our competitors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	announcements of technological innovations or new therapeutic products or methods by us or others;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	actual or anticipated variations in our quarterly operating results;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	changes in estimates of our financial results or recommendations by securities analysts or failure to meet such financial expectations;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	changes in government regulations or policies;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	changes in patent legislation or patent decisions or adverse changes to patent law;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	additions or departures of key personnel or members of our board of directors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	the publication of negative research or articles about our company, our business or our products by industry analysts or others;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	market rumors or press reports;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	publicity regarding actual or potential transactions involving us; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	economic, political and other external factors beyond our control.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	We have been and may
	in the future be subject to litigation, which could harm our stock price, business, results of operations and financial condition.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have been the subject of litigation in the past and may be subject to litigation in the future. In the past, following periods of volatility
	in the market price of their stock, many companies, including us, have been the subjects of securities class action litigation. Any such litigation can result in substantial costs and diversion of management&#146;s attention and resources and could
	harm our stock price, business results of operations and financial condition. As a result of these factors, holders of our common stock might be unable to sell their shares at or above the price they paid for such shares.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If there are substantial sales of our common stock, our stock price could decline.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A small number of institutional investors and private equity funds hold a significant number of shares of our common stock. Sales by these
	stockholders of a substantial number of shares, or the expectation of such sales, could cause a significant reduction in the market price of our common stock.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition to our outstanding common stock, as of December&nbsp;31, 2016 there were a total of 6,686,764 shares of our common stock that we
	have registered and that we are obligated to issue upon the exercise of currently outstanding options and settlement of
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	34
</P>
<A NAME="eolPage37"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	restricted stock unit awards granted under our 2006 and 2016 Equity Incentive Plans. Upon the exercise of these options or settlement of the shares underlying these restricted stock units, as the
	case may be, in accordance with their respective terms, these shares may be resold freely, subject to restrictions imposed on our affiliates under Rule 144. If significant sales of these shares occur in short periods of time, these sales could
	reduce the market price of our common stock. Any reduction in the trading price of our common stock could impede our ability to raise capital on attractive terms, if at all.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If we fail to maintain the requirements for continued listing on The NASDAQ Global Market, our common stock could be delisted from
	trading, which would adversely affect the liquidity of our common stock and our ability to raise additional capital.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our common
	stock is currently listed for quotation on The NASDAQ Global Market. We are required to meet specified listing criteria in order to maintain our listing on The NASDAQ Global Market. If we fail to satisfy The NASDAQ Global Market&#146;s continued
	listing requirements, our common stock could be delisted from The NASDAQ Global Market, in which case we may transfer to The NASDAQ Capital Market, which generally has lower financial requirements for initial listing or, if we fail to meet its
	listing requirements, the over-the-counter bulletin board. Any potential delisting of our common stock from The NASDAQ Global Market would make it more difficult for our stockholders to sell our stock in the public market and would likely result in
	decreased liquidity and increased volatility for our common stock.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	If securities or industry analysts do not publish research or
	reports or publish unfavorable research about our business, our stock price and trading volume could decline.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The trading market
	for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. We currently have research coverage by securities and industry analysts. If one or more of the analysts who
	covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases coverage of our Company or fails to regularly publish reports on us, interest in the purchase of our stock could decrease, which could
	cause our stock price or trading volume to decline.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	You may experience future dilution as a result of future equity offerings.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In order to raise additional capital, we may in the future offer additional shares of our common stock or other securities
	convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in previous offerings. We may sell shares or other securities in any other offering at a price per share that is less than the price per
	share paid by investors in previous offerings, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock, or
	securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Our business could be negatively affected as a result of the actions of activist stockholders.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Proxy contests have been waged against many companies in the biopharmaceutical industry, including us, over the last several years. If faced
	with a proxy contest or other type of shareholder activism, we may not be able to respond successfully to the contest or dispute, which would be disruptive to our business. Even if we are successful, our business could be adversely affected by a
	proxy contest or shareholder dispute involving us or our partners because:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	responding to proxy contests and other actions by activist stockholders can be costly and time-consuming, disrupting operations and diverting the attention of management and employees;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	perceived uncertainties as to future direction may result in the loss of potential acquisitions, collaborations or in-licensing opportunities, and may make it more difficult to attract and retain qualified personnel and
	business partners; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	if individuals are elected to a board of directors with a specific agenda, it may adversely affect our ability to effectively and timely implement our strategic plan and create additional value for our stockholders.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	These actions could cause our stock price to experience periods of volatility.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Anti-takeover provisions in our charter and bylaws and under Delaware law, and our rights plan could prevent or delay a change in
	control of our company.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are a Delaware corporation and the anti-takeover provisions of Section&nbsp;203 of the Delaware General
	Corporation Law may discourage, delay or prevent a change in control by prohibiting us from engaging in a business combination with an interested stockholder for a period of three years after the person becomes an interested stockholder, even if a
	change of control would be beneficial to our existing stockholders. In addition, our amended and restated certificate of incorporation and bylaws may discourage, delay or prevent a change in our management or control over us that stockholders may
	consider favorable. Our amended and restated certificate of incorporation and bylaws:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	authorize the issuance of &#147;blank check&#148; preferred stock that could be issued by our board of directors to thwart a takeover attempt;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	35
</P>
<A NAME="eolPage38"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	do not provide for cumulative voting in the election of directors, which would allow holders of less than a majority of the stock to elect some directors;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	establish a classified board of directors, as a result of which the successors to the directors whose terms have expired will be elected to serve from the time of election and qualification until the third annual
	meeting following their election;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	require that directors only be removed from office for cause;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	provide that vacancies on the board of directors, including newly-created directorships, may be filled only by a majority vote of directors then in office;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	limit who may call special meetings of stockholders;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	prohibit stockholder action by written consent, requiring all actions to be taken at a meeting of the stockholders; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	establish advance notice requirements for nominating candidates for election to the board of directors or for proposing matters that can be acted upon by stockholders at stockholder meetings.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Moreover, in September 2008, our board of directors adopted a rights agreement that unless renewed expires in September 2018, the provisions
	of which could result in significant dilution of the proportionate ownership of a potential acquirer and, accordingly, could discourage, delay or prevent a change in our management or control over us.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Prolonged economic uncertainties or downturns, as well as unstable market, credit and financial conditions, may exacerbate certain risks
	affecting our business and have serious adverse consequences on our business.
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The global economic downturn and market instability
	has made the business climate more volatile and more costly. These economic conditions, and uncertainty as to the general direction of the macroeconomic environment, are beyond our control and may make any necessary debt or equity financing more
	difficult, more costly, and more dilutive. While we believe we have adequate capital resources to meet current working capital and capital expenditure requirements, a lingering economic downturn or significant increase in our expenses could require
	additional financing on less than attractive rates or on terms that are excessively dilutive to existing stockholders. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our
	stock price and could require us to delay or abandon clinical development plans.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Sales of our products will be dependent, in large part,
	on reimbursement from government health administration authorities, private health insurers, distribution partners and other organizations. As a result of negative trends in the general economy in the U.S. or other jurisdictions in which we may do
	business, these organizations may be unable to satisfy their reimbursement obligations or may delay payment. In addition, federal and state health authorities may reduce Medicare and Medicaid reimbursements, and private insurers may increase their
	scrutiny of claims. A reduction in the availability or extent of reimbursement could negatively affect our or our partners&#146; product sales and revenue.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In addition, we rely on third parties for several important aspects of our business. For example, we use third parties for sales,
	distribution, medical affairs and clinical research, and we rely upon several single source providers of raw materials and contract manufacturers for the manufacture of our products. During challenging and uncertain economic times and in tight
	credit markets, there may be a disruption or delay in the performance of our third party contractors, suppliers or partners. If such third parties are unable to satisfy their commitments to us, our business and results of operations would be
	adversely affected.
</P>
</EFX_RISK_FACTORS>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNRESOLVED_STAFF_COMMENTS>
<A NAME="FIS_UNRESOLVED_STAFF_COMMENTS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="TOP" ALIGN="LEFT">
<B>
	I
<A NAME="D474152D10K_HTM_TOC474152_4">
</A>
	TEM&nbsp;1B.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	UNRESOLVED STAFF COMMENTS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Not applicable.
</P>
</EFX_UNRESOLVED_STAFF_COMMENTS>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_PROPERTIES>
<A NAME="FIS_PROPERTIES"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_5">
</A>
	ITEM&nbsp;2.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	PROPERTIES
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our headquarters office consists of a total of 40,188 square feet of office
	space located at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. under operating leases and subleases that expire in 2026 and are subject to renewal options. In addition, we have 2,880 square feet of office space for our European headquarters in
	London under an operating lease that has a lease term ending in 2021 and is subject to a renewal option, and 1,249 square feet of office space in Berlin under a short-term operating lease. We believe that these facilities are suitable and adequate
	to meet our anticipated near-term needs. We anticipate that following the expiration of the leases, additional or alternative space will be available at commercially reasonable terms.
</P>
</EFX_PROPERTIES>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_LEGAL_PROCEEDINGS>
<A NAME="FIS_LEGAL_PROCEEDINGS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_6">
</A>
	ITEM&nbsp;3.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	LEGAL PROCEEDINGS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In June 2014, we filed suit against Roxane Laboratories, Inc.
	(Roxane) in the U.S. District Court for the District of Delaware (the Delaware District Court). The suit seeks an adjudication that Roxane has infringed one or more claims of our U.S. Patent
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	36
</P>
<A NAME="eolPage39"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	No.&nbsp;8,586,610 (the &#145;610 Patent) by submitting to the U.S. Food and Drug Administration (the FDA) an Abbreviated New Drug Application (ANDA) for a generic version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	prior to the expiration of the &#145;610 Patent in November 2027. In addition, pursuant to the settlement agreement with Novartis Pharma AG (Novartis), we assumed Novartis&#146; patent
	infringement action against Roxane in the Delaware District Court. That suit alleges that Roxane has infringed one or more claims of U.S. Patent RE39198 (the &#145;198 Patent), which is licensed exclusively to us, by filing an ANDA for a generic
	version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	prior to the expiration of the &#145;198 Patent in November 2016. These two cases against Roxane were consolidated by agreement of the parties and were tried together in a
	five-day bench trial that concluded on March&nbsp;4, 2016. On August&nbsp;25, 2016, the Delaware District Court ruled in our favor, finding that Roxane&#146;s ANDA product infringed the asserted claims of the &#145;610 Patent and the &#145;198
	Patent. The Delaware District Court ruled that we are entitled to a permanent injunction against Roxane enjoining Roxane from infringing the &#145;610 Patent, including the manufacture, use, sale, offer to sell, sale, distribution or importation of
	any generic iloperidone product described in the &#145;610 Patent ANDA until the expiration of the &#145;610 Patent in November 2027. If we obtain pediatric exclusivity, the injunction against Roxane would be extended until May 2028 under the
	Delaware District Court&#146;s order. On September&nbsp;23, 2016, Roxane filed a notice of appeal with the Federal Circuit Court of Appeals. Roxane filed its opening appellate brief on February&nbsp;7, 2017.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In 2015, we filed six separate patent infringement lawsuits in the Delaware District Court against Roxane, Inventia Healthcare Pvt. Ltd.
	(Inventia), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (Taro), and Apotex Inc. and Apotex Corp., (collectively, the Defendants). The lawsuits each seek an adjudication
	that the respective Defendants infringed one or more claims of the &#145;610 Patent and/or our U.S. Patent No.&nbsp;9,138,432 (the &#145;432 Patent) by submitting to the FDA an ANDA for a generic version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	prior to the expiration of the &#145;610 Patent in November 2027 or the &#145;432 Patent in September 2025. The Defendants have denied infringement and counterclaimed for declaratory judgment of
	invalidity and noninfringement of the &#145;610 Patent and the &#145;432 Patent. A trial on these matters was scheduled to begin on May&nbsp;15, 2017. On December&nbsp;15, 2016, following a submission by the parties that it may be appropriate to
	remove the May&nbsp;15, 2017 trial from the Delaware District Court&#146;s calendar pending the Federal Circuit&#146;s decision in Roxane&#146;s appeal of the Delaware District Court&#146;s August&nbsp;25, 2016 ruling finding that Roxane&#146;s
	proposed products infringed the asserted claims of the &#145;610 Patent, the Delaware District Court removed the May&nbsp;15, 2017 trial from the calendar and adopted a new schedule for discovery. The parties agreed that within 14 days after any
	decision on the merits in the Roxane appeal, the parties will submit to the Delaware District Court a status report and request a schedule for trial. We entered into a confidential stipulation with Inventia regarding any potential launch of
	Inventia&#146;s generic ANDA product. We also entered into a confidential stipulation with Lupin regarding any potential launch of Lupin&#146;s generic ANDA product.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Lupin filed counter claims for declaratory judgment of invalidity and noninfringement of seven of our method of treatment patents that are
	listed in the
<I>
	Approved Drug Products with Therapeutic Equivalence Evaluations
</I>
	(the Orange Book) related to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(such seven patents, the Method of Treatment Patents). We have not
	sued Lupin for infringing the Method of Treatment Patents. On October&nbsp;13, 2016, we, along with Lupin, filed a Stipulation of Dismissal in the Delaware District Court pursuant to which Lupin&#146;s counterclaims relating to the Method of
	Treatment Patents were dismissed without prejudice in recognition of an agreement reached between Lupin and us by which we would not assert those patents against Lupin absent certain changes in Lupin&#146;s proposed prescribing information for its
	iloperidone tablets.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On October&nbsp;24, 2016, we entered into a License Agreement with Taro to resolve our patent litigation against
	Taro regarding Taro&#146;s ANDA seeking approval of its generic version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(the Taro License Agreement). Under the Taro License Agreement, we granted Taro a non-exclusive license to
	manufacture and commercialize Taro&#146;s version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. effective November&nbsp;2, 2027, unless prior to that date we obtain pediatric exclusivity for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, in which case, the license will be effective May&nbsp;2, 2028. Taro may enter the market earlier under certain limited circumstances. The Taro License Agreement, which is subject to review by
	the U.S. Federal Trade Commission (FTC) and the U.S. Department of Justice (DOJ), provides for a full settlement and release by us and Taro of all claims that are the subject of the litigation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On December&nbsp;7, 2016, we entered into a License Agreement with Apotex to resolve our patent litigation against Apotex regarding
	Apotex&#146;s ANDA seeking approval of its generic version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(the Apotex License Agreement). Under the Apotex License Agreement, we granted Apotex a non-exclusive license to
	manufacture and commercialize Apotex&#146;s version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. effective November&nbsp;2, 2027, unless prior to that date we obtain pediatric exclusivity for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, in which case, the license will be effective May&nbsp;2, 2028. Apotex may enter the market earlier under certain limited circumstances. The Apotex License Agreement, which is subject to review
	by the FTC and the DOJ, provides for a full settlement and release by us and Apotex of all claims that are the subject of the litigation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On February&nbsp;26, 2016, Roxane filed suit against us in the U.S. District Court for the Southern District of Ohio (Ohio District Court).
	The suit seeks a declaratory judgment of invalidity and noninfringement of the Method of Treatment Patents. We have not sued Roxane for infringing the Method of Treatment Patents. We filed a motion to dismiss this lawsuit for lack of personal
	jurisdiction or to transfer the lawsuit to the Delaware District Court. On December&nbsp;20, 2016, the Ohio District Court ruled in our favor, dismissing Roxane&#146;s suit without prejudice for lack of personal jurisdiction.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	37
</P>
<A NAME="eolPage40"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On February&nbsp;26, 2016, Roxane filed a Petition for
<I>
	Inter Partes
</I>
	Review (IPR) of the
	&#145;432 Patent with the Patent Trials and Appeals Board (PTAB) of the United States Patent and Trademark Office. We filed a Preliminary Response on June&nbsp;7, 2016, and on August&nbsp;30, 2016, the PTAB denied the request by Roxane to institute
	an IPR of the &#145;432 Patent. On September&nbsp;29, 2016, Roxane filed a Petition for Rehearing with the PTAB, and on October&nbsp;13, 2016, we filed a Response to Roxane&#146;s Petition. On November&nbsp;4, 2016, the PTAB denied Roxane&#146;s
	Petition for Rehearing.
</P>
</EFX_LEGAL_PROCEEDINGS>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_MINE_SAFETY_DISCLOSURE>
<A NAME="FIS_MINE_SAFETY_DISCLOSURE"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_7">
</A>
	ITEM&nbsp;4.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	MINE SAFETY DISCLOSURES
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Not applicable.
</P>
</EFX_MINE_SAFETY_DISCLOSURE>
</EFX_PART_I>
<EFX_PART_II>
<A NAME="FIS_PART_II"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	PART II
</B>
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_MARKET>
<A NAME="FIS_MARKET"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_8">
</A>
	ITEM&nbsp;5.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	MARKET FOR REGISTRANT&#146;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our common stock is quoted on The NASDAQ Global Market under the symbol &#147;VNDA.&#148; The following table sets forth, for the periods
	indicated, the range of high and low sale prices of our common stock as reported on The NASDAQ Global Market:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_7"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="82%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<B>
	Year Ended December&nbsp;31, 2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	High
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Low
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	First quarter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9.58
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6.91
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Second quarter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11.40
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8.02
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Third quarter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	18.00
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10.81
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fourth quarter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	17.65
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	13.55
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="4">
</TD>
<TD HEIGHT="16" COLSPAN="4">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<B>
	Year Ended December&nbsp;31, 2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	High
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Low
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	First quarter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15.00
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8.80
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Second quarter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	13.92
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8.92
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Third quarter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	14.50
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10.57
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fourth quarter
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12.28
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8.00
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of February&nbsp;6, 2017, there were 9 holders of record of our common stock. The number of holders of
	record of our common stock does not reflect the number of beneficial holders whose shares are held by depositors, brokers or other nominees.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Dividends
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have not paid dividends to our stockholders (other than a dividend of preferred share purchase rights which was declared in
	September 2008) since our inception and do not plan to pay dividends in the foreseeable future. We currently intend to retain earnings, if any, to finance our growth.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	38
</P>
<A NAME="eolPage41"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Market Price of and Dividends on the Registrant&#146;s Common Equity and Related Stockholder Matters
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following graph shows the cumulative five-year total return on our common stock relative to the cumulative total returns of the NASDAQ
	Composite Index and the NASDAQ Biotechnology Index. An investment of $100 (with reinvestment of dividends) is assumed to have been made in our common stock and in each of the indexes on December&nbsp;31, 2011 and its relative performance is tracked
	through December&nbsp;31, 2016. The comparisons in the table are required by the Securities and Exchange Commission (SEC) and are not intended to forecast or be indicative of possible future performance of our common stock. We have not paid
	dividends to our stockholders since the inception (other than a dividend of preferred share purchase rights which was declared in September 2008) and do not plan to pay dividends in the foreseeable future. The following graph and related information
	is being furnished solely to accompany this annual report on Form 10-K pursuant to Item&nbsp;201(e) of Regulation S-K and shall not be deemed &#147;soliciting materials&#148; or to be &#147;filed&#148; with the SEC (other than as provided in
	Item&nbsp;201), nor shall such information be incorporated by reference into any of our filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, and
	irrespective of any general incorporation language in any such filing.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="CENTER">
<IMG SRC="http://content.edgar-online.com/edgar_conv_img/2017/02/17/0001193125-17-047317_G474152G36O43.JPG" ALT="LOGO">
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Securities Authorized for Issuance under Equity Incentive Plans
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Information regarding securities authorized for issuance under equity incentive plans will be contained in our Proxy Statement for the 2017
	Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December&nbsp;31, 2016, under the captions &#147;Equity Compensation Plan Information&#148; and &#147;Security Ownership of Certain
	Beneficial Owners and Management&#148; and is incorporated herein by reference pursuant to General Instruction G(3) to Form 10-K.
</P>
</EFX_MARKET>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_FINANCIAL_DATA>
<A NAME="FIS_FINANCIAL_DATA"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR STYLE = "PAGE-BREAK-INSIDE:AVOID">
<TD WIDTH="10%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_9">
</A>
	ITEM&nbsp;6.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	SELECTED CONSOLIDATED FINANCIAL DATA
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The consolidated statements of operations data for
	the years ended December&nbsp;31, 2016, 2015 and 2014 and the consolidated balance sheet data as of December&nbsp;31, 2016 and 2015 are each derived from our audited consolidated financial statements included in this annual report on Form 10-K. The
	consolidated statements of operations data for the years ended December&nbsp;31, 2013 and 2012, and the consolidated balance sheet data as of December&nbsp;31, 2014, 2013 and 2012 are each derived from our audited consolidated financial statements
	not included herein. Our historical results for any prior period are not necessarily indicative of results to be expected in any future period.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	39
</P>
<A NAME="eolPage42"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following data should be read together with our consolidated financial statements and
	accompanying notes and the section entitled
<I>
	Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations
</I>
	included in this annual report on Form 10-K.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_8"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="51%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="18" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands, except for share and per share amounts)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014 (1)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2012
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Statements of Operations Data
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total revenues
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	146,017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	109,925
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,157
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	33,879
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	32,727
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Operating expenses:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cost of goods sold, excluding amortization
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	24,712
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	23,462
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,583
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	129
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	29,156
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	29,145
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	19,230
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	28,502
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	45,764
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Selling, general and administrative
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	99,787
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	84,531
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	84,644
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,082
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	14,517
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Intangible asset amortization
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,933
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,972
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,254
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,495
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,495
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Gain on arbitration settlement
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(77,616
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total operating expenses
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	164,588
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	150,110
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,095
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	55,079
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	61,905
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Income (loss) from operations
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(18,571
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(40,185
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,062
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(21,200
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(29,178
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other income
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	665
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	320
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	124
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	145
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	561
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Income (loss) before income taxes
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(17,906
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(39,865
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,186
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(21,055
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(28,617
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Provision for income taxes
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	104
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net income (loss)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(18,010
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(39,865
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,186
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(21,055
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(28,617
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net income (loss) per share:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Basic
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.41
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.94
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.58
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.69
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1.01
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Diluted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.41
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.94
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.55
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.69
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1.01
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Weighted average shares outstanding:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Basic
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	43,449,441
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	42,250,254
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	34,774,163
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,351,353
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	28,228,409
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Diluted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	43,449,441
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	42,250,254
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	36,686,723
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,351,353
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	28,228,409
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="20">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="18" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2013
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2012
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balance Sheet Data
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cash and cash equivalents
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	40,426
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,843
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	60,901
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	64,764
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	88,772
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	100,914
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	92,337
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	68,921
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	65,586
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	31,631
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Working capital
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	123,855
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	115,230
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	133,944
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	102,763
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	93,705
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	210,374
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	213,050
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	171,704
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	143,349
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	135,448
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	79,044
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	80,023
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,887
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	99,225
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	125,543
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accumulated deficit
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(345,859
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(327,849
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(287,984
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(308,170
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(287,115
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total stockholders&#146; equity
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	131,330
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	133,027
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	160,817
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	44,124
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,905
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="LINE-HEIGHT:8.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Net income for the year ended December&nbsp;31, 2014 includes a gain on arbitration settlement of $77.6 million, or $2.23 and $2.12&nbsp;per basic and diluted share, respectively.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	40
</P>
<A NAME="eolPage43"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_FINANCIAL_DATA>
<EFX_MANAGEMENTS_DISCUSSION>
<A NAME="FIS_MANAGEMENTS_DISCUSSION"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_10">
</A>
	ITEM&nbsp;7.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	You should read the following discussion and analysis of our financial condition and results of operations together with Selected
	Consolidated Financial Data and our consolidated financial statements and related notes appearing in this annual report on
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Form&nbsp;10-K.
</FONT>
	Some of the information contained in this discussion and analysis or
	set forth elsewhere in this annual report on
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Form&nbsp;10-K
</FONT>
	include historical information and other information with respect to our plans and strategy for our business and contain forward-looking statements
	that involve risks, uncertainties and assumptions. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of certain factors, including but not limited to those set forth under the &#147;Risk
	Factors&#148; section of this report and elsewhere in this annual report on Form 10-K.
</I>
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Overview
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vanda Pharmaceuticals Inc. (we, our or Vanda) is a global biopharmaceutical company focused on the development and commercialization of
	innovative therapies to address high unmet medical needs and improve the lives of patients. We commenced operations in 2003 and our product portfolio includes:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24), was approved by the U.S. Food and Drug Administration (FDA) in
	January 2014 and launched commercially in the U.S. in April 2014. In July 2015, the European Commission (EC) granted centralized marketing authorization with unified labeling for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for
	the treatment of Non-24 in totally blind adults. HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was commercially launched in Germany in August 2016. HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	has potential
	utility in a number of other circadian rhythm disorders and is presently in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome (SMS).
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(iloperidone), a product for the treatment of schizophrenia, the oral formulation of which was approved by the FDA in May 2009 and launched commercially
	in the U.S. by Novartis Pharma AG (Novartis) in January of 2010. Novartis transferred all the U.S. and Canadian commercial rights to the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	franchise to us on December&nbsp;31, 2014.
	Additionally, our distribution partners launched Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Israel and Mexico in 2014. Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	has potential utility in a number of
	other disorders. An assessment of new Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	clinical opportunities is ongoing.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is presently in clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Trichostatin A, a small molecule histone deacetylase (HDAC) inhibitor.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Operational Highlights
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Enrollment of patients for a Jet Lag Disorder clinical study is ongoing. Results are expected in the second half of 2017.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Enrollment in the Smith-Magenis Syndrome (SMS) clinical study is ongoing with results expected in 2018.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	A pharmacokinetic study of the HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	pediatric formulation is enrolling with results expected in 2018.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	An expansion of the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	U.S. field sales team is expected to be completed during the first quarter of 2017.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The Marketing Authorization Application (MAA) for oral Fanaptum
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	tablets is under evaluation by the European Medicines Agency for the treatment of schizophrenia
	in adults. A decision on the Fanaptum
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	MAA is expected during the second half of 2017.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	An assessment of new Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	clinical opportunities is ongoing.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Tradipitant
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Enrollment in a tradipitant clinical study for the treatment of chronic pruritus in patients with atopic dermatitis is approaching completion. Results are expected in mid 2017.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	A tradipitant clinical study for the treatment of gastroparesis began enrolling patients in the fourth quarter of 2016. Results are expected in the fourth quarter of 2017.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	41
</P>
<A NAME="eolPage44"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Trichostatin A
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Vanda expects to submit an investigational new drug application to the FDA in mid 2017 for trichostatin A, which will seek clearance to begin a clinical study of hematologic malignancies.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Since we began operations in March 2003, we have devoted substantially all of our resources to the in-licensing, clinical development and
	commercialization of our products. Our ability to generate meaningful product sales and achieve profitability largely depends on our ability to successfully commercialize HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and Europe, on our ability, alone or with others, to complete the development of our products, and to obtain the regulatory approvals for and to manufacture, market and sell our
	products. The results of our operations will vary significantly from year-to-year and quarter-to-quarter and depend on a number of factors, including risks related to our business, risks related to our industry, and other risks which are detailed in
<I>
	Risk Factors
</I>
	reported in Item&nbsp;1A of Part I of this annual report on Form 10-K.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As described in Part I, Item&nbsp;3,
<I>
	Legal
	Proceedings
</I>
	, of this annual report on Form 10-K, we have initiated lawsuits to enforce our patent rights against certain generic pharmaceutical companies.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Critical Accounting Policies
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The
	preparation of our consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of our financial
	statements, as well as the reported revenues and expenses during the reported periods. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the
	basis for making judgments about the carrying value of assets and liabilities that are not apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A summary of our significant accounting policies appears in the notes to our audited consolidated financial statements for the year ended
	December&nbsp;31, 2016 included in this annual report on Form 10-K. However, we believe that the following accounting policies are important to understanding and evaluating our reported financial results, and we have accordingly included them in
	this discussion.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Inventory.
</I>
	&nbsp;Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of
	third-party manufacturing and other direct and indirect costs and is valued using the first-in, first-out method. We capitalize inventory costs associated with our products upon regulatory approval when, based on management&#146;s judgment, future
	commercialization is considered probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development.&nbsp;Inventory is evaluated for impairment by consideration of factors such as lower
	of cost or net realizable value, obsolescence or expiry.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Net Product Sales.
</I>
	&nbsp;Our net product sales consist of sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. We apply the revenue recognition guidance in accordance with Financial Accounting Standards Board Accounting
	Standards Codification (ASC)
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Subtopic&nbsp;605-15,
</FONT>
<I>
	Revenue Recognition&#151;Products
</I>
	. We recognize revenue from product sales when there is persuasive evidence that an arrangement exists, title to
	product and associated risk of loss has passed to the customer, the price is fixed or determinable, collectability is reasonably assured and we have no further performance obligations.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is available in the U.S. for distribution through a limited number of
	specialty pharmacies, and is not available in retail pharmacies. Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is available in the U.S. for distribution through a limited number of wholesalers and is available in retail
	pharmacies. We invoice and record revenue when our customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse. Revenues and accounts receivable are concentrated with these customers.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have entered into distribution agreements with Probiomed S.A. de C.V. (Probiomed) for the commercialization of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Mexico and Megapharm Ltd. for the commercialization of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Israel.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	42
</P>
<A NAME="eolPage45"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Product Sales Discounts and Allowances.
</I>
	&nbsp;Product sales are recorded net of applicable
	discounts, chargebacks, rebates, co-pay assistance, service fees and product returns that are applicable for various government and commercial payors. Reserves established for discounts and returns are classified as reductions of accounts receivable
	if the amount is payable to direct customers, with the exception of service fees. Service fees are classified as a liability. Reserves established for chargebacks, rebates or co-pay assistance are classified as a liability if the amount is payable
	to a party other than customers. We currently record sales allowances for the following:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Prompt-pay:
</I>
	Specialty pharmacies and
	wholesalers are offered discounts for prompt payment. We expect that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deduct the full amount of these discounts from total product sales when revenues are
	recognized.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Rebates:&nbsp;
</I>
	Allowances for rebates include mandated and supplemental discounts under the Medicaid Drug Rebate
	Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector benefit
	providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and expected utilization. Estimates for the expected utilization of rebates are based on historical activity and, where available, actual and
	pending prescriptions for which we have validated the insurance benefits. Rebates are generally invoiced and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the current quarter&#146;s
	activity, plus an accrual balance for known prior quarter&#146;s unpaid rebates. If actual future invoicing varies from estimates, we may need to adjust accruals, which would affect net revenue in the period of adjustment.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Chargebacks:&nbsp;
</I>
	Chargebacks are discounts that occur when contracted customers purchase directly from specialty pharmacies and
	wholesalers. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, generally purchase the product at a
	discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the
	contracted customer. The allowance for chargebacks is based on historical activity and, where available, actual and pending prescriptions for which we have validated the insurance benefits.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Medicare Part&nbsp;D Coverage Gap:&nbsp;
</I>
	Medicare Part&nbsp;D prescription drug benefit mandates manufacturers to fund approximately 50%
	of the Medicare Part&nbsp;D insurance coverage gap for prescription drugs sold to eligible patients. Estimates for expected Medicare Part&nbsp;D coverage gap are based in part on historical activity and, where available, actual and pending
	prescriptions for which we have validated the insurance benefits. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current
	quarter&#146;s activity, plus an accrual balance for known prior quarter activity. If actual future funding varies from estimates, we may need to adjust accruals, which would affect net sales in the period of adjustment.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Service Fees:
</I>
	&nbsp;We also incur specialty pharmacy and wholesaler fees for services and their data. These fees are based on contracted
	terms and are known amounts. We accrue service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it receives an identifiable and separate benefit for the
	consideration and it can reasonably estimate the fair value of the benefit received. In which case, service fees are recorded as selling, general and administrative expense.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Co-payment Assistance:&nbsp;
</I>
	Patients who have commercial insurance and meet certain eligibility requirements may receive
<FONT STYLE="WHITE-SPACE:NOWRAP">
	co-payment
</FONT>
	assistance. Co-pay assistance utilization is based on information provided by our third-party administrator. The allowance for co-pay assistance is based on actual sales and an estimate for pending sales
	based on either historical activity or pending sales for which we have validated the insurance benefits.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Product
	Returns:
</I>
	&nbsp;Consistent with industry practice, we generally offer direct customers a limited right to return as defined within our returns policy. We consider several factors in the estimation process, including historical return activity,
	expiration dates of product shipped to specialty pharmacies, inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table summarizes sales discounts and allowance activity as of and for the years ended December&nbsp;31, 2016, 2015 and 2014:
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	43
</P>
<A NAME="eolPage46"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_9"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="68%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Rebates&nbsp;&amp;
<BR>
	Chargebacks
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Discounts,
<BR>
	Returns
<BR>
	and Other
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Total
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balance at December&nbsp;31, 2013
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Provision related to current period sales
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	419
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	720
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,139
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Credits/payments made
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(51
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(452
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(503
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balance at December&nbsp;31, 2014
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	368
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	268
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	636
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Provision related to current period sales
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	57,424
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	17,940
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	75,364
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Adjustments for prior period sales
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(114
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(25
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(139
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Credits/payments made
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(24,255
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(14,626
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(38,881
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balance at December&nbsp;31, 2015
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	33,423
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,557
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	36,980
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Provision related to current period sales
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	56,133
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	19,451
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	75,584
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Adjustments for prior period sales
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,842
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	790
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,052
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Credits/payments made
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(56,512
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(17,340
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(73,852
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balance at December&nbsp;31, 2016
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	31,202
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6,458
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	37,660
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The provision for rebates and chargebacks of $56.1&nbsp;million and $57.4 million for the years ended
	December&nbsp;31, 2016 and 2015, respectively, primarily represents Medicaid rebates and contracted rebate programs applicable to sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. The provision for discounts, returns and
	other of $19.5&nbsp;million and $17.9 for the years ended December&nbsp;31, 2016 and 2015, respectively, primarily represents wholesaler distribution fees applicable to sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and
	prompt pay discounts applicable to the sales of both HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	License revenue.
</I>
	&nbsp;Our license revenues in 2014 were derived from the amended and restated sublicense agreement with Novartis and
	include an upfront payment and future milestone and royalty payments. Pursuant to the amended and restated sublicense agreement, Novartis had the right to commercialize and develop Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in
	the U.S. and Canada. Under the amended and restated sublicense agreement, we received an upfront payment of $200.0 million. Revenue related to the upfront payment was recognized ratably from the date the amended and restated sublicense agreement
	became effective (November 2009) through the expected duration of the Novartis commercialization of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. which was estimated to be through the expiry of the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	composition of patent, including a granted Hatch-Waxman extension (November 2016). In connection with the Settlement Agreement, we recognized the remaining deferred revenue as of
	December&nbsp;31, 2014 as part of the gain on arbitration settlement. See Note&nbsp;3,
<I>
	Settlement Agreement with Novartis,
</I>
	to the consolidated financial statements included in Part II of this annual report on Form&nbsp;10-K for additional
	information.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Stock-based compensation.
</I>
	&nbsp;We use the Black-Scholes-Merton option pricing model to determine the fair value of
	stock options. The determination of the fair value of stock options on the date of grant using an option pricing model is affected by our stock price as well as assumptions regarding a number of complex and subjective variables. These variables
	include the expected stock price volatility over the expected term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends. Expected volatility rates are based on the historical
	volatility of our publicly traded common stock and other factors. The risk-free interest rates are based on the U.S. Treasury yield for a period consistent with the expected term of the option in effect at the time of the grant. We have not paid
	dividends to our stockholders since our inception (other than a dividend of preferred share purchase rights which was declared in September 2008) and do not plan to pay dividends in the foreseeable future. Stock-based compensation expense is also
	affected by the expected forfeiture rate for the respective option grants. If our estimates of the fair value of these equity instruments or expected forfeitures are too high or too low, it would have the effect of overstating or understating
	expenses.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Research and development expenses.
</I>
	Research and development expenses consist primarily of fees for services provided by
	third parties in connection with the clinical trials, costs of contract manufacturing services, milestone payments made under licensing agreements prior to regulatory approval, costs of materials used in clinical trials and research and development,
	costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. We
	expense research and development costs as they are incurred for products in the development stage, including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval,
	manufacturing and milestone payments made under license agreements are capitalized. Milestone payments are accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are
	expensed as incurred if the underlying technology is developed in connection with our research and development efforts and has no alternative future use.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	44
</P>
<A NAME="eolPage47"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Selling, general and administrative expenses.
</I>
	Selling, general and administrative expenses
	consist primarily of salaries, other related costs for personnel, including stock-based compensation, related to executive, finance, accounting, information technology, marketing, medical affairs and human resource functions. Other costs include
	facility costs not otherwise included in research and development expenses and fees for marketing, medical affairs, legal, accounting and other professional services. Selling, general and administrative expenses also include third party expenses
	incurred to support sales, business development, and other business activities. Additionally, selling, general and administrative expenses included our estimate for the annual Patient Protection and Affordable Care fee.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Income taxes.&nbsp;
</I>
	On a periodic basis, we evaluate the realizability of our deferred tax assets and liabilities and will adjust such
	amounts in light of changing facts and circumstances, including but not limited to future projections of taxable income, the reversal of deferred tax liabilities, tax legislation, rulings by relevant tax authorities and tax planning strategies.
	Settlement of filing positions that may be challenged by tax authorities could impact our income taxes in the year of resolution.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In
	assessing the realizability of deferred tax assets, we consider whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the
	generation of future taxable income during the period in which those temporary differences becomes deductible or the net operating losses (NOLs) and credit carryforwards can be utilized. When considering the reversal of the valuation allowance, we
	consider the level of past and future taxable income, the reversal of deferred tax liabilities, the utilization of the carryforwards and other factors. Revisions to the estimated net realizable value of the deferred tax asset could cause our
	provision for income taxes to vary significantly from period to period.
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_10"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Intangible Assets
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of our intangible assets as of December&nbsp;31, 2016:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="57%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31, 2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Estimated Useful
<BR>
	Life (Years)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Gross
<BR>
	Carrying
<BR>
	Amount
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Accumulated
<BR>
	Amortization
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Net
<BR>
	Carrying
<BR>
	Amount
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	January 2033
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	33,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,181
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,819
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
</SUP>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	November&nbsp;2016
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,941
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,941
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	60,941
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	33,122
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,819
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	HETLIOZ
</I>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<I>
	.
</I>
	In January 2014, we announced
	that the FDA had approved the NDA for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. As a result of this approval, we met a milestone under its license agreement with Bristol-Myers Squibb (BMS) that required us to make a license
	payment of $8.0&nbsp;million to BMS. The $8.0 million is being amortized on a straight-line basis over the remaining life of the U.S. patent for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, which prior to June 2014, we expected
	to last until December 2022. In June 2014, we received a notice of allowance from the U.S. Patent and Trademark Office for a patent covering the method of use of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. The patent expires
	in January 2033, thereby potentially extending the exclusivity protection in the U.S. beyond the composition of matter patent. As a result of the patent allowance, we extended the estimated useful life of the U.S. patent for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	from December 2022 to January 2033.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are obligated to make a future milestone
	payment to BMS of $25.0 million in the event that cumulative worldwide sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	reach $250.0 million. The likelihood of achieving the milestone and the related milestone obligation
	was determined to be probable during the year ended December&nbsp;31, 2015. As a result, the future obligation of $25.0 million was recorded as a non-current liability as of December&nbsp;31, 2016 and 2015. The $25.0 million was determined to be
	additional consideration for the acquisition of the HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	intangible asset, which was created upon FDA approval on January&nbsp;31, 2014. The actual payment of the $25.0 million will occur
	once the $250.0 million in cumulative worldwide sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is realized, which we expect to occur by the end of 2018. The intangible asset of $25.0 million is being amortized on a
	straight-line basis over the remaining life of the U.S. patent for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, which is expected to be January 2033. Amortization of intangible assets relating to HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	amounted to $1.7&nbsp;million, $2.9 million and $0.6 million for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively. In future periods we expect annual amortization of
	capitalized intangible asset costs relating to HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	will amount to $1.7 million until the expiration of the patent in 2033.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Fanapt
</I>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. In 2009, we announced that the FDA had approved the NDA for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. As a result of this approval, we met a milestone under our original sublicense agreement with Novartis that required us to make a license payment of $12.0 million to Novartis. The $12.0 million
	has been amortized on a straight-line basis over the remaining life of the U.S. composition of matter patent for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	to November 2016.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to the Settlement Agreement, Novartis transferred all U.S. and Canadian rights in the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	franchise to us. As a result, we recognized an intangible asset of $15.9 million on December&nbsp;31, 2014 related to the reacquired rights to
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, which has been amortized on a straight-line basis through November 2016. The useful life estimation for the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	intangible
	asset was based on the market participant methodology prescribed by ASC 805, and therefore does not reflect the impact of additional Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	patents solely owned by us with varying expiration
	dates, the latest of which is December 2031. Amortization of intangible assets relating to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was completed in November 2016 and amounted to $9.2 million, $10.1 million and $1.7 million
	for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	45
</P>
<A NAME="eolPage48"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Intangible assets are amortized over their estimated useful economic life using the straight line
	method. Total amortization expense was $10.9 million, $13.0 million and $2.3 million for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of the future intangible asset amortization schedule as of December&nbsp;31, 2016:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT" ALIGN="CENTER">
<TR>
<TD WIDTH="56%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Total
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2017
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2018
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2019
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2020
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2021
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Thereafter
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
</SUP>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,819
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,721
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,721
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,721
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,721
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,721
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	19,214
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Recent Accounting Pronouncements
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	See Note 2,
<I>
	Summary of Significant Accounting Policies,
</I>
	to the consolidated financial statements included in Part II of this annual
	report on Form 10-K for information on recent accounting pronouncements.
</P>
<EFX_RESULTS_OF_OPERATIONS>
<A NAME="FIS_RESULTS_OF_OPERATIONS"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Results of Operations
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We anticipate that our results of operations will fluctuate for the foreseeable future due to several factors, including our and our
	partners&#146; ability to successfully commercialize our products, any possible payments made or received pursuant to license or collaboration agreements, progress of our research and development efforts, the timing and outcome of clinical trials
	and related possible regulatory approvals. Our limited operating history makes predictions of future operations difficult. Since our inception, we have incurred significant losses resulting in an accumulated deficit of $345.9 million as of
	December&nbsp;31, 2016. Our total stockholders&#146; equity was $131.3 million as of December&nbsp;31, 2016.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Year ended
	December&nbsp;31, 2016 compared to year ended December&nbsp;31, 2015
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Revenues.
</I>
	&nbsp;Total revenues increased by $36.1
	million, or 33%, to $146.0 million for the year ended December&nbsp;31, 2016 compared to $109.9 million for the year ended December&nbsp;31, 2015. During the years ended December&nbsp;31, 2016 and 2015, revenues consisted of the following:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_11"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="66%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="14" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Net&nbsp;Change
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Percent
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
</SUP>
	product sales, net
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	71,671
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	44,302
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,369
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	62
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
</SUP>
	product sales, net
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	74,346
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	65,623
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,723
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	13
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	146,017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	109,925
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	36,092
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	33
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	product sales increased by $27.4 million, or
	62%, to $71.7 million for the year ended December&nbsp;31, 2016 compared to $44.3 million for the year ended December&nbsp;31, 2015.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	product sales increased by $8.7 million, or 13%, to $74.3 million for the
	year ended December&nbsp;31, 2016 compared to $65.6 million for the year ended December&nbsp;31, 2015.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Cost of goods
	sold.
</I>
	&nbsp;Cost of goods sold was $24.7 million for the year ended December&nbsp;31, 2016, compared to $23.5 million for the year ended December&nbsp;31, 2015. Cost of goods sold includes third party manufacturing costs of product sold, third
	party royalty costs and distribution and other costs. Third party royalty costs are 10% of net U.S. sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. Third party royalty costs were 23% of net U.S. sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	through November&nbsp;15, 2016 and 9% thereafter.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	cost of goods sold as a percentage of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	revenue depends upon our cost to manufacture inventory at normalized production levels with
	our third party manufacturers. We expect that, in the future, total HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	manufacturing costs included in cost of goods sold will be less than 2% of our net HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	product sales.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	work-in-process inventory and finished goods inventory acquired from Novartis as part of the acquisition of the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	business were recorded at fair value. The fair value of the inventory
	acquired from Novartis represents a higher cost than if new
<FONT STYLE="WHITE-SPACE:NOWRAP">
	work-in-process
</FONT>
	inventory and finished goods inventory was manufactured at this time. We expect that, in the future, total U.S. Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	manufacturing costs included in cost of goods sold will be less than 4% of our net U.S. Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	product sales.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Research and development expenses.
</I>
	&nbsp;Research and development expenses were $29.2 and $29.1 million for the years ended
	December&nbsp;31, 2016 and 2015, respectively. Increased clinical trial expenses associated with the HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	Jet Lag Disorder and SMS programs and the tradipitant chronic pruritus in atopic
	dermatitis program that were incurred for the year ended December&nbsp;31, 2016 were offset by the close out of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	clinical trial expenses transitioned to us as part of the Settlement
	Agreement with Novartis and regulatory expenses related to our sNDA filing incurred during the year ended December&nbsp;31, 2015. The following table summarizes the costs of our product development initiatives for the year ended December&nbsp;31,
	2016 and 2015.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	46
</P>
<A NAME="eolPage49"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_12"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="80%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended
<BR>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Direct project costs (1)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,658
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,444
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,598
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,501
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Tradipitant
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,010
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,006
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Trichostatin A
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,218
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,681
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	24,484
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	24,632
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indirect project costs (1)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Stock-based compensation
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,087
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,269
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other indirect overhead
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,585
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,244
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,672
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,513
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total research&nbsp;&amp; development expense
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	29,156
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	29,145
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="LINE-HEIGHT:8.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	We record direct costs, including personnel costs and related benefits, on a project-by-project basis. Many of our research and development costs are not attributable to any individual project because we share resources
	across several development projects. We record indirect costs that support a number of our research and development activities in the aggregate, including stock-based compensation expense.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We expect to incur significant research and development expenses as we continue to develop our products. In addition, we expect to incur
	licensing costs in the future that could be substantial, as we continue our efforts to develop our products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Selling, general and
	administrative expenses.
</I>
	&nbsp;Selling
<I>
	,
</I>
	general and administrative expenses increased by $15.3 million, or 18%, to $99.8 million for the year ended December&nbsp;31, 2016, compared with $84.5 million for the year ended December&nbsp;31,
	2015. The increase was primarily the result of marketing and sales efforts around Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Europe, an
	increase in the number of employees, including the hiring of new members of the executive management team at the end of 2015, as well as increased legal fees associated with ongoing patent litigation.
<I>
</I>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Intangible asset amortization.&nbsp;
</I>
	Intangible asset amortization decreased by $2.1 million, or 16&nbsp;%, to $10.9 million for year
	ended December&nbsp;31, 2016 compared to $13.0 million for the year ended December&nbsp;31, 2015. The likelihood of achieving a future milestone obligation that becomes payable to BMS when cumulative sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	equal $250.0 million was determined to be probable in the first quarter of 2015 resulting in an increase in capitalized intangible assets of $25.0 million. As a result, intangible asset
	amortization relating to HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for the year ended December&nbsp;31, 2015 had included additional amortization of $1.2 million for a catch-up adjustment to retroactively record cumulative
	amortization from February&nbsp;1 to December&nbsp;31, 2014 relating to the capitalized intangible asset of $25.0 million. We expect that annual amortization of capitalized intangible asset costs relating to HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	will amount to $1.7 million in future years until the expiration of the patent in 2033.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Amortization of intangible assets relating to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was completed in November 2016
	and amounted to $9.2 million for the year ended December&nbsp;31, 2016, compared to $10.1 million for the year ended December&nbsp;31, 2015. Pursuant to the terms of the Settlement Agreement with Novartis, Novartis transferred all U.S. and Canadian
	rights in the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	franchise to us on December&nbsp;31, 2014 resulting in an increase in capitalized intangible assets of $15.9 million that has been amortized until November 2016. The
	useful life estimation for the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	intangible asset was based on the market participant methodology prescribed by ASC&nbsp;805, and therefore does not reflect the impact of additional
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	patents solely owned by us with varying expiration dates, the latest of which is December 2031.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Provision for income taxes.
</I>
	The provision for income taxes was $0.1 million and zero for the years ended December&nbsp;31, 2016 and
	2015, respectively. The tax provision for the year ended December&nbsp;31, 2016 is attributable to activities at our foreign subsidiaries and state income taxes. The tax benefit relating to the loss before income taxes for the years ended
	December&nbsp;31, 2016 and 2015 in the U.S. was fully offset by a tax valuation allowance resulting from our assessment that it is more likely than not that our deferred tax assets will not be realized. The ultimate realization of deferred tax
	assets is dependent upon the generation of future taxable income during the period in which NOLs and credit carryforwards can be utilized.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	47
</P>
<A NAME="eolPage50"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Year ended December&nbsp;31, 2015 compared to year ended December&nbsp;31, 2014
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Revenues.
</I>
	&nbsp;Total revenues increased by $59.8 million, or 119%, to $109.9 million for the year ended December&nbsp;31,
	2015 compared to $50.2 million for the year ended December&nbsp;31, 2014. During the years ended December&nbsp;31, 2015 and 2014, revenues consisted of the following:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_13"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="65%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="14" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Net&nbsp;Change
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Percent
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
</SUP>
	product sales, net
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	44,302
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,802
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	31,500
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	246
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
</SUP>
	product sales, net
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	65,623
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	107
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	65,516
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
</SUP>
	royalty revenue
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6,502
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(6,502
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	-100
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
</SUP>
	licensing agreement
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,746
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(30,746
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	-100
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	109,925
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,157
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	59,768
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	119
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="LINE-HEIGHT:8.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Percentage change not meaningful.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was commercially launched in the U.S. in April 2014. Pursuant to the terms
	of the Settlement Agreement, Novartis transferred all U.S. and Canadian rights in the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	franchise to us in December 2014. We began selling Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	commercially in the U.S. in January 2015. Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	royalty revenue for the year ended December&nbsp;31, 2014 represented amounts due from
	Novartis based on quarterly U.S. sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	by Novartis, and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	license revenue for the year ended December&nbsp;31, 2014
	represented amortization of deferred revenue from the $200.0 million up-front license fee received from Novartis. Pursuant to the Settlement Agreement, royalties from Novartis ceased, and the remaining balance of the deferred revenue as of
	December&nbsp;31, 2014 related to the up-front license fee was recognized as part of gain on arbitration settlement in the consolidated statement of operations for the year ended December&nbsp;31, 2014.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Cost of goods sold.
</I>
	&nbsp;Cost of goods sold was $23.5 million for the year ended December&nbsp;31, 2015, compared to $1.6 million for
	the year ended December&nbsp;31, 2014. HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was commercially launched in the U.S. in April 2014, and we began selling Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	commercially in the U.S. in January 2015. Cost of goods sold includes third party manufacturing costs of product sold, third party royalty costs and distribution and other costs. Third party royalty costs are 10% of net U.S. sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and 23% of net U.S. sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	cost of goods sold as a percentage of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	revenue depends upon our cost to manufacture inventory at normalized production levels with our third party manufacturers. We expect that, in the future, total HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	manufacturing costs included in cost of goods sold will be less than 2% of our net HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	product sales.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	work-in-process inventory and finished goods inventory acquired from Novartis
	as part of the acquisition of the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	business were recorded at fair value. The fair value of the inventory acquired from Novartis represents a higher cost than if new
<FONT STYLE="WHITE-SPACE:NOWRAP">
	work-in-process
</FONT>
	inventory and finished goods inventory was manufactured at this time. We expect that, in the future, total U.S. Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	manufacturing costs
	included in cost of goods sold will be less than 4% of our net U.S. Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	product sales.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Research and development expenses.
</I>
	&nbsp;Research and development expenses increased by $9.9 million, or 52%, to $29.1 million for year
	ended December&nbsp;31, 2015 compared to $19.2 million for the year ended December&nbsp;31, 2014. The increase is primarily the result of the close out of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	clinical trial expenses
	transitioned to us as part of the Settlement Agreement and regulatory expenses related to our sNDA and EMA filings. The following table summarizes the costs of our product development initiatives for the years ended December&nbsp;31, 2015 and 2014.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	48
</P>
<A NAME="eolPage51"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_14"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="80%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended
<BR>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Direct project costs (1)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,444
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,478
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,501
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	160
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Tradipitant
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,006
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,303
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Trichostatin A
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,681
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	335
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	24,632
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15,276
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Indirect project costs (1)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Stock-based compensation
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,269
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,933
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other indirect overhead
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,244
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,021
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,513
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,954
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total research&nbsp;&amp; development expense
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	29,145
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	19,230
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="LINE-HEIGHT:8.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	We record direct costs, including personnel costs and related benefits, on a project-by-project basis. Many of our research and development costs are not attributable to any individual project because we share resources
	across several development projects. We record indirect costs that support a number of our research and development activities in the aggregate, including stock-based compensation expense.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We expect to incur significant research and development expenses as we continue to develop our products. In addition, we expect to incur
	licensing costs in the future that could be substantial, as we continue our efforts to develop our products.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Selling, general and
	administrative expenses.
</I>
	&nbsp;Selling
<I>
	,
</I>
	general and administrative expenses were $84.5 million for the year ended December&nbsp;31, 2015, relatively unchanged from $84.6 million for the year ended December&nbsp;31, 2014. We incurred costs
	associated with our Non-24 Disease Awareness campaign and HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	branded advertising campaign during the year ended December&nbsp;31, 2014. During the year ended December&nbsp;31, 2015, we
	continued to incur costs associated with these campaigns but at reduced amounts when compared with the year ended December&nbsp;31, 2014. The decrease associated with these campaigns was partially offset by marketing and sales efforts around both
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S., an increase in the number of employees during the year ended December&nbsp;31, 2015, as well as
	increased legal fees associated with ongoing patent litigation. Stock-based compensation expense associated with selling, general and administrative expense increased by $1.8 million, or 46%, to $5.7 million, for year ended December&nbsp;31, 2015
	compared to $3.9 million for the year ended December&nbsp;31, 2014. The increase in expense was primarily the result of an increase in the number of employees during 2015 due to the hiring of new members of the executive management team, the
	field-based sales team and the medical affairs team.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Intangible asset amortization.&nbsp;
</I>
	Intangible asset amortization increased
	by $10.7 million to $13.0 million for year ended December&nbsp;31, 2015 compared to $2.3 million for the year ended December&nbsp;31, 2014. The increase reflects additional amortization of $8.3 million relating to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. Pursuant to the terms of the Settlement Agreement, Novartis transferred all U.S. and Canadian rights in the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	franchise to us in
	December 2014 resulting in an increase in capitalized intangible assets of $15.9 million that is being amortized until November 2016. The increase also reflects additional amortization of $2.4 million relating to HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. The likelihood of achieving a future milestone obligation that becomes payable to BMS when cumulative sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	equal $250.0
	million was determined to be probable in the first quarter of 2015 resulting in an increase in capitalized intangible assets of $25.0 million and a corresponding increase in accrued non-current liabilities. The additional amortization relating to
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in 2015 includes a catch-up adjustment of $1.2 million to retroactively record cumulative amortization from February&nbsp;1, 2014 to December&nbsp;31, 2014. We expect that annual
	amortization of capitalized intangible asset costs relating to HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	will amount to $1.7 million in future years until the expiration of the patent in 2033.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Gain on arbitration settlement.
</I>
	&nbsp;Pursuant to the Settlement Agreement with Novartis, we recorded a gain of $77.6 million for the
	year ended December&nbsp;31, 2014.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Provision (benefit) for income taxes.&nbsp;
</I>
	The tax provision (benefit) for the years ended
	December&nbsp;31, 2015 and 2014 was fully offset by a tax valuation allowance resulting from our assessment that it is more likely than not that our deferred tax assets will not be realized. The ultimate realization of deferred tax assets is
	dependent upon the generation of future taxable income during the period in which NOLs and credit carryforwards can be utilized.
</P>
</EFX_RESULTS_OF_OPERATIONS>
<EFX_LIQUIDITY_CAPITAL>
<A NAME="FIS_LIQUIDITY_CAPITAL"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Liquidity and Capital
	Resources
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of December&nbsp;31, 2016, our total cash and cash equivalents and marketable securities were $141.3 million compared to
	$143.2 million at December&nbsp;31, 2015. Our cash and cash equivalents are deposits in operating accounts and highly liquid investments
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	49
</P>
<A NAME="eolPage52"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	with an original maturity of 90 days or less at date of purchase and consist of investments in money market funds with commercial banks and financial institutions, and commercial paper of
	high-quality corporate issuers. Our marketable securities consist of investments in government sponsored enterprises and commercial paper.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our liquidity resources as of December&nbsp;31, 2016 and December&nbsp;31, 2015 are summarized as follows:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_15"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="72%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
<BR>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
<BR>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cash and cash equivalents
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	40,426
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,843
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Marketable securities:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	U.S. Treasury and government agencies
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,647
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	44,057
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Corporate debt
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,267
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	48,280
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	100,914
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	92,337
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total cash and cash equivalents
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	141,340
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	143,180
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of December&nbsp;31, 2016, we maintained all of our cash and cash equivalents in three financial
	institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits, but we do not anticipate any losses with respect to such deposits.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We expect to incur substantial costs and expenses throughout 2017 and beyond in connection with our U.S. commercial activities for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, including Medicaid rebates, the European commercial launch activities for
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and a probable future milestone payment of $25.0 million to BMS in the event cumulative worldwide sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	reach
	$250.0 million. During this time, we will evaluate the commercial opportunity for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Europe, assuming EMA approval. Additionally, we continue to pursue market approval of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in other regions. Because of the uncertainties discussed above, the costs to advance our research and development projects and
	the U.S. commercial activities for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	are difficult to estimate and may vary significantly. Management believes that
	our existing funds will be sufficient to meet our operating plans for the foreseeable future. Our future capital requirements and the adequacy of our available funds will depend on many factors, primarily including our ability to generate revenue,
	the scope and costs of our commercial, manufacturing and process development activities and the magnitude of our discovery, preclinical and clinical development programs.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We may need or desire to obtain additional capital to finance our operations through debt, equity or alternative financing arrangements. We
	may also seek capital through collaborations or partnerships with other companies. The issuance of debt could require us to grant liens on certain of our assets that may limit our flexibility and debt securities may be convertible into common stock.
	If we raise additional capital by issuing equity securities, the terms and prices for these financings may be much more favorable to the new investors than the terms obtained by our existing stockholders. These financings also may significantly
	dilute the ownership of our existing stockholders. If we are unable to obtain additional financing, we may be required to reduce the scope of our future activities which could harm our business, financial condition and operating results. There can
	be no assurance that any additional financing required in the future will be available on acceptable terms, if at all.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	50
</P>
<A NAME="eolPage53"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Cash flow
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table summarizes our net cash flows from operating, investing and financing activities for the years ended December&nbsp;31,
	2016, 2015 and 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_16"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="70%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Net cash provided by (used in):
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Operating activities:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net income (loss)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(18,010
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(39,865
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,186
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Deferred licensing revenues
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(30,572
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Gain on arbitration settlement with Novartis Pharma AG
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(77,616
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other
<FONT STYLE="WHITE-SPACE:NOWRAP">
	non-cash
</FONT>
	charges
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	21,015
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	22,675
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,075
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net change in operating assets and liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(11,108
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	29,639
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(2,627
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Operating activities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(8,103
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,449
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(81,554
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Investing activities:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net purchases of marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(8,618
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(24,071
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(3,513
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,453
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(2,527
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(8,524
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Investing activities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(10,071
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(26,598
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(12,037
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Financing activities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net proceeds from common stock offerings
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	87,313
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Proceeds from exercise of employee stock options and other
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,751
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,091
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,415
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Financing activities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,751
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,091
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	89,728
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Effect of foreign currencies on cash and cash equivalents
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net decrease in cash and cash equivalents
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(10,417
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(10,058
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(3,863
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Year ended December&nbsp;31, 2016 compared to year ended December&nbsp;31, 2015
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net cash used in operating activities was $8.1 million for the year ended December&nbsp;31, 2016, a decrease of $20.6 million compared with net
	cash provided of $12.4 million for the year ended December&nbsp;31, 2015. The decrease reflects a net reduction of $40.7 million from the net change in operating assets and liabilities, including a decrease in accrued government and other rebates of
	$36.5 million primarily from sales allowances relating to our initial sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in 2015 and a decrease in accounts payable and accrued liabilities of $8.9 million, partly offset by a
	net decrease of $8.4 million in accounts receivable primarily relating to initial U.S. sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in 2015. The effect of the net changes in operating assets and liabilities was partially
	offset by a reduction in the net loss of $21.9 million.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Year ended December&nbsp;31, 2015 compared to year ended December&nbsp;31,
	2014
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net cash provided by operating activities was $12.4 million for the year ended December&nbsp;31, 2015, an increase of
	$94.0&nbsp;million from net cash used in operating activities of $81.6 million for the year ended December&nbsp;31, 2014. The increase resulted from a reduction in the net loss of $17.6 million, excluding the non-cash gain of $77.6 million on
	arbitration settlement recognized in the year ended December&nbsp;31, 2014, non-cash amortization of deferred licensing revenue of $30.6 million relating to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the year ended
	December&nbsp;31, 2014, and an increase of $13.6 million in other non-cash charges primarily from an increase the amortization of intangible assets relating to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. In addition, the
	increase in net cash provided by operating activities reflects a net increase in accrued government and other rebates of $34.6 million primarily for sales allowances relating to initial sales of
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in 2015 and an increase in accounts payable and accrued liabilities of $8.4 million. The increase in net cash provided by operating activities was partly offset by a net increase of
	$11.1 million in accounts receivable resulting from U.S. sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	which we commenced in 2015.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Off-balance sheet arrangements
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We have
	no off-balance sheet arrangements, as defined in Item&nbsp;303(a)(4)&nbsp;of the Securities and Exchange Commission&#146;s
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Regulation&nbsp;S-K.
</FONT>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	51
</P>
<A NAME="eolPage54"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Contractual obligations and commitments
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of our non-cancellable long-term contractual cash obligations as of December&nbsp;31, 2016:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_17"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="55%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="26" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Cash payments due by year (1) (2)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Total
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2017
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2018
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2019
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2010
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2021
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Thereafter
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Operating leases
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	21,623
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,981
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,216
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,271
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,327
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,170
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,658
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Milestone obligation (3)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	46,623
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,981
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,216
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,271
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,327
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,170
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,658
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="LINE-HEIGHT:8.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	This table does not include various agreements that we have entered into for services with third party vendors, including agreements to conduct clinical trials, to manufacture products, and for consulting and other
	contracted services due to the cancelable nature of the services. We accrued the costs of these agreements based on estimates of work completed to date. Additionally, this table does not include rebates, chargebacks or discounts recorded as
	liabilities at the time that product sales are recognized as revenue.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(2)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	This table does not include potential future milestone obligations under our license agreement with Eli Lilly for the exclusive rights to develop and commercialize tradipitant where we could be obligated to make future
	milestone payments of up to $4.0&nbsp;million for pre-NDA approval milestones and up to $95.0 million for future regulatory approval and sales milestones.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(3)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	This table includes a probable future milestone obligation under our license agreement with BMS, where we will be obligated to make a future milestone payment of $25.0 million in the event cumulative worldwide sales of
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	reach $250.0 million. This probable obligation has been accrued as a non-current liability in our consolidated balance sheet as of December&nbsp;31, 2016.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Operating leases
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Commitments relating to operating leases represent the minimum annual future payments under operating leases and subleases for a total of
	40,188 square feet of office space for our headquarters office at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. that expire in 2026, the operating lease for 2,880 square feet of office space for our European headquarters in London that has a
	noncancellable lease term ending in 2021, and 1,249 square feet of office space in Berlin under a short-term operating lease.
</P>
</EFX_LIQUIDITY_CAPITAL>
</EFX_MANAGEMENTS_DISCUSSION>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_MARKET_RISK>
<A NAME="FIS_MARKET_RISK"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_11">
</A>
	ITEM&nbsp;7A.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	QUALITATIVE AND QUANTITATIVE DISCLOSURES ABOUT MARKET RISK
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Interest rate risks
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our exposure to market risk is currently confined to our cash and cash equivalents, marketable securities and restricted cash. We currently do
	not hedge interest rate exposure. We have not used derivative financial instruments for speculation or trading purposes. Because of the short-term maturities of our cash and cash equivalents and marketable securities, we do not believe that an
	increase in market rates would have any significant impact on the realized value of our investments.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Concentrations of credit risk
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We deposit our cash with financial institutions that we consider to be of high credit quality and purchase marketable securities which are
	generally investment grade, liquid, short-term fixed income securities and money-market instruments denominated in U.S. dollars. Our marketable securities consist of certificates of deposit, commercial paper, corporate notes and U.S. government
	agency notes.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Revenues and accounts receivable are concentrated with specialty pharmacies and wholesalers. There were five major
	customers that each accounted for more than 10% of total revenues and, as a group, represented 86% of total revenues for the year ended December&nbsp;31, 2016. There were five major customers that each accounted for more than 10% of accounts
	receivable and, as a group, represented 92% of total accounts receivable at December&nbsp;31, 2016. We mitigate our credit risk relating to accounts receivable from customers by performing ongoing credit evaluations.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Foreign currency risk
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We are exposed to
	risks related to changes in foreign currency exchange rates relating to our foreign operations. The functional currency of our international subsidiaries is the local currency. We are exposed to foreign currency risk to the extent that we enter into
	transactions denominated in currencies other than our subsidiaries&#146; respective functional currencies. We are also exposed to unfavorable fluctuations of the U.S. dollar, which is our reporting currency, against the currencies of our operating
	subsidiaries when their respective financial statements are translated into U.S. dollars for inclusion in our consolidated financial statements. We do not currently hedge our foreign currency exchange rate risk. Foreign currency has not had a
	material impact on our results of operations.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	52
</P>
<A NAME="eolPage55"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Effects of inflation
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Inflation has not had a material impact on our results of operations.
</P>
</EFX_MARKET_RISK>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_FINANCIAL_STATEMENTS>
<A NAME="FIS_FINANCIAL_STATEMENTS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_12">
</A>
	ITEM&nbsp;8.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The consolidated financial statements and
	related financial statement schedules required to be filed are listed in the Index to Consolidated Financial Statements and are incorporated in Item&nbsp;15 of Part IV of this annual report on Form 10-K.
</P>
</EFX_FINANCIAL_STATEMENTS>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_ACCOUNTING_CHANGES>
<A NAME="FIS_ACCOUNTING_CHANGES"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_13">
</A>
	ITEM&nbsp;9.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	None.
</P>
</EFX_ACCOUNTING_CHANGES>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_CONTROL_AND_PROCEDURES>
<A NAME="FIS_CONTROL_AND_PROCEDURES"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_14">
</A>
	ITEM&nbsp;9A.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	CONTROLS AND PROCEDURES
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer,
	we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Rules&nbsp;13a-15(e)
</FONT>
	and 15d-15(e) under the Securities and Exchange Act of 1934 (Exchange
	Act)) as of December&nbsp;31, 2016. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures are effective as of December&nbsp;31, 2016, the end of the period covered
	by this annual report on Form 10-K, to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the
	SEC&#146;s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Management&#146;s Report on Internal Control over Financial Reporting
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Our management is responsible for establishing and maintaining an adequate system of internal control over financial reporting, as defined in
	the Exchange Act Rule 13a-15(f). Management conducted an assessment of our internal control over financial reporting based on the original framework established in 2013 by the Committee of Sponsoring Organizations of the Treadway Commission in
<I>
	Internal Control &#151; Integrated Framework.
</I>
	Based on the assessment, management concluded that, as of December&nbsp;31, 2016, our internal control over financial reporting was effective. The effectiveness of our internal control over
	financial reporting as of December&nbsp;31, 2016 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report included in this annual report on Form 10-K.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Changes in Internal Control over Financial Reporting
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act)
	during the fourth quarter of 2016 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting, other than additional controls related to the consolidation of our foreign subsidiaries.
</P>
</EFX_CONTROL_AND_PROCEDURES>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_OTHER_INFORMATION>
<A NAME="FIS_OTHER_INFORMATION"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_15">
</A>
	ITEM&nbsp;9B.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	OTHER INFORMATION
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	None.
</P>
</EFX_OTHER_INFORMATION>
</EFX_PART_II>
<EFX_PART_III>
<A NAME="FIS_PART_III"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	PART III
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_DIRECTORS_AND_OFFICERS>
<A NAME="FIS_DIRECTORS_AND_OFFICERS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_16">
</A>
	ITEM&nbsp;10.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Information required under this
	item will be contained in our Proxy Statement for the 2017 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December&nbsp;31, 2016, under the captions &#147;Election of Directors,&#148;
	&#147;Executive Officers,&#148; &#147;Corporate Governance,&#148; and &#147;Section 16(a) Beneficial Ownership Reporting Compliance&#148; and is incorporated herein by reference pursuant to General Instruction G(3) to Form 10-K.
</P>
</EFX_DIRECTORS_AND_OFFICERS>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_COMPENSATION>
<A NAME="FIS_COMPENSATION"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_17">
</A>
	ITEM&nbsp;11.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	EXECUTIVE COMPENSATION
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Information required under this item will be contained in our
	Proxy Statement for the 2017 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December&nbsp;31, 2016, under the captions &#147;Corporate Governance&#148; and &#147;Executive
	Compensation,&#148; and is incorporated herein by reference pursuant to General Instruction G(3) to
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Form&nbsp;10-K,
</FONT>
	except that information required by Item&nbsp;407(e)(5) of Regulation S-K will be deemed
	furnished in this Form 10-K and will not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate it
	by reference into such filing.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	53
</P>
<A NAME="eolPage56"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_COMPENSATION>
<EFX_SECURITY_OWNERS>
<A NAME="FIS_SECURITY_OWNERS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_18">
</A>
	ITEM&nbsp;12.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Information required under this item will be contained in our Proxy Statement for the 2017 Annual Meeting of Stockholders to be filed with the
	SEC within 120 days after the end of the fiscal year ended December&nbsp;31, 2016, under the captions &#147;Equity Compensation Plan Information&#148; and &#147;Security Ownership of Certain Beneficial Owners and Management&#148; and is incorporated
	herein by reference pursuant to General Instruction G(3) to Form 10-K.
</P>
</EFX_SECURITY_OWNERS>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_OFFICER_TRANSACTIONS>
<A NAME="FIS_OFFICER_TRANSACTIONS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_19">
</A>
	ITEM&nbsp;13.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Information
	required under this item will be contained in our Proxy Statement for the 2017 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December&nbsp;31, 2016, under the caption &#147;Corporate
	Governance&#148; and is incorporated herein by reference pursuant to General Instruction G(3) to Form 10-K.
</P>
</EFX_OFFICER_TRANSACTIONS>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_ACCOUNTANT_FEES>
<A NAME="FIS_ACCOUNTANT_FEES"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_20">
</A>
	ITEM&nbsp;14.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	PRINCIPAL ACCOUNTANT FEES AND SERVICES
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Information required under this item will be
	contained in our Proxy Statement for the 2017 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year ended December&nbsp;31, 2016, under the caption &#147;Ratification of Selection of Independent
	Registered Public Accounting Firm&#148; and is incorporated herein by reference pursuant to General Instruction&nbsp;G&nbsp;(3) to Form 10-K.
</P>
</EFX_ACCOUNTANT_FEES>
</EFX_PART_III>
<EFX_PART_IV>
<A NAME="FIS_PART_IV"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	PART IV
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_EXHIBITS>
<A NAME="FIS_EXHIBITS"></A>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%" VALIGN="TOP" ALIGN="LEFT">
<B>
<A NAME="D474152D10K_HTM_TOC474152_21">
</A>
	ITEM&nbsp;15.
</B>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<B>
	EXHIBITS AND FINANCIAL STATEMENTS SCHEDULES
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The consolidated financial statements filed
	as part of this annual report on Form 10-K are listed in the Index to Consolidated Financial Statements. Certain schedules are omitted because they are not applicable, or not required, or because the required information is included in the
	consolidated financial statements or notes thereto. The Exhibits are listed in the Exhibit Index.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	54
</P>
<A NAME="eolPage57"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_EXHIBITS>
</EFX_PART_IV>
<EFX_SIGNATURES>
<A NAME="FIS_SIGNATURES"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D474152D10K_HTM_TOC474152_22">
</A>
	Signatures
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to the requirements of Section&nbsp;13 and 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused
	this annual report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="45%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="4%">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD WIDTH="3%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="45%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" COLSPAN="3">
	Vanda&nbsp;Pharmaceuticals&nbsp;Inc.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	February&nbsp;17, 2017
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
	&nbsp;&nbsp;By:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	/s/&nbsp;&nbsp;&nbsp;&nbsp;Mihael H. Polymeropoulos, M.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Mihael H. Polymeropoulos, M.D.
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<B>
	President and Chief Executive Officer
</B>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to the requirements of the Securities Act of 1934, this annual report on Form 10-K has been signed
	below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="37%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="44%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="15%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:20.00PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Name
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:15.95PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Title
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:16.00PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Date
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/s/&nbsp;&nbsp;&nbsp;&nbsp;Mihael H. Polymeropoulos,
	M.D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Mihael H. Polymeropoulos, M.D.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	President and Chief Executive Officer and Director (principal executive officer)
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
	February&nbsp;17, 2017
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/s/&nbsp;&nbsp;&nbsp;&nbsp;James P. Kelly&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	James P. Kelly
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Senior Vice President, Chief Financial Officer and Treasurer (principal financial officer and principal accounting officer)
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
	February&nbsp;17, 2017
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/s/&nbsp;&nbsp;&nbsp;&nbsp;H. Thomas
	Watkins&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	H. Thomas Watkins
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Chairman of the Board and
<BR>
	Director
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
	February&nbsp;17, 2017
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/s/&nbsp;&nbsp;&nbsp;&nbsp;Kenneth M.
	Bate&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Kenneth M. Bate
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Director
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
	February&nbsp;17, 2017
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/s/&nbsp;&nbsp;&nbsp;&nbsp;Michael Cola&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Michael Cola
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Director
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
	February&nbsp;17, 2017
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/s/&nbsp;&nbsp;&nbsp;&nbsp;Richard W.
	Dugan&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Richard W. Dugan
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Director
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
	February&nbsp;17, 2017
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	/s/&nbsp;&nbsp;&nbsp;&nbsp;Vincent J.
	Milano&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Vincent J. Milano
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	Director
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" NOWRAP ALIGN="CENTER">
	February&nbsp;17, 2017
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	55
</P>
<A NAME="eolPage58"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Vanda Pharmaceuticals Inc.
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D474152D10K_HTM_INDEX">
</A>
	Index to Consolidated Financial Statements
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="96%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Page
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TX474152_1">
	Report of Independent Registered Public Accounting Firm
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	57
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TX474152_2">
	Consolidated Balance Sheets at December&nbsp;31, 2016 and 2015
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	58
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TX474152_3">
	Consolidated Statements of Operations for the years ended December&nbsp;
	31, 2016, 2015 and 2014
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	59
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TX474152_4">
	Consolidated Statements of Comprehensive Income (Loss) for the years ended December&nbsp;31,
	2016, 2015 and 2014
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	60
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TX474152_5">
	Consolidated Statements of Changes in Stockholders&#146; Equity for the years ended
	December&nbsp;31, 2016, 2015 and 2014
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	61
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TX474152_6">
	Consolidated Statements of Cash Flows for the years ended December&nbsp;
	31, 2016, 2015 and 2014
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	62
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<A HREF="#D474152D10K_HTM_TX474152_7">
	Notes to the Consolidated Financial Statements
</A>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	63
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	56
</P>
<A NAME="eolPage59"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_SIGNATURES>
<EFX_AUDITORS_OPINION>
<A NAME="FIS_AUDITORS_OPINION"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D474152D10K_HTM_TX474152_1">
</A>
	Report of Independent Registered Public Accounting Firm
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	To the Board of Directors and Stockholders of Vanda Pharmaceuticals Inc.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In our opinion, the accompanying consolidated balance sheets and the related consolidated statements of operations, of comprehensive income
	(loss), of changes in stockholders&#146; equity, and of cash flows present fairly, in all material respects, the financial position of Vanda Pharmaceuticals Inc. and its subsidiaries at December&nbsp;31, 2016 and 2015, and the results of their
	operations and their cash flows for each of the three years in the period ended December&nbsp;31, 2016 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all
	material respects, effective internal control over financial reporting as of December&nbsp;31, 2016, based on criteria established in Internal Control&#151;Integrated Framework (2013)&nbsp;issued by the Committee of Sponsoring Organizations of the
	Treadway Commission (COSO). The Company&#146;s management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over
	financial reporting, included in Management&#146;s Report on Internal Control over Financial Reporting appearing under item 9A. Our responsibility is to express opinions on these financial statements and on the Company&#146;s internal control over
	financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain
	reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included
	examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement
	presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and
	operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our
	opinions.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	A company&#146;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the
	reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#146;s internal control over financial reporting includes those policies and
	procedures that (i)&nbsp;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii)&nbsp;provide reasonable assurance that transactions are
	recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management
	and directors of the company; and (iii)&nbsp;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#146;s assets that could have a material effect on the financial
	statements.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
	projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ PricewaterhouseCoopers LLP
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Baltimore, Maryland
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	February&nbsp;17, 2017
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	57
</P>
<A NAME="eolPage60"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
</EFX_AUDITORS_OPINION>
<EFX_BALANCE_SHEET>
<A NAME="FIS_BALANCE_SHEET"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	VANDA PHARMACEUTICALS INC.
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D474152D10K_HTM_TX474152_2">
</A>
	CONSOLIDATED BALANCE SHEETS
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="82%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands, except for share and per share amounts)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
<BR>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
<BR>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	ASSETS
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Current assets:
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cash and cash equivalents
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	40,426
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,843
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	100,914
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	92,337
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accounts receivable, net
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,268
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	16,331
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Inventory
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	779
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,294
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Prepaid expenses and other current assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11,788
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,742
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:7.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total current assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	174,175
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	166,547
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Property and equipment, net
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,015
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,570
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Intangible assets, net
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,819
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	38,752
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Non-current
</FONT>
	inventory and other
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,365
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,181
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:7.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	210,374
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	213,050
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	LIABILITIES AND STOCKHOLDERS&#146; EQUITY
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Current liabilities:
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accounts payable and accrued liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	16,196
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15,767
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accrued government and other rebates
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	34,124
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	35,550
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:7.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total current liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,320
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	51,317
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Milestone obligation under license agreement
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other
<FONT STYLE="WHITE-SPACE:NOWRAP">
	non-current
</FONT>
	liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,724
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,706
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:7.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	79,044
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	80,023
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Commitments and contingencies (Notes 13 and 18)
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Stockholders&#146; equity:
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Preferred stock, $0.001 par value; 20,000,000 shares authorized, and no shares issued or
	outstanding
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Common stock, $0.001 par value; 150,000,000 shares authorized; 44,000,614 and 42,815,291 shares
	issued and outstanding at December&nbsp;31, 2016 and December&nbsp;31, 2015, respectively
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	44
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	43
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Additional
<FONT STYLE="WHITE-SPACE:NOWRAP">
	paid-in
</FONT>
	capital
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	477,087
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	460,794
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accumulated other comprehensive income
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	58
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	39
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accumulated deficit
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(345,859
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(327,849
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total stockholders&#146; equity
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	131,330
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	133,027
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total liabilities and stockholders&#146; equity
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	210,374
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	213,050
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_BALANCE_SHEET>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	The accompanying notes are an integral part of these consolidated financial statements.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	58
</P>
<A NAME="eolPage61"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_INCOME_STATEMENT>
<A NAME="FIS_INCOME_STATEMENT"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	VANDA PHARMACEUTICALS INC.
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D474152D10K_HTM_TX474152_3">
</A>
	CONSOLIDATED STATEMENTS OF OPERATIONS
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="71%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands, except for share and
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	&nbsp;&nbsp;&nbsp;&nbsp;per share amounts)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Revenues:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net product sales
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	146,017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	109,925
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,909
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Royalty revenue
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6,502
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Licensing agreement
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,746
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total revenues
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	146,017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	109,925
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,157
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Operating expenses:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cost of goods sold, excluding amortization
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	24,712
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	23,462
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,583
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	29,156
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	29,145
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	19,230
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Selling, general and administrative
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	99,787
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	84,531
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	84,644
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Intangible asset amortization
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,933
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,972
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,254
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Gain on arbitration settlement
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(77,616
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total operating expenses
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	164,588
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	150,110
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,095
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Income (loss) from operations
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(18,571
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(40,185
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,062
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other income
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	665
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	320
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	124
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Income (loss) before income taxes
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(17,906
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(39,865
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,186
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Provision for income taxes
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	104
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net income (loss)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(18,010
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(39,865
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,186
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net income (loss) per share:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Basic
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.41
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.94
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.58
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Diluted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.41
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.94
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.55
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Weighted average shares outstanding:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Basic
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	43,449,441
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	42,250,254
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	34,774,163
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Diluted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	43,449,441
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	42,250,254
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	36,686,723
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_INCOME_STATEMENT>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	The accompanying notes are an integral part of these consolidated financial statements.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	59
</P>
<A NAME="eolPage62"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_18"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	VANDA PHARMACEUTICALS INC.
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D474152D10K_HTM_TX474152_4">
</A>
	CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="80%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net income (loss)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(18,010
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(39,865
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,186
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other comprehensive income (loss):
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net foreign currency translation loss
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Change in net unrealized gain (loss) on marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	23
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(5
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Tax provision on other comprehensive income (loss)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other comprehensive income (loss), net of tax
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	19
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	23
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(5
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Comprehensive income (loss)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(17,991
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(39,842
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,181
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The accompanying notes are an integral part of these consolidated financial statements.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	60
</P>
<A NAME="eolPage63"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_STOCKHOLDERS_EQUITY>
<A NAME="FIS_STOCKHOLDERS_EQUITY"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	VANDA PHARMACEUTICALS INC.
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D474152D10K_HTM_TX474152_5">
</A>
	CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#146; EQUITY
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="52%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Common Stock
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Additional
<BR>
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Paid-in
</FONT>
</B>
<BR>
<B>
	Capital
</B>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	O ther
<BR>
	Comprehensive
</B>
<BR>
<B>
	Income (Loss)
</B>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Accumulated
</B>
<BR>
<B>
	Deficit
</B>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands, except for share amounts)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Shares
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Par&nbsp;Value
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Total
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balances at December&nbsp;31, 2013
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	33,338,543
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	33
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	352,240
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	21
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(308,170
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	44,124
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net proceeds from public offering of common stock
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,750,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	62,308
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	62,313
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Issuance of common stock to Novartis Pharma AG
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,808,973
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,903
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,905
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Issuance of common stock from the exercise of stock options and settlement of restricted stock
	units
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	621,231
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,851
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,852
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Shares withheld upon settlement of restricted stock units
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(32,386
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(436
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(436
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Stock-based compensation expense
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,878
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,878
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net income
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,186
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,186
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other comprehensive loss, net of tax
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(5
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(5
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balances at December&nbsp;31, 2014
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	41,486,361
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	41
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	448,744
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	16
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(287,984
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	160,817
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Issuance of common stock from the exercise of stock options and settlement of restricted stock
	units
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,353,877
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,372
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,374
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Shares withheld upon settlement of equity awards
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(24,947
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(283
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(283
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Stock-based compensation expense
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,961
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,961
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(39,865
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(39,865
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other comprehensive income, net of tax
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	23
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	23
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balances at December&nbsp;31, 2015
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	42,815,291
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	43
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	460,794
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	39
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(327,849
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	133,027
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Issuance of common stock from the exercise of stock options and settlement of restricted stock
	units
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,185,323
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,750
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,751
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Stock-based compensation expense
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,543
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,543
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(18,010
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(18,010
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other comprehensive income, net of tax
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	19
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	19
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balances at December&nbsp;31, 2016
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	44,000,614
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	44
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	477,087
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	58
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(345,859
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	131,330
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_STOCKHOLDERS_EQUITY>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	The accompanying notes are an integral part of these consolidated financial statements.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	61
</P>
<A NAME="eolPage64"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_CASH_FLOW>
<A NAME="FIS_CASH_FLOW"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	VANDA PHARMACEUTICALS INC.
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D474152D10K_HTM_TX474152_6">
</A>
	CONSOLIDATED STATEMENTS OF CASH FLOWS
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="77%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Cash flows from operating activities
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net income (loss)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(18,010
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(39,865
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,186
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Adjustments to reconcile net income (loss) to net cash provided by (used in) operating
	activities:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Depreciation of property and equipment
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	935
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	582
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	530
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Stock-based compensation
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,543
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,961
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,878
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Amortization of discounts and premiums on marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	62
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	677
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	174
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Intangible asset amortization
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,933
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,972
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,254
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Deferred income taxes
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(104
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Deferred licensing revenues
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(30,572
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Gain on arbitration settlement with Novartis Pharma AG
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(77,616
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other
<FONT STYLE="WHITE-SPACE:NOWRAP">
	non-cash
</FONT>
	adjustments, net
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	646
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	483
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	239
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Changes in operating assets and liabilities:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accounts receivable
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(4,298
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(12,677
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,623
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Prepaid expenses and other assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(6,159
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(2,558
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(318
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Inventory
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	200
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	387
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(2,210
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accounts payable and accrued liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	575
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,432
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,029
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accrued government and other rebates
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,426
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	35,055
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	495
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net cash provided by (used in) operating activities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(8,103
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,449
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(81,554
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Cash flows from investing activities
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Acquisition of intangible assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(8,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Purchases of property and equipment
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,407
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(2,527
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(769
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Purchases of marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(165,405
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(193,111
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(93,343
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Proceeds from sale of marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	999
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,948
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Maturities of marketable securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	156,787
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	168,041
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	80,882
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Change in restricted cash
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(46
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	245
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net cash used in investing activities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(10,071
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(26,598
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(12,037
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Cash flows from financing activities
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net proceeds from public offering of common stock
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	62,313
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net proceeds from offering common stock to Novartis Pharma AG
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Proceeds from exercise of employee stock options
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,751
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,374
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,851
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Tax obligations paid in connection with settlement of restricted stock units
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(283
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(436
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:5.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net cash provided by financing activities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,751
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,091
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	89,728
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Effect of foreign currencies on cash and cash equivalents
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net decrease in cash and cash equivalents
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(10,417
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(10,058
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(3,863
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Cash and cash equivalents
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Beginning of year
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,843
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	60,901
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	64,764
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	End of year
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	40,426
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,843
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	60,901
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_CASH_FLOW>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	The accompanying notes are an integral part of these consolidated financial statements.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	62
</P>
<A NAME="eolPage65"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	VANDA PHARMACEUTICALS INC.
</B>
</P>
<EFX_NOTES_TO_FINANCIAL_STATEMENT>
<A NAME="FIS_NOTES_TO_FINANCIAL_STATEMENT"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D474152D10K_HTM_TX474152_7">
</A>
	NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	1.&nbsp;Business Organization and Presentation
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Business organization
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vanda Pharmaceuticals Inc. (the Company) is a global biopharmaceutical company focused on the development and commercialization of innovative
	therapies to address high unmet medical needs and improve the lives of patients. The Company commenced its operations in 2003 and operates in one reporting segment. The Company&#146;s portfolio includes the following products:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(tasimelteon), a product for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24), was approved by the U.S. Food and Drug Administration (FDA) in
	January 2014 and launched commercially in the U.S. in April 2014. In July 2015, the European Commission (EC) granted centralized marketing authorization with unified labeling for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for
	the treatment of Non-24 in totally blind adults. HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was commercially launched in Germany in August 2016. HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	has potential
	utility in a number of other circadian rhythm disorders and is presently in clinical development for the treatment of Pediatric Non-24, Jet Lag Disorder and Smith-Magenis Syndrome (SMS).
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(iloperidone), a product for the treatment of schizophrenia, the oral formulation of which was approved by the FDA in May 2009 and launched commercially
	in the U.S. by Novartis Pharma AG (Novartis) in January of 2010. Novartis transferred all the U.S. and Canadian commercial rights to the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	franchise to the Company on December&nbsp;31,
	2014. Additionally, the Company&#146;s distribution partners launched Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Israel and Mexico in 2014. Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	has potential
	utility in a number of other disorders. An assessment of new Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	clinical opportunities is ongoing.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, which is presently in clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Trichostatin A, a small molecule histone deacetylase (HDAC) inhibitor.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Basis of
	presentation
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The accompanying consolidated financial statements includes the accounts of Vanda Pharmaceuticals Inc. and its
	wholly-owned subsidiaries and have been prepared in accordance with accounting principles generally accepted in the United States of America. All intercompany accounts and transactions have been eliminated in consolidation.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	2. Summary of Significant Accounting Policies
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Use of Estimates
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires
	management to make estimates that affect the reported amounts of assets and liabilities at the date of the financial statements, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting
	period. The Company has estimated its annual fees for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	under the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of
	2010, however, the amount of the estimated liability could increase, but the range of this increase is not reasonably estimable at this time. Management continually re-evaluates its estimates, judgments and assumptions, and management&#146;s
	evaluation could change. Actual results could differ from those estimates.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Cash and Cash Equivalents
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	For purposes of the consolidated balance sheets and consolidated statements of cash flows, cash equivalents represent highly-liquid investments
	with a maturity date of three months or less at the date of purchase. Restricted cash of $0.8 million relating primarily to leases for office space is included in other current and other non-current assets at December&nbsp;31, 2016 and 2015.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Marketable Securities
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company classifies all of its marketable securities as available-for-sale securities. The Company&#146;s investment policy requires the
	selection of high-quality issuers, with bond ratings of AAA to A1+/P1. Available-for-sale securities are carried at fair market value, with unrealized gains and losses reported as a component of stockholders&#146; equity in accumulated other
	comprehensive income/loss. Interest and dividend income is recorded when earned and included in interest income. Premiums and discounts on marketable securities are amortized and accreted, respectively, to maturity and included in interest income.
	The Company uses the specific identification method in computing realized gains and losses on the sale of investments, which would be included in the consolidated statements of operations when generated. Marketable securities with a maturity of more
	than one year as of the balance sheet date and which the Company does not intend to sell within the next twelve months are classified as non-current. All other marketable securities are classified as current.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	63
</P>
<A NAME="eolPage66"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Inventory
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Inventory, which is recorded at the lower of cost or net realizable value, includes the cost of third-party manufacturing and other direct and
	indirect costs and is valued using the first-in, first-out method. The Company capitalizes inventory costs associated with its products upon regulatory approval when, based on management&#146;s judgment, future commercialization is considered
	probable and the future economic benefit is expected to be realized; otherwise, such costs are expensed as research and development.&nbsp;Inventory is evaluated for impairment by consideration of factors such as lower of cost or net realizable
	value, obsolescence or expiry. Inventory not expected to be consumed within 12 months following the balance sheet date are classified as non-current.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Intangible Assets
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Costs incurred for products not yet approved by the FDA and for which no alternative future use exists are recorded as expense. In the event a
	product has been approved by the FDA or an alternative future use exists for a product, patent and license costs are capitalized and amortized over the expected patent life of the related product. Milestone payments to the Company&#146;s partners
	are recognized when it is deemed probable that the milestone event will occur.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Property and Equipment
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Property and equipment are stated at cost less accumulated depreciation. The costs of leasehold improvements funded by or reimbursed by the
	lessor are capitalized and amortized as leasehold improvements along with a corresponding deferred rent liability. Depreciation of most property and equipment is provided on a straight-line basis over the estimated useful lives of the assets.
	Leasehold improvements are amortized using a straight-line basis over the lesser of the estimated useful lives of the assets or the terms of the related leases. The costs of additions and improvements are capitalized, and repairs and maintenance
	costs are charged to operations in the period incurred. Upon retirement or disposition of property and equipment, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is reflected in the statement of
	operations for that period.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Accounts Payable and Accrued Liabilities
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company&#146;s management is required to estimate accrued liabilities as part of the process of preparing financial statements. The
	estimation of accrued liabilities involves identifying services that have been performed on the Company&#146;s behalf, and then estimating the level of service performed and the associated cost incurred for such services as of each balance sheet
	date in the financial statements. Accrued liabilities include professional service fees, such as lawyers and accountants, contract service fees, such as those under contracts with clinical monitors, data management organizations and investigators in
	conjunction with clinical trials, fees to contract manufacturers in conjunction with the production of clinical materials, and fees for marketing and other commercialization activities. Pursuant to management&#146;s assessment of the services that
	have been performed on clinical trials and other contracts, the Company recognizes these expenses as the services are provided. Such management assessments include, but are not limited to: (i)&nbsp;an evaluation by the project manager of the work
	that has been completed during the period, (ii)&nbsp;measurement of progress prepared internally and/or provided by the third-party service provider, (iii)&nbsp;analyses of data that justify the progress, and (iv)&nbsp;management&#146;s judgment. In
	the event that the Company does not identify certain costs that have begun to be incurred or the Company under- or over-estimates the level of services performed or the costs of such services, the Company&#146;s reported expenses for such period
	would be too low or too high.
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_19"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Net Product Sales
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company&#146;s net product sales consist of sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and, beginning in
	2015, sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. Net sales by product for the years ended December&nbsp;31, 2016, 2015 and 2014 were as follows:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="71%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	product sales, net
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	71,671
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	44,302
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,802
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
</SUP>
	product sales, net
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	74,346
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	65,623
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	107
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	146,017
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	109,925
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,909
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company applies the revenue recognition guidance in accordance with Financial Accounting Standards Board
	(FASB) Accounting Standards Codification (ASC) Subtopic 605-15,&nbsp;
<I>
	Revenue Recognition&#151;Products
</I>
	. The Company recognizes revenue from product sales when there is persuasive evidence that an arrangement exists, title to product and
	associated risk of loss has passed to the customer, the price is fixed or determinable, collectability is reasonably assured and the Company has no further performance obligations.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	64
</P>
<A NAME="eolPage67"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Product Sales Discounts and Allowances
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company&#146;s product sales are recorded net of applicable discounts, chargebacks, rebates, co-pay assistance, service fees and product
	returns that are applicable for various government and commercial payors. Reserves established for discounts and returns are classified as reductions of accounts receivable if the amount is payable to direct customers, with the exception of service
	fees. Service fees are classified as a liability. Reserves established for chargebacks, rebates or co-pay assistance are classified as a liability if the amount is payable to a party other than customers. The Company currently records sales
	allowances for the following:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Rebates:
</I>
	&nbsp;Allowances for rebates include mandated and supplemental discounts under the Medicaid
	Drug Rebate Program as well as contracted rebate programs with other payors. Rebate amounts owed after the final dispensing of the product to a benefit plan participant are based upon contractual agreements or legal requirements with public sector
	benefit providers, such as Medicaid. The allowance for rebates is based on statutory or contracted discount rates and expected utilization. Estimates for the expected utilization of rebates are based on historical activity and, where available,
	actual and pending prescriptions for which the Company has validated the insurance benefits. Rebates are generally invoiced and paid in arrears, such that the accrual balance consists of an estimate of the amount expected to be incurred for the
	current quarter&#146;s activity, plus an accrual balance for known prior quarter&#146;s unpaid rebates. If actual future invoicing varies from estimates, the Company may need to adjust accruals, which would affect net revenue in the period of
	adjustment.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Chargebacks:&nbsp;
</I>
	Chargebacks are discounts that occur when contracted customers purchase directly from specialty
	pharmacies and wholesalers. Contracted customers, which currently consist primarily of Public Health Service institutions, non-profit clinics, and Federal government entities purchasing via the Federal Supply Schedule, generally purchase the product
	at a discounted price. The specialty pharmacy or wholesaler, in turn, charges back the difference between the price initially paid by the specialty pharmacy or wholesaler and the discounted price paid to the specialty pharmacy or wholesaler by the
	contracted customer. The allowance for chargebacks is based on historical activity and, where available, actual and pending prescriptions for which the Company has validated the insurance benefits.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Medicare Part&nbsp;D Coverage Gap:&nbsp;
</I>
	Medicare Part&nbsp;D prescription drug benefit mandates manufacturers to fund approximately 50%
	of the Medicare Part&nbsp;D insurance coverage gap for prescription drugs sold to eligible patients. Estimates for expected Medicare Part&nbsp;D coverage gap are based in part on historical activity and, where available, actual and pending
	prescriptions for which the Company has validated the insurance benefits. Funding of the coverage gap is generally invoiced and paid in arrears so that the accrual balance consists of an estimate of the amount expected to be incurred for the current
	quarter&#146;s activity, plus an accrual balance for known prior quarter activity. If actual future funding varies from estimates, the Company may need to adjust accruals, which would affect net revenue in the period of adjustment.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Service Fees:
</I>
	&nbsp;The Company also incurs specialty pharmacy and wholesaler fees for services and their data. These fees are based on
	contracted terms and are known amounts. The Company accrues service fees at the time of revenue recognition, resulting in a reduction of product sales and the recognition of an accrued liability, unless it receives an identifiable and separate
	benefit for the consideration and it can reasonably estimate the fair value of the benefit received. In which case, service fees are recorded as selling, general and administrative expense.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Co-payment Assistance:&nbsp;
</I>
	Patients who have commercial insurance and meet certain eligibility requirements may receive co-payment
	assistance. Co-pay assistance utilization is based on information provided by the Company&#146;s third-party administrator. The allowance for co-pay assistance is based on actual sales and an estimate for pending sales based on either historical
	activity or pending sales for which the Company has validated the insurance benefits.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Prompt-pay:&nbsp;
</I>
	Specialty pharmacies and
	wholesalers are offered discounts for prompt payment. The Company expects that the specialty pharmacies and wholesalers will earn prompt payment discounts and, therefore, deducts the full amount of these discounts from total product sales when
	revenues are recognized.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Product Returns:
</I>
	Consistent with industry practice, the Company generally offers direct customers a
	limited right to return as defined within the Company&#146;s returns policy. The Company considers several factors in the estimation process, including historical return activity, expiration dates of product shipped to specialty pharmacies,
	inventory levels within the distribution channel, product shelf life, prescription trends and other relevant factors. The following table summarizes activity for product returns as of and for the years ended December&nbsp;31, 2016, 2015 and 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_20"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="89%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	(in thousands)
</I>
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balance at December&nbsp;31, 2013
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Additions
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	85
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balance at December&nbsp;31, 2014
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	85
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Additions
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	986
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Credits/payments
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(12
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balance at December&nbsp;31, 2015
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,059
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Additions
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,507
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Credits/payments
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(486
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balance at December&nbsp;31, 2016
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,080
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	65
</P>
<A NAME="eolPage68"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	License Revenue
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company&#146;s license and royalty revenue for the year ended December&nbsp;31, 2014 was derived from the amended and restated sublicense
	agreement with Novartis. Pursuant to the amended and restated sublicense agreement, Novartis had the right to commercialize and develop Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and Canada. Under the amended and
	restated sublicense agreement, the Company received an upfront payment of $200.0 million. Revenue related to the upfront payment was recognized ratably from the date the amended and restated sublicense agreement became effective (November 2009)
	through the expected duration of the Novartis commercialization of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. which was estimated to be through the expiry of the
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	composition of patent, including a granted Hatch-Waxman extension (November 2016). In connection with the Settlement Agreement with Novartis, the Company recognized the remaining
	deferred revenue as of December&nbsp;31, 2014 as part of the gain on arbitration settlement. See Note 3,
<I>
	Settlement Agreement with Novartis
</I>
	, for additional information.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Major Customers
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is only available in the U.S. for distribution through a limited number of
	specialty pharmacies, and is not available in retail pharmacies. Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is available in the U.S. for distribution through a limited number of wholesalers and is available in retail
	pharmacies. The Company invoices and records revenue when its customers, specialty pharmacies and wholesalers, receive product from the third-party logistics warehouse. Revenues and accounts receivable are concentrated with these customers. The
	following table presents each major customer that represented more than 10% of total revenues for the years ended December&nbsp;31, 2016, 2015 and 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_21"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="82%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year&nbsp;Ended&nbsp;December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
	Percent of Total Revenues
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Distributor A
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	23
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	14
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Distributor B
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	16
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	18
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Distributor C
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	16
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	19
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Distributor D
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	16
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	14
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Distributor E
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	17
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Distributor F
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Novartis royalty revenue
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	13
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Novartis license agreement
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	61
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table presents each major customer that represented more than 10% of accounts receivable, net,
	as of December&nbsp;31, 2016 and 2015:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_22"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="88%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
	Percent of Accounts Receivable, Net
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Distributor A
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	22
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Distributor B
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	19
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	24
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Distributor C
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	17
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Distributor D
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Distributor E
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	22
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Cost of Goods Sold
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cost of goods sold includes royalties payable, the cost of inventory sold, manufacturing and supply chain costs and product shipping and
	handling costs related to U.S. sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	to the Company&#146;s distribution partners.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Research and Development Expenses
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development expenses consist primarily of fees for services provided by third parties in connection with the clinical trials,
	costs of contract manufacturing services, milestone payments, costs of materials used in clinical trials and research and development, costs for regulatory consultants and filings, depreciation of capital resources used to develop products, related
	facilities costs, and salaries, other employee-related costs and stock-based compensation for research and development personnel. The Company expenses research and development costs as they are incurred for products in the development stage,
	including manufacturing costs and milestone payments made under license agreements prior to FDA approval. Upon and subsequent to FDA approval, manufacturing and milestone payments related to license agreements are capitalized. Milestone payments are
	accrued when it is deemed probable that the milestone event will be achieved. Costs related to the acquisition of intellectual property are expensed as incurred if the underlying technology is developed in connection with the Company&#146;s research
	and development efforts and has no alternative future use.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	66
</P>
<A NAME="eolPage69"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Selling, General and Administrative Expenses
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Selling, general and administrative expenses consist of salaries, stock-based compensation, facilities and third party expenses. Selling,
	general and administrative expenses are associated with the activities of the executive, finance, accounting, information technology, business development, commercial support, trade and distribution, sales, marketing, legal, medical affairs and
	human resource functions. Additionally, selling, general and administrative expenses included an estimate for the annual Patient Protection and Affordable Care fee.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Stock-Based Compensation
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Compensation costs for all stock-based awards to employees and directors are measured based on the grant date fair value of those awards and
	recognized over the period during which the employee or director is required to perform service in exchange for the award. The fair value of stock options granted and restricted stock units (RSUs) awarded are amortized using the straight-line
	method. As stock-based compensation expense recognized in the consolidated statements of operations is based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. Forfeitures are required to be estimated at the time
	of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Advertising Expense
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company expenses the costs of advertising, including branded promotional expenses, as incurred. Branded advertising expenses,
	recorded in selling, general and administrative expenses, were&nbsp;$1.4 million, $3.4 million and $5.0 million for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Foreign Currency
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The reporting currency of the Company is the U.S. dollar. The functional currency of the Company&#146;s international subsidiaries is the local
	currency. Assets and liabilities, including inter-company balances for which settlement is anticipated in the foreseeable future, denominated in foreign currencies are translated at exchange rates in effect at the balance sheet date. Foreign
	currency equity balances are translated at historical rates. Revenues and expenses denominated in foreign currencies are translated at average exchange rates for the respective periods. Foreign currency translation adjustments are recorded in
	accumulated other comprehensive income.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Transactions denominated in currencies other than subsidiaries&#146; functional currencies are
	recorded based on exchange rates at the time such transactions arise. Changes in exchange rates with respect to amounts recorded in the consolidated balance sheets related to these items will result in unrealized foreign currency transaction gains
	and losses based upon period-end exchange rates. The Company also records realized foreign currency transaction gains and losses upon settlement of the transactions. Foreign currency transaction gains and losses are included in other income and
	amounted to a loss&nbsp;of $0.2 million for&nbsp;the year ended December&nbsp;31, 2016. Foreign currency transaction gains and losses were not material for the years ended December&nbsp;31, 2015 and 2014.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Income Taxes
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The
	Company accounts for income taxes in accordance with the authoritative guidance on accounting for income taxes, which requires companies to account for deferred income taxes using the asset and liability method. Under the asset and liability method,
	current income tax expense or benefit is the amount of income taxes expected to be payable or refundable for the current year. A deferred income tax asset or liability is recognized for future tax consequences attributable to differences between the
	financial statement carrying amounts of existing assets and liabilities and their respective tax bases and tax credits and loss carryforwards. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more
	likely than not that some portion or all of the deferred tax assets will not be realized. Tax rate changes are reflected in income during the period such changes are enacted. Changes in ownership may limit the amount of NOL carryforwards that can be
	utilized in the future to offset taxable income.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Non-Cash Investing and Financing Activities
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Purchases of property and equipment accrued in current liabilities amounted to $0.2 million for each of the years ended
	December&nbsp;31,&nbsp;2016 and 2015 and zero for the year ended December&nbsp;31, 2014. The acquisition of an intangible asset relating to HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	accrued in non-current liabilities amounted
	to $25.0 million for the year ended December&nbsp;31, 2015. The reacquired right relating to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	resulted in an intangible asset of $15.9 million, inventories of $3.0 million and a prepaid
	asset of $0.1 million for the year ended December&nbsp;31, 2014.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Certain Risks and Uncertainties
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company&#146;s products under development require approval from the FDA or other international regulatory agencies prior to commercial
	sales. There can be no assurance the products will receive the necessary clearance. If the Company is denied clearance or clearance is delayed, it may have a material adverse impact on the Company.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	67
</P>
<A NAME="eolPage70"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company&#146;s products are concentrated in rapidly-changing, highly-competitive markets,
	which are characterized by rapid technological advances, changes in customer requirements and evolving regulatory requirements and industry standards. Any failure by the Company to anticipate or to respond adequately to technological developments in
	its industry, changes in customer requirements or changes in regulatory requirements or industry standards or any significant delays in the development or introduction of products or services could have a material adverse effect on the
	Company&#146;s business, operating results and future cash flows.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company depends on single source suppliers for critical raw
	materials for manufacturing, as well as other components required for the administration of its products. The loss of these suppliers could delay the clinical trials or prevent or delay commercialization of the products.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Concentrations of Credit Risk
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Financial instruments, which potentially subject the Company to significant concentrations of credit risk, consist primarily of cash, cash
	equivalents and marketable securities. The Company places its cash, cash equivalents and marketable securities with highly-rated financial institutions. At December&nbsp;31, 2016, the Company maintained all of its cash, cash equivalents and
	marketable securities in three financial institutions. Deposits held with these institutions may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand, and the Company believes there is
	minimal risk of losses on such balances.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Segment and Geographic Information
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company operates in one reporting segment and, accordingly, no segment disclosures are presented herein. HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was commercially launched in Germany in August 2016. Foreign sales were not material for the year ended December&nbsp;31, 2016.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Recent Accounting Pronouncements
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In November 2016 the FASB issued Accounting Standards Update (ASU) 2016-18,
<I>
	Restricted Cash
</I>
	. The new standard requires that a statement
	of cash flows explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Therefore, amounts generally described as restricted cash and restricted
	cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for annually reporting periods beginning
	after December&nbsp;15, 2017, and interim periods within annual periods beginning after December&nbsp;15, 2017. Early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material impact on the
	Company&#146;s consolidated financial statements.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In August&nbsp;2016, the FASB issued ASU 2016-15,
<I>
	Statement of Cash Flows &#150;
	Classification of Certain Cash Receipts and Cash Payments
</I>
	, to clarify guidance on the classification of certain cash receipts and cash payments in the statement of cash flow. The standard is effective for annual reporting periods beginning after
	December&nbsp;15, 2017, and interim periods within annual periods beginning after December&nbsp;15, 2017. Early adoption is permitted. Adoption of this new standard is not expected to have a material impact on the Company&#146;s consolidated
	financial statements.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In June 2016, the FASB issued ASU 2016-13,
<I>
	Financial Instruments &#150; Credit Losses,
</I>
	related to the
	measurement of credit losses on financial instruments. The standard will require the use of an &#147;expected loss&#148; model for instruments measured at amortized cost. The standard is effective for years beginning after December&nbsp;15, 2019,
	and interim periods within annual periods beginning after December&nbsp;15, 2019. The Company is evaluating this standard to determine if adoption will have a material impact on the Company&#146;s consolidated financial statements.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In March 2016, the FASB issued ASU 2016-09,
<I>
	Improvements to Employee Share-Based Payment Accounting,
</I>
	to simplify various aspects
	related to how share-based payments are accounted for and presented in the financial statements. The ASU provides that all of the tax effects related to share-based payments are recorded as part of the provision for income taxes, allows entities to
	withhold an amount up to the employees&#146; maximum individual tax rate in the relevant jurisdiction, allows entities to estimate the effect of forfeitures or recognized forfeitures when they occur, and other improvements to the accounting for
	share-based awards. The new standard is effective for annual periods beginning after December&nbsp;15, 2016, and interim periods within annual periods beginning after December&nbsp;15, 2016. Early adoption is permitted. Adoption of this new standard
	is not expected to have a material impact on the Company&#146;s consolidated financial statements.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In February 2016, the FASB issued ASU
	2016-02,
<I>
	Leases
</I>
	. The new standard requires that lessees will need to recognize a right-of-use asset and a lease liability for virtually all of their leases (other than leases that meet the definition of a short-term lease). The liability will
	be equal to the present value of lease payments. The asset will be based on the liability subject to certain adjustments. For income statement purposes, the FASB retained a dual model, requiring leases to be classified as either operating or
	finance. Operating leases will result in straight-line expense (similar to current operating leases) while finance leases will result in a front-loaded expense pattern (similar to current capital leases).&nbsp;The new standard is effective for
	annual periods ending after December&nbsp;15, 2018, and interim periods within annual periods beginning after December&nbsp;15, 2018. Early adoption is permitted. The Company is evaluating this standard to determine if adoption will have a material
	impact on the Company&#146;s consolidated financial statements.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	68
</P>
<A NAME="eolPage71"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In July 2015, the FASB issued ASU 2015-11,
<I>
	Simplifying the Measurement of Inventory,
</I>
	dealing with changes to the subsequent measurement of inventory. Currently, an entity is required to measure its inventory at the lower of cost or market, whereby market can be replacement cost, net realizable value, or net realizable value less an
	approximately normal profit margin. The changes require that inventory be measured at the lower of cost and net realizable value, thereby eliminating the use of the other two market methodologies. Net realizable value is defined as the estimated
	selling prices in the ordinary course of business less reasonably predictable costs of completion, disposal, and transportation. The new standard is effective for periods beginning after December&nbsp;15, 2016. The Company adopted this new standard
	in the second quarter of 2016, and adoption did not have a material impact on the Company&#146;s consolidated financial statements.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In
	August 2014, the FASB issued ASU 2014-15,
<I>
	Presentation of Financial Statements &#150; Going Concern
</I>
	. The new standard requires management of public and private companies to evaluate whether there is substantial doubt about the entity&#146;s
	ability to continue as a going concern and, if so, disclose that fact. Management will also be required to evaluate and disclose whether its plans alleviate that doubt. The new standard is effective for annual periods ending after December&nbsp;15,
	2016, and interim periods within annual periods beginning after December&nbsp;15, 2016. The Company adopted this new standard for the year ended December&nbsp;31, 2016, and adoption did not have a material impact on the Company&#146;s consolidated
	financial statements.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In May 2014, the FASB issued ASU 2014-09,
<I>
	Revenue from Contracts with Customers
</I>
	. This new standard requires
	companies to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which a company expects to be entitled in exchange for those goods or services. Under the new standard, revenue
	is recognized when a customer obtains control of a good or service. The standard allows for two transition methods&#151;entities can either apply the new standard (i)&nbsp;retrospectively to each prior reporting period presented, or
	(ii)&nbsp;retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. In July 2015, the FASB issued ASU 2015-14,
<I>
	Revenue from Contracts with Customers
</I>
	, which defers the effective
	date by one year to December&nbsp;15, 2017 for fiscal years, and interim periods within those fiscal years, beginning after that date. Early adoption of the standard is permitted, but not before the original effective date of December&nbsp;15, 2016.
	In March 2016, the FASB issued ASU 2016-08
<I>
	Revenue from Contracts with Customers, Principal versus Agent Considerations (Reporting Revenue versus Net),
</I>
	in April 2016, the FASB issued ASU 2016-10,
<I>
	Revenue from Contracts with Customers,
	identifying Performance Obligations and Licensing
</I>
	, and in May 2016, the FASB issued ASU 2016-12,
<I>
	Revenue from Contracts with Customers, Narrow-Scope Improvements and Practical Expedients,
</I>
	which provide additional clarification on certain
	topics addressed in ASU 2014-09. ASU 2016-08, ASU 2016-10, and ASU 2016-12 follow the same implementation guidelines as ASU 2014-09 and ASU 2015-14. The initial analysis identifying areas that will be impacted by the new guidance is substantially
	complete, and the Company is currently analyzing the potential impacts to the consolidated financial statements and related disclosures. Revenue from the Company&#146;s product sales is expected to remain substantially unchanged.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	3.&nbsp;Settlement Agreement with Novartis
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In May 2014, the Company commenced arbitration proceedings with Novartis relating to the license of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	Arbitration). In December 2014, the Company entered into a settlement agreement with Novartis and certain of its affiliates
	(the Settlement Agreement). Pursuant to the terms of the Settlement Agreement, the Company and Novartis dismissed the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	Arbitration and released each other from any related claims. In
	addition, in connection with the Settlement Agreement, Novartis (i)&nbsp;transferred all U.S. and Canadian rights in the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	franchise to the Company, (ii)&nbsp;purchased $25.0 million of
	the Company&#146;s common stock at a price per share equal to $13.82, and (iii)&nbsp;granted to the Company an exclusive worldwide license to AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to the stock purchase agreement entered into as part of the Settlement Agreement, Novartis purchased $25.0 million of the
	Company&#146;s common stock. The Company issued to Novartis an aggregate of 1,808,973 shares at $13.82 per share, which per share represented a 10% premium to the average closing prices of the Company&#146;s common stock for the ten trading days
	prior to December&nbsp;22, 2014. The Company recorded a loss of $0.9 million as part of gain on arbitration settlement in the consolidated statement of operations for the year ended December&nbsp;31, 2014 related to the issuance of stock, which was
	valued using the Company&#146;s closing stock price on December&nbsp;31, 2014, the effective date of the transaction.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In connection with
	the Settlement Agreement, the Company received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize AQW051. Under the AQW051 license agreement, the
	Company is obligated to use its commercially reasonable efforts to develop and commercialize AQW051 and is responsible for all development costs under the AQW051 license agreement. Novartis is eligible to receive tiered-royalties on net sales at
	percentage rates up to the mid-teens. The Company evaluated AQW051 and determined that the asset is both incomplete and has substance. However, given the early stage of AQW051 and the future costs of development, no transaction value was allocated
	to this asset.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company accounted for the Settlement Agreement in accordance with the provisions of ASC Subtopic 805,&nbsp;
<I>
	Business
	Combinations
</I>
	(ASC 805). Under the provisions of ASC 805, the acquisition date for a business is the date on which the company obtains control of the acquiree. The Company obtained control on December&nbsp;31, 2014, the effective date of the
	Settlement Agreement.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	69
</P>
<A NAME="eolPage72"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following summarizes the fair value of consideration exchanged as part of the Settlement Agreement:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="87%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Equity issued
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25,904
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Cash received
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(25,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Settlement of
<FONT STYLE="WHITE-SPACE:NOWRAP">
	pre-existing
</FONT>
<FONT STYLE="WHITE-SPACE:NOWRAP">
	non-contractual
</FONT>
	relationship
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	18,087
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	18,991
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Assets acquired and recorded at fair value as of December&nbsp;31, 2014 were as follows:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_23"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="88%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Inventory
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,960
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Intangible&#151;Re-acquired
</FONT>
	right
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15,940
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Prepaid services
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	91
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	18,991
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company recorded the reacquired right as an intangible asset as of December&nbsp;31, 2014 and has
	amortized the reacquired right on a straight-line basis through November 2016.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Due to the effective date of the Settlement Agreement
	being December&nbsp;31, 2014, the Company did not recognize any revenue or operating expenses related to U.S. or Canadian commercial sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the consolidated statement of
	operations for the year ended December&nbsp;31, 2014.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In connection with the Settlement Agreement, the Company and Novartis terminated
	the 2009 Amended Sublicense Agreement (the 2009 Agreement). Given the termination of this pre-existing contractual relationship and that there is no further obligation under the 2009 Agreement, the Company recognized a gain of $59.5 million,
	representing the remaining deferred revenue related to the $200.0 million upfront payment received from Novartis under the 2009 Agreement. This amount was included in gain on arbitration settlement in the consolidated statement of operations in the
	fourth quarter of 2014.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Settlement Agreement provided for a mutual release of claims and dismissed the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	Arbitration, which effectively settled a pre-existing non-contractual relationship. As a result, the Company recorded an $18.1 million gain on the settlement of arbitration, which represented the
	value of a potential future arbitration outcome. This amount was valued based on a probability weighted scenario analysis that took into consideration the probability of each potential future alternative outcomes of the arbitration between the
	parties. This amount is included in gain on arbitration settlement in the consolidated statement of operations for the year ended December&nbsp;31, 2014.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	4.&nbsp;Earnings per Share
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Basic
	earnings per share (EPS) is calculated by dividing the net income (loss) by the weighted average number of shares of common stock outstanding. Diluted EPS is computed by dividing the net income (loss) by the weighted average number of shares of
	common stock outstanding, plus potential outstanding common stock for the period. Potential outstanding common stock includes stock options and shares underlying RSUs, but only to the extent that their inclusion is dilutive.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	70
</P>
<A NAME="eolPage73"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following table presents the calculation of basic and diluted net income (loss) per share of
	common stock for the years ended December&nbsp;31, 2016, 2015, and 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_24"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="62%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands, except for share and per share amounts)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Numerator:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net income (loss)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(18,010
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(39,865
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	20,186
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Denominator:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Weighted average shares outstanding: Basic
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	43,449,441
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	42,250,254
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	34,774,163
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Effect of dilutive securities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,912,560
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Weighted average shares outstanding: Diluted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	43,449,441
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	42,250,254
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	36,686,723
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net income (loss) per share, basic and diluted:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Basic
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.41
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.94
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.58
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Diluted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.41
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.94
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.55
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Antidilutive securities excluded from calculations of diluted net income (loss) per share
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,943,797
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,660,199
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,524,656
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company incurred a net loss for each of the years ended December&nbsp;31, 2016 and 2015 causing inclusion
	of any potentially dilutive securities to have an anti-dilutive effect, resulting in dilutive loss per share and basic loss per share attributable to common stockholders being equivalent.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	5.&nbsp;Marketable Securities
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The
	following is a summary of the Company&#146;s available-for-sale marketable securities as of December&nbsp;31, 2016, all of which have contract maturities of less than one year:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_25"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="63%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	December&nbsp;31, 2016
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	(in
	thousands)
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Amortized
<BR>
	Cost
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Gross
<BR>
	Unrealized
<BR>
	Gains
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Gross
<BR>
	Unrealized
<BR>
	Losses
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Fair
<BR>
	Market
<BR>
	Value
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	U.S. Treasury and government agencies
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,661
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(17
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,647
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Corporate debt
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,194
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	89
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(16
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,267
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	100,855
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	92
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(33
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	100,914
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of the Company&#146;s available-for-sale marketable securities as of
	December&nbsp;31, 2015:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_26"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="65%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	December&nbsp;31, 2015
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	(in
	thousands)
</I>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Amortized
<BR>
	Cost
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Gross
<BR>
	Unrealized
<BR>
	Gains
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Gross
<BR>
	Unrealized
<BR>
	Losses
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Fair
<BR>
	Market
<BR>
	Value
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	U.S. Treasury and government agencies
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	44,059
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(8
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	44,057
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Corporate debt
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	48,239
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	46
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(5
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	48,280
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	92,298
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	52
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(13
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	92,337
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	6.&nbsp;Fair Value Measurements
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Authoritative guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers
	include:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Level 1 &#151; defined as observable inputs such as quoted prices in active markets
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Level 2 &#151; defined as inputs other than quoted prices in active markets that are either directly or indirectly observable
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">
	&nbsp;
</TD>
<TD WIDTH="2%" VALIGN="TOP" ALIGN="LEFT">
	&#149;
</TD>
<TD WIDTH="1%" VALIGN="TOP">
	&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Level 3 &#151; defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Marketable securities classified in Level 1 and Level 2 as of December&nbsp;31, 2016 and 2015 consist of available-for-sale marketable
	securities. The valuation of Level 1 instruments is determined using a market approach, and is based upon unadjusted quoted prices for identical assets in active markets. The valuation of investments classified in Level 2 also is determined using a
	market approach based upon quoted prices for similar assets in active markets, or other inputs that are observable for substantially the full term of the financial instrument. Level 2 securities include certificates of deposit, commercial paper and
	corporate notes that use as their basis readily observable market parameters. The Company did not transfer any assets between Level 2 and Level 1 during the years ended December&nbsp;31, 2016 and 2015.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	71
</P>
<A NAME="eolPage74"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company held certain assets that are required to be measured at fair value on a recurring
	basis as of December&nbsp;31, 2016, as follows:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_27"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="49%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Fair Value Measurement as of December&nbsp;31, 2016 Using
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<I>
	(in thousands)
</I>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
<BR>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Quoted&nbsp;Prices&nbsp;in
<BR>
	Active&nbsp;Markets&nbsp;for
<BR>
	Identical Assets
<BR>
	(Level 1)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Significant&nbsp;Other
</B>
<BR>
<B>
	Observable&nbsp;Inputs
</B>
<BR>
<B>
	(Level 2)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Significant
</B>
<BR>
<B>
	Unobservable
</B>
<BR>
<B>
	Inputs
</B>
<BR>
<B>
	(Level 3)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<FONT STYLE="WHITE-SPACE:NOWRAP">
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Available-for-sale
</FONT>
</FONT>
	securities:
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	U.S. Treasury and government agencies
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,647
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,647
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Corporate debt
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,267
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,267
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	100,914
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,647
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	50,267
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company held certain assets that are required to be measured at fair value on a recurring basis as of
	December&nbsp;31, 2015, as follows:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_28"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="8%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Fair&nbsp;Value&nbsp;Measurement&nbsp;as&nbsp;of&nbsp;December&nbsp;31,&nbsp;2015&nbsp;Using
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<I>
	(in thousands)
</I>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
<BR>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Quoted&nbsp;Prices&nbsp;in
<BR>
	Active&nbsp;Markets&nbsp;for
<BR>
	Identical Assets
<BR>
	(Level 1)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Significant&nbsp;Other
<BR>
	Observable&nbsp;Inputs
<BR>
	(Level 2)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Significant
<BR>
	Unobservable
<BR>
	Inputs
</B>
<BR>
<B>
	(Level 3)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<FONT STYLE="WHITE-SPACE:NOWRAP">
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Available-for-sale
</FONT>
</FONT>
	securities:
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	U.S. Treasury and government agencies
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	44,057
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	44,057
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Corporate debt
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	48,280
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	48,280
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	92,337
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	44,057
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	48,280
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company also has financial assets and liabilities, not required to be measured at fair value on a
	recurring basis, which primarily consist of cash and cash equivalents, accounts receivable, restricted cash, accounts payable and accrued liabilities, the carrying value of which materially approximate their fair values.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	7.&nbsp;Inventory
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company evaluates
	expiry risk by evaluating current and future product demand relative to product shelf life. The Company builds demand forecasts by considering factors such as, but not limited to, overall market potential, market share, market acceptance and patient
	usage. Inventory levels are evaluated for the amount of inventory that would be sold within one year. At certain times, the level of inventory&nbsp;can exceed the forecasted level of cost of goods sold for the next twelve months. The Company
	classifies the estimate of such inventory as non-current. Inventory consisted of the following as of December&nbsp;31, 2016 and 2015:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_29"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="82%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Current assets
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="WHITE-SPACE:NOWRAP">
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Work-in-process
</FONT>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	17
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Finished goods
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	762
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,294
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	779
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,294
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Non-Current
</FONT>
	assets
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Raw materials
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	127
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	127
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="WHITE-SPACE:NOWRAP">
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Work-in-process
</FONT>
</FONT>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,225
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,369
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Finished goods
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	83
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,435
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,496
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	72
</P>
<A NAME="eolPage75"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	8.&nbsp;Prepaid Expenses and Other Current Assets
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of the Company&#146;s prepaid expenses and other current assets as of December&nbsp;31, 2016 and 2015:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_30"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="81%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development expenses
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,397
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,948
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Consulting and other professional fees
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6,051
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,815
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Prepaid royalties
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,761
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,579
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	979
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11,788
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,742
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	9.&nbsp;Property and Equipment
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of the Company&#146;s property and equipment, at cost, as of December&nbsp;31, 2016 and 2015:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_31"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="71%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="5%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ROWSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Estimated
</B>
<BR>
<B>
	Useful&nbsp;Life
</B>
<BR>
<B>
	(Years)
</B>
</TD>
<TD VALIGN="BOTTOM" ROWSPAN="2">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	December&nbsp;31,
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Computer and other equipment
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	3
</TD>
<TD NOWRAP VALIGN="TOP">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,426
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,046
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Furniture and fixtures
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	5 - 7
</TD>
<TD NOWRAP VALIGN="TOP">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,412
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,318
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Leasehold improvements
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
	5&nbsp;-11
</TD>
<TD NOWRAP VALIGN="TOP">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,408
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,519
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,246
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6,883
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="4">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accumulated depreciation and amortization
</P>
</TD>
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(3,231
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(2,313
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,015
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,570
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Depreciation expense was $0.9 million, $0.6 million and $0.5 million for the years ended December&nbsp;31,
	2016, 2015 and 2014, respectively.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	10.&nbsp;Intangible Assets
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of the Company&#146;s intangible assets as of December&nbsp;31, 2016:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_32"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="57%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31, 2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Estimated Useful
<BR>
	Life (Years)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Gross
<BR>
	Carrying
<BR>
	Amount
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Accumulated
<BR>
	Amortization
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Net
<BR>
	Carrying
<BR>
	Amount
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	January 2033
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	33,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,181
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,819
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
</SUP>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	November&nbsp;2016
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,941
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,941
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	60,941
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	33,122
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,819
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of the Company&#146;s intangible assets as of December&nbsp;31, 2015:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_33"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="57%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD COLSPAN="2" VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31, 2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Estimated Useful
<BR>
	Life (Years)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Gross
<BR>
	Carrying
<BR>
	Amount
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Accumulated
<BR>
	Amortization
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Net
<BR>
	Carrying
<BR>
	Amount
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	January&nbsp;2033
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	33,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,460
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	29,540
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
</SUP>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
	November&nbsp;2016
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,941
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	18,729
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9,212
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	60,941
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	22,189
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	38,752
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	HETLIOZ
</I>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<I>
	.
</I>
	In January 2014, the Company
	announced that the FDA had approved the NDA for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. As a result of this approval, the Company met a milestone under its license agreement with Bristol-Myers Squibb (BMS) that required
	the Company to make a license payment of $8.0 million to BMS. The $8.0 million is being amortized on a straight-line basis over the remaining life of the U.S. patent for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, which prior
	to June 2014, the Company expected to last until December 2022. In June 2014, the Company received a notice of allowance from the U.S. Patent and Trademark Office for a patent covering the method of use of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. The patent expires in January 2033, thereby potentially extending the exclusivity protection in the U.S. beyond the composition of matter patent. As a result of the patent allowance, the Company
	extended the estimated useful life of the U.S. patent for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	from December 2022 to January 2033.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	73
</P>
<A NAME="eolPage76"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company is obligated to make a future milestone payment to BMS of $25.0 million in the event
	that cumulative worldwide sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	reach $250.0 million. The likelihood of achieving the milestone and the related milestone obligation was determined to be probable during the year
	ended December&nbsp;31, 2015. As a result, the future obligation of $25.0 million was recorded as a non-current liability as of December&nbsp;31, 2016 and 2015. The $25.0 million was determined to be additional consideration for the acquisition of
	the HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	intangible asset, which was created upon FDA approval on January&nbsp;31, 2014. The actual payment of the $25.0 million will occur once the $250.0 million in cumulative worldwide
	sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is realized, which the Company expects to occur by the end of 2018. The intangible asset of $25.0 million is being amortized on a straight-line basis over the remaining life
	of the U.S. patent for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, which is expected to be January 2033. Amortization of intangible assets relating to HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	amounted
	to $1.7 million, $2.9 million and $0.6 million for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively. In future periods the Company expects annual amortization of capitalized intangible asset costs relating to HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	will amount to $1.7 million until the expiration of the patent in 2033.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Fanapt
</I>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. In 2009, the Company announced that the FDA had approved the NDA for
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. As a result of this approval, the Company met a milestone under its original sublicense agreement with Novartis that required the Company to make a license payment of $12.0 million to
	Novartis. The $12.0 million has been amortized on a straight-line basis over the remaining life of the U.S. composition of matter patent for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	to November 2016.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to the Settlement Agreement, Novartis transferred all U.S. and Canadian rights in the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	franchise to the Company. As a result, the Company recognized an intangible asset of $15.9 million on December&nbsp;31, 2014 related to the reacquired rights to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, which has been amortized on a straight-line basis through November 2016. The useful life estimation for the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	intangible asset was
	based on the market participant methodology prescribed by ASC 805, and therefore does not reflect the impact of additional Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	patents solely owned by the Company with varying expiration
	dates, the latest of which is December 2031. Amortization of intangible assets relating to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	was completed in November 2016 and amounted to $9.2 million, $10.1 million and $1.7 million
	for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Intangible assets are amortized over their estimated useful
	economic life using the straight line method. Total amortization expense was $10.9 million, $13.0 million and $2.3 million for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of the future intangible asset amortization schedule as of December&nbsp;31, 2016:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT" ALIGN="CENTER">
<TR>
<TD WIDTH="56%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Total
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2017
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2018
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2019
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2020
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2021
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Thereafter
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
</SUP>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,819
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,721
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,721
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,721
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,721
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,721
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	19,214
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	11.&nbsp;Accounts Payable and Accrued Liabilities
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of the Company&#146;s accounts payable and accrued liabilities as of December&nbsp;31, 2016 and 2015:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_34"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="80%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development expenses
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,024
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,199
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Consulting and other professional fees
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,192
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,088
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Compensation and employee benefits
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,291
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	468
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Royalties payable
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,555
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,328
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,134
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,684
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	16,196
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	15,767
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	12.&nbsp;Deferred Licensing Revenue
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of changes in deferred licensing revenue for the year ended December&nbsp;31, 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_35"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="84%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="9%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended
<BR>
	December&nbsp;31,
<BR>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balance December&nbsp;31, 2013
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	90,275
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Licensing revenue recognized
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(30,746
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Recognized as part of gain on arbitration settlement
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(59,529
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Balance December&nbsp;31, 2014
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	During the year ended December&nbsp;31, 2014, the Company recognized revenue of $30.7 million related to the
	amended and restated sublicense agreement with Novartis entered into in 2009. In connection with the Settlement Agreement, the Company
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	recognized the
	remaining deferred revenue balance of $59.5 million during year ended December&nbsp;31, 2014, as part of the gain on arbitration settlement. See Note 3,
<I>
	Settlement Agreement with Novartis
</I>
	, for additional information.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	74
</P>
<A NAME="eolPage77"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	13.&nbsp;Commitments and Contingencies
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Operating Leases
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Commitments relating to operating leases represent the minimum annual future payments under operating leases and subleases for a total of
	40,188 square feet of office space for the Company&#146;s headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. that expire in 2026, the operating lease for 2,880 square feet of office space for the Company&#146;s European headquarters
	in London that has a noncancellable lease term ending in 2021, and 1,249 square feet of office space in Berlin under a short-term operating lease. The following is a summary of the minimum annual future payments under operating leases and subleases
	for office space as of December&nbsp;31, 2016:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT" ALIGN="CENTER">
<TR>
<TD WIDTH="56%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="26" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Cash payments due by year
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Total
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2017
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2018
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2019
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2010
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2021
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Thereafter
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Operating leases
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	21,623
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,981
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,216
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,271
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,327
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,170
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10,658
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In 2011, the Company entered into an operating lease for its headquarters at 2200 Pennsylvania Avenue, N.W. in
	Washington, D.C. A lease amendment in 2014 increased the office space under lease to 30,260 square feet, and a lease amendment in June 2016 extended the lease term from April 2023 to September&nbsp;2026. Subject to the prior rights of other tenants,
	the Company has the right to renew the lease for five years following its expiration. The Company has the right to sublease or assign all or a portion of the premises, subject to standard conditions. The lease may be terminated early by the Company
	or the landlord under certain circumstances.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In June 2016, the Company entered into a sublease under which the Company will lease 9,928
	square feet of office space for its headquarters at 2200 Pennsylvania Avenue, N.W. in Washington, D.C. The sublease term begins in January&nbsp;2017 and ends in July&nbsp;2026, but may be terminated earlier by either party under certain
	circumstances. The Company has the right to sublease or assign all or a portion of the premises, subject to standard conditions.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Rent
	expense under operating leases and subleases, was $2.5 million, $1.9 million and $1.7 million for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Guarantees and Indemnifications
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company has entered into a number of standard intellectual property indemnification agreements in the ordinary course of its business.
	Pursuant to these agreements, the Company indemnifies, holds harmless, and agrees to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#146;s business partners or customers, in connection
	with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company&#146;s products. The term of these indemnification agreements is generally perpetual from the date of execution of
	the agreement. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. Since inception, the Company has not incurred costs to defend lawsuits or settle claims related
	to these indemnification agreements. The Company also indemnifies its officers and directors for certain events or occurrences, subject to certain conditions.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	License Agreements
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company&#146;s rights to develop and commercialize its products are subject to the terms and conditions of licenses granted to the Company
	by other pharmaceutical companies.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	HETLIOZ
</I>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<I>
	.
</I>
	In February 2004, the
	Company entered into a license agreement with BMS under which it received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. In partial consideration for the license, the Company paid BMS an initial license fee of $0.5 million. The Company made a milestone payment to BMS of $1.0 million under the license agreement in
	2006 relating to the initiation of its first Phase III clinical trial for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	. As a result of the FDA acceptance of the Company&#146;s NDA for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for the treatment of Non-24 in July 2013, the Company incurred a $3.0 million milestone obligation under the license agreement with BMS. As a result of the FDA&#146;s approval of the HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	NDA in January 2014, the Company incurred an $8.0 million milestone obligation in the first quarter of 2014 under the same license agreement that was capitalized as an intangible asset and is
	being amortized over the expected HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	patent life in the U.S. The Company is obligated to make a future milestone payment to BMS of $25.0 million in the event that cumulative worldwide
	sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	reach $250.0 million. During the first quarter of 2015, the likelihood of achieving the milestone and the related milestone obligation was determined to be probable. As such,
	the $25.0 million milestone obligation was capitalized as an intangible asset and is being amortized over the expected HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	patent life in the U.S. The actual payment of the $25.0 million
	will occur once the $250.0 million in cumulative worldwide sales of HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	is realized, which is expected to be in 2018. Additionally, the Company is obligated to make royalty payments on
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	net sales to BMS in any territory where the
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	75
</P>
<A NAME="eolPage78"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Company commercializes HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	for a period equal to the greater of 10 years following the first commercial sale in the territory or the
	expiry of the new chemical entity patent in that territory. During the period prior to the expiry of the new chemical entity patent in a territory, the Company is obligated to pay a 10% royalty on net sales in that territory.&nbsp;The royalty rate
	is decreased by half for countries in which no new chemical entity patent existed or for the remainder of the 10 years after the expiry of the new chemical entity patent. The Company is also obligated under the license agreement to pay BMS a
	percentage of any sublicense fees, upfront payments and milestone and other payments (excluding royalties) that it receives from a third party in connection with any sublicensing arrangement, at a rate which is in the mid-twenties. The Company has
	agreed with BMS in the license agreement for HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	to use its commercially reasonable efforts to develop and commercialize HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The license agreement was amended in April 2013 to add a process that would allow BMS to waive the right to develop and commercialize
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in those countries not covered by a development and commercialization agreement. Subsequent to the execution of the April 2013 amendment, BMS provided the Company with formal written
	notice that it irrevocably waived the option to exercise the right to reacquire any or all rights to any product (as defined in the license agreement) containing HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, or to develop or
	commercialize any such product, in the countries not covered by a development and commercialization agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Either party may terminate
	the HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	license agreement under certain circumstances, including a material breach of the agreement by the other. In the event the Company terminates the license, or if BMS terminates the
	license due to the Company&#146;s breach, all rights licensed and developed by the Company under the license agreement will revert or otherwise be licensed back to BMS on an exclusive basis.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Fanapt
</I>
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
<I>
	.
</I>
	A predecessor company of Sanofi, Hoechst Marion Roussel, Inc.
	(HMRI) discovered Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	and completed early clinical work on the product. In 1996, following a review of its product portfolio, HMRI licensed its rights to the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	patents and patent applications to Titan Pharmaceuticals, Inc. (Titan) on an exclusive basis. In 1997, soon after it had acquired its rights, Titan sublicensed its rights to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	on an exclusive basis to Novartis. In June 2004, the Company acquired exclusive worldwide rights to these patents and patent applications, as well as certain Novartis patents and patent
	applications to develop and commercialize Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, through a sublicense agreement with Novartis. In October 2009, subsequent to the FDA&#146;s approval of the NDA for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, the Company entered into an amended and restated sublicense agreement with Novartis, which amended and restated the June 2004 sublicense agreement. Pursuant to the amended and restated
	sublicense agreement, Novartis had exclusive commercialization rights to all formulations of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and Canada. Novartis began selling Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. during the first quarter of 2010. Novartis was responsible for the further clinical development activities in the U.S. and Canada. The Company also received royalties equal to 10% of
	net sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. and Canada up to December&nbsp;31, 2014. The Company retained exclusive rights to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	outside the
	U.S. and Canada and was obligated to make royalty payments to Sanofi S.A. (Sanofi) on Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	sales outside the U.S. and Canada.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to the terms of the Settlement Agreement with Novartis, Novartis transferred all U.S. and Canadian rights in the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	franchise to the Company on December&nbsp;31, 2014. The Company is obligated to make royalty payments to Sanofi and Titan, at a percentage rate equal to 23% on annual U.S. net sales of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	up to $200.0 million, and at a percentage rate in the mid-twenties on sales over $200.0 million through November 2016. In February 2016, the Company amended the agreement with Sanofi and Titan to
	remove Titan as the entity through which royalty payments from the Company are directed to Sanofi following the expiration of the new chemical entity (NCE) patent for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. on
	November&nbsp;15, 2016. Under the amended agreement, the Company will pay directly to Sanofi a fixed royalty of 3% of net sales from November&nbsp;16, 2016 through December&nbsp;31, 2019 related to manufacturing know-how. The Company made a $2.0
	million payment during the year ended December&nbsp;31, 2016 that applied to this 3% manufacturing know-how royalty and will make additional royalty payments only to the extent that the Company&#146;s cumulative royalty obligations during this
	period exceed the amount of the pre-payment. No further royalties on manufacturing know-how are payable by the Company after December&nbsp;31, 2019. This amended agreement does not alter Titan&#146;s obligation under the license agreement to make
	royalty payments to Sanofi prior to November&nbsp;16, 2016 or the Company&#146;s obligations under the sublicense agreement to pay Sanofi a fixed royalty on Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	net sales equal up to 6% on
	Sanofi know-how not related to manufacturing under certain conditions for a period of up to 10 years in markets where the NCE patent has expired or was not issued.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company has entered into distribution agreements with Probiomed S.A. de C.V. for the commercialization of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Mexico and Megapharm Ltd. for the commercialization of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in Israel.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Tradipitant.
</I>
	In April 2012, the Company entered into a license agreement with Eli Lilly and Company (Lilly) pursuant to which the
	Company acquired an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize an NK-1R antagonist, tradipitant, for all human indications. The patent
	describing tradipitant as a new chemical entity expires in April 2023, except in the U.S., where it expires in June 2024 absent any applicable patent term adjustments. Pursuant to the license agreement, the Company paid Lilly an initial license fee
	of $1.0 million and will be responsible for all development costs. The initial license fee was recognized as research and development expense in the consolidated statement of operations for the year ended December&nbsp;31, 2012. Lilly is also
	eligible to receive additional payments based upon achievement of specified development and commercialization milestones as well as tiered-royalties on net sales at percentage rates up to the low
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	76
</P>
<A NAME="eolPage79"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	double digits. These milestones include $4.0 million for pre-NDA approval milestones and up to $95.0 million for future regulatory approval and sales milestones. The Company is obligated to use
	its commercially reasonable efforts to develop and commercialize tradipitant. Either party may terminate the license agreement under certain circumstances, including a material breach of the license agreement by the other. In the event that the
	Company terminates the license agreement, or if Lilly terminates due to the Company&#146;s breach or for certain other reasons set forth in the license agreement, all rights licensed and developed by the Company under the license agreement will
	revert or otherwise be licensed back to Lilly on an exclusive basis, subject to payment by Lilly to the Company of a royalty on net sales of products that contain tradipitant.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	AQW051.
</I>
	In connection with the settlement agreement with Novartis relating to
	Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, the Company received an exclusive worldwide license under certain patents and patent applications, and other licenses to intellectual property, to develop and commercialize AQW051, a
	Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. Pursuant to the license agreement, the Company is obligated to use its commercially reasonable efforts to develop and commercialize AQW051 and is responsible for all development
	costs under the AQW051 license agreement. The Company has no milestone obligations; however, Novartis is eligible to receive tiered-royalties on net sales at percentage rates up to the mid-teens.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Research and Development and Marketing Agreements
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In the course of its business, the Company regularly enters into agreements with clinical organizations to provide services relating to
	clinical development and clinical manufacturing activities under fee service arrangements. The Company&#146;s current agreements for clinical services may be terminated on generally 60 days&#146; notice without incurring additional charges, other
	than charges for work completed but not paid for through the effective date of termination and other costs incurred by the Company&#146;s contractors in closing out work in progress as of the effective date of termination.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	14. Income Taxes
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company recorded
	total tax expense of $0.1 million on consolidated pretax loss of $17.9 million, consisting of $18.1 million of pretax loss in the U.S. and $0.2 million of pretax income from foreign subsidiaries. The following is a summary of the provision (benefit)
	for income taxes for the years ended December&nbsp;31, 2016, 2015 and 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_36"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="79%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Current:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Federal
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	State
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	66
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Foreign
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	142
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Deferred:
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Federal
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	State
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Foreign
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(104
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Provision for income taxes
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	104
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Deferred tax assets are reduced by a tax valuation allowance when, in the opinion of management, it is more
	likely than not that some portion or all of the deferred tax assets will not be realized. The fact that the Company has historically generated pretax losses in the U.S. serves as strong evidence that it is more likely than not that deferred tax
	assets in the U.S. will not be realized in the future. Therefore, the Company had a full tax valuation allowance against all deferred tax assets in the U.S. as of December&nbsp;31, 2016 and 2015. As a result of the tax valuation allowance against
	deferred tax assets in the U.S., there was no benefit for income taxes for the years ended December&nbsp;31, 2016 and 2015 and there was no provision for income taxes for the years ended December&nbsp;31, 2015 and 2014.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	77
</P>
<A NAME="eolPage80"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is reconciliation between the federal statutory tax rate and the Company&#146;s
	effective tax rate for the years ended December&nbsp;31, 2016, 2015 and 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_37"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="79%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Federal tax at statutory rate
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	35.0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	35.0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	34.0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	State taxes
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.8
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	-0.1
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7.2
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Change in valuation allowance
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	-38.4
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	-25.4
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	-59.7
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development credit
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.8
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.5
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.3
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Orphan drug credit
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7.6
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.6
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8.5
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Section 162(m) limitation
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	-5.7
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.1
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Tax rate change
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.9
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	-0.3
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.8
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Change in state NOLs
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	-1.4
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<FONT STYLE="WHITE-SPACE:NOWRAP">
	Non-deductible
</FONT>
	stock-based compensation
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	-12.5
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	-5.1
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other
<FONT STYLE="WHITE-SPACE:NOWRAP">
	non-deductible
</FONT>
	items
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	-0.8
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	-0.1
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2.8
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Effective tax rate
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	-0.6
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of the components of the Company&#146;s deferred tax assets, net, and the related
	tax valuation allowance as of December&nbsp;31, 2016 and 2015:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_38"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="76%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="6" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Deferred tax assets:
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net operating loss carryforwards
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	84,177
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	83,686
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Stock-based compensation
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,443
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,919
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Accrued and deferred expenses
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,558
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,443
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development and orphan drug credit carryforwards
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	41,104
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	38,333
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Intangible assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,477
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,954
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,019
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	802
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total deferred tax assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	146,778
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	140,137
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Deferred tax liabilities:
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Other
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(666
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,100
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Total deferred tax liabilities
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(666
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(1,100
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Deferred tax assets, net
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	146,112
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	139,037
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Valuation allowance
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(146,012
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(139,037
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net deferred tax assets
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	100
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	$
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
	&#151;&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company&#146;s net deferred tax asset of $0.1 million as of December&nbsp;31, 2016 was included as a
	component of non-current inventory and other in the consolidated balance sheet.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of changes in the
	Company&#146;s tax valuation allowance for the years ended December&nbsp;31, 2016, 2015 and 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_39"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="62%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Balance at
<BR>
	Beginning
<BR>
	of Year
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Additions
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Reductions
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Balance at
<BR>
	End of
<BR>
	Year
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Year Ended:
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	December&nbsp;31, 2016
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	139,037
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11,031
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(4,056
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	146,012
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	December&nbsp;31, 2015
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	128,890
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	17,002
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(6,855
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	139,037
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	December&nbsp;31, 2014
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	141,150
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,893
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(40,153
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	128,890
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of December&nbsp;31, 2016, the Company had federal and state net operating loss (NOL) carryforwards of
	$228.0 million, including $8.7 million of gross excess windfall benefits generated from stock-based compensation from which the tax benefit would be recorded to Additional Paid-in Capital if realized. As of December&nbsp;31, 2016, the Company also
	had research and development credits of $7.5 million and orphan drug carryforward credits of $33.7 million. These NOL carryforwards and credits will begin to expire in 2028 and 2024, respectively.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Because the Company has generated NOLs from inception through December, 31, 2016, all income tax returns filed by the Company are open to
	examination by tax jurisdictions. As of December&nbsp;31, 2016, the Company&#146;s income tax returns had not been under examination by any federal or state tax jurisdictions. As of December&nbsp;31, 2016 and 2015, the Company had no uncertain tax
	positions.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	78
</P>
<A NAME="eolPage81"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Certain tax attributes of the Company, including NOLs and credits, are potentially subject to a
	limitation should an ownership change as defined under the Internal Revenue Code of 1986, as amended (IRC), Section&nbsp;382, occur. The limitations resulting from a change in ownership could affect the Company&#146;s ability to use NOLs and credit
	carryforward (tax attributes). Ownership changes did occur as of December&nbsp;31, 2014 and December&nbsp;31, 2008. However, the Company believes that it had sufficient Built-In-Gain to offset the IRC Section&nbsp;382 limitation generated by the
	ownership changes. Any future ownership changes may cause the Company&#146;s existing tax attributes to have additional limitations. Additionally, the Company maintains a valuation allowance on its tax attributes, therefore, any IRC Section&nbsp;382
	limitation would not have a material impact on the Company&#146;s provision for income taxes as of December&nbsp;31, 2016.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	15.&nbsp;Public Offering of
	Common Stock
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In October 2014, the Company completed a public offering of 5,750,000 shares of common stock at a price to the public of
	$11.60 per share. Net cash proceeds from the public offering were $62.3 million, after deducting the underwriting discounts and commissions and offering expenses.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	16.&nbsp;Equity Incentive Plans
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	As of
	December&nbsp;31, 2016, there were 6,686,764 shares that were subject to outstanding options and RSUs under the 2006 Equity Incentive Plan (the 2006 Plan) and the 2016 Equity Incentive Plan (the 2016 Plan) (collectively, the Plans). The 2006 Plan
	expired by its terms on April&nbsp;12, 2016. Outstanding options and RSUs under the 2006 Plan remain in effect and the terms of the 2006 Plan continue to apply, but no additional awards can be granted under the 2006 Plan. On June&nbsp;16, 2016, the
	Company&#146;s stockholders approved the 2016 Plan. There are 2,000,000 shares of common stock reserved for issuance under the 2016 Plan, of which 1,822,500 shares remained available for future grant as of December&nbsp;31, 2016.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Stock Options
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The
	Company has granted option awards under the Plans with service conditions (service option awards) that are subject to terms and conditions established by the compensation committee of the board of directors. Service option awards have 10-year
	contractual terms and all service option awards granted prior to December&nbsp;31, 2006, service option awards granted to new employees, and certain service option awards granted to existing employees vest and become exercisable on the first
	anniversary of the grant date with respect to the 25% of the shares subject to service option awards. The remaining 75% of the shares subject to the service option awards vest and become exercisable monthly in equal installments thereafter over
	three years. Certain service option awards granted to existing employees after December&nbsp;31, 2006 vest and become exercisable monthly in equal installments over four years. The initial service option awards granted to directors upon their
	election vest and become exercisable in equal monthly installments over a period of four years, while the subsequent annual service option awards granted to directors vest and become exercisable in equal monthly installments over a period of one
	year. Certain service option awards to executives and directors provide for accelerated vesting if there is a change in control of the Company. Certain service option awards to employees and executives provide for accelerated vesting if the
	respective employee&#146;s or executive&#146;s service is terminated by the Company for any reason other than cause or permanent disability. As of December&nbsp;31, 2016, $8.9 million of unrecognized compensation costs related to unvested service
	option awards are expected to be recognized over a weighted average period of 1.2 years. No option awards are classified as a liability as of December&nbsp;31, 2016.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company&#146;s equity incentive plan, the Second Amended and Restated Management Equity Plan (the 2004 Plan), expired by its terms in 2014
	and no additional options will be granted under the 2004 Plan. There were no shares subject to outstanding options granted under the 2004 Plan as of December&nbsp;31, 2016 and 2015. The following is a summary of option activity for the 2004 Plan for
	the years ended December&nbsp;31, 2015 and 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_40"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="55%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	2004 Plan
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	(in thousands, except
	for share and per share amounts)
</I>
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Number&nbsp;of
<BR>
	Shares
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Weighted&nbsp;Average
<BR>
	Exercise&nbsp;Price&nbsp;at
<BR>
	Grant Date
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Weighted&nbsp;Average
<BR>
	Remaining Term
<BR>
	(Years)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Aggregate
<BR>
	Intrinsic
<BR>
	Value
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Outstanding at December&nbsp;31, 2013
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	670,744
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.79
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.78
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,124
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Exercised
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(17,934
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3.57
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Outstanding at December&nbsp;31, 2014
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	652,810
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.74
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0.78
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,212
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Exercised
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(652,810
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.74
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6,129
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Outstanding at December&nbsp;31, 2015
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<B>
	&nbsp;
</B>
</TD>
<TD NOWRAP VALIGN="BOTTOM" ALIGN="RIGHT">
<B>
	&#151;&nbsp;&nbsp;
</B>
</TD>
<TD NOWRAP VALIGN="BOTTOM">
<B>
	&nbsp;&nbsp;
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	79
</P>
<A NAME="eolPage82"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of option activity for the 2006 Plan and the 2016 Plan for the years
	ended December&nbsp;31, 2016, 2015, and 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_41"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="52%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="7%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	2006 and 2016 Plans
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	(in
	thousands, except for share and per share amounts)
</I>
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Number of
<BR>
	Shares
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Weighted&nbsp;Average
<BR>
	Exercise&nbsp;Price&nbsp;at
<BR>
	Grant Date
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Weighted&nbsp;Average
<BR>
	Remaining Term
<BR>
	(Years)
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Aggregate
<BR>
	Intrinsic
<BR>
	Value
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Outstanding at December&nbsp;31, 2013
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,533,618
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10.98
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6.93
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	21,264
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Granted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,324,337
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12.17
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Forfeited
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(237,108
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8.35
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Exercised
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(393,735
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7.08
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,923
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Outstanding at December&nbsp;31, 2014
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6,227,112
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11.58
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6.71
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	28,523
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Granted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,056,500
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11.74
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Forfeited
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(496,854
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10.75
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Expired
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(64,336
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	25.69
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Exercised
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(469,974
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7.02
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,594
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Outstanding at December&nbsp;31, 2015
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6,252,448
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11.87
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6.16
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,498
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Granted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	866,011
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8.43
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Forfeited
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(392,700
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11.23
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Expired
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(279,766
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	17.38
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Exercised
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(897,657
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8.63
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4,264
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Outstanding at December&nbsp;31, 2016
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,548,336
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11.62
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.58
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	32,453
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Exercisable at December&nbsp;31, 2016
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,983,012
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12.07
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	4.45
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	23,924
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vested and expected to vest at December&nbsp;31, 2016
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,450,280
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11.66
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.52
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	31,850
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The weighted average grant-date fair value of options granted was $4.53, $6.59 and $6.99 per share for the
	years ended December&nbsp;31, 2016, 2015 and 2014, respectively. Proceeds from the exercise of stock options amounted to $7.8 million, $4.4 million and $2.9 million for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Restricted Stock Units
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	An RSU is a stock award that entitles the holder to receive shares of the Company&#146;s common stock as the award vests. The fair value of
	each RSU is based on the closing price of the Company&#146;s stock on the date of grant. The Company has granted RSUs under the Plans with service conditions (service RSUs) that vest in four equal annual installments provided that the employee
	remains employed with the Company. As of December&nbsp;31, 2016, $8.2 million of unrecognized compensation costs related to unvested service RSUs are expected to be recognized over a weighted average period of 1.8 years. No RSUs are classified as a
	liability as of December&nbsp;31, 2016.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	80
</P>
<A NAME="eolPage83"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of RSU activity for the 2006 Plan and the 2016 Plan for the years
	ended December&nbsp;31, 2016, 2015, and 2014:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_42"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="76%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="6%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
	RSUs
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Number of
<BR>
	Shares
<BR>
	Underlying
<BR>
	RSUs
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Weighted
<BR>
	Average
<BR>
	Grant&nbsp;Date
<BR>
	Fair Value
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Unvested at December&nbsp;31, 2013
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	883,690
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7.70
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Granted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	436,115
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12.28
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Forfeited
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(84,282
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6.75
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vested
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(209,562
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6.67
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Unvested at December&nbsp;31, 2014
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,025,961
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9.94
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Granted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	417,000
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	11.51
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Forfeited
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(189,187
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10.60
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vested
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(231,093
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7.96
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Unvested at December&nbsp;31, 2015
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,022,681
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10.90
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Granted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	657,742
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8.71
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Forfeited
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(254,329
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10.38
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:3.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vested
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(287,666
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	9.65
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Unvested at December&nbsp;31, 2016
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,138,428
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	10.07
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The grant date fair value for the 287,666 shares underlying RSUs that vested during the year ended
	December&nbsp;31, 2016 was $2.8&nbsp;million.
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_43"></A>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:2%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
<I>
	Stock-Based Compensation Expense
</I>
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Stock-based compensation expense recognized for the years ended December&nbsp;31, 2016, 2015 and 2014 was allocated as follows:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="76%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year Ended December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Research and development
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,087
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	2,269
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1,933
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Selling, general and administrative
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6,456
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,692
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	3,945
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:1.00PX SOLID #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	8,543
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	7,961
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5,878
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PX; ">
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-TOP:3.00PX DOUBLE #000000">
	&nbsp;
</P>
</TD>
<TD>
	&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option
	pricing model that uses the assumptions noted in the following table. Expected volatility rates are based on the historical volatility of the Company&#146;s publicly traded common stock. The risk-free interest rates are based on the U.S. Treasury
	yield for a period consistent with the expected term of the option in effect at the time of the grant. The Company has not paid dividends to its stockholders since its inception (other than a dividend of preferred share purchase rights, which was
	declared in September 2008) and does not plan to pay dividends in the foreseeable future. Assumptions used in the Black-Scholes-Merton option pricing model for employee and director stock options granted during the years ended December&nbsp;31,
	2016, 2015 and 2014 were as follows:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_44"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="82%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="10" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Year&nbsp;Ended&nbsp;December&nbsp;31,
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2016
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2015
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	2014
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Expected dividend yield
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	0
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Weighted average expected volatility
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	57
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	60
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	62
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Weighted average expected term (years)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6.08
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	6.00
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	5.90
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Weighted average risk-free rate
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.37
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.67
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	1.73
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	%&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	17. Employee Benefit Plan
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Company has a defined contribution plan under IRC Section&nbsp;401(k). This plan covers substantially all employees who meet minimum age
	and service requirements and allows participants to defer a portion of their annual compensation on a pre-tax basis. Currently, the Company matches 50 percent up to the first six percent of employee contributions. All matching contributions have
	been paid by the Company. The Company match vests over a four-year period and amounted to $0.4 million, $0.3 million and $0.2&nbsp;million for the years ended December&nbsp;31, 2016, 2015 and 2014, respectively.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	81
</P>
<A NAME="eolPage84"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	18. Legal Matters
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In June 2014, the Company filed suit against Roxane Laboratories, Inc. (Roxane) in the U.S. District Court for the District of Delaware (the
	Delaware District Court). The suit seeks an adjudication that Roxane has infringed one or more claims of the Company&#146;s U.S. Patent No.&nbsp;8,586,610 (the &#145;610 Patent) by submitting to the FDA an Abbreviated New Drug Application (ANDA) for
	a generic version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	prior to the expiration of the &#145;610 Patent in November 2027. In addition, pursuant to the settlement agreement with Novartis, the Company assumed
	Novartis&#146; patent infringement action against Roxane in the Delaware District Court. That suit alleges that Roxane has infringed one or more claims of U.S. Patent RE39198 (the &#145;198 Patent), which is licensed exclusively to the Company, by
	filing an ANDA for a generic version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	prior to the expiration of the &#145;198 Patent in November 2016. These two cases against Roxane were consolidated by agreement of the parties
	and were tried together in a five-day bench trial that concluded on March&nbsp;4, 2016. On August&nbsp;25, 2016, the Delaware District Court ruled in favor of the Company, finding that Roxane&#146;s ANDA product infringed the asserted claims of the
	&#145;610 Patent and the &#145;198 Patent. The Delaware District Court ruled that the Company is entitled to a permanent injunction against Roxane enjoining Roxane from infringing the &#145;610 Patent, including the manufacture, use, sale, offer to
	sell, sale, distribution or importation of any generic iloperidone product described in the &#145;610 Patent ANDA until the expiration of the &#145;610 Patent in November 2027. If the Company obtains pediatric exclusivity, the injunction against
	Roxane would be extended until May 2028 under the Delaware District Court&#146;s order. On September&nbsp;23, 2016, Roxane filed a notice of appeal with the Federal Circuit Court of Appeals. Roxane filed its opening appellate brief on
	February&nbsp;7, 2017.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	In 2015, the Company filed six separate patent infringement lawsuits in the Delaware District Court against
	Roxane, Inventia Healthcare Pvt. Ltd. (Inventia), Lupin Ltd. and Lupin Pharmaceuticals, Inc. (Lupin), Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (Taro), and Apotex Inc. and Apotex Corp., (collectively, the Defendants).
	The lawsuits each seek an adjudication that the respective Defendants infringed one or more claims of the &#145;610 Patent and/or the Company&#146;s U.S. Patent No.&nbsp;9,138,432 (the &#145;432 Patent) by submitting to the FDA an ANDA for a generic
	version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	prior to the expiration of the &#145;610 Patent in November 2027 or the &#145;432 Patent in September 2025. The Defendants have denied infringement and counterclaimed for
	declaratory judgment of invalidity and noninfringement of the &#145;610 Patent and the &#145;432 Patent. A trial on these matters was scheduled to begin on May&nbsp;15, 2017. On December&nbsp;15, 2016, following a submission by the parties that it
	may be appropriate to remove the May&nbsp;15, 2017 trial from the Delaware District Court&#146;s calendar pending the Federal Circuit&#146;s decision in Roxane&#146;s appeal of the Delaware District Court&#146;s August&nbsp;25, 2016 ruling finding
	that Roxane&#146;s proposed products infringed the asserted claims of the &#145;610 Patent, the Delaware District Court removed the May&nbsp;15, 2017 trial from the calendar and adopted a new schedule for discovery. The parties agreed that within 14
	days after any decision on the merits in the Roxane appeal, the parties will submit to the Delaware District Court a status report and request a schedule for trial. The Company entered into a confidential stipulation with Inventia regarding any
	potential launch of Inventia&#146;s generic ANDA product. The Company also entered into a confidential stipulation with Lupin regarding any potential launch of Lupin&#146;s generic ANDA product.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Lupin filed counter claims for declaratory judgment of invalidity and noninfringement of seven of the Company&#146;s method of treatment
	patents that are listed in the
<I>
	Approved Drug Products with Therapeutic Equivalence Evaluations
</I>
	(the Orange Book) related to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(such seven patents, the Method of Treatment
	Patents). The Company has not sued Lupin for infringing the Method of Treatment Patents. On October&nbsp;13, 2016, the Company and Lupin filed a Stipulation of Dismissal in the Delaware District Court pursuant to which Lupin&#146;s counterclaims
	relating to the Method of Treatment Patents were dismissed without prejudice in recognition of an agreement reached between the parties by which the Company would not assert those patents against Lupin absent certain changes in Lupin&#146;s proposed
	prescribing information for its iloperidone tablets.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On October&nbsp;24, 2016, the Company entered into a License Agreement with Taro to
	resolve the Company&#146;s patent litigation against Taro regarding Taro&#146;s ANDA seeking approval of its generic version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(the Taro License Agreement). Under the Taro License
	Agreement, the Company granted Taro a non-exclusive license to manufacture and commercialize Taro&#146;s version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. effective November&nbsp;2, 2027, unless prior to that
	date the Company obtains pediatric exclusivity for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, in which case, the license will be effective May&nbsp;2, 2028. Taro may enter the market earlier under certain limited
	circumstances. The Taro License Agreement, which is subject to review by the U.S. Federal Trade Commission (FTC) and the U.S. Department of Justice (DOJ), provides for a full settlement and release by the Company and Taro of all claims that are the
	subject of the litigation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On December&nbsp;7, 2016, the Company entered into a License Agreement with Apotex to resolve the
	Company&#146;s patent litigation against Apotex regarding Apotex&#146;s ANDA seeking approval of its generic version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	(the Apotex License Agreement). Under the Apotex License
	Agreement, the Company granted Apotex a non-exclusive license to manufacture and commercialize Apotex&#146;s version of Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	in the U.S. effective November&nbsp;2, 2027, unless prior to
	that date the Company obtains pediatric exclusivity for Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, in which case, the license will be effective May&nbsp;2, 2028. Apotex may enter the market earlier under certain limited
	circumstances. The Apotex License Agreement, which is subject to review by the FTC and the DOJ, provides for a full settlement and release by the Company and Apotex of all claims that are the subject of the litigation.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	82
</P>
<A NAME="eolPage85"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On February&nbsp;26, 2016, Roxane filed suit against the Company in the U.S. District Court for
	the Southern District of Ohio. The suit seeks a declaratory judgment of invalidity and noninfringement of the Method of Treatment Patents. The Company has not sued Roxane for infringing the Method of Treatment Patents. The Company filed a motion to
	dismiss this lawsuit for lack of personal jurisdiction or to transfer the lawsuit to the Delaware District Court. On December&nbsp;20, 2016, the Ohio District Court ruled in our favor, dismissing Roxane&#146;s suit without prejudice for lack of
	personal jurisdiction.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	On February&nbsp;26, 2016, Roxane filed a Petition for
<I>
	Inter Partes
</I>
	Review (IPR) of the &#145;432 Patent
	with the Patent Trials and Appeals Board (PTAB) of the United States Patent and Trademark Office. The Company filed a Preliminary Response on June&nbsp;7, 2016, and on August&nbsp;30, 2016 the PTAB denied the request by Roxane to institute an IPR of
	the &#145;432 Patent. On September&nbsp;29, 2016, Roxane filed a Petition for Rehearing with the PTAB, and on October&nbsp;13, 2016 the Company filed a Response to Roxane&#146;s Petition. On November&nbsp;4, 2016, the PTAB denied Roxane&#146;s
	Petition for Rehearing.
</P>
<P STYLE="MARGIN-TOP:18PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	19. Quarterly Financial Data (Unaudited)
</B>
</P>
<P STYLE="MARGIN-TOP:6PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The following is a summary of quarterly financial data for the years ended December&nbsp;31, 2016 and 2015:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_45"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="64%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<B>
<I>
	(in thousands, except for per share amounts)
</I>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	First
<BR>
	Quarter
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Second
<BR>
	Quarter
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Third
<BR>
	Quarter
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" COLSPAN="2" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Fourth
<BR>
	Quarter
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<B>
<U>
	Year Ended December&nbsp;31, 2016
</U>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Revenue
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	33,262
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	36,029
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	38,482
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	38,244
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Gross profit (1)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	24,363
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	26,593
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	28,549
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	30,867
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Loss from operations
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(12,475
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(4,789
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(653
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(654
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(12,358
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(4,618
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(430
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(604
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss per share, basic and diluted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.29
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.11
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.01
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.01
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<B>
<U>
	Year Ended December&nbsp;31, 2015
</U>
</B>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Revenue
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	22,150
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	27,582
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	28,344
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	31,849
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Gross profit (1)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	12,991
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	18,874
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	18,891
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	22,735
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Loss from operations
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(10,293
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(5,458
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(9,541
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(14,893
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR BGCOLOR="#CCEEFF" STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(10,221
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(5,386
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(9,461
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(14,797
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Net loss per share, basic and diluted
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.24
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.13
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.22
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	$
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	(0.35
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	)&nbsp;
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="LINE-HEIGHT:8.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	(1)
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Gross profit includes revenue less cost of goods sold, excluding amortization and intangible asset amortization.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	83
</P>
<A NAME="eolPage86"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<A NAME="D474152D10K_HTM_TOC474152_23">
</A>
	VANDA PHARMACEUTICALS INC.
</B>
</P>
</EFX_NOTES_TO_FINANCIAL_STATEMENT>
<EFX_EXHIBIT_INDEX>
<A NAME="FIS_EXHIBIT_INDEX"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	EXHIBIT INDEX
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_46"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="4%">
</TD>
<TD WIDTH="92%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:28.45PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Exhibit
<BR>
	Number
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:39.50PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Description
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;3.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Form of Amended and Restated Certificate of Incorporation of the registrant (filed as Exhibit 3.8 to Amendment No. 2 to the registrant&#146;s registration statement on Form S-1 (File No. 333-130759) on March 17, 2006 and
	incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;3.2
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Form of Certificate of Designation of Series A Junior Participating Preferred Stock (filed as Exhibit 3.10 to the registrant&#146;s current report on Form 8-K (File No. 001-34186) on September 25, 2008 and incorporated herein by
	reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;3.3
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Fourth Amended and Restated Bylaws of the registrant, as amended and restated on December&nbsp;17, 2015 (filed as Exhibit&nbsp;3.1 to the registrant&#146;s current report on Form&nbsp;8-K (File No.&nbsp;001-34186) on
	December&nbsp;21, 2015 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;4.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Specimen certificate representing the common stock of the registrant (filed as Exhibit 4.4 to Amendment No. 2 to the registrant&#146;s registration statement on Form S-1 (File No. 333-130759) on March 17, 2006, and incorporated
	herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;4.2
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Rights Agreement, dated as of September 25, 2008, by and between the registrant and American Stock Transfer &amp; Trust Company, LLC, as Rights Agent (filed as Exhibit 4.5 to the registrant&#146;s current report on Form 8-K (File
	No. 001-34186) on September 25, 2008 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	&nbsp;&nbsp;4.3
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Amendment to Rights Agreement, dated as of December 22, 2009, by and between the registrant and American Stock Transfer &amp; Trust Company, LLC, as Rights Agent (filed as Exhibit 4.6 to the registrant&#146;s current report on Form
	8-K (File No. 001-34186) on December 22, 2009 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.1&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Registrant&#146;s Second Amended and Restated Management Equity Plan (filed as Exhibit 10.1 to the registrant&#146;s registration statement on Form S-1 (File No. 333-130759) on December 29, 2005 and incorporated herein by
	reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.2#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Amended and Restated License, Development and Commercialization Agreement, dated July 24, 2005, by and between Bristol-Myers Squibb Company and the registrant (relating to
	HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	) (filed as Exhibit 10.3 to Amendment No. 1 to the registrant&#146;s registration Statement on Form S-1 (File No. 333-130759) on February 16, 2006 and incorporated herein by
	reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.3
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Summary Plan Description provided for the registrant&#146;s 401(k) Profit Sharing Plan &amp; Trust (filed as Exhibit 10.10 to the registrant&#146;s registration statement on Form S-1 (File No. 333-130759) on December 29, 2005 and
	incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.4
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Form of Indemnification Agreement entered into by directors and executive officers (filed as Exhibit 10.11 to the registrant&#146;s registration statement on Form S-1 (File No. 333-130759) on December 29, 2005 and incorporated
	herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.5&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	2006 Equity Incentive Plan, as amended (filed as Exhibit 10.38 to the registrant&#146;s current report on Form 8-K (File No. 001-34186) on March 7, 2010 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.6
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Form of Tax Indemnity Agreement (filed as Exhibit 10.20 to the registrant&#146;s quarterly report on Form 10-Q (File No. 000-51863) on August 8, 2007 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.7&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Amended and Restated Employment Agreement, dated December 16, 2008, by and between Mihael H. Polymeropoulos and the registrant (filed as Exhibit 10.34 to the registrant&#146;s quarterly report on Form 10-Q (File No. 001-34186) on
	August 10, 2009 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.8&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Employment Agreement, dated December 13, 2010, by and between James Kelly and the registrant (filed as Exhibit 10.38 to the registrant&#146;s annual report on Form 10-K (File No. 001-34186) on March 10, 2011 and incorporated herein
	by reference).
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	84
</P>
<A NAME="eolPage87"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_47"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD WIDTH="92%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:28.45PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Exhibit
<BR>
	Number
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:39.50PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Description
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.9&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Amendment to Amended and Restated Employment Agreement, dated December&nbsp;16, 2010, by and between Mihael H. Polymeropoulos and the registrant (filed as Exhibit 10.39 to the registrant&#146;s annual report on Form 10-K (File No.
	001-34186) on March&nbsp;10, 2011 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.10
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Amended and Restated Tax Indemnity Agreement, dated December 16, 2010, by and between Mihael H. Polymeropoulos and the registrant (filed as Exhibit 10.41 to the registrant&#146;s annual report on Form 10-K (File No. 001-34186) on
	March 10, 2011 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.11
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Lease, effective as of July&nbsp;25, 2011, by and between Square 54 Office Owner LLC and the registrant (filed as Exhibit 10.42 to the registrant&#146;s quarterly report on Form 10-Q (File No. 001-34186) on November&nbsp;7, 2011 and
	incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.12&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Form of Notice of Stock Option Grant and Stock Option Agreement under 2006 Equity Incentive Plan 2011 (filed as Exhibit 10.44 to the registrant&#146;s annual report on Form 10-K (File No. 001-34186) on March 9, 2012 and incorporated
	herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.13&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Form of Restricted Stock Unit Award Agreement under 2006 Equity Incentive Plan 2011 (filed as Exhibit 10.45 to the registrant&#146;s annual report on Form 10-K (File No. 001-34186) on March 9, 2012 and incorporated herein by
	reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.14
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Amendment to Amended and Restated License, Development and Commercialization Agreement, dated as of April 15, 2010, by and between Bristol-Myers Squibb Company and the registrant (filed as Exhibit 10.38 to the registrant&#146;s
	current report on Form 8-K (File No. 001-34186) on April 19, 2010 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.15
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Amendment to Amended and Restated License, Development and Commercialization Agreement, dated as of May 24, 2012, by and between Bristol-Myers Squibb Company and the registrant (filed as Exhibit 10.46 to the registrant&#146;s
	current report on Form 8-K (File No. 001-34186) on May 30, 2012 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.16#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	License, Development and Commercialization Agreement, dated as of April 12, 2012, by and between Eli Lilly and Company and the registrant (filed as Exhibit 10.48 to the registrant&#146;s quarterly report on Form 10-Q (File No.
	001-34186) on August 3, 2012 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.17
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Amendment to Amended and Restated License, Development and Commercialization Agreement, dated as of April 25, 2013, by and between Bristol-Myers Squibb Company and the registrant (filed as Exhibit 10.50 to the registrant&#146;s
	current report on Form 8-K (File No. 001-34186) on April 29, 2013 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.18&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Employment Agreement, dated as of April 15, 2013, by and between Paolo Baroldi and the registrant (filed as Exhibit 10.51 to the registrant&#146;s quarterly report on Form 10-Q (File No. 001-34186) on July 31, 2013 and incorporated
	herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.19#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Manufacturing Agreement, dated January 24, 2014, by and between Patheon Pharmaceuticals Inc. and the registrant (relating to HETLIOZ
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	) (filed as Exhibit 10.53 to the
	registrant&#146;s quarterly report on Form 10-Q (File No. 001-34186) on May 8, 2014 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.20
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Amendment to Lease Agreement, dated March 18, 2014, by and between Square 54 Office Owner LLC and the registrant (filed as Exhibit 10.54 to the registrant&#146;s quarterly report on Form 10-Q (File No. 001-34186) on May 8, 2014 and
	incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.21
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Settlement Agreement and Mutual General Release, dated December 22, 2014, by and among Novartis Pharma AG and the registrant (filed as Exhibit 10.55 to the registrant&#146;s annual report on Form 10-K (File No. 001-34186) on March
	13, 2015 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.22#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Asset Transfer Agreement, dated December 22, 2014, by and among Novartis Pharma AG, Novartis AG and the registrant (relating to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	) (filed as Exhibit 10.56 to the
	registrant&#146;s annual report on Form 10-K/A (File No. 001-34186) on June 10, 2015 and incorporated herein by reference).
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	85
</P>
<A NAME="eolPage88"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_48"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD WIDTH="92%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:28.45PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Exhibit
<BR>
	Number
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:39.50PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Description
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	10.23#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Sublicense Agreement, dated November&nbsp;20, 1997, by and between Titan Pharmaceuticals, Inc. and Novartis Pharma AG (filed as Exhibit 10.30 to Titan Pharmaceutical Inc.&#146;s registration statement on Form S-3 (File No.
	333-42367) on December&nbsp;16, 1997 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.24#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Amendment No. 1 to Sublicense Agreement by and between Titan Pharmaceuticals, Inc. and Novartis Pharma AG, dated November 30, 1998 (filed as Exhibit 10.58 to the registrant&#146;s annual report on Form 10-K for the year ended
	December&nbsp;31, 2014 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.25#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Amendment No. 2 to Sublicense Agreement, dated April 10, 2001, by and between Titan Pharmaceuticals, Inc. and Novartis Pharma AG (filed as Exhibit 10.59 to the registrant&#146;s annual report on Form 10-K/A (File No. 001-34186)
	on June 10, 2015 and incorporated herein by reference)
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.26#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Amendment No. 3 to Sublicense Agreement, dated June 4, 2004, by and between Titan Pharmaceuticals, Inc. and Novartis Pharma AG (filed as Exhibit 10.60 to the registrant&#146;s annual report on Form 10-K (File No. 001-34186) on
	March 13, 2015 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.27
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Stock Purchase Agreement, dated December 22, 2014, by and between Novartis AG and the registrant (filed as Exhibit 10.61 to the registrant&#146;s annual report on Form 10-K (File No. 001-34186) on March 13, 2015 and incorporated
	herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.28#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	License Agreement, dated December 22, 2014, by and between Novartis Pharma AG and the registrant (relating to AQW051) (filed as Exhibit 10.62 to the registrant&#146;s annual report on Form 10-K (File No. 001-34186) on March 13,
	2015 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.29&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Employment Agreement, dated April&nbsp;20, 2015, by and between Thomas E. Gibbs, Senior Vice President and Chief Commercial Officer, and the registrant (filed as Exhibit 10.65 to the registrant&#146;s quarterly report on Form
	10-Q (File No. 001-34186) on July&nbsp;31, 2015 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.30&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Employment Agreement, dated September&nbsp;3, 2015, by and between Gian Piero Reverberi, Senior Vice President and General Manager Europe, and the registrant (filed as Exhibit 10.64 to the registrant&#146;s quarterly report on
	Form 10-Q (File No. 001-34186) on November 4, 2015 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.31&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Employment Agreement, dated September&nbsp;14, 2015, by and between Richard L. Gulino, Senior Vice President, General Counsel and Secretary, and the registrant (filed as Exhibit 10.65 to the registrant&#146;s quarterly report on
	Form 10-Q (File No. 001-34186) on November 4, 2015 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.32
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Agreement, dated February 2, 2016, by and among Titan Pharmaceuticals, Inc., Aventisub LLC, the successor-in-interest to Aventisub II Inc. Sanofi-Aventis and the registrant (filed as Exhibit 10.1 to the registrant&#146;s current
	report on Form 8-K (File No. 001-34186) on February 4, 2016 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.33&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	UK Sub Plan under the 2006 Equity Incentive Plan (filed as Exhibit 10.33 to the registrant&#146;s annual report on Form 10-K (File No. 001-34186) on February 12, 2016 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.34&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Form of Stock Option Grant and Stock Option Agreement under the UK Sub Plan (filed as Exhibit 10.34 to the registrant&#146;s annual report on Form 10-K (File No. 001-34186) on February 12, 2016 and incorporated herein by
	reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.35&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Form of Restricted Stock Unit Award Agreement under the UK Sub Plan (filed as Exhibit 10.35 to the registrant&#146;s annual report on Form 10-K (File No. 001-34186) on February 12, 2016 and incorporated herein by
	reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.36&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Vanda Pharmaceuticals Inc. 2016 Equity Incentive Plan, effective as of June 16, 2016 (filed as Exhibit 10.36 to the registrant&#146;s registration statement on Form S-8 (File No. 333-212255) on June 27, 2016 and incorporated
	herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.37&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Form of Notice of Stock Option Grant and Stock Option Agreement under 2016 Equity Incentive Plan (filed as Exhibit 10.37 to the registrant&#146;s registration statement on Form S-8 (File No. 333-212255) on June 27, 2016 and
	incorporated herein by reference).
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	86
</P>
<A NAME="eolPage89"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<H5 ALIGN="LEFT">
<A HREF="#D474152D10K_HTM_TOC">
	Table of Contents
</A>
</H5>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_49"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="3%">
</TD>
<TD WIDTH="91%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:28.45PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Exhibit
<BR>
	Number
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:39.50PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Description
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.38&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Form of Restricted Stock Unit Award Agreement under 2016 Equity Incentive Plan (filed as Exhibit 10.38 to the registrant&#146;s registration statement on Form S-8 (File No. 333-212255) on June&nbsp;27, 2016 and incorporated
	herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.39&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	UK Sub Plan under the 2016 Equity Incentive Plan (filed as Exhibit 10.39 to the registrant&#146;s registration statement on Form S-8 (File No. 333-212255) on June 27, 2016 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.40&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Form of Stock Option Grant and Stock Option Agreement under the UK Sub Plan under the 2016 Equity Incentive Plan (filed as Exhibit 10.40 to the registrant&#146;s registration statement on Form S-8 (File No. 333-212255) on June
	27, 2016 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.41&#134;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Form of Restricted Stock Unit Award Agreement under the UK Sub Plan under the 2016 Equity Incentive Plan (filed as Exhibit 10.41 to the registrant&#146;s registration statement on Form S-8 (File No. 333-212255) on June 27, 2016
	and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.42#
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Manufacturing Agreement, dated May 6, 2016, by and between Patheon Pharmaceuticals Inc. and the registrant (relating to Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	) (filed as Exhibit 10.42 to the
	registrant&#146;s quarterly report on Form 10-Q (File No. 001-34186) on July 31, 2016 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.43
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Second Amendment to Lease Agreement, dated June 20, 2016, by and between Square 54 Office Owner LLC and the registrant (filed as Exhibit 10.43 to the registrant&#146;s quarterly report on Form 10-Q (File No. 001-34186) on July
	31, 2016 and incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.44
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Sublease Agreement, dated June 22, 2016, by and between Hunton &amp; Williams LLP and the registrant (filed as Exhibit 10.44 to the registrant&#146;s quarterly report on Form 10-Q (File No. 001-34186) on July 31, 2016 and
	incorporated herein by reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.45&#135;*
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	License Agreement, dated October 24, 2016, by and among Taro Pharmaceuticals USA, Inc., Taro Pharmaceuticals Industries Ltd. and the registrant.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	10.46&#135;*
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	License Agreement, dated December 7, 2016, by and between Apotex, Inc. and the registrant.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	18.1
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Preferability Letter of Independent Public Accounting Firm, dated May 8, 2014 (filed as Exhibit 18.1 to the registrant&#146;s quarterly report on Form 10-Q (File No. 001-34186) on May 8, 2014 and incorporated herein by
	reference).
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	21.1*
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	List of Subsidiaries.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	23.1*
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	31.1*
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Certification of the Chief Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	31.2*
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Certification of the Chief Financial Officer as required by Section 302 of the Sarbanes-Oxley Act of 2002.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	32.1*
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Certification of the Chief Executive Officer and Chief Financial Officer as required by Section 906 of the Sarbanes-Oxley Act of 2002.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="8">
</TD>
<TD HEIGHT="8" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" NOWRAP>
	101*
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	The following financial information from this annual report on Form 10-K for the fiscal year ended December 31, 2016, formatted in XBRL (eXtensible Business Reporting Language) and furnished electronically herewith: (i) Consolidated
	Balance Sheets as of December 31, 2016 and 2015; (ii) Consolidated Statements of Operations for the years ended December 31, 2016, 2015 and 2014; (iii) Consolidated Statements of Comprehensive Income (Loss) for the years ended December 31, 2016,
	2015 and 2014; (iv) Consolidated Statements of Changes in Stockholders&#146; Equity for the years ended December 31, 2016, 2015 and 2014; (v) Consolidated Statements of Cash Flows for the years ended December 31, 2016, 2015 and 2014; and (vi) Notes
	to the Consolidated Financial Statements.
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="LINE-HEIGHT:8.0PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:2PT;BORDER-BOTTOM:1PX SOLID #000000;WIDTH:10%">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	&#134;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Indicates management contract or compensatory plan.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	#
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Confidential treatment has been granted with respect to certain provisions of this exhibit.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	&#135;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment. The omitted portions of this exhibit have been filed with the Securities and Exchange Commission.
</TD>
</TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	*
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Filed herewith.
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	87
</P>
</EFX_EXHIBIT_INDEX>
</EFX_FORM>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage90"></A>
<A NAME="D474152DEX1045_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 10.45
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<U>
	LICENSE AGREEMENT
</U>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
</B>
	THIS LICENSE AGREEMENT (this &#147;
<B>
	Agreement
</B>
	&#148;) dated as of October&nbsp;24, 2016 (the &#147;
<B>
	Effective Date
</B>
	&#148;) is
	entered into between Vanda Pharmaceuticals Inc., a Delaware corporation with an address at 2200 Pennsylvania Avenue, N.W., Washington, DC 20037, on behalf of itself and its Affiliates (collectively, &#147;
<B>
	Vanda
</B>
	&#148;), and Taro
	Pharmaceuticals USA, Inc., a New York corporation, with a place of business at Three Skyline Drive, Hawthorne, NY 10532 (&#147;
<B>
	Taro USA
</B>
	&#148;) and Taro Pharmaceutical Industries Ltd., a corporation organized and existing under the laws of
	Israel, with a place of business at 14 Hakitor Street, Haifa Bay, 2624761, Israel (&#147;
<B>
	Taro Israel
</B>
	&#148;) on behalf of themselves and each of their Affiliates (collectively, &#147;
<B>
	Taro
</B>
	&#148;).
<B>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
</I>
	WHEREAS Vanda is the owner of the Patent Rights (as the term is defined below) and has sued Taro USA and Taro Israel in an action
	captioned
<I>
	Vanda Pharmaceuticals Inc.
</I>
	v.
<I>
	Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries Ltd.
</I>
	, Case No.&nbsp;1:15-cv-00920-GMS (D. Del.) (the &#147;
<I>
</I>
<B>
	Litigation
</B>
<I>
</I>
	&#148;) which is pending in the United
	States District Court, District of Delaware (the &#147;
<I>
</I>
<B>
	Court
</B>
<I>
</I>
	&#148;), in which Vanda alleges that Taro USA&#146;s filing of Abbreviated New Drug Application (&#147;ANDA&#148;) No.&nbsp;207098 infringes U.S. Patent Nos. 8,586,610
	(&#147;the &#146;610 patent&#148;) and 9,138,432 (&#147;the &#146;432 patent&#148;), and Taro has filed counterclaims in the Litigation alleging that the &#146;610 and &#146;432 patents are invalid and not infringed;
<I>
</I>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	WHEREAS the parties desire to settle the Litigation and Taro desires to receive, and Vanda desires to grant to Taro, a non-exclusive, ****
	license under the Patent Rights to make, use, sell, offer for sale and import Generic Product (as the term is defined below), all on the terms and conditions of this Agreement; and
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	WHEREAS the settlement between the Parties will help bring a Generic Product for which Taro has an approved ANDA to the market prior to the
	expiry of the patents covering Fanapt Products or the use thereof;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	NOW, THEREFORE, in consideration of the foregoing premises and the
	mutual covenants herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.
<U>
	DEFINITIONS.
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.1
	&#147;
<B>
	Affiliate
</B>
	&#148; means, with respect to any entity, any other entity that directly or indirectly controls, is controlled by, or is under common control with, such entity. An entity shall be regarded as in control of another entity if it
	owns, or directly or indirectly controls, at least fifty percent (50%)&nbsp;of the voting stock or other ownership interest of the other entity, or if it directly or indirectly possesses the power to direct or cause the direction of the management
	and policies of the other entity by any means whatsoever.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.2 &#147;****&#148; shall mean the **** (as defined below).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.3 &#147;
<B>
	Authorized Generic
</B>
	&#148; shall mean a generic version of Fanapt Products (defined below) that is marketed, distributed or
	sold in the United States by any Third Party (defined below) and/or Vanda or any of its Affiliates as an authorized generic iloperidone tablets under the Vanda NDA, without a tradename.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="FONT-SIZE:24PT; MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<A NAME="eolPage91"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.4 &#147;
<B>
	Business Day
</B>
	&#148; shall mean any day other than a Saturday, a Sunday or a
	day on which the state or federal courts located in the State of Delaware are authorized or obligated by law or executive order to be closed.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.5 &#147;
<B>
	Confidential Information
</B>
	&#148; means all non-public materials, information and data concerning the disclosing party and its
	operations that is disclosed by the disclosing party to the receiving party pursuant to this Agreement, orally or in written, electronic or tangible form, or otherwise obtained by the receiving party through observation or examination of the
	disclosing party&#146;s operations. Confidential Information includes, but is not limited to, information about the disclosing party&#146;s financial condition and projections; business, marketing or strategic plans; sales information; customer
	lists; price lists; databases; trade secrets; product prototypes and designs; techniques, formulae, algorithms and other non-public process information. Notwithstanding the foregoing, Confidential Information of a party shall not include that
	portion of such materials, information and data that, and only to the extent, that the recipient can establish by written documentation: (a)&nbsp;is known to the recipient as evidenced by its written records before receipt thereof from the
	disclosing party, (b)&nbsp;is disclosed to the recipient free of confidentiality obligations by a Third Party who has the right to make such disclosure without obligations of confidentiality, (c)&nbsp;is or becomes part of the public domain through
	no fault of the recipient, or (d)&nbsp;the recipient can reasonably establish is independently developed by persons on behalf of recipient without the use of the information disclosed by the disclosing party.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.6 &#147;
<B>
	Fanapt Products
</B>
	&#148; means the form, formulation, and dosage of the current FDA-approved Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	products listed on Exhibit A approved under the Vanda NDA. For avoidance of doubt, Fanapt Products shall not include any ****.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.7 &#147;
<B>
	FDA
</B>
	&#148; means the United States Food and Drug Administration or any successor entity thereto.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.8 &#147;
<B>
	Generic Product
</B>
	&#148; means&#151;regardless of whether a product is considered generic, branded, private-labeled or
	otherwise&#151;a product for which FDA approval is sought as, or that has been deemed by FDA to be, bioequivalent to one of the Fanapt Products and has the same strength and dosage form as one of the Fanapt Products, including any Authorized
	Generic. For the avoidance of doubt, &#147;Generic Product&#148; does not include the Fanapt Products themselves.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.9 &#147;
<B>
	Orange
	Book
</B>
	&#148; means the current edition (in electronic or hard copy form) of the FDA&#146;s publication
<I>
	Approved Drug Products with Therapeutic Equivalence Evaluations
</I>
	, as may be amended from time to time, and any successor publication
	thereto.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.10 &#147;
<B>
	Patent Rights
</B>
	&#148; means (a)&nbsp;the patents listed on Exhibit B to this Agreement and the patent
	applications giving rise thereto, (b)&nbsp;all provisional applications, divisionals, continuations, continuations-in-part, reissues and renewals that claim priority to, or common priority with, the patent applications that resulted in the patents
	described in clause (a)
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	2
</P>
<A NAME="eolPage92"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	above, and all patents granted thereon, (c)&nbsp;all patents that have issued or in the future issue from any
	of the foregoing patent applications, including utility, model and design patents and certificates of invention, together with any reexamination certificates, reissues, renewals, extensions, and extended exclusivities or restorations by existing or
	future extension or restoration mechanisms, or additions thereto, and (d)&nbsp;all other relevant patents and patent applications, if any, that cover Fanapt Products or an approved use of a Fanapt Product.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.11 &#147;
<B>
	Third Party
</B>
	&#148; means any person or entity other than Vanda or Taro.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.12 &#147;
<B>
	Trigger Date
</B>
	&#148; means, with respect to a Generic Product for which Taro has an approved ANDA, on a
	Generic-Product-by-Generic-Product basis, the earliest of:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) The date of expiration of the &#146;610 patent, i.e.,
	November&nbsp;2, 2027, unless prior to that date Vanda obtains pediatric exclusivity pursuant to 21 U.S.C. &#167; 355A with respect to the &#146;610 patent (as reflected in the Orange Book), in which case the date for purposes of this subsection
	1.12(a) shall be May&nbsp;2, 2028;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) the date on which (i)&nbsp;a final decision by a court from which no appeal can be
	taken is entered holding that all of the then-asserted claims of the Patent Rights as to such Generic Product are unpatentable or invalid or unenforceable or not infringed by the applicable Generic Product (for the avoidance of doubt, a court of
	appeals&#146; judgment or order is not &#147;final&#148; until issuance of the mandate); or (ii)&nbsp;a final decision by the U.S. Patent and Trademark Office, from which no appeal can be taken, is entered holding that all of the then-asserted
	claims of the Patent Rights as to such Generic Product are unpatentable or invalid or unenforceable (for the avoidance of doubt, a court of appeals&#146; judgment or order is not &#147;final&#148; until issuance of the mandate);
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(c) the date on which such Generic Product is first sold in the United States by a Third Party that holds an approved ANDA to
	manufacture and sell such Generic Product in the United States (&#147;
<B>
	Third Party ANDA Holder
</B>
	&#148;) after the Effective Date ****
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	3
</P>
<A NAME="eolPage93"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(d) the first date when such Generic Product is sold in the United States by a Third Party who is under authority or license
	of Vanda; or
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(e) if any license or settlement agreement between Vanda and a Third Party allows or causes to allow a Third
	Party rights under the Patent Rights to sell Generic Product on a specific date that is earlier than the operative date under subsection 1.12(a) above, then Vanda shall notify Taro in writing of such specific date within **** of learning of such
	date, including, but not limited to, within **** of learning of the activation of a &#147;trigger date&#148; in a settlement agreement or license agreement with a Third Party, and Taro shall receive the benefit of such specific date. For the
	avoidance of doubt, a &#147;specific date&#148; may be either a specified date (i.e. wherein the license agreement or settlement agreement identifies a specific date by day, month and year), or may also be, for example, a &#147;trigger date&#148;
	that is defined by the terms of a settlement agreement or license agreement with a Third Party.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.13 &#147;
<B>
	United States
</B>
	&#148; means the United States of America, including its territories, commonwealths and possessions, including
	the Commonwealth of Puerto Rico and the District of Columbia.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.14 &#147;
<B>
	Valid Claim
</B>
	&#148; means a claim in an issued patent
	within the Patent Rights that has not (a)&nbsp;expired; (b)&nbsp;been disclaimed (but, if terminally disclaimed, only after the patent to which the terminal disclaimer is tied has expired); (c)&nbsp;been declared invalid or unenforceable in a final
	decision of a court, or (d)&nbsp;been declared invalid or unenforceable in a final decision by the U.S. Patent and Trademark Office, from which no appeal can be taken (for the avoidance of doubt, a court of appeals&#146; judgment or order is not
	&#147;final&#148; until issuance of the mandate).
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	4
</P>
<A NAME="eolPage94"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.15 &#147;
<B>
	Vanda NDA
</B>
	&#148; means the New Drug Application **** and any supplements or
	amendments thereto.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.
<U>
	RELEASE; PATENT RIGHTS.
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.1
<U>
	Release
</U>
	. Taro, on its own behalf and on behalf of any person or entity within its control or with whom it contracts in any way with
	respect to the ANDA and/or any Generic Product, represents and warrants that, as of the Effective Date, neither Taro nor any person or entity within its control or with whom it has contracted with respect to the ANDA and/or Generic Product, has
	manufactured, used, sold, offered for sale, imported or distributed in the United States any Generic Product except for purposes that would not constitute infringement of the Patent Rights as a result of the application of 35 U.S.C. &#167;
	271(e)(1). In consideration for the covenants set forth in this Agreement, and in reliance on the representation and warranty in the preceding sentence, Vanda hereby as of the Effective Date irrevocably releases Taro **** from all claims and other
	Losses (as that term is defined below) arising from the manufacture, use, sale, offer for sale, importation or distribution of Taro&#146;s Generic Product prior to the Effective Date.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.2
<U>
	Prior to Trigger Dates
</U>
	.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.2.1 Commencing on the Effective Date and continuing until the Trigger Date, Taro shall not&#151;and shall not directly or indirectly
	encourage or assist any Third Party to&#151;develop, make, use, sell, offer for sale, or import into the United States any Generic Product. Notwithstanding the foregoing, ****. Vanda agrees that ****
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.2.2 Nothing in this Agreement shall be construed as prohibiting Taro from engaging in any activity that would not constitute infringement of
	the Patent Rights as a result of the application of 35 U.S.C. &#167; 271(e)(1).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.3
<U>
	Validity of Vanda&#146;s Patents
</U>
	. Taro hereby
	admits that the claims of the Patent Rights are valid and enforceable. Taro hereby admits that the making, using, offering to sell, selling, and/or importation into the United States of a Generic Product is covered by one or more claims of the
	Patent Rights under 35 U.S.C. &#167; 271. Within five days of the Effective Date, Vanda and Taro shall execute and cause to be filed with the Court in the Litigation a consent judgment in the form attached hereto as Exhibit C (the &#147;
<B>
	Consent
	Judgment and Injunction
</B>
	&#148;).
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	5
</P>
<A NAME="eolPage95"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The foregoing admissions and the Consent Judgment and Injunction shall be binding on Taro and admissible
	against Taro in any dispute or litigation between the parties regarding the Patent Rights, and Taro shall not challenge such admission. Taro shall not assist any Third Party in an action to invalidate or render unenforceable any Valid Claim, and
	Taro shall not disclose any of its proprietary or confidential information relating to the validity or enforceability of any Valid Claim, except to the extent required by court order or other applicable law. This paragraph is limited to (a)&nbsp;the
	claims of issued patents within the Patent Rights as they exist as of the Effective Date and (b)&nbsp;the claims of patent applications within the Patent Rights as such claims are drafted as of the Effective Date and the claims issuing therefrom to
	the extent such issued claims are the same as drafted as of the Effective Date.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.
<U>
	LICENSE
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.1
<U>
	License Grants
</U>
	. Subject to the terms and conditions of this Agreement, and effective on the Trigger Date, Vanda hereby grants to
	Taro a non-exclusive **** license under the Patents Rights to make, have made, use, sell, offer for sale and import the applicable Generic Products and ****. For the avoidance of doubt, the use or resale of a Generic Product by a supplier or
	customer of Taro following the Trigger Date, to the extent such Generic Product was first manufactured and sold by or on behalf of Taro within the scope of the foregoing license, shall not constitute an infringement of the Patent Rights as set forth
	in this Agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.2
<U>
	No Other Licenses
</U>
	. Except as otherwise provided herein, nothing in this Agreement shall be construed as:
	(a)&nbsp;an obligation to bring or prosecute actions or suits against Third Parties for infringement of any patent, whether within the Patent Rights or otherwise; (b)&nbsp;granting a license or conferring any right under any patent with respect to
	actions taken wholly after the expiration of such patent; (c)&nbsp;conferring a right to use in advertising, publicity, promotion or otherwise any of Vanda&#146;s trademarks, including in the trademark Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, trade dresses, service marks, or other intellectual property other than the Patent Rights; or (d)&nbsp;granting by implication, estoppel or otherwise, any licenses or rights under the Patent
	Rights or any other patents.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4. TERM AND TERMINATION.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.1
<U>
	Term
</U>
	. Subject to Sections 4.2 and 4.3, this Agreement shall expire on the expiration of the last to expire of the Patent Rights;
	provided, however, that if there are no valid, issued patents within the Patent Rights, but there are at such time pending patent applications within the Patent Rights, then subject to the terms and conditions of this Agreement, the term of this
	Agreement shall continue for the pendency of such pending patent applications.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.2
<U>
	Termination for Cause
</U>
	. Either party may
	terminate this Agreement upon or after the material breach of any material provision of this Agreement by the other party if the other party has not cured such breach within **** after receipt of express written notice thereof by the non-breaching
	party. If this Agreement is terminated as the result of a material breach by Taro prior to expiration of the last of the Patent Rights, then Taro shall not
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	6
</P>
<A NAME="eolPage96"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	make, have made, use, sell, offer for sale, import or distribute the applicable Generic Product until (i)&nbsp;there are no Valid Claims covering the Generic
	Product, (ii)&nbsp;a final decision by a court from which no appeal can be taken is entered holding that all of the said applicable Patent Rights as to as to such Generic Product are unpatentable or invalid or unenforceable or not infringed by the
	applicable Generic Product (for the avoidance of doubt, a court of appeals&#146; judgment or order is not &#147;final&#148; until issuance of the mandate); or (iii)&nbsp;a final decision by the U.S. Patent and Trademark Office, from which no appeal
	can be taken, is entered holding that all the said applicable Patent Rights as to such Generic Product are unpatentable, invalid or unenforceable (for the avoidance of doubt, a court of appeals&#146; judgment or order is not &#147;final&#148; until
	issuance of the mandate).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.3
<U>
	Termination for Challenge
</U>
	. Vanda shall have the right to immediately terminate this Agreement at any
	time after the Effective Date in the event Taro contests or challenges, or supports or assists any Third Party to contest or challenge, with the U.S. Patent Office or any U.S. court, U.S. regulatory agency or other forum, Vanda&#146;s ownership of
	or rights in, or the validity, enforceability or scope of, any of the Patent Rights in connection with a Generic Product.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.4
<U>
	Effect
	of Expiration or Termination
</U>
	. Expiration or termination of this Agreement shall not relieve the parties of any obligation accruing prior to such expiration or termination, and the provisions of Sections 1, 2.1, 2.2, 2.3, 3.2, 4.2, 4.4, 5, 7 and
	8 shall survive the expiration or termination of this Agreement. No other provisions shall survive expiration or termination of this Agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5. CONFIDENTIALITY.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.1
<U>
	Confidentiality
</U>
	. Except as otherwise provided herein, until the date that is five (5)&nbsp;years after the expiration or earlier termination of this Agreement&#151;except with respect to any Confidential Information constituting a trade
	secret, in which case the receiving party&#146;s obligation pursuant to this paragraph continues in perpetuity, provided such receiving party has been informed as to the status of such Confidential Information as a trade secret&#151;each party shall
	maintain in confidence all Confidential Information disclosed by the other party and the terms of this Agreement, and shall not use, grant the use of, or disclose to any Third Party any Confidential Information of the other party other than as
	expressly permitted hereby. Each party shall notify the other promptly upon discovery of any unauthorized use or disclosure of the other party&#146;s Confidential Information or the terms of this Agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.2
<U>
	Permitted Disclosures
</U>
	. Either party may disclose Confidential Information of the disclosing party (a)&nbsp;on a need-to-know basis,
	to such party&#146;s directors, officers and employees to the extent such disclosure is reasonably necessary in connection with such party&#146;s activities as expressly authorized by this Agreement, and (b)&nbsp;to those agents and consultants, and
	contract manufacturers who need to know such information to accomplish the purposes of this Agreement (collectively, &#147;
<B>
	Permitted Recipients
</B>
	&#148;); provided such Permitted Recipients are bound to maintain such Confidential Information in
	confidence at least to the same extent as set forth in Section&nbsp;5.1.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	7
</P>
<A NAME="eolPage97"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.3
<U>
	Litigation and Governmental Disclosure
</U>
	. Each party may disclose Confidential Information of the other party to the extent such
	disclosure is reasonably necessary (i)&nbsp;to comply with a court order or applicable law, governmental regulations or investigative requests, or (ii)&nbsp;in the reasonable opinion of the disclosing party&#146;s counsel is mandated by a subpoena,
	discovery request or other compulsory process, provided that if a party is required or permitted to produce Confidential Information for any reasons set forth above (except for disclosure requested or required by the I.R.S.) it will give reasonable
	advance notice to the other party of such disclosure requirement and will use good faith efforts to assist such other party to secure a protective order or confidential treatment of such Confidential Information required to be disclosed.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.4
<U>
	Return of Confidential Information
</U>
	. Upon expiration or termination of this Agreement for any reason, the Receiving Party, upon
	receipt of a written request from the Disclosing Party, shall return to the Disclosing Party all copies of the Confidential Information received from the Disclosing Party hereunder, provided, however, that the Receiving Party&#146;s legal counsel
	may retain one copy of such Confidential Information in a secure location solely for purposes of determining the Receiving Party&#146;s continuing obligations under this Agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.5
<U>
	Publicity
</U>
	. Except as expressly authorized hereunder, neither party shall make any publicity releases, interviews or other
	dissemination of information concerning this Agreement or its terms, or either party&#146;s performance hereunder, to communication media, financial analysts or others without the prior written approval of the other party, which approval shall not
	be unreasonably withheld, delayed or conditioned. Notwithstanding anything to the contrary in this Agreement, the parties understand and agree that either party, may disclose the existence and/or terms of this Agreement or other Confidential
	Information of the other party (a)&nbsp;to comply with its obligations under the law, including, without limitation, the United States Securities Act of 1933, as amended and the United States Securities Exchange Act of 1934, as amended (the
	&#147;
<B>
	Exchange Act
</B>
	&#148;); (b)&nbsp;in order to comply with the listing standards, rules, regulations or agreements of any national or international securities exchange, The NASDAQ Global Market or New York Stock Exchange or other similar
	laws, rules or regulations of a governmental or regulatory authority; (c)&nbsp;to respond to an inquiry of a governmental authority or regulatory authority as required by law; or (d)&nbsp;in a judicial, administrative or arbitration proceeding, if,
	in the reasonable opinion of the disclosing party&#146;s counsel, the production of such Confidential Information is mandated by a subpoena, discovery request or other compulsory process. In any such event the party making such disclosure shall
	(i)&nbsp;provide the other party with as much advance notice as reasonably practicable of the required disclosure, (ii)&nbsp;cooperate with the other party in any reasonable attempt to prevent or limit the disclosure, and (iii)&nbsp;limit any
	disclosure to the specific purpose at issue. In furtherance of the foregoing, the parties acknowledge that Vanda will be permitted pursuant to the rules and regulations promulgated under the Exchange Act to file a Current Report on Form 8-K
	disclosing the entry into this Agreement by Vanda and a description of the terms and conditions hereof and thereof. In connection with any filing of a copy of this Agreement with the Securities and Exchange Commission, the filing party shall
	endeavor to obtain confidential treatment of economic and trade secret information, and shall keep the other party informed as to the planned filing (including, but not limited to providing the other party with the proposed filing reasonably in
	advance of making the planned filing) and consider the reasonable requests of the other party regarding such confidential treatment.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	8
</P>
<A NAME="eolPage98"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.
<U>
	REPRESENTATIONS AND WARRANTIES.
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.1
<U>
	Representations
</U>
	. Each party hereby represents and warrants as of the Effective Date to the other party that (a)&nbsp;the person
	executing this Agreement is authorized to execute this Agreement; (b)&nbsp;this Agreement is legal and valid and the obligations binding upon such party are enforceable by their terms; and (c)&nbsp;the execution, delivery and performance of this
	Agreement does not conflict with any agreement, instrument or understanding, oral or written, to which such party may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction
	over it.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.2
<U>
	Disclaimer of Warranties
</U>
	. Except as explicitly set forth herein, neither party makes any warranty, written, oral,
	express or implied, with respect to this Agreement. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT HEREBY ARE DISCLAIMED BY
	BOTH PARTIES.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.3
<U>
	Limitation of Liability
</U>
	. WITH THE EXCEPTION OF DAMAGES RESULTING FROM A PARTY&#146;S BREACH OF ITS
	CONFIDENTIALITY OBLIGATIONS UNDER THIS AGREEMENT OR ITS OBLIGATIONS UNDER SECTION 7 (INDEMNIFICATION), OR A BREACH BY TARO OF SECTION 2, UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE LIABLE FOR LOSS OF USE OR PROFITS OR OTHER COLLATERAL, SPECIAL,
	CONSEQUENTIAL, INCIDENTAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, WHETHER SUCH CLAIMS ARE FOUNDED IN TORT OR CONTRACT.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.4
<U>
	Equitable Relief Against Taro
</U>
	. Taro acknowledges and agrees that the obligations and undertakings of Taro pursuant to Section&nbsp;2 of this Agreement are reasonable and necessary to protect the legitimate interests of Vanda, that Vanda would
	not have entered into this Agreement in the absence of such provisions, and that Taro&#146;s breach or threatened breach or failure to comply with Section&nbsp;2 shall cause Vanda significant and irreparable harm, the amount of which shall be
	extremely difficult to estimate and ascertain, and for which money damages shall not be adequate. Taro further acknowledges and agrees that Vanda shall have the right to apply to any court of competent jurisdiction for an injunction order
	restraining any breach or threatened breach of Section&nbsp;2 of this Agreement and specifically enforcing the terms and provisions of such Sections of this Agreement, without the necessity of posting any bond or security, in addition to seeking any
	other remedy available to Vanda in law or equity. Taro agrees that it shall not challenge any of the foregoing acknowledgements and agreements concerning injunctive relief in any proceeding brought by Vanda.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.
<U>
	INDEMNIFICATION.
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.1
	Taro shall indemnify, defend and hold harmless Vanda, its directors, managers, members, officers, employees, authorized subcontractors and agents (collectively the
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	9
</P>
<A NAME="eolPage99"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&#147;
<B>
	Vanda Indemnified Parties
</B>
	&#148;) from and against any and all liabilities, losses, damages,
	costs and expenses (including, without limitation, reasonable attorney&#146;s fees and costs) (collectively, &#147;Losses&#148;) incurred as a result of any claims, demands, actions or other proceedings by a **** against a Vanda Indemnified Party,
	****. Taro&#146;s obligation to indemnify Vanda Indemnified Parties shall exclude any claim asserted by any ****.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.2 A Vanda Indemnified
	Party that intends to claim indemnification under this Section&nbsp;7 shall promptly notify Taro in writing of any claim, demand, action, or other proceeding in respect of which the Vanda Indemnified Party intends to claim such indemnification;
	provided, however, that failure to provide such notice within a reasonable period of time shall not relieve Taro of any of its obligations hereunder except to the extent Taro is prejudiced by such failure. The Vanda Indemnified Party shall permit
	Taro, at its discretion, to settle any such action, claim or other matter. Notwithstanding the foregoing, Taro shall not enter into any settlement that would adversely affect the Vanda Indemnified Party&#146;s rights hereunder, or impose any
	obligations on the Vanda Indemnified Party in addition to those set forth herein, in order for it to exercise such rights, without the Vanda Indemnified Party&#146;s prior written consent, which shall not be unreasonably withheld or delayed. No such
	action, claim or other matter shall be settled without the prior written consent of Taro, which shall not be unreasonably withheld or delayed. The Vanda Indemnified Party shall reasonably cooperate with Taro and its legal representatives in the
	investigation and defense of any claim, demand, action, or other proceeding covered by the indemnification obligations of this Section&nbsp;7. The Vanda Indemnified Party shall have the right, but not the obligation, to be represented in such
	defense by counsel of its own selection at its own expense.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.3 Vanda shall indemnify, defend and hold harmless Taro, its directors,
	managers, members, officers, employees, authorized subcontractors and agents (collectively the &#147;
<B>
	Taro Indemnified Parties
</B>
	&#148;) from and against any and all liabilities, losses, damages, costs and expenses (including, without limitation,
	reasonable attorney&#146;s fees and costs) (collectively, &#147;Losses&#148;) incurred as a result of any claims, demands, actions or other proceedings by a **** against a Taro Indemnified Party, **** Vanda&#146;s obligation to indemnify Taro
	Indemnified Parties shall exclude any claim asserted by any ****.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.4 A Taro Indemnified Party that intends to claim indemnification
	under this Section&nbsp;7 shall promptly notify Vanda in writing of any claim, demand, action, or other proceeding in respect of which the Taro Indemnified Party intends to claim such indemnification; provided, however, that failure to provide such
	notice within a reasonable period of time shall not relieve Vanda of any of its obligations hereunder except to the extent Vanda is prejudiced by such failure. The Taro Indemnified Party shall permit Vanda, at its discretion, to settle any such
	action, claim or other matter. Notwithstanding the foregoing, Vanda shall not enter into any settlement that would adversely affect the Taro Indemnified Party&#146;s rights hereunder, or impose any obligations on the Taro Indemnified Party in
	addition to
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	10
</P>
<A NAME="eolPage100"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	those set forth herein, in order for it to exercise such rights, without the Taro Indemnified Party&#146;s prior written consent, which shall not be
	unreasonably withheld or delayed. No such action, claim or other matter shall be settled without the prior written consent of Vanda, which shall not be unreasonably withheld or delayed. The Taro Indemnified Party shall reasonably cooperate with
	Vanda and its legal representatives in the investigation and defense of any claim, demand, action, or other proceeding covered by the indemnification obligations of this Section&nbsp;7. The Taro Indemnified Party shall have the right, but not the
	obligation, to be represented in such defense by counsel of its own selection at its own expense.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.
<U>
	GENERAL PROVISIONS.
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.1
<U>
	Notices
</U>
	. All notices hereunder shall be delivered by facsimile (confirmed by overnight delivery), or by overnight delivery with a
	reputable overnight delivery service, to the following address of the respective parties:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_50"></A>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="7%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="11%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="80%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	If&nbsp;to&nbsp;Vanda:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vanda Pharmaceuticals Inc.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2200 Pennsylvania
	Avenue, N.W.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Washington, DC 20037
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Attn: Chief Executive
	Officer
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Facsimile:
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	with&nbsp;a&nbsp;copy&nbsp;to:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vanda Pharmaceuticals Inc.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2200 Pennsylvania
	Avenue, N.W.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Washington, DC 20037
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Attn: General Counsel
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Facsimile:
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	If to Taro:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Taro Pharmaceuticals USA, Inc.,
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3, Skyline
	Drive, Hawthorne, NY 10532
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Attn : Stephen J. Manzano
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	General
	Counsel
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Notices shall be effective on the day of receipt. A party may change its address listed above by notice to the
	other party given in accordance with this Section&nbsp;8.1.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.2
<U>
	Entire Agreement
</U>
	. The parties hereto acknowledge that this
	Agreement sets forth the entire agreement and understanding of the parties and supersede all prior written or oral agreements or understandings with respect to the subject matter hereof. No modification of any of the terms of this Agreement, or any
	amendments thereto, shall be deemed to be valid unless in writing and signed by an authorized agent or representative of both parties hereto. No course of dealing or usage of trade shall be used to modify the terms and conditions herein. This
	Agreement shall be binding on each of Taro and Vanda and their respective permitted successors and assigns.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.3
<U>
	Waiver
</U>
	. None of
	the provisions of this Agreement shall be considered waived by any party hereto unless such waiver is agreed to, in writing, by authorized agents of such party. The failure of a party to insist upon strict conformance to any of the terms and
	conditions hereof, or failure or delay to exercise any rights provided herein or by law shall not be deemed a waiver of any rights of any party hereto.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	11
</P>
<A NAME="eolPage101"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.4
<U>
	Obligations to Third Parties
</U>
	. Each party warrants and represents that this Agreement does not conflict with any contractual
	obligations, expressed or implied, undertaken with any Third Party.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.5
<U>
	Assignment
</U>
	. Neither party shall assign this Agreement or
	any part hereof or any interest herein (whether by operation of law or otherwise) to any Third Party (or use any subcontractor) without the written approval of the other party; provided, however, that either party may assign this Agreement without
	such consent (i)&nbsp;to any Affiliate; and (ii)&nbsp;in the case of a merger, consolidation, change in control or sale of all or substantially all of the assets related to this Agreement, provided further that with respect to Taro, any such
	Affiliate or Third Party agrees to be bound by the terms and conditions of this Agreement. No assignment shall be valid unless the permitted assignee(s) assumes all obligations of its assignor under this Agreement. No assignment shall relieve any
	party of responsibility for the performance of its obligations hereunder. Any purported assignment in violation of this Section&nbsp;8.5 shall be void.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.6
<U>
	Governing Law
</U>
	. Any action brought regarding the validity, construction or enforcement of this Agreement shall be governed in all
	respects by the laws of the State of Delaware, without regard to the principles of conflicts of laws. The federal and state courts in the State of Delaware shall have exclusive jurisdiction over the parties hereto in all such actions, and each party
	irrevocably consents to the personal jurisdiction of those courts and agrees not to challenge the venue of such courts or to seek to transfer any such action to any other forum.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.7
<U>
	Severability
</U>
	. If any term or provision of this Agreement shall for any reason be held invalid, illegal or unenforceable in any
	respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof, and this Agreement shall be interpreted and construed as if such term or provision, to the extent the same shall have been held to be
	invalid, illegal or unenforceable, had never been contained herein.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.8
<U>
	Headings, Interpretation
</U>
	. The headings used in this
	Agreement are for convenience only and are not part of this Agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.9
<U>
	Counterparts
</U>
	. The Agreement may be executed in two or
	more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<I>
	[Remainder of this page intentionally blank]
</I>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	12
</P>
<A NAME="eolPage102"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by their duly-authorized representatives effective as of the Effective
	Date.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="13%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="86%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
	VANDA PHARMACEUTICALS INC.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	By:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Name:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Title:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="13%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="86%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
	TARO PHARMACEUTICALS USA, INC.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	By:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Name:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Title:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="13%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="86%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
	TARO PHARMACEUTICAL INDUSTRIES, LTD.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	By:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Name:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Title:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<A NAME="eolPage103"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	EXHIBIT A
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<U>
	Fanapt Products
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<U>
	PRODUCT
</U>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	****
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	****
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	****
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	****
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	****
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	****
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	****
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<A NAME="eolPage104"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	EXHIBIT B
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	US Patent No.&nbsp;8,586,610
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	US
	Patent No.&nbsp;9,138,432
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	****
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<A NAME="eolPage105"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_51"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	EXHIBIT C
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<U>
	Consent Judgement
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	IN THE UNITED STATES DISTRICT COURT
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	FOR THE DISTRICT OF DELAWARE
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="29%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="67%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	VANDA PHARMACEUTICALS INC.,
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Plaintiff,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="LEFT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	v.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	TARO&nbsp;PHARMACEUTICALS&nbsp;USA,
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	INC.&nbsp;and&nbsp;TARO&nbsp;PHARMACEUTICAL
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	INDUSTRIES, LTD.,
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Defendants.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	)
<BR>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:1PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	C.A. No. 15-00920&#151;GMS
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	STIPULATION FOR ENTRY OF CONSENT JUDGMENT AND
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	PERMANENT INJUNCTION AS TO TARO PHARMACEUTICALS USA, INC.
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<U>
	AND TARO PHARMACEUTICAL INDUSTRIES, LTD
</U>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Plaintiff Vanda Pharmaceuticals Inc. and Defendants Taro Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. having met,
	conferred, and agreed to resolve their dispute upon execution of a separate License Agreement, hereby stipulate to entry of the executed Consent Judgment and Permanent Injunction submitted herewith, subject to the Court&#146;s approval.
</P>
<A NAME="eolPage106"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="48%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	M
<SMALL>
	ORRIS
</SMALL>
	, N
<SMALL>
	ICHOLS
</SMALL>
	, A
<SMALL>
	RSHT
</SMALL>
	&nbsp;&amp; T
<SMALL>
	UNNELL
</SMALL>
	LLP
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:1PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Jack B. Blumenfeld (#1014)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Karen Jacobs
	(#2881)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Derek J. Fahnestock (#4705)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1201 North Market
	Street
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	P.O. Box 1347
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Wilmington, DE 19899
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(302) 658-9200
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	jblumenfeld@mnat.com
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	kjacobs@mnat.com
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	dfahnestock@mnat.com
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Attorneys for Plaintiff
</I>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Vanda Pharmaceuticals Inc.
</I>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	OF COUNSEL:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Nicholas
	Groombridge
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Eric Alan Stone
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Kira A. Davis
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Josephine Young
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Daniel J. Klein
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	James Razick
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	PAUL, WEISS, RIFKIND, WHARTON
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&amp; GARRISON LLP
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1285
	Avenue of the Americas
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	New York, NY 10019
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(212) 373-3000
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="48%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	RICHARDS, LAYTON&nbsp;&amp; FINGER, P.A.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:1PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Kelly E. Farnan (#4395)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Christine D. Haynes
	(#4697)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	One Rodney Square
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	920 North King Street
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Wilmington, DE 19801
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	302-651-7700
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Farnan@rlf.com
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Haynes@rlf.com
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Attorneys for Defendants
</I>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Taro Pharmaceuticals USA, Inc. and Taro
</I>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Pharmaceutical
	Industries, Ltd.
</I>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	2
</P>
<A NAME="eolPage107"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	OF COUNSEL:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	William R. Zimmerman
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	KNOBBE, MARTENS, OLSON&nbsp;&amp; BEAR,
	LLP
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1717 Pennsylvania Avenue N.W., Suite 900
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Washington, DC
	20006
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Phone: (202)&nbsp;640-6400
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Bill.Zimmerman@knobbe.com
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	William O. Adams
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	KNOBBE, MARTENS, OLSON&nbsp;&amp; BEAR,
	LLP
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2040 Main Street
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fourteenth Floor
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Irvine, CA 92614
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Phone: (949)&nbsp;760-0404
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	William.Adams@knobbe.com
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Nathanael R. Luman
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Caleb A. Bates
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	KNOBBE, MARTENS, OLSON&nbsp;&amp; BEAR, LLP
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	12790 El Camino Real, Suite 100
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	San Diego, CA 92130
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Phone: (858-707-4000)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Nate.Luman@knobbe.com
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Caleb.Bates@knobbe.com
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Dated: October __, 2016
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	3
</P>
<A NAME="eolPage108"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_52"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	IN THE UNITED STATES DISTRICT COURT
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	FOR THE DISTRICT OF DELAWARE
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="29%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="67%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	VANDA PHARMACEUTICALS INC.,
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Plaintiff,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="LEFT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	v.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	TARO&nbsp;PHARMACEUTICALS&nbsp;USA,
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	INC.&nbsp;and&nbsp;TARO&nbsp;PHARMACEUTICAL
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	INDUSTRIES, LTD.,
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Defendants.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	)
<BR>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:1PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	C.A. No. 15-00920&#151;GMS
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONSENT JUDGMENT AND PERMANENT INJUNCTION
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	AS TO TARO PHARMACEUTICALS USA, INC.
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<U>
	AND TARO PHARMACEUTICAL INDUSTRIES, LTD
</U>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	This matter is before the Court on the unopposed motion of Plaintiff Vanda Pharmaceuticals Inc. (&#147;Vanda&#148;) and Defendants Taro
	Pharmaceuticals USA, Inc. and Taro Pharmaceutical Industries, Ltd. (together, &#147;Taro&#148;).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS
</B>
	, Vanda owns United States
	Patent Nos. 8,586,610 (&#147;the &#146;610 patent&#148;) and 9,138,432 (&#147;the &#146;432 patent&#148;).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	Taro
	Pharmaceuticals USA, Inc. submitted Abbreviated New Drug Application No.&nbsp;207098 (&#147;Taro&#146;s ANDA&#148;) to the FDA under 21 U.S.C. &#167;&nbsp;355(j) seeking to obtain approval to commercially manufacture and sell generic iloperidone for
	the treatment of schizophrenia.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS
</B>
	, in this Action, Vanda alleges that Taro infringed one or more of claims 1-9, 11-13, and
	16 of the &#146;610 patent and claim 1 of the &#146;432 patent under 35 U.S.C. &#167;&nbsp;271(e)(2) by virtue of Taro Pharmaceutical USA, Inc.&#146;s submission of Taro&#146;s ANDA to the FDA.
</P>
<A NAME="eolPage109"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	in this Action, Vanda alleges that it would be irreparably harmed if Taro were
	not enjoined from infringing or actively inducing or contributing to infringement of one or more of claims 1-9, 11-13, and 16 of the &#145;610 patent and claim 1 of the &#146;432 patent.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	in this Action, Vanda requested that this Court enter a permanent injunction enjoining Taro from infringing the &#146;610 and
	&#146;432 patents.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	Vanda and Taro have reached an agreement to finally settle the Litigation as set forth in this Consent
	Judgment and Permanent Injunction as to Taro and a separate License Agreement (&#147;License Agreement&#148;) which is contemporaneously and separately being executed.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	final settlement of this Action will help Vanda and Taro avoid the substantial uncertainty and risks involved with prolonged
	litigation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	final settlement of this Action will permit Vanda and Taro to save litigation costs, as well as adhere to the
	judicially recognized mandate that encourages the settlement of litigation whenever possible.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	final settlement of the
	Action serves the public interest by saving judicial resources and avoiding the risks to each of Vanda and Taro associated with infringement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	Vanda and Taro each consent to personal jurisdiction in Delaware for purposes of enforcing the License Agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	IT IS HEREBY ORDERED, DECREED, and ADJUDGED as follows:
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1. The Court has jurisdiction over Vanda and Taro and the subject matter of this Litigation.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	2
</P>
<A NAME="eolPage110"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2. Taro acknowledges Vanda&#146;s ownership and standing to sue for infringement of United States
	Patent Nos. 8,586,610 (&#147;the &#146;610 patent&#148;) and 9,138,432 (&#147;the &#146;432 patent&#148;).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3. Taro acknowledges that the
	&#146;610 and &#146;432 patents are valid and enforceable, as described more fully in the License Agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4. Taro acknowledges that it
	has infringed the &#146;610 and &#146;432 patents under 35 U.S.C. &#167;&nbsp;271(e)(2) and that Vanda did not authorize the manufacture, use, sale, offer for sale, importation and distribution of the product described in Taro&#146;s ANDA.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5. Taro and its affiliates are permanently enjoined as of the date hereof from infringing the &#146;610 and &#146;432 patents by the
	manufacture, use, offer to sell, sale, importation, or distribution of any generic iloperidone products that are the subject of Taro&#146;s ANDA that is not pursuant to a license granted by Vanda, and from inducing others to infringe or contributing
	to the infringement of the &#146;610 and &#146;432 patents by inducing others to manufacture, use, offer to sell, sale, import, or distribute or contributing to others&#146; manufacture, use, offer for sale, sale, importation, or distribution of any
	generic iloperidone products that are the subject of Taro&#146;s ANDA that is not pursuant to a license granted by Vanda.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6. All claims
	and counterclaims in this Action are hereby dismissed without prejudice.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7. Each party shall bear its own costs and attorneys&#146; fees.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	3
</P>
<A NAME="eolPage111"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8. This Court shall retain jurisdiction over Taro and Vanda for the purpose of enforcing the
	terms of this Consent Judgment and Permanent Injunction and over any matters related to or arising from the interpretation or enforcement of the License Agreement or any legal or equitable claim concerning the License Agreement by any third party.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	IT IS SO ORDERED, DECREED AND ADJUDGED
</B>
	this &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day of
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016 by:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="100%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; FONT-SIZE:3PT">
	&nbsp;
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Honorable Gregory M. Sleet
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	United States District Judge
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	4
</P>
<A NAME="eolPage112"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_53"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Agreed to:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="51%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="47%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	MORRIS, NICHOLS, ARSHT &amp; TUNNELL LLP
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Jack B. Blumenfeld (#1014)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Karen Jacobs (#2881)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Derek J. Fahnestock (#4705)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1201 North Market Street
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	P.O. Box 1347
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Wilmington, DE 19899
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(302) 658-9200
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	jblumenfeld@mnat.com
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	kjacobs@mnat.com
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	dfahnestock@mnat.com
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Attorneys for Plaintiff
</I>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Vanda Pharmaceuticals Inc.
</I>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	OF COUNSEL:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Nicholas Groombridge
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Eric Alan Stone
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Kira A. Davis
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Josephine Young
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Daniel J. Klein
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	James Razick
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	PAUL, WEISS, RIFKIND, WHARTON &amp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;GARRISON LLP
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1285 Avenue of the Americas
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	New York, NY 10019
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(212) 373-3000
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	RICHARDS, LAYTON &amp; FINGER, P.A.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT;BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Kelly E. Farnan (#4395)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Christine D. Haynes (#4697)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	One Rodney Square
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	920 North King Street
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Wilmington, DE 19801
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	302-651-7700
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Farnan@rlf.com
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Haynes@rlf.com
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Attorneys for Defendants
</I>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Taro Pharmaceuticals USA, Inc. and
</I>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Taro Pharmaceutical
	Industries, Ltd.
</I>
</P>
<P STYLE="FONT-SIZE:24PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	OF COUNSEL:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	William R. Zimmerman
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	KNOBBE, MARTENS, OLSON&amp; BEAR, LLP
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1717 Pennsylvania Avenue
	N.W., Suite 900
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Washington, DC 20006
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Phone: (202)
	640-6400
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Bill.Zimmerman@knobbe.com
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	William O. Adams
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	KNOBBE, MARTENS, OLSON&amp; BEAR, LLP
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2040 Main Street
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Fourteenth Floor
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Irvine, CA 92614
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Phone: (949) 760-0404
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	William.Adams@knobbe.com
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Nathanael R. Luman
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Caleb A. Bates
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	KNOBBE, MARTENS, OLSON&amp; BEAR, LLP
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	12790 El Camino Real, Suite
	100
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	San Diego, CA 92130
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Phone: (858-707-4000)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Nate.Luman@knobbe.com
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Caleb.Bates@knobbe.com
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	5
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage113"></A>
<A NAME="D474152DEX1046_HTM"></A>
<EFX_EXHIBIT_10>
<A NAME="FIS_EXHIBIT_10_2"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
<U>
	Exhibit 10.46
</U>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<U>
	LICENSE AGREEMENT
</U>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
</B>
	THIS LICENSE AGREEMENT (this &#147;
<B>
	Agreement
</B>
	&#148;) dated as of December&nbsp;7, 2016 (the &#147;
<B>
	Effective Date
</B>
	&#148;) is
	entered into between Vanda Pharmaceuticals Inc., a Delaware corporation with an address at 2200 Pennsylvania Avenue, N.W., Washington, DC 20037, on behalf of itself and its Affiliates (collectively, &#147;
<B>
	Vanda
</B>
	&#148;), and Apotex Inc., a
	corporation organized and existing under the laws of Canada, with a place of business at 150 Signet Drive, Toronto, Ontario M9L 1T9, Canada, and Apotex Corp., a Delaware corporation with a place of business at 2400 North Commerce Parkway, Suite 400,
	Weston, FL 33326, on behalf of themselves and each of their Affiliates (collectively, &#147;
<B>
	Apotex
</B>
	&#148;).
<B>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
</I>
	WHEREAS
	Vanda is the owner of the Patent Rights (as the term is defined below) and has sued Apotex Inc. and Apotex Corp. in an action captioned
<I>
	Vanda Pharmaceuticals Inc.
</I>
	v.
<I>
	Apotex Inc. and Apotex Corp.
</I>
	, Case No.&nbsp;1:15-cv-00922-GMS (D.
	Del.) (the &#147;
<I>
</I>
<B>
	Litigation
</B>
<I>
</I>
	&#148;) which is pending in the United States District Court, District of Delaware (the &#147;
<I>
</I>
<B>
	Court
</B>
<I>
</I>
	&#148;), in which Vanda alleges that Apotex Inc.&#146;s filing of Abbreviated New
	Drug Application (&#147;ANDA&#148;) No.&nbsp;208367 infringes U.S. Patent Nos. 8,586,610 (&#147;the &#146;610 patent&#148;) and 9,138,432 (&#147;the &#146;432 patent&#148;), and Apotex has filed counterclaims in the Litigation alleging that the
	&#146;610 and &#146;432 patents are invalid and not infringed; and
<I>
</I>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	WHEREAS the parties desire to settle the Litigation and Apotex
	desires to receive, and Vanda desires to grant to Apotex, a non-exclusive, **** license under the Patent Rights to make, use, sell, offer for sale and import Generic Product (as the term is defined below), all on the terms and conditions of this
	Agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for other good and
	valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.
<U>
	DEFINITIONS.
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.1 &#147;
<B>
	Affiliate
</B>
	&#148; means, with respect to any entity, any other entity that directly or indirectly
	controls, is controlled by, or is under common control with, such entity. An entity shall be regarded as in control of another entity if it owns, or directly or indirectly controls, at least fifty percent (50%)&nbsp;of the voting stock or other
	ownership interest of the other entity, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other entity by any means whatsoever.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.2 &#147;****&#148; shall mean the **** (as defined below).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.3 &#147;
<B>
	Authorized Generic
</B>
	&#148; shall mean any product that is sold, offered for sale or distributed in the United States pursuant
	to&nbsp;**** but not under the Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	tradename or another trademark or tradename owned by Vanda or its Affiliates.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<A NAME="eolPage114"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.4 &#147;
<B>
	Business Day
</B>
	&#148; shall mean any day other than a Saturday, a Sunday or a
	day on which the state or federal courts located in the State of Delaware are authorized or obligated by law or executive order to be closed.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.5 &#147;
<B>
	Confidential Information
</B>
	&#148; means all non-public materials, information and data concerning the disclosing party and its
	operations that is disclosed by the disclosing party to the receiving party pursuant to this Agreement, orally or in written, electronic or tangible form, or otherwise obtained by the receiving party through observation or examination of the
	disclosing party&#146;s operations. Confidential Information includes, but is not limited to, information about the disclosing party&#146;s financial condition and projections; business, marketing or strategic plans; sales information; customer
	lists; price lists; databases; trade secrets; product prototypes and designs; techniques, formulae, algorithms and other non-public process information. Notwithstanding the foregoing, Confidential Information of a party shall not include that
	portion of such materials, information and data that, and only to the extent, that the recipient can establish by written documentation: (a)&nbsp;is known to the recipient as evidenced by its written records before receipt thereof from the
	disclosing party, (b)&nbsp;is disclosed to the recipient free of confidentiality obligations by a Third Party who has the right to make such disclosure without obligations of confidentiality, (c)&nbsp;is or becomes part of the public domain through
	no fault of the recipient, or (d)&nbsp;the recipient can reasonably establish is independently developed by persons on behalf of recipient without the use of the information disclosed by the disclosing party.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.6 &#147;
<B>
	Fanapt Products
</B>
	&#148; means the form, formulation, and dosage of the current FDA-approved Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	products listed on Exhibit A. For the avoidance of doubt, Fanapt Products shall not include any **** (collectively, &#147;****&#148;). For any such **** Vanda agrees that, if ****.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.7 &#147;
<B>
	FDA
</B>
	&#148; means the United States Food and Drug Administration or any successor entity thereto.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.8 &#147;
<B>
	Generic Product
</B>
	&#148; means&#151;regardless of whether a product is considered generic, branded, private-labeled or
	otherwise&#151;a product for which FDA approval is sought as, or that has been deemed by FDA to be, bioequivalent to one of the Fanapt Products and has the same strength and dosage form as one of the Fanapt Products. For the avoidance of doubt,
	&#147;Generic Product&#148; does not include the Fanapt Products themselves but does include any Authorized Generic.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	2
</P>
<A NAME="eolPage115"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.9 &#147;
<B>
	Orange Book
</B>
	&#148; means the current edition (in electronic or hard copy
	form) of the FDA&#146;s publication
<I>
	Approved Drug Products with Therapeutic Equivalence Evaluations
</I>
	, as may be amended from time to time, and any successor publication thereto.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.10 &#147;
<B>
	Patent Rights
</B>
	&#148; means (a)&nbsp;the patents listed on Exhibit B to this Agreement and the patent applications giving rise
	thereto, (b)&nbsp;all provisional applications, divisionals, continuations, continuations-in-part, reissues and renewals that claim priority to, or common priority with, any patent application that resulted in the patents described in clause
	(a)&nbsp;above, and all patents granted thereon, (c)&nbsp;all patents that have issued or in the future issue from any of the foregoing patent applications, including utility, model and design patents and certificates of invention, together with any
	reexamination certificates (including any amended claims from an
<I>
	inter partes
</I>
	review or post-grant review proceeding), reissues, renewals, extensions, and extended exclusivities or restorations by existing or future extension or restoration
	mechanisms, or additions thereto, and (d)&nbsp;all other relevant patents and patent applications, if any, that cover Fanapt Products or an approved use of a Fanapt Product.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.11 &#147;
<B>
	Third Party
</B>
	&#148; means any person or entity other than Vanda or Apotex.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.12 &#147;
<B>
	Trigger Date
</B>
	&#148; means, with respect to a Generic Product for which Apotex has an approved ANDA, on a
	Generic-Product-by-Generic-Product basis, the earliest of:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(a) The date of expiration of the &#146;610 patent,
<I>
	i.e
</I>
	., November&nbsp;2, 2027, **** and further providing that if the &#145;610 patent does not lapse and Vanda obtains pediatric exclusivity pursuant to 21 U.S.C. &#167; 355A with respect to the &#146;610 patent (as reflected in the Orange
	Book), then in such case the date for purposes of this subsection 1.12(a) shall be May&nbsp;2, 2028;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(b) the date on
	which (i)&nbsp;a final decision by a court from which no appeal can be taken, other than a petition for a writ of certiorari, is entered holding that all of the then-asserted claims of the Patent Rights as to such Generic Product are unpatentable or
	invalid or unenforceable or not infringed by the applicable Generic Product (for the avoidance of doubt, a court of appeals&#146; judgment or order is not &#147;final&#148; until issuance of the mandate); or (ii)&nbsp;a final decision by the U.S.
	Patent and Trademark Office, from which no appeal can be taken, is entered holding that all of the then-asserted claims of the Patent Rights as to such Generic Product are unpatentable or invalid or unenforceable (for the avoidance of doubt, a court
	of appeals&#146; judgment or order is not &#147;final&#148; until issuance of the mandate);
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(c) the date on which such
	Generic Product is first sold in the United States by a Third Party that holds or is otherwise licensed under an approved ANDA to manufacture and/or sell such Generic Product in the United States (&#147;Third Party ANDA Holder&#148;) after the
	Effective Date ****;
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	3
</P>
<A NAME="eolPage116"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(d) the first date when such Generic Product is licensed to be sold in the United States by a Third Party who is under
	authority or license of Vanda;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(e) ****; and
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:8%; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(f) if any license or settlement agreement between Vanda and a Third Party allows or causes to allow a Third Party rights
	under the Patent Rights to sell Generic Product on a specific date that is earlier than the operative date under subsection 1.12(a), 1.12(c), 1.12(d), and as to any entity under 1.12(e), above (each an &#147;
<B>
	Earlier Trigger Date
</B>
	&#148;), then
	Vanda shall notify Apotex in writing of the Earlier Trigger Date within **** of learning of or granting of the Earlier Trigger Date, including, but not limited to, within **** of learning of the activation of a corresponding &#147;trigger date&#148;
	in a settlement agreement or license agreement with a Third Party or Affiliate of Vanda, and this Agreement shall automatically be amended to include such Earlier Trigger Date as subsection 1.12(g), and further providing that ****. For the avoidance
	of doubt, a &#147;specific date&#148; may be either a specified date (
<I>
	i.e
</I>
	. wherein the license agreement or settlement agreement identifies a specific date by day, month and year), or may also be, for example, a &#147;trigger date&#148; that
	is defined by the terms of a settlement agreement or license agreement with a Third Party.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	4
</P>
<A NAME="eolPage117"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.13 &#147;
<B>
	United States
</B>
	&#148; means the United States of America, including its territories and possessions.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.14 &#147;
<B>
	Valid Claim
</B>
	&#148; means a claim in an issued patent within the Patent Rights that has not (a)&nbsp;expired; (b)&nbsp;been
	disclaimed (but, if terminally disclaimed, only after the patent to which the terminal disclaimer is tied has expired); (c)&nbsp;been declared invalid or unenforceable in a final decision of a court, or (d)&nbsp;been declared invalid or
	unenforceable in a final decision by the U.S. Patent and Trademark Office, from which no appeal can be taken (for the avoidance of doubt, a court of appeals&#146; judgment or order is not &#147;final&#148; until issuance of the mandate).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1.15 &#147;
<B>
	Vanda NDA
</B>
	&#148; means the New Drug Application **** and any supplements or amendments thereto.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.
<U>
	RELEASE; PATENT RIGHTS; COVENANTS.
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.1
<U>
	Release
</U>
	. Apotex, on its own behalf and on behalf of any person or entity within its control or with whom it contracts in any way
	with respect to the ANDA and/or any Generic Product, represents and warrants that, as of the Effective Date, neither Apotex nor any person or entity within its control or with whom it has contracted with respect to the ANDA and/or Generic Product,
	has manufactured, used, sold, offered for sale, imported or distributed in the United States any Generic Product except for purposes that would not constitute infringement of the Patent Rights as a result of the application of 35 U.S.C. &#167;
	271(e)(1). In consideration for the covenants set forth in this Agreement, and in reliance on the representation and warranty in the preceding sentence, Vanda hereby as of the Effective Date fully, finally, and irrevocably releases Apotex and its
	Affiliates **** (collectively, the &#147;Apotex Releasees&#148;) from all claims and other Losses (as that term is defined below) arising from the manufacture, use, sale, offer for sale, importation or distribution of Apotex&#146;s Generic Product
	prior to the Effective Date (the &#147;Released Claims&#148;).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.2
<U>
	Prior to Trigger Dates
</U>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	5
</P>
<A NAME="eolPage118"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.2.1 Commencing on the Effective Date and continuing until the Trigger Date, Apotex shall
	not&#151;and shall not directly or indirectly encourage or assist any Third Party to&#151;develop, make, use, sell, offer for sale, or import into the United States any Generic Product. Notwithstanding the foregoing, ****. For the avoidance of
	doubt, and further notwithstanding the foregoing, ****.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.2.2 If Vanda enters into any agreement allowing a Third Party ANDA Holder ****
	then this Agreement shall automatically ****.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.2.3 Nothing in this Agreement shall be construed as prohibiting Apotex from engaging in
	any activity that would not constitute infringement of the Patent Rights as a result of the application of 35 U.S.C. &#167; 271(e)(1).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.3
<U>
	Validity of Vanda&#146;s Patents
</U>
	. Apotex hereby admits that, ****, the claims of the Patent Rights are valid and enforceable.
	Apotex hereby admits that, absent a license or applicable exemption under 21 U.S.C. &#167; 271(e)(1), the commercial making, using, offering to sell, selling, and/or importation into the United States of a Generic Product is covered by one or more
	claims of the Patent Rights under 35 U.S.C. &#167; 271. Within five days of the Effective Date, Vanda and Apotex shall execute and cause to be filed with the Court in the Litigation a consent judgment in the form attached hereto as Exhibit C (the
	&#147;
<B>
	Consent Judgment and Injunction
</B>
	&#148;). Subject to Article 2.4(d), the foregoing admissions and the Consent Judgment and Injunction shall be binding on Apotex and admissible against Apotex in any dispute or litigation between the
	parties regarding the Patent Rights, and Apotex shall not challenge such admission. Apotex shall not assist any Third Party in an action to invalidate or render unenforceable any Valid Claim, and Apotex shall not disclose any of its proprietary or
	confidential information relating to the validity or enforceability of any Valid Claim, except to the extent required by court order or other applicable law. This paragraph is limited to (a)&nbsp;the claims of issued patents within the Patent Rights
	as they exist as of the Effective Date and (b)&nbsp;the claims of patent applications within the Patent Rights as such claims are drafted as of the Effective Date and the claims issuing therefrom to the extent such issued claims are the same as
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	6
</P>
<A NAME="eolPage119"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	drafted as of the Effective Date. For the avoidance of doubt, ****. Nothing herein shall prevent Apotex from
	maintaining a &#147;Paragraph IV Certification&#148; pursuant to 21 U.S.C. &#167; 355(j)(2)(A)(vii)(IV) (as amended or replaced) for its Generic Product with respect to the Patent Rights on the basis that any sale by Apotex in accordance with this
	Agreement will be a licensed sale.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2.4
<U>
	Covenants.
</U>
	Vanda, for itself and its Affiliates, hereby covenants as of the Effective Date
	of this Agreement and thereafter during the time that this Agreement is in effect:
</P>
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_54"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	a) ****;
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	b) ****
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	c) ****.
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.
<U>
	LICENSE; EXCLUSIVITY WAIVER
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.1
<U>
	License Grants
</U>
	. Subject to the terms and conditions of this Agreement, and effective on the Trigger Date, Vanda hereby grants to
	Apotex a non-exclusive, **** license under the Patents Rights to make, have made, use, sell, offer for sale and import the applicable Generic Products ****. For the avoidance of doubt, the use or resale of a Generic Product by a supplier or customer
	of Apotex following the Trigger Date, to the extent such Generic Product was first manufactured and sold by or on behalf of Apotex within the scope of the foregoing license, shall not constitute an infringement of the Patent Rights as set forth in
	this Agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.2
<U>
	****.
</U>
	With respect to the sale of Generic Product in accordance with this Agreement on or after the Trigger
	Dates provided for in Sections 1.12(a) and Sections 1.12(c), Vanda hereby grants to Apotex ****.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:13%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.3
<U>
	No Other Licenses
</U>
	. Except as
	otherwise provided herein, nothing in this Agreement shall be construed as: (a)&nbsp;an obligation to bring or prosecute actions or suits against Third Parties for infringement of any patent, whether within the Patent Rights or otherwise; (b)
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	7
</P>
<A NAME="eolPage120"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	granting a license or conferring any right under any patent with respect to actions taken wholly after the
	expiration of such patent; (c)&nbsp;conferring a right to use in advertising, publicity, promotion or otherwise any of Vanda&#146;s trademarks, including in the trademark Fanapt
<SUP STYLE="FONT-SIZE:85%; VERTICAL-ALIGN:TOP">
	&reg;
</SUP>
	, trade
	dresses, service marks, or other intellectual property other than the Patent Rights; or (d)&nbsp;granting by implication, estoppel or otherwise, any licenses or rights under the Patent Rights or any other patents.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3.4
<U>
	Effect of an At-Risk Launch.
</U>
	For the avoidance of doubt, in the event that any entity other than Vanda or its Affiliates, or Apotex
	or its Affiliates, sells an unlicensed Generic Product on a date prior to the Trigger Date (the &#147;Unlicensed Launch Date&#148;), then the terms of Section&nbsp;1.12(c) shall apply, including as modified, if at all, by Section&nbsp;1.12(f).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.
<U>
	TERM AND TERMINATION.
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.1
<U>
	Term
</U>
	. Subject to Sections 4.2 and 4.3, this Agreement shall expire on the expiration of the last to expire of the Patent Rights;
	provided, however, that if there are no valid, issued patents within the Patent Rights, but there are at such time pending patent applications within the Patent Rights, then subject to the terms and conditions of this Agreement, the term of this
	Agreement shall continue for the pendency of such pending patent applications.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.2
<U>
	Termination for Cause
</U>
	. Either party may
	terminate this Agreement upon or after the material breach of any material provision of this Agreement by the other party if the other party has not cured such breach within **** after receipt of express written notice thereof by the non-breaching
	party. If this Agreement is terminated as the result of a material breach by Apotex prior to expiration of the last of the Patent Rights, then Apotex shall not make, have made, use, sell, offer for sale, import or distribute the applicable Generic
	Product until (i)&nbsp;there are no Valid Claims covering the Generic Product, (ii)&nbsp;a final decision by a court from which no appeal can be taken is entered holding that all of the said applicable Patent Rights as to as to such Generic Product
	are unpatentable or invalid or unenforceable or not infringed by the applicable Generic Product (for the avoidance of doubt, a court of appeals&#146; judgment or order is not &#147;final&#148; until issuance of the mandate); or (iii)&nbsp;a final
	decision by the U.S. Patent and Trademark Office, from which no appeal can be taken, is entered holding that all the said applicable Patent Rights as to such Generic Product are unpatentable, invalid or unenforceable (for the avoidance of doubt, a
	court of appeals&#146; judgment or order is not &#147;final&#148; until issuance of the mandate).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.3
<U>
	Termination for Challenge
</U>
	.
	Vanda shall have the right to immediately terminate this Agreement at any time after the Effective Date in the event Apotex contests or challenges, or supports or assists any Third Party to contest or challenge, with the U.S. Patent Office or any
	U.S. court, U.S. regulatory agency or other forum, Vanda&#146;s ownership of or rights in, or the validity, enforceability or scope of, any of the Patent Rights in connection with a Generic Product.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4.4
<U>
	Effect of Expiration or Termination
</U>
	. Expiration or termination of this Agreement shall not relieve the parties of any obligation
	accruing prior to such expiration or termination, and the provisions of Sections 1, 2.1, 3.3, 4.2, 4.4, 5, 7 and 8 shall survive the expiration or termination of this Agreement. No other provisions shall survive expiration or termination of this
	Agreement.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	8
</P>
<A NAME="eolPage121"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5. CONFIDENTIALITY.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.1
<U>
	Confidentiality
</U>
	. Except as otherwise provided herein, until the date that is five (5)&nbsp;years after the expiration or earlier
	termination of this Agreement&#151;except with respect to any Confidential Information constituting a trade secret, in which case the receiving party&#146;s obligation pursuant to this paragraph continues in perpetuity, provided such receiving party
	has been informed as to the status of such Confidential Information as a trade secret&#151;each party shall maintain in confidence all Confidential Information disclosed by the other party and the terms of this Agreement, and shall not use, grant
	the use of, or disclose to any Third Party any Confidential Information of the other party other than as expressly permitted hereby. Each party shall notify the other promptly upon discovery of any unauthorized use or disclosure of the other
	party&#146;s Confidential Information or the terms of this Agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.2
<U>
	Permitted Disclosures
</U>
	. Either party may disclose
	Confidential Information of the disclosing party (a)&nbsp;on a need-to-know basis, to such party&#146;s directors, officers and employees to the extent such disclosure is reasonably necessary in connection with such party&#146;s activities as
	expressly authorized by this Agreement, and (b)&nbsp;to those agents and consultants, and contract manufacturers who need to know such information to accomplish the purposes of this Agreement (collectively, &#147;
<B>
	Permitted Recipients
</B>
	&#148;);
	provided such Permitted Recipients are bound to maintain such Confidential Information in confidence at least to the same extent as set forth in Section&nbsp;5.1.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.3
<U>
	Litigation and Governmental Disclosure
</U>
	. Each party may disclose Confidential Information of the other party to the extent such
	disclosure is reasonably necessary for prosecuting or defending litigation or complying with a court order or applicable law, governmental regulations or investigation, provided that if a party is required by court order, law or regulation (except
	for disclosure requested or required by the I.R.S.) to make any such disclosure of the other party&#146;s Confidential Information it will give reasonable advance notice to the other party of such disclosure requirement and will use good faith
	efforts to assist such other party to secure a protective order or confidential treatment of such Confidential Information required to be disclosed.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.4
<U>
	Return of Confidential Information
</U>
	. Upon expiration or termination of this Agreement for any reason, the Receiving Party, upon
	receipt of a written request from the Disclosing Party, shall return to the Disclosing Party all copies of the Confidential Information received from the Disclosing Party hereunder, provided, however, that the Receiving Party&#146;s legal counsel
	may retain one copy of such Confidential Information in a secure location solely for purposes of determining the Receiving Party&#146;s continuing obligations under this Agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5.5
<U>
	Publicity
</U>
	. Except as expressly authorized hereunder, neither party shall make any publicity releases, interviews or other
	dissemination of information concerning this Agreement or its terms, or either party&#146;s performance hereunder, to communication media, financial analysts or others without the prior written approval of the other party, which approval
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	9
</P>
<A NAME="eolPage122"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
</B>
	shall not be unreasonably withheld, delayed or conditioned. Notwithstanding anything to the contrary in this Agreement, the parties understand and agree that either party, may disclose the
	existence and/or terms of this Agreement or other Confidential Information of the other party (a)&nbsp;to comply with its obligations under the law, including, without limitation, the United States Securities Act of 1933, as amended and the United
	States Securities Exchange Act of 1934, as amended (the &#147;
<B>
	Exchange Act
</B>
	&#148;); (b)&nbsp;in order to comply with the listing standards, rules, regulations or agreements of any national or international securities exchange, The NASDAQ
	Global Market or New York Stock Exchange or other similar laws, rules or regulations of a governmental or regulatory authority; (c)&nbsp;to respond to an inquiry of a governmental authority or regulatory authority as required by law; or (d)&nbsp;in
	a judicial, administrative or arbitration proceeding. In any such event the party making such disclosure shall (i)&nbsp;provide the other party with as much advance notice as reasonably practicable of the required disclosure, (ii)&nbsp;cooperate
	with the other party in any reasonable attempt to prevent or limit the disclosure, and (iii)&nbsp;limit any disclosure to the specific purpose at issue. In furtherance of the foregoing, the parties acknowledge that Vanda will be permitted pursuant
	to the rules and regulations promulgated under the Exchange Act to file a Current Report on Form 8-K disclosing the entry into this Agreement by Vanda and a description of the terms and conditions hereof and thereof. In connection with any filing of
	a copy of this Agreement with the Securities and Exchange Commission, the filing party shall endeavor to obtain confidential treatment of economic and trade secret information, and shall keep the other party informed as to the planned filing
	(including, but not limited to providing the other party with the proposed filing reasonably in advance of making the planned filing) and consider the reasonable requests of the other party regarding such confidential treatment.
<B>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.
<U>
	REPRESENTATIONS AND WARRANTIES.
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.1
<U>
	Representations
</U>
	. Each party hereby represents and warrants as of the Effective Date to the other party that (a)&nbsp;the person
	executing this Agreement is authorized to execute this Agreement; (b)&nbsp;this Agreement is legal and valid and the obligations binding upon such party are enforceable by their terms; and (c)&nbsp;the execution, delivery and performance of this
	Agreement does not conflict with any agreement, instrument or understanding, oral or written, to which such party may be bound, nor violate any law or regulation of any court, governmental body or administrative or other agency having jurisdiction
	over it.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.2
<U>
	Disclaimer of Warranties
</U>
	. Except as explicitly set forth herein, neither party makes any warranty, written, oral,
	express or implied, with respect to this Agreement. ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT HEREBY ARE DISCLAIMED BY
	BOTH PARTIES.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.3
<U>
	Limitation of Liability
</U>
	. WITH THE EXCEPTION OF DAMAGES RESULTING FROM A PARTY&#146;S BREACH OF ITS
	CONFIDENTIALITY OBLIGATIONS UNDER THIS AGREEMENT OR ITS OBLIGATIONS UNDER SECTION 7 (INDEMNIFICATION), OR A BREACH BY APOTEX OF SECTION 2, UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE LIABLE FOR LOSS OF USE OR PROFITS OR OTHER COLLATERAL, SPECIAL,
	CONSEQUENTIAL, INCIDENTAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT, WHETHER SUCH CLAIMS ARE FOUNDED IN TORT OR CONTRACT.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	10
</P>
<A NAME="eolPage123"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6.4
<U>
	Equitable Relief Against Apotex
</U>
	. Apotex acknowledges and agrees that the
	obligations and undertakings of Apotex pursuant to Section&nbsp;2 of this Agreement are reasonable and necessary to protect the legitimate interests of Vanda, that Vanda would not have entered into this Agreement in the absence of such provisions,
	and that Apotex&#146;s material breach or threatened breach or failure to comply with Section&nbsp;2 shall cause Vanda significant and irreparable harm, the amount of which shall be extremely difficult to estimate and ascertain, and for which money
	damages shall not be adequate. Apotex further acknowledges and agrees that Vanda shall have the right to apply to any court of competent jurisdiction for an injunction order restraining any material breach or threatened breach of Section&nbsp;2 of
	this Agreement and specifically enforcing the terms and provisions of such Sections of this Agreement. Apotex agrees that it shall not challenge any of the foregoing acknowledgements and agreements in this Section concerning injunctive relief in any
	proceeding brought by Vanda.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.
<U>
	INDEMNIFICATION.
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.1 Apotex shall indemnify, defend and hold harmless Vanda, its directors, managers, members, officers, employees, authorized subcontractors
	and agents (collectively the &#147;
<B>
	Vanda Indemnified Parties
</B>
	&#148;) from and against any and all liabilities, losses, damages, costs and expenses (including, without limitation, reasonable attorney&#146;s fees and costs) (collectively,
	&#147;Losses&#148;) incurred as a result of any claims, demands, actions or other proceedings by a **** against a Vanda Indemnified Party, ****. Apotex&#146;s obligation to indemnify Vanda Indemnified Parties shall exclude any claim asserted by any
	****.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.2 A Vanda Indemnified Party that intends to claim indemnification under this Section&nbsp;7 shall promptly notify Apotex in
	writing of any claim, demand, action, or other proceeding in respect of which the Vanda Indemnified Party intends to claim such indemnification; provided, however, that failure to provide such notice within a reasonable period of time shall not
	relieve Apotex of any of its obligations hereunder except to the extent Apotex is prejudiced by such failure. The Vanda Indemnified Party shall permit Apotex, at its discretion, to settle any such action, claim or other matter. Notwithstanding the
	foregoing, Apotex shall not enter into any settlement that would adversely affect the Vanda Indemnified Party&#146;s rights hereunder, or impose any obligations on the Vanda Indemnified Party in addition to those set forth herein, in order for it to
	exercise such rights, without the Vanda Indemnified Party&#146;s prior written consent, which shall not be unreasonably withheld or delayed. No such action, claim or other matter shall be settled without the prior written consent of Apotex, which
	shall not be unreasonably withheld or delayed. The Vanda Indemnified Party shall reasonably cooperate with Apotex and its legal representatives in the investigation and defense of any claim, demand, action, or other proceeding covered by the
	indemnification obligations of this Section&nbsp;7.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	11
</P>
<A NAME="eolPage124"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Vanda Indemnified Party shall have the right, but not the obligation, to be represented in such defense
	by counsel of its own selection at its own expense.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.3 Vanda shall indemnify, defend and hold harmless Apotex, its directors, managers,
	members, officers, employees, authorized subcontractors and agents (collectively the &#147;
<B>
	Apotex Indemnified Parties
</B>
	&#148;) from and against any and all Losses (as defined above) incurred as a result of any claims, demands, actions or other
	proceedings by a **** against an Apotex Indemnified Party, ****. Vanda&#146;s obligation to indemnify Apotex Indemnified Parties shall exclude any ****.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7.4 An Apotex Indemnified Party that intends to claim indemnification under this Section&nbsp;7 shall promptly notify Vanda in writing of any
	claim, demand, action, or other proceeding in respect of which the Apotex Indemnified Party intends to claim such indemnification; provided, however, that failure to provide such notice within a reasonable period of time shall not relieve Vanda of
	any of its obligations hereunder except to the extent Vanda is prejudiced by such failure. The Apotex Indemnified Party shall permit Vanda, at its discretion, to settle any such action, claim or other matter. Notwithstanding the foregoing, Vanda
	shall not enter into any settlement that would adversely affect the Apotex Indemnified Party&#146;s rights hereunder, or impose any obligations on the Apotex Indemnified Party in addition to those set forth herein, in order for it to exercise such
	rights, without the Apotex Indemnified Party&#146;s prior written consent, which shall not be unreasonably withheld or delayed. No such action, claim or other matter shall be settled without the prior written consent of Vanda, which shall not be
	unreasonably withheld or delayed. The Apotex Indemnified Party shall reasonably cooperate with Vanda and its legal representatives in the investigation and defense of any claim, demand, action, or other proceeding covered by the indemnification
	obligations of this Section&nbsp;7. The Apotex Indemnified Party shall have the right, but not the obligation, to be represented in such defense by counsel of its own selection at its own expense.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.
<U>
	GENERAL PROVISIONS.
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.1
<U>
	Notices
</U>
	. All notices hereunder shall be delivered by facsimile (confirmed by overnight delivery), or by overnight delivery with a
	reputable overnight delivery service, to the following address of the respective parties:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="7%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="8%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="81%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<EFX_UNIDENTIFIED_TABLE>
<TD VALIGN="TOP">
<A NAME="FIS_UNIDENTIFIED_TABLE_55"></A>
	If&nbsp;to&nbsp;Vanda:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vanda Pharmaceuticals Inc.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2200 Pennsylvania
	Avenue, N.W.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Washington, DC 20037
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Attn: Chief Executive
	Officer
</P>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Facsimile:
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	12
</P>
<A NAME="eolPage125"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_56"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="7%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="11%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="80%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	with&nbsp;a&nbsp;copy&nbsp;to:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vanda Pharmaceuticals Inc.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2200 Pennsylvania
	Avenue, N.W.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Washington, DC 20037
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Attn: General Counsel
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Facsimile:
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	If to Apotex:
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Apotex Inc.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Attn: Chief Executive
	Officer
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	150 Signet Drive
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Toronto, Ontario M9L 1T9
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Canada
</P>
</TD>
</TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="7%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="10%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="81%">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	with&nbsp;a&nbsp;copy&nbsp;to
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(which shall not constitute and is not necessary for notice):
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Mark Mitchell
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Senior Patent Counsel, Global Intellectual Property
	Dept.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Apotex Inc.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	150 Signet Drive
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Toronto, Ontario M9L 1T9
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Canada
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Email: ****
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	and
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Stephen R. Auten
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Taft Stettinius&nbsp;&amp; Hollister
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	111 East Wacker Drive, Suite 2800
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Chicago, IL 60601
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Email: ****
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Notices shall be effective on the day of receipt. A party may change its address listed above by notice to the
	other party given in accordance with this Section&nbsp;8.1.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.2
<U>
	Entire Agreement
</U>
	. The parties hereto acknowledge that this
	Agreement sets forth the entire agreement and understanding of the parties and supersede all prior written or oral agreements or understandings with respect to the subject matter hereof. No modification of any of the terms of this Agreement, or any
	amendments thereto, shall be deemed to be valid unless in writing and signed by an authorized agent or representative of both parties hereto. No course of dealing or usage of trade shall be used to modify the terms and conditions herein. This
	Agreement shall be binding on each of Apotex and Vanda and their respective permitted successors and assigns.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.3
<U>
	Waiver
</U>
	. None of
	the provisions of this Agreement shall be considered waived by any party hereto unless such waiver is agreed to, in writing, by authorized agents of such party. The failure of a party to insist upon strict conformance to any of the terms and
	conditions hereof, or failure or delay to exercise any rights provided herein or by law shall not be deemed a waiver of any rights of any party hereto.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	13
</P>
<A NAME="eolPage126"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.4
<U>
	Obligations to Third Parties
</U>
	. Each party warrants and represents that this
	Agreement does not conflict with any contractual obligations, expressed or implied, undertaken with any Third Party.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.5
<U>
	Assignment
</U>
	. Neither party shall assign this Agreement or any part hereof or any interest herein (whether by operation of law or otherwise) to any Third Party (or use any subcontractor) without the written approval of the other party, which
	shall not be unreasonably withheld, conditioned, or delayed; provided, however, that either party may assign this Agreement without such consent (i)&nbsp;to any Affiliate; and (ii)&nbsp;in the case of a merger, consolidation, change in control or
	sale of all or substantially all of the assets related to this Agreement, provided further that with respect to Apotex, any such Affiliate or Third Party agrees to be bound by the terms and conditions of this Agreement. No assignment shall be valid
	unless the permitted assignee(s) assumes all obligations of its assignor under this Agreement. No assignment shall relieve any party of responsibility for the performance of its obligations hereunder. Any purported assignment in violation of this
	Section&nbsp;8.5 shall be void.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.6
<U>
	Governing Law
</U>
	. Any action brought regarding the validity, construction or enforcement of this
	Agreement shall be governed in all respects by the laws of the State of Delaware, without regard to the principles of conflicts of laws. The federal and state courts in the State of Delaware shall have exclusive jurisdiction over the parties hereto
	in all such actions, and each party irrevocably consents to the personal jurisdiction of those courts and agrees not to challenge the venue of such courts or to seek to transfer any such action to any other forum.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.7
<U>
	Severability
</U>
	. If any term or provision of this Agreement shall for any reason be held invalid, illegal or unenforceable in any
	respect, such invalidity, illegality or unenforceability shall not affect any other term or provision hereof, and this Agreement shall be interpreted and construed as if such term or provision, to the extent the same shall have been held to be
	invalid, illegal or unenforceable, had never been contained herein.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.8
<U>
	Headings, Interpretation
</U>
	. The headings used in this
	Agreement are for convenience only and are not part of this Agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8.9
<U>
	Counterparts
</U>
	. The Agreement may be executed in two or
	more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<I>
	[Remainder of this page intentionally blank]
</I>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	14
</P>
<A NAME="eolPage127"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	IN WITNESS WHEREOF, the parties hereto have each caused this Agreement to be executed by their
	duly-authorized representatives effective as of the Effective Date.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="13%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="86%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
	VANDA PHARMACEUTICALS INC.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	By:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Name:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Title:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="13%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="86%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
	APOTEX CORP.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	By:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Name:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Title:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="13%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="86%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" COLSPAN="3">
	APOTEX INC.
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	By:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Name:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	Title:
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<A NAME="eolPage128"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	EXHIBIT A
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<U>
	Fanapt Products
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<U>
	PRODUCT
</U>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	****
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	****
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	****
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	****
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	****
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	****
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	****
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<A NAME="eolPage129"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	EXHIBIT B
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	US Patent No.&nbsp;8,586,610
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	US
	Patent No.&nbsp;9,138,432
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	****
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	****C
<SMALL>
	ERTAIN
</SMALL>
<SMALL>
	INFORMATION
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	AND
</SMALL>
<SMALL>
	FILED
</SMALL>
<SMALL>
	SEPARATELY
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	THE
</SMALL>
	C
<SMALL>
	OMMISSION
</SMALL>
	. C
<SMALL>
	ONFIDENTIAL
</SMALL>
<SMALL>
	TREATMENT
</SMALL>
<SMALL>
	HAS
</SMALL>
<SMALL>
	BEEN
</SMALL>
<SMALL>
	REQUESTED
</SMALL>
<SMALL>
	WITH
</SMALL>
<SMALL>
	RESPECT
</SMALL>
<SMALL>
	TO
</SMALL>
<SMALL>
	THE
</SMALL>
<SMALL>
	OMITTED
</SMALL>
<SMALL>
	PORTIONS
</SMALL>
	.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<A NAME="eolPage130"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_57"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	EXHIBIT C
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<U>
	Consent Judgement
</U>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	IN
	THE UNITED STATES DISTRICT COURT
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	FOR THE DISTRICT OF DELAWARE
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="29%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="67%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	VANDA&nbsp;PHARMACEUTICALS&nbsp;INC.,
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Plaintiff,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="LEFT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	v.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	APOTEX&nbsp;INC.&nbsp;and&nbsp;APOTEX&nbsp;CORP.,
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	&nbsp;
<BR>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:1PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
</TD>
<TD VALIGN="TOP">
	)
<BR>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:1PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
</TD>
<TD NOWRAP VALIGN="TOP">
	&nbsp;&nbsp;
<BR>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:1PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	C.A. No. 15-00922&#151;GMS
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Defendants.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	)
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	STIPULATION FOR ENTRY OF CONSENT JUDGMENT AND
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<U>
	PERMANENT INJUNCTION AS TO APOTEX INC. AND APOTEX CORP.
</U>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:8%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Plaintiff Vanda Pharmaceuticals Inc. and Defendants Apotex Inc. and Apotex Corp. having met, conferred, and agreed to resolve their dispute
	upon execution of a separate License Agreement, hereby stipulate to entry of the executed Consent Judgment and Permanent Injunction submitted herewith, subject to the Court&#146;s approval.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<DIV ALIGN="RIGHT">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="100%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	M
<SMALL>
	ORRIS
</SMALL>
	, N
<SMALL>
	ICHOLS
</SMALL>
	, A
<SMALL>
	RSHT
</SMALL>
	&nbsp;&amp; T
<SMALL>
	UNNELL
</SMALL>
	LLP
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT SIZE="1">
	&nbsp;
</FONT>
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; FONT-SIZE:3PT">
	&nbsp;
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Jack B. Blumenfeld (#1014)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Karen Jacobs
	(#2881)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Derek J. Fahnestock (#4705)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1201 North Market
	Street
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	P.O. Box 1347
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Wilmington, DE 19899
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(302) 658-9200
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	jblumenfeld@mnat.com
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	kjacobs@mnat.com
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	dfahnestock@mnat.com
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Attorneys for Plaintiff
</I>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Vanda Pharmaceuticals Inc.
</I>
</P>
</TD>
</TR>
</TABLE>
</DIV>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<A NAME="eolPage131"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	OF COUNSEL:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Nicholas Groombridge
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Eric Alan Stone
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Kira A. Davis
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Josephine Young
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Daniel J. Klein
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	James Razick
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	PAUL, WEISS, RIFKIND, WHARTON
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&amp; GARRISON LLP
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1285
	Avenue of the Americas
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	New York, NY 10019
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(212) 373-3000
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<DIV ALIGN="RIGHT">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="100%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	SMITH KATZENSTEIN&nbsp;&amp; JENKINS LLP
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
<FONT SIZE="1">
	&nbsp;
</FONT>
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; FONT-SIZE:3PT">
	&nbsp;
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Neal C. Belgam (No. 2721)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Eve H. Ormerod
	(No. 5369)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1000 West Street, Suite 1501
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	P.O. Box 410
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Wilmington, DE 19899 (courier 19801)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	302-652-8400
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<U>
	nbelgam@skjlaw.com
</U>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Attorneys for Defendants
</I>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Apotex Inc. and Apotex
	Corp.
</I>
</P>
</TD>
</TR>
</TABLE>
</DIV>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	OF COUNSEL:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Richard T.
	Ruzich
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Stephen R. Auten
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Joseph Bennett-Paris, Ph.D.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	TAFT STETTINIUS&nbsp;&amp; HOLLISTER LLP
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	111 East Wacker
	Drive&#151;Suite 2800
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Chicago, IL 60601
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	312-527-4000
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	rruzich@taftlaw.com
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	sauten@taftlaw.com
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Dated: February&nbsp;10, 2017
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	2
</P>
<A NAME="eolPage132"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_58"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONFIDENTIAL TREATMENT REQUESTED
</B>
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	IN THE UNITED STATES DISTRICT COURT
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	FOR THE DISTRICT OF DELAWARE
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="29%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD>
</TD>
<TD>
</TD>
<TD>
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="67%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	VANDA&nbsp;PHARMACEUTICALS&nbsp;INC.,
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Plaintiff,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT" ALIGN="LEFT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	v.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	APOTEX&nbsp;INC.&nbsp;and&nbsp;APOTEX&nbsp;CORP.,
</P>
<P STYLE="FONT-SIZE:12PT; MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT">
	&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	&nbsp;
<BR>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:1PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
</TD>
<TD VALIGN="TOP">
	)
<BR>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
<P STYLE="MARGIN-BOTTOM:1PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	)
</P>
</TD>
<TD NOWRAP VALIGN="TOP">
	&nbsp;&nbsp;
<BR>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:0PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
<P STYLE="MARGIN-BOTTOM:1PT; MARGIN-TOP:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	C.A. No. 15-[XXX]&#151;GMS
</P>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	Defendants.
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="RIGHT">
	)
</TD>
<TD NOWRAP VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONSENT JUDGMENT AND PERMANENT INJUNCTION
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
<U>
	AS TO APOTEX INC. AND APOTEX CORP.
</U>
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	This matter is before the Court on the unopposed motion of Plaintiff Vanda Pharmaceuticals Inc. (&#147;Vanda&#148;) and Defendants Apotex Inc.
	and Apotex Corp. (together, &#147;Apotex&#148;).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS
</B>
	, Vanda owns United States Patent Nos. 8,586,610 (&#147;the &#146;610
	patent&#148;) and 9,138,432 (&#147;the &#146;432 patent&#148;).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	Apotex Inc. submitted Abbreviated New Drug Application
	No.&nbsp;208367 (&#147;Apotex&#146;s ANDA&#148;) to the FDA under 21 U.S.C. &#167;&nbsp;355(j) seeking to obtain approval to commercially manufacture and sell generic iloperidone.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS
</B>
	, in this Action, Vanda alleges that Apotex infringed one or more of claims 1-9, 11-13, and 16 of the &#146;610 patent and claim
	1 of the &#146;432 patent under 35 U.S.C. &#167;&nbsp;271(e)(2) by virtue of Apotex Inc.&#146;s submission of Apotex&#146;s ANDA to the FDA.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	in this Action, Vanda alleges that it would be irreparably harmed if Apotex were not enjoined from infringing or actively
	inducing or contributing to infringement of one or more of claims 1-9, 11-13, and 16 of the &#145;610 patent and claim 1 of the &#146;432 patent.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:18PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<A NAME="eolPage133"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	in this Action, Vanda requested that this Court enter a permanent injunction
	enjoining Apotex from infringing the &#146;610 and &#146;432 patents.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS
</B>
	, in this Action, Apotex has denied that the
	&#145;610 patent or the &#145;432 patent is valid, enforceable, and infringed by the product described in Apotex&#146;s ANDA.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	Vanda and Apotex have reached an agreement to finally settle the Litigation as set forth in this Consent Judgment and Permanent Injunction as to Apotex and a separate License Agreement (&#147;License Agreement&#148;), which is contemporaneously
	and separately being executed.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	final settlement of this Action will help Vanda and Apotex avoid the substantial
	uncertainty and risks involved with prolonged litigation.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	final settlement of this Action will permit Vanda and Apotex to
	save litigation costs, as well as adhere to the judicially recognized mandate that encourages the settlement of litigation whenever possible.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	final settlement of the Action serves the public interest by saving judicial resources and avoiding the risks to each of Vanda
	and Apotex associated with infringement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	WHEREAS,
</B>
	Vanda and Apotex each consent to personal jurisdiction in Delaware for purposes
	of enforcing the License Agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	IT IS HEREBY ORDERED, DECREED, and ADJUDGED as follows:
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1. The Court has jurisdiction over Vanda and Apotex and the subject matter of this Litigation.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	2
</P>
<A NAME="eolPage134"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	2. Apotex acknowledges Vanda&#146;s ownership and standing to sue for infringement of United
	States Patent Nos. 8,586,610 (&#147;the &#146;610 patent&#148;) and 9,138,432 (&#147;the &#146;432 patent&#148;).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	3. Apotex acknowledges
	that the &#146;610 and &#146;432 patents are valid and enforceable, as described more fully and subject to the restrictions contained in the License Agreement.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	4. Apotex acknowledges that it has technically infringed the &#146;610 and &#146;432 patents under 35 U.S.C. &#167;&nbsp;271(e)(2) and that
	Vanda did not authorize the commercial manufacture, use, sale, offer for sale, importation and distribution of the product described in Apotex&#146;s ANDA.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	5. Apotex and its affiliates are permanently enjoined as of the date hereof from infringing the &#146;610 and &#146;432 patents by the
	commercial manufacture, use, offer to sell, sale, importation, or distribution of any generic iloperidone products that are the subject of Apotex&#146;s ANDA that is not pursuant to a license granted by Vanda or otherwise exempt from infringement
	under 35 U.S.C. &#167; 271(e)(1), and from inducing others to infringe or contributing to the infringement of the &#146;610 and &#146;432 patents by inducing others to manufacture, use, offer to sell, sale, import, or distribute or contributing to
	others&#146; manufacture, use, offer for sale, sale, importation, or distribution of any generic iloperidone products that are the subject of Apotex&#146;s ANDA that is not pursuant to a license granted by Vanda or otherwise exempt under 35 U.S.C.
	&#167; 271(e)(1).
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	6. All claims and counterclaims in this Action are hereby dismissed without prejudice.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	7. Each party shall bear its own costs and attorneys&#146; fees.
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	3
</P>
<A NAME="eolPage135"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	8. This Court shall retain jurisdiction over Apotex and Vanda for the purpose of enforcing the
	terms of this Consent Judgment and Permanent Injunction and over any matters related to or arising from the interpretation or enforcement of the License Agreement or any legal or equitable claim concerning the License Agreement by any third party.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	IT IS SO ORDERED, DECREED AND ADJUDGED
</B>
	this &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day of
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016 by:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="100%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; FONT-SIZE:3PT">
	&nbsp;
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Honorable Gregory M. Sleet
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	United States District Judge
</P>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	4
</P>
<A NAME="eolPage136"></A>
<P STYLE='PAGE-BREAK-BEFORE:ALWAYS'>
<HR SIZE="3" STYLE="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<EFX_UNIDENTIFIED_TABLE>
<A NAME="FIS_UNIDENTIFIED_TABLE_59"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Agreed to:
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="51%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="47%">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="24">
</TD>
<TD HEIGHT="24" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	MORRIS, NICHOLS, ARSHT &amp; TUNNELL LLP
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Jack B. Blumenfeld (#1014)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Karen Jacobs (#2881)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Derek J. Fahnestock (#4705)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1201 North Market Street
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	P.O. Box 1347
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Wilmington, DE 19899
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(302) 658-9200
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	jblumenfeld@mnat.com
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	kjacobs@mnat.com
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	dfahnestock@mnat.com
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Attorneys for Plaintiff
</I>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Vanda Pharmaceuticals Inc.
</I>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	OF COUNSEL:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Nicholas Groombridge
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Eric Alan Stone
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Kira A. Davis
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Josephine Young
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Daniel J. Klein
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	James Razick
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	PAUL, WEISS, RIFKIND, WHARTON
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&amp; GARRISON LLP
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1285 Avenue of the Americas
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	New York, NY 10019
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	(212) 373-3000
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	SMITH KATZENSTEIN &amp; JENKINS LLP
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1PX SOLID #000000; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Neal C. Belgam (No.
	2721)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Eve H. Ormerod (No. 5369)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	1000 West Street, Suite
	1501
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	P.O. Box 410
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Wilmington, DE 19899 (courier 19801)
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	302-652-8400
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<U>
	nbelgam@skjlaw.com
</U>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Attorneys for Defendants
</I>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	Apotex Inc. and Apotex Corp.
</I>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	OF COUNSEL:
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Richard T. Ruzich
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Stephen R. Auten
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Joseph Bennett-Paris, Ph.D.
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	TAFT STETTINIUS &amp; HOLLISTER
	LLP
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	111 East Wacker Drive&#151;Suite 2800
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Chicago, IL
	60601
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	312-527-4000
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	rruzich@taftlaw.com
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	sauten@taftlaw.com
</P>
</TD>
</TR>
</TABLE>
</EFX_UNIDENTIFIED_TABLE>
<P STYLE="MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT ; FONT-SIZE:8PT">
	&nbsp;
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
	5
</P>
</EFX_EXHIBIT_10>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage137"></A>
<A NAME="D474152DEX211_HTM"></A>
<EFX_EXHIBIT_21>
<A NAME="FIS_EXHIBIT_21"></A>
<EFX_SUBSIDIARIES>
<A NAME="FIS_SUBSIDIARIES"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	EXHIBIT 21.1
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Vanda Pharmaceuticals Inc.
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	List of Subsidiaries
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="34%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="32%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="BOTTOM" NOWRAP>
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; BORDER-BOTTOM:1.00PT SOLID #000000; WIDTH:121.45PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Name of Wholly-Owned Subsidiary
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN">
<B>
	Jurisdiction&nbsp;of&nbsp;Organization
</B>
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1.00PT SOLID #000000">
<B>
	Name under
<BR>
	which&nbsp;the&nbsp;subsidiary&nbsp;conducts&nbsp;business
</B>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vanda Pharmaceuticals Limited
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	United Kingdom
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Vanda&nbsp;Pharmaceuticals&nbsp;Limited
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vanda Pharmaceuticals GmbH
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Switzerland
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM">
	Vanda Pharmaceuticals GmbH
</TD>
</TR>
</EFX_SUBSIDIARIES>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
<P STYLE=" MARGIN-TOP:0PT ; MARGIN-BOTTOM:0PT; MARGIN-LEFT:1.00EM; TEXT-INDENT:-1.00EM; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Vanda Pharmaceuticals Germany GmbH
</P>
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP">
	Germany
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="BOTTOM" NOWRAP>
	Vanda&nbsp;Pharmaceuticals&nbsp;Germany&nbsp;GmbH
</TD>
</TR>
</TABLE>
</EFX_EXHIBIT_21>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage138"></A>
<A NAME="D474152DEX231_HTM"></A>
<EFX_EXHIBIT_23>
<A NAME="FIS_EXHIBIT_23"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	Exhibit 23.1
</B>
</P>
<EFX_EXPERTS_CONSENT>
<A NAME="FIS_EXPERTS_CONSENT"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	We hereby consent to the incorporation by reference in the Registration Statements on Forms S-8 (No. 333-133368, No.&nbsp;333-138070, No.&nbsp;333-141571,
	No.&nbsp;333-148924, No.&nbsp;333-156995, No.&nbsp;333-164567, No.&nbsp;333-171962, No.&nbsp;333-179265, No.&nbsp;333-186509, No.&nbsp;333-193614, No.&nbsp;333-201754, No.&nbsp;333-209144 and No.&nbsp;333-212255) and on Form S-3
	(No.&nbsp;333-205513) of Vanda Pharmaceuticals Inc. of our report dated February&nbsp;17, 2017 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	/s/ PricewaterhouseCoopers LLP
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Baltimore, Maryland
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	February&nbsp;17, 2017
</P>
</EFX_EXPERTS_CONSENT>
</EFX_EXHIBIT_23>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage139"></A>
<A NAME="D474152DEX311_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	EXHIBIT 31.1
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CERTIFICATION OF CHIEF EXECUTIVE OFFICER
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	&nbsp;&nbsp;&nbsp;&nbsp;
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	I, Mihael H. Polymeropoulos, certify that:
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	1.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	I have reviewed this annual report on Form 10-K of Vanda Pharmaceuticals Inc.;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	2.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
	statements were made, not misleading with respect to the period covered by this report;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	3.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
	registrant as of, and for, the periods presented in this report;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	4.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
	over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	a.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
	consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	b.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
	financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	c.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
	the period covered by this report based on such evaluation; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	d.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
	in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	5.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
	registrant&#146;s board of directors (or persons performing the equivalent functions):
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	a.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
	process, summarize and report financial information; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	b.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TR>
<TD WIDTH="50%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="1%">
</TD>
<TD WIDTH="49%">
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	February&nbsp;17, 2017
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	/s/ Mihael H. Polymeropoulos, M.D.
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<B>
	Mihael H. Polymeropoulos, M.D.
</B>
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;
</TD>
<TD VALIGN="BOTTOM" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	President and Chief Executive Officer
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(Principal Executive Officer)
</B>
</P>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage140"></A>
<A NAME="D474152DEX312_HTM"></A>
<EFX_EXHIBIT_31>
<A NAME="FIS_EXHIBIT_31_2"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	EXHIBIT 31.2
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_2"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CERTIFICATION OF CHIEF FINANCIAL OFFICER
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; TEXT-INDENT:4%; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	I, James P. Kelly, certify that:
</P>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	1.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	I have reviewed this annual report on Form 10-K of Vanda Pharmaceuticals Inc.;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	2.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
	statements were made, not misleading with respect to the period covered by this report;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	3.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
	registrant as of, and for, the periods presented in this report;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	4.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
	over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	a.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
	consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	b.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
	financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	c.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
	the period covered by this report based on such evaluation; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	d.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
	in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	5.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
	registrant&#146;s board of directors (or persons performing the equivalent functions):
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	a.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
	process, summarize and report financial information; and
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:6PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">
	&nbsp;
</TD>
<TD WIDTH="4%" VALIGN="TOP" ALIGN="LEFT">
	b.
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting.
</TD>
</TR>
</TABLE>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="51%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="47%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	February&nbsp;17, 2017
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	/s/ James P. Kelly
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	James P. Kelly
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Senior Vice President, Chief Financial Officer and Treasurer
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(Principal Financial Officer and Principal Accounting Officer)
</B>
</P>
</TD>
</TR>
</TABLE>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_31>

<DIV CLASS="eolNewPage"></DIV>
<A NAME="eolPage141"></A>
<A NAME="D474152DEX321_HTM"></A>
<EFX_EXHIBIT_32>
<A NAME="FIS_EXHIBIT_32"></A>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="RIGHT">
<B>
	EXHIBIT 32.1
</B>
</P>
<EFX_CERTIFICATION>
<A NAME="FIS_CERTIFICATION_3"></A>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(Subsections (a)&nbsp;and (b)&nbsp;of Section&nbsp;1350, Chapter 63 of Title 18, United States Code)
</B>
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	Pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&nbsp;and (b)&nbsp;of section 1350, chapter 63 of title 18, United States
	Code), each of the undersigned officers of Vanda Pharmaceuticals Inc., (the &#147;Company&#148;), does hereby certify, to the best of such officer&#146;s knowledge, that:
</P>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
	The Annual Report on Form 10-K for the year ended December&nbsp;31, 2016 (the Form 10-K) of the Company fully complies with the requirements of
	Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-K fairly presents, in all material respects, the consolidated financial condition and results of operations of the Company.
</P>
<P STYLE="FONT-SIZE:12PT;MARGIN-TOP:0PT;MARGIN-BOTTOM:0PT">
	&nbsp;
</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT" ALIGN="CENTER">
<TR>
<TD WIDTH="51%">
</TD>
<TD VALIGN="BOTTOM" WIDTH="2%">
</TD>
<TD WIDTH="47%">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	February&nbsp;17, 2017
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	/s/&nbsp;Mihael H. Polymeropoulos, M.D.
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Mihael H. Polymeropoulos, M.D.
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	President and Chief Executive Officer
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(Principal Executive Officer)
</B>
</P>
</TD>
</TR>
<TR STYLE="FONT-SIZE:1PT">
<TD HEIGHT="16">
</TD>
<TD HEIGHT="16" COLSPAN="2">
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:10PT">
<TD VALIGN="TOP">
	February&nbsp;17, 2017
</TD>
<TD VALIGN="BOTTOM" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER" STYLE="BORDER-BOTTOM:1PX SOLID #000000">
	/s/&nbsp;James P. Kelly
</TD>
</TR>
<TR STYLE="FONT-FAMILY:TIMES NEW ROMAN; FONT-SIZE:8PT">
<TD VALIGN="TOP">
</TD>
<TD VALIGN="BOTTOM">
	&nbsp;&nbsp;
</TD>
<TD VALIGN="TOP" ALIGN="CENTER">
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	James P. Kelly
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:0PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	Senior Vice President, Chief Financial Officer and Treasurer
</B>
</P>
<P STYLE="MARGIN-TOP:0PT; MARGIN-BOTTOM:1PT; FONT-SIZE:8PT; FONT-FAMILY:TIMES NEW ROMAN" ALIGN="CENTER">
<B>
	(Principal Financial Officer and Principal Accounting Officer)
</B>
</P>
</TD>
</TR>
</TABLE>
<P STYLE="MARGIN-TOP:12PT; MARGIN-BOTTOM:0PT; FONT-SIZE:10PT; FONT-FAMILY:TIMES NEW ROMAN">
<I>
	A signed original of this written statement required by Section&nbsp;906 has been provided to the Company and will be
	retained by the Company and furnished to the Securities and Exchange Commission (SEC) or its staff upon request. This certification &#147;accompanies&#148; the Form 10-K to which it relates, is not deemed filed with the SEC and is not to be
	incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general
	incorporation language contained in such filing.
</I>
</P>
</EFX_CERTIFICATION>
</EFX_EXHIBIT_32>

<!-- FOOTER LOGO -->
</BODY>
</HTML>
